var title_f28_19_28976="Deforming arthritis in MCTD";
var content_f28_19_28976=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Joint deformity in mixed connective tissue disease (MCTD)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Deforming arthritis in mixed connective tissue disease characterized by ulnar deviation and swan neck deformities. These abnormalities are also seen in rheumatoid arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert M Bennett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_19_28976=[""].join("\n");
var outline_f28_19_28976=null;
var title_f28_19_28977="Midgut volvulus";
var content_f28_19_28977=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Midgut volvulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 483px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Volvulus occurs because the narrow mesenteric base, which develops as a result of malrotation, allows the small bowel to twist around the superior mesenteric artery. This leads to vascular compromise of large portions of the midgut.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_19_28977=[""].join("\n");
var outline_f28_19_28977=null;
var title_f28_19_28978="Acute epiglottitis";
var content_f28_19_28978=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Normal epiglottis and acute epiglottitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Normal epiglottis. B) Characteristic erythematous, edematous epiglottis of acute epiglottitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_19_28978=[""].join("\n");
var outline_f28_19_28978=null;
var title_f28_19_28979="Focal distribution of HAT";
var content_f28_19_28979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    The focal distribution of human African trypanosomiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left of the red line: Trypanosoma brucei gambiense foci in West and Central Africa. Right of the red line: T. b. rhodesiense foci in Eastern and South Africa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Report of the Scientific Working Group meeting on African trypanosomiasis Geneva, 4-8 June, 2001. Reproduced with permission from the World Health Organization. Copyright &copy; 2001 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_19_28979=[""].join("\n");
var outline_f28_19_28979=null;
var title_f28_19_28980="Burkholderia pseudomallei Gram stain";
var content_f28_19_28980=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Gram stain showing scant gram-negative bacilli of Burkholderia pseudomallei",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 344px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFYAeADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1JIGEiyee74JOw9PpUjF/MXbgKfvZHOfSoG8xUZEGHbJ3imI88d7+8laSGZAFiK48oj0PfNXfzPYsT3ECzf635xjG09DVLUITbxDa5a3z8oPVT6fSrzOvdhjsfWo7mFZUK3DMyN8qqOAPemOLtuZkOkNFcCS5ZWRh8sascg+9X7qSS2gItgWGAWVuQv0qC2l+xzmC5kzuOEYnI+lSapOILSbzAwbjYQMg0ktS223qTabcpcN5ZKCRxuDE8H1qP7dG12Y4YpiOFLbcKTXNXV3AsawJNHNvUOcf8s/b60razdRW5hjmVoc7gSuWB+tUldFqg2dfAzRqfM++D0PpUFysuwFZpXz8yr/CDWF4Q1Bbq4voZJNpRQ6KzdyeetdA0IDFULIrD5sHkmlLS6MnHldh9lEkVv5flkOPvk9WPc0NbW5mkKxIW2YGc4BpsRuGZPMClsEAocfTNRT3MdogSX52JxnODnr+VJaisWJZUTy42IVdud2OB7CnCQ/KWbep7EYbNYkmpzCUF490Z+5ge9WW1oGXzJIGQA42EHcw9fanZlcjNKGUyJvKlXzwvfFQLIiTvJBM0jNk+WRxuPfPpUUOL+ITRS/uXJyeh4qwkaR22yMuFXPDdalsVh8SKwVpE2yOOQD09aI2RUYou3nCjqW+tQQuwmQS7hJ/CwHykUOJYYSEbIZt3I6GgLDzG7OFZ2yp3HAyn+RSTO08bKm0uZNu8fwgd/pU6sRu6gMOD6N6VFahYoWLEKoJ3k9qQD4i0JKTOdqjBCHOT9adA3mxSBTGTnDZ5YA+tRuy5R4/XO7+8PQU5QBIwBQ7yWU4wfx+lMLBHGsXlxm4Z2jP8XUip1kO5v3THB65wMVHGqQ8BiVIyM8kepzTlYFvMQFgBjJ6UgsNgZzvby4wGON2ctUoIBGW5649aahRtyIeRyRQxUnaTz93jqD/AEoAZPG2Gw23eRlTyKinEiSIYWZEz8y5wpz0zVj5hjB3445/nUd1EZ7d4QQu7oeuKLjRBL5UN8Gdwox8wX6VYYho1MLF1U9SDkVBHbqoZwnmFCAqkY3etSRl2jDeY3J5GMjH+NHQbHMTJMoZGDIDtU9/8ac6nzkaQAZ4JTjPHeomRwwfcS4HBJ/lRE3JwC23kfNimIV1DKrRgRADJOOaRgzYOR5gAcD1pwnJRnYKFGDkdPpTXdnDMjbSCFX2PvS1ACZIgzIomcj7ucH8zUQSRAzspWU8ctk496mlZshiWI6Mo7GmNJnZ5QLEtgjHRfWmriGSFYnj3EL820Ec4+tWP9k/pUUEKW4kEfWRtzse5owULMnIH8J9PajoBSiJt9XkiA2QtHuVjz+Z+tW4J85JkDBuCAOAajllFxCrQjcu7GD1/wD1VIoVjuIXcCRwOlCulZgxJ41kcKW+THKgdD60QwyRYCOCM5K9vwpMBH8xWxxznoRTmxPGGViE6jHf2o2DcVpl81QELZ4DCnbuTnIxwQe1VhlGw5BVeQo/xp8hcFZAmMryDzj60XshWJ8jp/k02RguWY4WqrGSK1RhI+WOTjqPanws/l5Mu8EdCAefSnfsFiWRgEy2SvbAzmolxHFggvtIJHcZ9aYMIiRsQhHIz0FRi4b7Q5jxvIwVA+9igLFo4bKguvc4HApRuW3ZY1VXwdo7E+9RlmWIbWQSlSSM5B9cUkbNHa/IDITypPXBoAlfBjAzhgAeOuaGAGJAcEDr61CAy4dcsM9T1p8pyAzKwjHXFMRKnBzuzu5zURdwsnBL9NtNZUVUKlhGeetLNkR7oz0557ihjQ1FaOIFiVbGDk1KsnzAFW2t3x0NMCrIiMQfl5waablA/DZToTjjNPqIlDpHIIjIS7DIUjint90kAH/ZPFV5GJBYkYXkGgOjpw4J65pboChqMutrd2iaSkEVqdrzSzxeYh+fDxsdwKfJ8ylQSWOOADWuHR5iy/dA4B6gUwKWOfM+TrjFBdfMy+QQMjbR1uFhvnNvIcBcDp1/GpAQ3G4cd88iq4k8xFaMhSeMsODUe+GMzKXUzqvY/l/+uo8irE8q7A3lp82ctjrSXcYmVQsh3r8wxUUW+BHa6YCMj7+c4qxEFCbl6NyGPcdqL9gtYYyQzxiC7gKqw249PcH1rn7prm2hewvGEozlJCcBwOg+tdLlt+McDqTVO+06O+glicj5vus3VD3xRexpCST1PP5rACd5DI24dMcEVUvJLlfkh3BQOT2FdjPYtExW8RZJQ2FlHoKi0+ysZrt1vgnlEYG44BrRVXu9TsU1a5P4L0+G3s3u7+NRJNhY/MXkDucVpm9W2uWjI3AygK+egz1I9KZfXcMkymGZSETywSOBioYLi1jijJtyZcnex53ZPFZ3l13ZyyXM7m75glx5WAuc7s9vpUFzbrIyOOZd2d7Ht3zVdtVgjTZbxM0pHAwAufeo5L6eVQVEcTjptOeab8zNQdyZkeSUqElCxNhV4wfepRbR43zSZzzhmxj8azfOnnfImd3AwQgOBVS4XdMqyLIrn1U4NRZdTRR8zfgls40ESzxqCThQelPIjniKQyNkfNvHJz6Vj2+nxzjcxkRcYBA7+la4iSGJVXKovRj1zTv2JlFdBRvCgyMVkORtQ8L71BYFxDOZt0jqwBbOaf8AaIlCCWblj8xAzilWZmuWeDCgLtbcOG9DjtT1JJZTJ5RVGXzsbkB6ED+tRR3Ec1mZ4QXjYYkPYHoeD6U9D5zssnDIBkAY/EGlW4E6uFUFVyGAHb6UgI4Hjlnw3zMRhCpypHrTgGF1Gy75IkJVWPQZHIqpLKft4W0wi8Kh28e+atXqSKYBblY5wTIYy2A+O350rjsWnbCGUJlgO9UtNusqBlpN+Qf7o+nvUoMpj3ShRKVyyg5wfrVG6kMbAoTGWbkBehx1Ip3GloX5rkNITbEmT7rM3AUetNs+dQeSS43OVx0wW/pTYraFzh96hwWwTjd60t3bqYVEUKoQeBnFK9g0Lm98EvsG5ThVbpj3pUbCI27AI54rOVpYQ0U4DRP3x0+hpXvYlWBTubaRwpqtxcpd8xUieQkrEnzAk8kd6LWVJod8fQknafvD6jtVSIpLdyu4fymfcqnpnHX6VNJujlaVFXL43OR2HakKxYYjB5z+FQZzKFZBwOM/xe1SngsRgdzVUtKGaVZNhduN3UCgCWNN7bmlYqwyqbMBSOuaNjuTwqurAuB0NOWR9yh8fN91v51C0h3DJKM7fL2zimBJ5yy+YjNtxxz3qNQYt0cOASc5PORUrbTJ8w+fHzcd6h3Su4WQAbf7p7dqBD2cbjHkJIRlSeR9cfWmtvyWChwBt3A9/UVA0Uz3M4l2hHwY3Xk8djUgmjhhUO7E9cEc0LVDtYZIyw2wSNG3gjPy9RnrQ93CkZKM8pB+6owSTU6SrKDsYg9+ecfSontgWyHbdjB47Um2gViv9q3zx2+wRmRSQ7MCMj+H6mpo0QR78E7uCAfu1DfWzPAkaLDvDB0cryrDuauEvvbaFUYzu9+9CYNLoRh0nQBSyvnFLcYCrEoJ56E9qpwuzarJYzQMmIxLBOgO2Ve4J9QauzjeQoI8wEdDyB609RNWJYzkEMyMQccdqqSRR2yboiRufLL6+uKndgmdi5Zuy9/eo2YMymbr/CuOM+tHW6ENuSj8YUjOcHtUKjMikHBByCODTWDCRpBgqfvEevrViKMNgqQQeQeuaS7gxRGA3mLjcOpqQPIxRgoC5wWzzQoxlSRn070wBhKUJx/y0H+FV5CJIs7SpPQn/wDVTJVOGKlunTtSTSmI8gBSeWAyKbJITMiLnBPT1pMaGrGGMeXK4fdgHr9RVonkk4zUMLh13hNvJGDT25+nbmqEOAXr3qtJsMyIhAJ4x2FLJchRtUHJOOf50sAKyyZ+Vjjg9KW7GtAIUyBMkkdR0FSJGmc7FB9ajZVyrE4GeTRBI8kjEOGCnlfUetNCZOUQkH8iO1Mjw0rNjJXg0TOV6cDuQKWAbU2kcDkn1pAMMaGDY5XbycA9DTGSNlaaGOLfNhHcryQKRokEqvIQzcnjoDUoILFUYHaORU7lbEaAIx3sHKjau79aSGRRjaAyt3U5C+1SOQjMxXJK4x/Oo5JI98iBtoVQ2AMEUAE1ysV3bwIuTIcZPH4Zq0AQ7A/nniqsyLdW/lyPtYYbK9asqVKDa2VwOeuadwaKGov9knjlGx1c7XVhnFVLvToZY2lgk245cYzgnpitWZfMdUAUqDvbjv2pYspGhmKGRuCQMBqXXQtTaRmWKLFFGHtIyW9+nvWmsKkncqkNxjHT3qGSB1b5CgGeB6e1PimDzPC5KyrwVIxgUlruJtifYYGjAdctjBI4/GiKzhiRvNVGQcgn+tTTyeSm9iuzp7/UVC0v2mGaO3jYkLuLEU9BXZNCYgNkJRV67V4zT0Yljkcqc4aqUAcrGMbgpzz2JqyH2SOshBI5Gzk0tGGpLIPMjKtz9Kr3hHkiQby24A46++aczqBlW3HOOKiLNK2Q7q33QiDIH1oYLcgijwrbU4ccBeTirNk65kjThGAIVlOT7g01Y5ovOYFCDgAqeR9aeZdjhXlXaRjKtkAn0pIpiShiQkDZfO088r/9ani3iE5ABGACB/e9aeFWULJt2dQT3+hpzoTGQMnjHvQxJjUjbLZkzzjp29KcPLibYzAMc7SxzkelQW8zqrRNgTKcYZT1qeaLfJHIQNyjlcdvUH2piZBqDr9ik2v85wDjsueadayhrnaIyoKkhgc8Vax84ynLAgYHWsS3maG7B+58xypG3r/npS66lJXRrXC5aA4BwSDzyAR2qD7agnWIK4TBBDZwMd6mt28+43Jux/dzkCkMQuZjIpOOU3ZGAw7Gi9gSIbmeRz5DLHtdsBhyR64FUpBFNcLFCPlJwGJ6e9W4Csl7EQpadNx3gfKQOnFVNpkvGQfups7iDxg+1Ba8jbVSAFbBwMYA6VXlDShUDZC/MSOvX0qR2nVDul82UcjKgZHrRHHsUliWY8nHancyI5Q06g27vCRlSXHUelMEMrBEZsSr+IwPerLMAwXPJHU96jkYrIu3JJ+UdgKBjbYIFaUqcknDMeAvt7USlHXc+WQOPvHpTgww8c8iqVOAcYzVXYyMUmBPmEHP970Pt9KLhYnZXlGEfbtbJdecj396kA2j5cnPVs80IMbt5+8Og7Uvck4xVIli9DxUbqrA5VeeCxFD9VBwM9Bmo5XEflKkbncewzS0BEojRWLhcHoTTsj1596ayg5Bwcdu1LkEZbA96BA+SvykA55z6VHITEjMWBTPTGSPpTm+b5c44zmmMoMqKTtOMkk8f/rouNCSRsrRMryhFOSM9PwoAi3/ACjPqxPamTvudWSQqMen86bO0cCqytulPCqR1+tCHYnhP3sYBB2g/wB6olRowzH7m8lgTk5P9KeN3lRAp85HI/un1pkkYZwWYg7SGHrQxISIosgiQEEE844pvkIgLFSMcKEPJpplMMWSVYgAAd8f41PGhjA+YgjnHXBo8wIs7CgRDvPVzyR7VYVQo5JJz9496jiVlkdvMLKx7jn86ieQiQIZBjG75hii/cLEsmWO0cYO7OMhqejh138ADOQfWokyI96PuzyAelVnl2MQ4fLHcMLnNF+gWLsWNhxnBOTntRgEHvUQDrgqucDk5xTGkZk+cHb0OO1DaBIkUxmYgj5McH3ps8jeXtjckg8HFLhYIN2MY5yOc1C0kksgy4AJwAOKL20QJE7BpFDBfmxjaehqMsLeVSMEufmI7e1IrtIxXkk9McYpjRNKSSwU+9F7O4WL4XLllfJxjA6CkChAzAFuOQO9VFt8yIxkYBR0Xv8AWliZFmeNN+frwad+wrEh2FjCuBIR90elIIlIwgPIGSTgsfrVC+nEMzLGSJB1c/w+opi6hd20QEUcNxEv8JGGI+tKxfKzYBLLkqUOOh/nSFQ8ZIOUI71E7i5t4pInxxkxg8j2+opVePyXViQFG0+pJ9KW4hzQqBuUMEEfATqf8ar2kjsFe0G6KUBhvGADSwefaqjSuVU9w2duKisktbFpJzcSqlxy8X3lDZ4YdxmjpoUloWp+IiZOFbqEOD+BpsnADKCYwMqD0FMiIu5We4VhCP8AVhvlx9RUpAjOPNMnmNgIxHFAiXeHjBKlVPLZ6VXeSGWJvnB2sFyRypq2B8u3aCo4IqvcqsUZYfdH3lAzmgSF2/v4wyjK9CwyM+1PTY0jl2A6j0qKNFhlWMEkgkhicnHrU0QMcbrPh3BycjGAelIZVsTJuIQoAOW5ycehq0yupZomAmbsRw1NhWTaDGFDnoMdf8ahglR/NkO55EY9e3bAoGSqWXLNH1J2BaILkOxRk2zA4wDwTSwyj5Y2bcwXll6ZqSVA20NtVgc5A5zRYQsXmFAJQvmHrjpUdyIlhdXjXB+UbB0NQz4EUtvM+4OMKduWLdqtQqgVIwQTtHB9fegNirNLKIYnjt0kZsKQDzn1xVgmRlCSALnrjv7VDCwWbCo5YsSV/ujuRQt1mVUuYzAXOIZhzG2OgJ7MaFcdrkpbY1xtIJGAWc9RUlykqxsEJ8s4ZsHLDHXHrUb5JRcBg5xjtn3pyiOGN4/Mby2Q78nv7elHQOoyyZzCjzSyKZM4L9VHbHtWXcSxzajGhBeINja3Vm+vvWlaypHbw+ZIpQAjcedtUbplmvHuoRiM4UOwwCfUe9D7lQNQC3kQbUwoO3glSh9KzruwSJSYZMgNu2PnDnPr60yxvCwRBb4DvgsWzxWjFPvUr80pdsbVToBR6CasBju9qZkRCqjbsXJjPofWqMzqsyi5bfcL3A5ANaKzFf3flP5390jrTzbxP80kYZ8gknv7fSla2wJ9yGCYSOJCxdgfL3Y4AqdSWAbDID0U8EUhEZQxKEVWbcwXtipBzjpgetUSxABhTtHtntVe4VZJI0ZT5gYdDxU0jFV+QfOeEHvUcUhjgUNHmTABB6n3pCRHPErmTKEKMZJbqD3qZifNG0ZQDPJyKjG5rg7OPlwS3VqbEz7yhKEoNpPXr6UXHYsls5Jzz1po6/L16daZuJcnGGA5Oc/nUTpIQd5VlJA8sDG4fX1p3FYfeKWtZNoG9BuU56Y9TWXpwnmZ3BlVgwaFjk8//qrVjkjaNjgrEwKMrD7vY1hpJcwR+Ukg2wHCOMjHv+VLqUtjbEpJEjeXk8bV4x/jSSvsBVFDdcnPFRwXCGRYSBgKOg/i+tSynawHCgj5uMZHpmqJtqRwTI7sqMruFBO09KRE3DLyLKOgZu1PUxsENuEwg4xwB7VWFx5QSNY/3jE7cjhvcUuoFieUwooRN8zcIo6fWo7a3ZC8k20yk5DdcGpYo2jzI3zytjLensKdIMoyjIBB5BxigPJFbdud/mKFMr6bj7U26lkhs2cRmSXgKO9SbZARhhkfdPf8aWRnMTjCmZeSM8GjoAghC2yoqkMwDHcckE9qRpGj+8jMnqvapw29A/XcoPSmNx7Zos1sAkMglXcoxz0qRhnghfypFB9PrTicKe39KBFdyGulAJGxckdqmU8YzUcAAMoDhsN25xT16ZxQthsdkEkY5AyMVBu37HlUhiNox0x70TSspQIBuJ61EZRPL5S7kHRwwwfrRuFiyrEqyuo3dCO1RNCUKbMYHJpYwil4ySZB/EecjsaUSQxFQZFyeDzzRa4bCRxLsDA7Zc5BH+FOTCxjzyvmA8ntmieRljJjUFh69xSpLGyryNxGcYo9AEMmT0C+hJ601dqygoPViMdTipFjUHgcZzjFSADcDgA49adtbiMfUIZGmJMeS5ypPeoXjnjcOYWTPqvFbS5UhTjaemetOOSGjbPzcA9cilqaKfQz7EuZHZiE3jrIMZHtV0eWobz3jUseGByCPUVWe2lkPlmbfGuWwV/QVHdQR29u3mJmBvlRAx+U/wCFCDRsh1K5FzaKqHaM/wAXVqo2CrNqUBupm8vOW5+7j1pLK2FzfJCssgCEfM3PHrWrBp8cZkQyuUkbG/AJzTk+hekVYW4umuXI8t/LzwV54FT24ZZhMql0K7FymDiqq2moRhlVlUJwrDHI9auRSylFEu2F2IjCnqTj7wqfJEMsKykZXKnOMGmtOqsAUkZG7qOhqO42tt/eY2EAv1APcY9aeJRIzAbyvUfL1HrTIsMcM6RNjDBvukckUE+WrI3MgGSp6kfWpJkMsTgfOSMqR1qDcRceT5e+RR0b0x60hosNLEAAHyGHBBx+VQQmVJ0DKRDKPvZAMZHqe4NKodk+cKoUYXv+NNlR2ZgGZomIwNvy5x6UMaJkMe47ggyc5HG6q8F06RYcJuLHvytP8orFtZ2ZUx93qv0+lK2AHL5Ykja4/iNHoA9ohvMiNgg5LDnNEe1rskuQroN2Rg57CoIYMTloTwDk88Z9CKmkknhmdlAZHXOSMkHpkelIBbicopwoR8YRs5B560+4OLcKTGS5xzyBTYSJcAxBY2ycOOSR2+lMmWK3mV9o8vbzGTghvX/61MEF4HlijkYHyY852jgZ6k+1SxBXSMwuruMbw3Rh6/SkJjbYof5T0Q9CfSpo4I4vlEYUk5O3+X0oEzPurg2N/wCcER4X6kjI3emO1TQTvdIEcK0TEE4PGfpSa1C0unlo1BlX7uBge9crEd8eA7FOwzQlfc1jHmVzqVsSzMUm8tQeFK5z7mh1ntFUKuQxz5iev061Qg1ea2EaSxRyg9PM4bH1qeLVhJJGJY3xG2QI+pz2PtQ49g5ZdSxJ9puEjZYyOdyHcMnH61fgnMoJlVYXHLAHODVVzbyDMcciMDklTgn1FUPMaSDDhg2cgE/1o2J5blxp0MiyoSWBJHy4wvr/APWq5GzvvyoUcbSR1FZ2ns/nggByowWfge1ah3FQWHzegPegmSsQX8qQQqXV2DttxH978KdcBpFWOMgM3Rz/AAjHWq90omEnnNHGY/liIGSf/r1LGontfKPygLhkU8/j7Utw2KFus0UX2EqGcvuaVmJKircRUM+T8ydT03Dtipo40RAiYYDjJ5NI+HhKhNoU5BxzRqFx6FXyVIYgcjvVLU4zJbxpFNLZzyuAs0ahjCRyCR3HarXlRcOgOTzvU+nrTLfersuSS2WD9h7fWmCMyB9Q+3C3mjknS6BcyqAEBHcdxn+7UnlgtmZMuGOSe+PanTwXAu8xE5X5gwbbg+n41JZyzNKyXACkAkDHIP8AWpvzFydye2OIhhWDN8xB45qpeyFLqPzB+5Y859PpV1RsaNXcfOmfr9Kp6haS3GWQlZmGShPylR6e9U+hEdxVcWtyoQh0k5dAc49OauqACZmPz4wG2/cHoKpW1rJaQo8jI8jfeXHCjHUe9TCUbZDklRgDA6/WmJokWTDOGyv93PQihvndYhuBHzFscD2pk/7xIyjDA7ZqsZLhHK+UHYnG4HrSuFi0jIDkTKcHGOoBqKSIsxUSnD8AheKWKEFD5WUB6kkHmn+UxIYyMWBGPQ0bhsJG0hZgADj/ADxSrMrbeo3HAz1NEm53O0Y28/WmTCNoFIKBSeD/ADx70JsLErZ3AEkew71V1C+FpCjmF5S7hBtOMZ7kmkmBhkTZIVt+pGctkd80xbOO/wBLMN4rlJiXZc8r6YNG+w0urLUDh3R4NvkyruVhx+dOhcySsPlyvGAevvUXkRLHCka4SFAiDvxTZLZJCCGZWHRlPINN6Ej183zJR6t1I4UU4xLvLuxdsYyRimWyTAyedJuJxnIp6FlVtzghckcdBS0SGKqxxKcdz35NNiUK7/LhyOCVzxUcEW6ISRybmkGd7DqKmLFVUHHPAp2EIgZUEZkwx5DelJaIqB+jfNweuPUUjqVcDILAZY47UfvtoaNUCE5wO9F1uwsTOC+RuIHfHeo5ZfJQJGpDHhT6U5CzDLIUP909qiuXKAE/gaH2BEx3EsylTnlVb+H8aUuDlQwDnnANNVlkkHGGA4xTRHuHm+WEwDn1x60Aixgccdvz9zQFVxsdVZSeh5zUHmKsCFeV4B29vwqTdtkQFTkAkEdBR5AUtPe1jvJYkBEshOw9Rgdj6VcYlAyptG7kbh3qultFb3srx/KXA4Iz78VLJ5hVHTcHP3g38qCnqyOaV0PlpEXTgO2eB9DU0scdxcA7jiLG0DsaRMBQhOW4yM5wPWlkQNIjH5QMggHrQIkfcWVo2VWyeCOG9zUMkjNcKqMm5VIZge3pTUnVZwjKp5wWHP5CqlppTW83mTSqyZJGOrZpFRS6l0M2BMjhUjO3gYBB9aWR8pvSN9wPyMO49qSNWDLGclf4h1LelWGyHyxAI7GgkqSyrHAZJsxpn53PJz2GPrU0UJN0ZstgKFCZ4DY5NQ3N4IkYwqDLjCh1yGJ7is2zmuI5VillYDJ3Nv5LGjYdrmpcGNb2MSHcr/JsXsfeprhV2svOWHAB7isyFrdruGOSch/NKAMeRnoc+9WNf1WHRbI3FxGzg5G0dSaFq7Iai27IdDPJ5whjUSFPmAB5A9fpU8E0tw3lJEV/iLucEj6V5nqGsTvMsnmuj4ysKfKEXvk1r+HNRlvLh7RzJIcb1JfBA9M+lU4tK5vLDuK5jubgEQsy5LA9SOfwqu1rFe25eUyAklixbOCD6elSq5eGREDq6DALfwt71BatJPabXLmNAUkGMfN61DMEixEp8orG7AFciTAbv0UVOdpjC7n6YyetQ2ipHBEqA5C9XP8AKpmOMZHPWmTuKd4kV1JyrZAzwRWZqWkxz3oubcIJJM7lzgE9jWoOScHjGSaqWUxvTJcGMrEPkiGfvD+9SfkVFtbGXcaNdnAieF8DBLHj86lhsrwJKHjiBXAJXoR61sAgjAOccHNGTvJ6q3BH0oK9ozKCTPiMf6x+AAccU9rNruWRbjMRj+QInIHuT6VpOQ2Cm0beBgfpTUG+AKVKeq5waBczGwwhITEr9s5HfFRy3G14Eh3vJK2Fx6U4zRRFmUbmTAUA560gdEEKMAsp5Uj7uc84NBIskq7LhIo2IB2lwM5PfA9qZYt5jSmSNUYYC49PWnFljjIh27lP3umCev1pUMkUbAuGeMBWyOCOxFGzBkyKqqxAwT1oBAY9Qf501WXG4EbTzyeKbM+0hlbL8FVH602xWImu7eMPmQqwfARhg5+npSy75JQI1A/vZ7VnXMpguMKyCQyF89WB+taEQ+WMiRZMj5nBzk1KdymrDcSwyFmIkiTn73T86LdWLPcH/VPhjjnH+FSj5pFR9uSv3cZrNffcCZLCIhEO1i/yge3vTAtGVRNH5YEjEkIOtWyNoZ3yu7v6VXjsorSVPIXeFUqwY9fcelKVWWEsnLEEbWbO36U72QmhZolkkifazYyCu7G4etNyLa2aaYM4UbmEa9foKfBloyxXaSAME+lSplQMHJ6ZBpCIrdo5lS5iH3snOME1Wvt8XlMELK8oQ7TyoPeru4semAKrXAmeWJY5Qgdww9eOtN9AJ8IjFY1AAp2cjk96jkcIWZ+B0JpWI6HkHuKb2FYrEyG8Ur8tqwILfxKfUU0ROkKfL5gV8oAPU80Xdu5YNbkrKBtDZ61PEzYLMpyoA3D+I9xUopohmmRpTEYVkRh8w9/TNWVOduUABGAAcgVjQ3QeUoybW5IBHTmp4n8o7NzKrHOAelUNxNFyFOGIH9aZI3l7TtDAnB56VXVRMWR2Ysp61ZLoBmQrketBFgdWY5WQDb8u0d6RkjVd74XAySf5VWe6ODsKq361RCfaGRZJmYZ6dqXkUl3LUepLJdrHHGPLHHB6/h2rQb5Sd23FURYxeYhLBGxgY4JqeUKyeU75C4yf8abegmlfQVXjY7lYbhwAT1ojl/fFMNg9B/dpsaKrOn3oidwyPu1IWVWXLc+1CExzugOWYDHBpx2sBwHHUGopUEm0cBAcnA5PtU3AHy8AdvSjoAcHcGCpsPB9RTcGZR8+wBuT601oQ6KE+XHPPPHpipfvBgoCKRgcUrgRbdjAyqMYyWHb3phQ4DwTgspztXkEelNaaQqFliVZGIVkJ4I9alZw6k2wwx7qOg96LjEhWTzBMwYAjO09amwCmWHyk880biZEDEbwvPvTckDywj4lBwfQUXsG40QxO0bxAgJkED3qQDnLYIXj04piN+94DeWw2hsc5HSnOUN1GrvkFThfRvc9qLhYbAhWQbQPlyoyMZJqRY8jMg2t6A8Clk3O5XaMEbi3vUas2Ars6qB8xA6egzRsAy5RshIsDHJDGpZgkcQdhuHUccfWljxJGSybWJ/H8aZNCTBIkTiNmPGT8uP7v40h7le/iXFsIFyjtkvn8qoeUkl2Lchtwz8w7EHvV/T4DLbCCZ3Uo3Q84PbHtTdNkkEsjeQ5kOVl45/zxSZRRu9MuhLFJFFE8YcFQpywOelYHjm6m1O9EUrCKCD7sYHLN1JPtXVQX6ytOnly4Lboy/GFHWuW8VQyG4eRMqSCMjnIq4aSsdGHS5rs4yf58uxIb+EDufeuw8F2mxDcXEZeNWV2bBIJHAGfTNYFtp73kwiiI7O5HULXpunrHBoKpaKY0X5cE43H3FVUlpyo3xNT3eUu+dks7AHdjIzjaf61FdSLscEFUI2jnkn6VLG6lFBRQvGw9j9akYKVCNFuQnBwM/jWR59yuiNlk2gKNoDs/GcdqmhjaJ5FJJjOMOT37/SmLBuYFzwh4UDv71KZgjLGQWb17AepoQMqahJwYC48wjIROCVPrWT9pubK7jiW6AH3VjP3VPuKvXJjW7DWytPfsDuC8nb2JogEV7p5tby1Kufm88AZBzwW7ihaalqy3LL3biLzGETErvLBsD8u1LFcyS2zygJErnenO5mX0x61iXcMcCL5MhlL8kKMce9TWlx5rwpGGaQH5McbaL6A0jXVjZRrG8sbxkbsjqpPbFVGvi13uAcq5wseMMv0PeoBYTPIGd47OHe2Z2OWLfSrMVu1vbrIcvOn3Mnrz8xHpRcVkXljiWYeXGScEktwR7Z9aiZZXBnmjSTZkqhOMe9Pt5FuPM+zykAnOJTk5PBp87LFBvdSQMJj1NFidhpUPErqMMRjb3qLYrXmWfY+0BQTw3tUd9eRWOJJImAOAxzjGaglC3lrctbXHmCIBmiYYOfY/Sn5jSLDQLvYQxq21wdrHIz6YqS3juvNka6jjSMnCYOSo9AB2pulMJmuJUj2xkqAS3JP+e9WUdWifGXjyVyOg9qQmUpYYbaSPyEC78h8jIAx19qn3CKD5V+VOCE5B96YLtVZ4337fuh1wyk024l2oVXKq3IKjt/QUr21HYq6hcurbYSVDJy46j2p2qTTWWnhInVoJUChdvzKepbd3zVOedxcsJJhIoI2gDAA9PrUWqzSx20ayhwcEqCe3r9KF0NIxuw0/XSzmK9beo4XjhPf3roEReJACFdfl/utXnvL/wAJDr+Ga6jw44l0V47q5CsJTtiY5wMdB7VpJaXQ6lNLVGtAI5o94DYLkFd2AD3+tPURQCKKNfLVmIAHQH3qJIQsCJCWjXllTqufWmSh0kUzFZ+DuXoQe1RcxsWeIkJlfO3k46kfSqwfzpVbZIuBwrdR+NKtukjbivGcjBwcU6UNEVTIRH49x70XCxOcAHAyP0pq4xhu46U1HiRQiSlB97ax/PFSZDcrjaB19qZIzG4cioXiPmbopAr9drHvVhmGPRv1qvdRxTqpk3LLEfk45o3GUtWgYKkiqvmYyxHf61jx3riQxztt59OTXUTFvnjBy+OVHf61HPHaqqNcRRs5P93nNON1oWpW3MuG5MmwAE84yeCTU8Mc0jNvTgdDVpooIYv3camNDkYH3aSCZ2VF+QAk/M3PFF7ib7DGjiicPnzHA+YEcEVPHgLiAqTnOfb0okZ887IwO5P3gaaFXy1eWPaw4AU9aCRbhWlC5IUA/iDUUSB0wgG7OWyODU/2eLkqGUsOeaakbh+SpUUlvYBpd1cmUAFfTpSbAxYxAqzfMTjp7VZABOaa+8PuQjHcEUeoiB5ZImRWU7Ac9M5FWQwZdy9KiBklRiVKsM7R60QttARiC7enY00+jAtK2ANwwT0OMA0YzkfjUZlJZw5Ix8uD0+tPk/eDcHAC8EULQRBfXEFtHCbo7dzhYyVzk/0p/mFGRSoJYZ2qe3rSuG8kpJGJIzy26mZH2dgoIcLkFRkfQGl6DJioJfcAuMEHFAZg+XOEAyD9fWoiTuCn5G+8VPUjtipGDNuUNw+DmgAMmwgIflblcdfwqKSMSRkQru9TwC340JDwyxyHKnAJ7+wqYfcIYd+lG49hqiYPGGJAbgrnJAp1wWRwcjyyOe5OPUUkWQz+ZzhvkB7CnOA6lSCeDtYcUB1GiWONM7iVPQjmleVXVxGAxwDkjisc3VzFI0KYR0flRgkk8Y+la8SiOAxOQZ0x5g6fMf5CgbViKZzbxrIjBX6EHnK1WutWt7KBmQGRt28K/BbPerlygkt2XgOflX1rH1DSrmabdar+8RMFcjmlonqXBJ7laLXI9QuwZd2MYUEYx7fSmzxvdyCOMfMThQeoGP0rnmVo7iWO4ieKRW+ZSMbTW/pupG1dJpex+YjqRVyhZ+6dLjy+9EqrGtuu6y/0WbP75iuWkA64q3pmovPM1rZjaTnLkF2C98k10YWG4iklghjUGPeHcY6evpWfocMAvHkgUNPIMoAQOSOc1nzKzujJzutSYXU0HlwzPvGNqlVBHHP41Yi86W5aUyyLAygfLwF49O9N0qSS7sYpLtf37ZRvkAwQSCaI91mrxAAyElhv6/XFDVnZmTJD5kUkKhgTKcbCeD9aVA7XTll2NJ3I4wOMClaSGVIA00bA8kseR+HaoGiMLTSKH+YjYuflA+ho8hFOe3nj1oOhwmzaSMZ9sCtJDFbs7kom4YfqCfrSrFbzujM584gkgNz6Uya3EsEYHzgZySRkj0+tA27kVzaA2zSxxbSMfMvXGelII1tHjkk/c7zsGz+D61Wl0OG81U3QnuTsXKwlyURscE+tXY7dJo1W93yybDuXnCn1zS0AlXy7n/j4RXC89crweDTJzJJe+QroZVXeAMDr2PoakRIXMaOuUT5QRxgeprmoATqN0ZJ9y5Jz/EeeP0p+oRVy7NZ+bdoYZhDkcyEk5I7DFa0qS+fHJJGVnSPCEHcrj6etVLW4CRRrICqZ+ZBjKj396kj5tICzuzs52/7ODx+lG+gSLEqxXFsy3kStCfvFjyCBxVW3slhsrfKrPvjAkEY2kejCrTRLJlbhCY2XcwY4O71FNGyHyrfPyIArMxAOPSgQ/T1WKHaIlMO7edvLD14qnpM4mkuX2eWWcvDA4271J9PWrc0kcKnaMHlcjjHr9aqwxQTJGWcwtCgRCowWPYii+oImv4FBElunlsBmRUGTx0wKz7q+hmEbRkLEBnb3wetXZp7mwgaSRS7sDtbrhx6+1clcySSPJK2C7EsSKFG5pCNy3JeIkjyRbSqrgHH8/es6e8ku3HznYRjk5IHt6UMUePEaBmPHHr71r+HtLkuJ2nnHlwKMoSPvkH07itLKOpu7QVzNs9OuLiXZH8m8Y3TAqCfrXT6Vpi6e0CmNZJQNskh/iH+zmrkt2yQMuoMpdT82OFOehHpUb3DyCK3RZGlb77gDCgd+alybOeU3Ikg4kYRTLxIQ0ZXLEf0qRliedyR+8BCnJ5P+fWoFU/apHAZpWXZu9PeiQyK6u8ibsgBiOo71KZmSbQJJEt3eORQAx6imENDEC4Lvu2qxOcg9qbCyia4JYYkcEMx54HarTKHBDKDgbuvf1p9Lh1IpUSRo4mRGCrkMf4fUCmICyviTaEOML39M1DJMPsu8yZRVILAc59aWNZIggWaMll5bb/OgB6b/ADi0/wA5I+Udh71IokdsOoCBevU1VminRBIJvN24CjGOPaiNr1QqoMAc/NjH0oVgsWoYvJDEsTnqeuaSViEbICr/AHscioUuZEyHiBI9COabHOPMXzmZF3ZAI457Zp76C21FPzOII2VgoG+Ttg9zSW42TojdVzgheCP6VYmXbHmLYpPHH8XtTI1WPDedndwcGktwCe3ilGTGrMowMjpTkw7FnHzDAHoKewPXOMDI96iifceTgkZ2mqQmTHmkAAz0oGcelL7/AIGgQeuKCOevSgHrk80vXOeKAEwT2/Wo5YSQPLwvOfxqXoPencetFguQvATwpyoXkN/OnjO3HVWGGB9ah3OJMsWIQ857ipCxlRJUGcjgjtS8xioBhQGIXBJz3pzo6oEiY7T1HoKZIwYRhgoV+GRuhoTG+RUyCR0zyKTY0h7lGfD43IMg4/rQeoGfu/MPXio5T5ivGWxwApYfeIpmW4jdThuN3qPQUXCwtwwKKQuX4YlT0p7rKzltxXIGFzkA+4pshJkdFZA6oH2jkqPX+lOLYUuUbLY4zxQMi3RrKwErksPmQc7T/SrEL/N5fG8DcVPp7VXkC7yyZi3LtkHUH61BdmONYTI0mcna3P5ZoT7BYsyW8TuskWInRuH25JJ9akKkByY90hYEgH71Fo7yW670bIOASMZ9KRizzSjzWCYGNg53U/MB3lS/avMaXy4goHlJyM+uamjGAQPXJJPOaqwSsjOkzOJAM/Ng7galmmVYy6KWKkAYPGT6mhaCaucd49ymuwupCl4ELgdWIJ5PvVfTLm3YMtwQshA2Njv2zXT3Ph5L03QnvHM8/wB0hQQpHTn0rhjG8Fw8TgiRGKnP8DDtVxacbdjupNSjY7yG1mOn+XPPtjbO2NBnf+NEyxw2KlGCzoS/pzjtXN+H9TukxD5ymFu0g6etdT5IvlcvIotz8riHoSO2azaadmYSi4vUTw/GF0mKAHew3PjP3dxz1q00YJJnUEA7FI5xmsHxPbXNoumTWktssMd2AUlVjn+6OD2roFmEqMcDzV+ZlXgbvbPah6rmb3uTKPXuRtDCkuWUlRwcDJz61NxIoYbj5fOCeD7GmwzRTBhuJbgEY557ipiDvYM2egpGbKr2ywu00W1ZAcqDyoz2NQwODyCqqx2vjqPcVoMBtIJz35/rVRwqzxEx8YO8xjGQKNSkRnz9rsFxcq23zkPEiDvjsfanMryTxNDO8o7sw4+vFR3E7W/mCzkBWTJ4Xk57f/XpBN5cSRmV+RjYnQH0o3G0TTx3SrlZkcAndgdBUSaPay7zcw4LEEvG+NxqaWecRsQmzaAPmX5WzQRPbIXV1fGBLGRgY9RSsK5Xg0xCZBKPMQMRnOOO2asoJfItlf8A1e7segHSpJ5FjjaQksmMhQR8341BBcPIFSJRvkGGaQkBT6UXB67lhxLG07uY2RuBu52ewFQm2E8ymfEiY5HYnFI0TzLKJHClPkBX1Heoi0kkjQtM0sZCnOza2BQBNDBGGVdrE8kF/u4Ht606dZN3yuBCQGHGTn0x6VJDjapAO08jPJqTfg5LDbTt1JKc+yQPHIGCs3I6ZH1rLfSoppXaycEk8Ix4A962/nkXEyKVIwCD2pgi2SMIECAj72cH6UtVqXGTWxhw6N5E/mXSxiBThgjct9K2oIFjOUcqEO5EVsjHvTPOEdll2WSYg4z2quj3Iv43Zf3f8LbMZGO4/rVXbYSk5bl7dHPMIp4gQo3DPI/GiAr5Ss2Fj3EKD1B96gmh2zoZSzb34Xb1GO5oa2iLKXyrr0IHf0pIli3M5jmwHwCvIA561FBNFMXkRVI3bctkrnuKdPbuYFDuHUkHGPmU+1Ot7VbYSqHLifBkB7EDg+3FL1DQepjeNliA3dBu/nUFuk4nhEwVI8kFg33vY1OiBQoK5ZenrSzkmPjG7II3c07dREiqqAhFVVzkgd6jLrEsjA4ZvmVT1AoWUvI0DqoYjqD1Ht71IqKo2qMgrs+bnin6CI4nHkKSxBdufr9KP9YzboyCDnIPDVC00du0cf3pnXjH8SjrVoZ2qW4yMheuKFqBGY42JMiqxIxlhUflqpIhdIyg+83I/KpWAJHGcdKYsO5y8uTk8A/1oeoIit4FdXMoyM/Ljj8af9kVWLxMVbjr0q1k96j2hMkZ5OTQFyvbuImaGVzuHzc+h9Kk8tAW4G5uc1DeRiTY6YEinAbPK1Cr3SMCGBXgDI60KV99x2LTFyMuAORwDU7cEZ7/AK1VDtOcE+WCMFBzzT4IQiBSSwQ8ZppktE+D60mwMCCOD0pcE9utCgZ6ZoEO/wD1UvHB600fpS5PrTAhc+XKI+ct3xwKiyYmBy2SeR2arUjbSBLgxH8warynkJnBHIHrSKHM6lwcHfnlSOAaV3Em35Dk568Go1RnYE/IRxnqce1SeWoQ9TjnLGkAheSKHmPzMcKT0qU8xqzdl3HH8qRt5Ta2d5AwR0xTgACeAP4moAiMCeWhiYRkchx95vY+1PZmRkEiqdx7dBxTJYi4LkAyE5B7EVCHUIF8r5FOWMh6H2oAk+z+ZKflXyH6gHBxUscr75Io8PKnO3PG0d6UykIJNgHOFDEZI+lQJDmdpJZCJJBkqnynb2B9aQx0C790uZF3ZAw3BGeoFSKohcqMnzW4+oodo4YTwvyjhcY3UkjMIUaRcoT8u08qaoQskUTtulj3MB1BwRVeWBo0+eTdG3fGOfeledLIqspJD/cJ5ye9RyalC4MTQTMQfnBGAw9KTKSZFqOotaQM8YIVwVjdTn5q5ORCVEb4KuxJYnLMf8a19adZblfLTCBfkUHharBdzNInOMZx2NNbHVT91aGVZpLEcZJCv/476V11hcTQW32eJU3ghgdvLD+tc5EpSfcxwrtgj0Nb0UixENHjzYQdq9AfanNhVfNoacSR3cZW8UOsMolQP1Vx0P0FLNaHZHsfbOzfK0hGOvOarojNAlxGSpI6AcfjV9TJdT4aNdiruUcHn1NZ3uc7uihbXcts7w3CBgW4IGcD8OtawVSd6kMCA6nOQahn8nMeMB+h9/rUdtHHDPsiJQFchGOdvt9M00rEvUssdqg5yc/maqyy/vjCpwgOC/cHHIFWiDg4BJA6etV4grx5Co5YkMQeM0NAu5HHbI+Sx+fH/fQqeFUgiEaLlc9xzmpSMbdirn0qJ22xySshCAZ4OTQkFx0sjxxsRhgBlgewNMlMgZUl3ZK/Lt5Jp7pE0ToxZCwy2G5x9ar2sUcbRqNxnYEo+/qvvQBla3GIijK+6NTkhmwFb0xWjpV55mmIzq6tnGGjK5HqKmNra+ageBTJncCeQT/jVm5kkEeUO6QkIMjOKNbDbRUudRjhYiOKSTH3yMLs/Pr9KhW5FxPLLZBmijUFmA2tn+ox2qxNCjyk3CpKgyDjjORViERlQluiiNRgKo4FLV6hoiFZ40PzbIlOCoPYU4EAMytG4BzgHnmllijIKtED36dKqy2+JkaKPfO3YjAHHY0XtuLcthl59e9DKTwoHXis661ZLVkikt2kuAoLqHGBn+tSNqKgp9mjMsJJJcHlT/dI7U90HKx8X+jQMFjXOSST3Jqv5tzGskl0jIMbFAbc2P6VJHDJIWKy7A2GIByevareHUu7BJNykEHq30pD2I9Pl82Fz8wkXjcT94diKkuIw6DC/MpDgf3iOxqP7IuyNSTuA5KHGfSm7lkdZVkL7flweRkdqokQvJLqQY/LEikbcc5NWAF6A1BLOxmDpFvRFw3Ygk+lSpIjjKHd82089KFsDH8Dv+VQsSXMZAJC/KB1NOnmWKKRu6jOKYymQAysqq6Ahl/l9aW4EXlfPGVY70bkEcmnTTXDODDbhlfoxcAKPX606RNrkSKXBXLJ/e9hTYZWRY1jibHsM7fTmgBkWLyDbMmFX5WUjBxn+tWwMYAGPYenpUYQRzb1WTc6/Mh6A06F/Ni3LgHJGM9xVITI5mcYRQF3cEnpmpY5FfKgjcpKn3qC5ErCOSAq6I/Q+vv603CTXvyAoFXdgD5WNJMGiy3yklmwe4pJflGUUsfSo5PnZUdyoBOGHPIqrdXN1bzMIHjjj/iyN+f8KLhYs7EZN38TDkg1WUBWOEfHb2NNtI7qNHN0QNhyAq4B98dqtxA7xIpKkrgg8jFFtRjFDyTkqQXVc5PBPtT7SR5QxkUKQcEd1NSFec9T2PtULK/mB0weRuU96a00JLGecH/9dG7ac5qNJAqM7YBGeBSK+9AXjxjnP+FFwsTIysoI5FOPXH41EoGQQcj1qQEN93k+1UIeBnPGajZEIRnAHp7GpiDgbTjnvTNnCrgeUeo9PekBGUy20Fgc5JH8qUwjfjexU9VNOG915BAU8DvQUSTDDJGO3pQMJvlTJOAOq5+8KjLjYfk4Ax83pUioiE5wFPA3Hv8AjTmw2VZcgnn3FAEalvkAjyjDjHTHb6U148AjBJyCBUixkTAiR8FSNpPWmqWjdjIWcbcgUADiPJBQiQ/dJ7mnNsSNmZSdo3cdR7VFJJsVSSYwTkBhnA+tSTF/lK4MaEbmHNIZErmXBkIyAMlOStWJY33lg4YHnb/dPtVWxCiWVAzOrksrkYJ9qtxpGzvtQqRwRnpQgZi6xLLcPEM+Xt3DaByvvzTWknKhGCyTom3J7jtk+tWNWhKGK5mkyjSbAc/MadKg2IYlYKegHb2qWjWL0Mu8tiAzndvHORyPwqgJhb+YrHduBB+lbXnuzeW6qYyNq5PK81SntFQMjbXjY/eXj8jTi+jNYysYkIW4cxnO1hgjOMVJG72xKykzIOFIOGB9/WqurQG3+5kpyMk1Ui1BwcPGWbp8wrZq60NuVNXLtpJeyyti6kS23f6oHBJrfinmtwrO5XnCorYZs+tc2jxTruEpSTHOK1vC18s+u21vqIXdzH8304Pt25qZXevYzqQSVzrrdnefdtJgdcbto64pmr3IsbM3S7VkJxjP3/pQUk0+eSNmDW7t/GfuH61538Tdblku0tVmxGrYhVFwFHdvcms1HmaijGnBzlYuat8QpIpRBbhVkUfvDEOD9apWvjMlFkgtmaRH4jB6jv8AjXB+XKSDGAM9Wzzn1pbQyJdRZPzBgMDv610RpQT2PTeFgon0KmoWl1bRXNpMnlzJuC9Shx0PoRUcsTLGqxgzO393uf5VzHgO9NtbXUE2JUncPt6EkCuujYPF9oVirDKlM4/SueWjseU48rsCQFCnmYDt/D6D+RqOc/Z9p+4Ixtyo4OR1rIuH/szV21MzSvaXrrHJbklzDJwoYDsp710VzAHikhlYgEbcoeQfWhx0uv67/cDViIbZbaN96vhcqwPfufrTpCVI3yLj7yjuajR444FSZVSMDapxgMR7djWdEkjyR3cVuJFiO44fGD0/H6Um0tCUrkqXM2MS2YhjPUmUM3/fI7VKTGuzfvSLqSucrxwfpVee7tI55nkQi4HCxY+bGOp7VWurr7aDlPstuUO5nPzEUO+9ilC7JP7eTeYreHft5VmPUe9adtKl9ZmXaY0kUqTnp6kVwjNJanzEHUEbnHrXYWt/HdR2yWjiJEVd47kjriqkkkaVIcqTRHb6NZW8igxs6gfvS7nBPQEelEdo1umVeEDftUDk49SavzeaExGkZII4Y9aiupiDGqQOBIpJIAYH2HpU77mV2RXMe0mQfNOh4GdvNEcs6pLMWX96QR/sD1pzFykjREpIY8qrjlj7UmyeKBi0UZLr+8I6gY/nQImTzfs6NDLAQedxyQPeqttGSvzMA33iVPAGeRirNlGsNssYj2MMFgec57+9Na2VrpzlzDIMlAcYb2PpTasJERLC8aSPfKWOC3RQvpikkm4C2xAVzg4X5gO5p32XCiOd28vcSCDjB9M9xSGV4SZJHTYh6beWHrS6DFAM7K1uYmI4OTgY9frTy4it1V0LQAEb26/jWTpup2wnuA6lHkBHHTFbUdxE6r5bgkDlMZ/SqcWhNNbjUYJCrZLEqSrr1PsKYfNR4izeW7jIJ5yPf3pquElMKPGN54jQZJ+voBVkKoBKqRzzn1pb6iKsqXfmBouTnAycfXI9KrFbszsksEcZOSZQfkYDsPetUqDj0PSqmo7I4klkTc8bgxn8aLWBMktlijQIsW2Qgk5Od1CSKqx5Cxqwxgj7p96jVGV/NQ+W5yvTg1K/zsq7ldWXG0L973zTv1CxFL+6md1BkcgZPUD2qCOYNJmdVQM2Q3cY9vQVZit4XUPG78ZUqpwAaZNbstwHt2DMw+eN+ePVT/SkroNyZZGmdiSGGfvAcMPWmlisyiTK7yQuelMjN1HtSG3R4ScnLYI9Rio5UmnaN5UUwq25VB+YU7q6sFi4wDcj7p9KYF9vzpBMTNJn5UUZ2kdDTjKo+XJ3jnGPyp6CsMKb5VBHDArnPenCTaVEg2MDt9j70jEuyfKRtOTzVS63TS7XPKkZI9KXkFi0u3dI4QggcEHg09I3QEK3P3hUKRYlPzEpjAQnj61NHuUcgM46+1MC1gZ4PHXFREiJ22KGYnpmpWYAjceSeMDpUKKivuIZ3ByeKbJHsjb1IwidSO+aa6v5qhDhP7vb3p4Kq4Q4wcmlTJbgMNo4z3FTYorX89pbWEt1fSLHaQAyvKylggHc4BOKn2vsXLADgqVGOKVJcSFlcqMYC9wfX2pzHGcnrxTEQOsrSIuduTyR0xUpUMoDAEZyAaHUtHhiUPXPXFOQho1JwN3IFIZGxDqfMjHy8YxnPNMWOPDxMy7A27AbGR2BqwcHILbcDr6VWJVl8v8A1jkjIAxkd8n1oAkn3+ZHFGhWUANlTgBfajynfnajEHcSWxk1HvijjcHcnmc70yxQehq4MhEyc8cH2osDZl6tEXWFtrBN+OBkIcelVbmeSKJUA3ZOPQD1rYuYFlicNIYV5YN1x9a5mGd5UKz5YZxx/OixrB3HG6AuQQVBI5JFT2wMszeaqsnUY9O4NVZIkZiVdflTbsxT7N8yGGGeNdg+cnIweuKTWmhZDewRzBmWPjPyjPB+grmr6y8snLNE5bjn9K6wvFE5M0gT6/54pbXTNK1uExSNtvmY/OxwR7jsaaly69DWNRxRwmwmTaQN4OTmrykyoGb93KowHXvS+ItFl04PhnJU9R1xWXb3rw22c/OjZKHkmtviV0zpS50eg+FNXjS2e01MYLHKuTlRxyDXL/EK1gvLpZrPFxFDjDDgY9PwpmmXMzR4liIDcliOKv3CMkYLmNwRkrjkis7WnzIxVP2ctDzy9tmmOYSE2n1/T61p6Zp5R45lj3KoGM+tdHJYW4eKRYYwWwZCvJQd8V1kXhyx068s2N+JLeRg+yQAMBjrn0qnUVrGlXEaWRT8LWUxEjMgjAAJbqw9hXUrFE7qDGdwwCM9fxqG5jgt5WPMSSAqpQjLegqxA6xR+W0iBiM7nbPPtWV76nBNtsx7mEWetpv814mAZGB754Ga1GuljSVr5TE6nnPRvSodZdmhVWKKEfoRgkeuayNf1i1S0EUMzSykAkkZAHpn1pK72KjDnaMzXdYa7DRREqgPTPOfp3q1pGn3N2Gy8kXRmYNgKPT3NYdtLaq/mSBmkyGJzg/Suv0jV2K+RPFHGqABSD0+tX8KsjepHlWiJI7UaUpuEjjnVmw7MfmyenWqetaiWkmFxEhJQbFI5QCpdRvLLzFhuLoOFO7Zj5SawtQVNRkMscoTrgr92oSu7sinFt3Yt5cRS2qGNSynAJ7r9auiI2sCzwyjyujDcMLVO00UzRvFal544gDI5OOTzgVUa2u7ZZYSGwx4BXeD9PetElsmavl2Ou0u/hvbMQ/JHcRc8nhh61LFf7JJQwEttH8omi6Z/wAPeuXhsbqYeUEkTHDcYCj3rrdOsBp2nPC0hmJBZmHAx6ClJJa3OapGMdh8szh4iYWw/QNwV71LtBzknbjPBqlLIGtrW4aTMDgEHGNvrV2Nt28YYkN0Pp7UkYsY0JZW2sQW7imWz+ev7lFKcnH8S4qxkqoPlttHXb1AqkgQuGZ9k7H5AvBwP50dQ3RJJD5jzoZD8yfJnovvVa3LmVkvQDIgChc/Kcd81Yu7jCjYMvnp/wDWqr5ySXLyOBuTDFR93jrmlZPQZTs9Lt0uWFySs24srdVYA9a1rEqVY7g03O7j5sZ4qWUxSp82OThQByB/hSfM4O6NTjo4PJNVr1E5XGtCA6yLkHIHQfzqbGd24ENnBB7VTcPKrBwMDoAcc0X93/Z9vJdXLSNbqVRUVdzMx4xQuyFZstqjY/dqSO3tUHnxI+2Y5l3YwBkVlxQ3F9dR3eq3BihUh7eyRSpQjoW9SetWI5Tc3AWT925YnA70PeyKcbElzcNDGHuTiJphH8q5IzVpY0F0zqegAAFORyylSAccHA6+9Cyp5jcncx5CjNFrEXHcBd3Cr1zjimMJAwVAjKwJG7r+FVppZi6rJF5YB4fsR6Ux7yK3nMMcMzOefmIG3Pp7UJ3HYuKCuSwOcc4pocm4VFVW4JJznFRJdGVHSNVEqjlS3amyqEkWWBZAO+BnBoEWXVWTM2MjgmqpjDMwjRwE/iJ4IqySkrlXTleQKjW4WSY7QwK8uv8AjRbUExQVWJ3U5AH4io4l2RiNirM5O4j7w9jUrlZT5a8L1Zx29qin2AZLKJnAA/26aWo7jbiY2l1ZxrEr+e4jyT90dyKveWquWQe1Q3MCST2sz7g1sSyKOhJGM09JeSJGw5PyjHQetNbeYpW6EnLN8nQjHPekjZciNTwBSjbtAVsbePWoY2EY2yna27OR3o2ETjkjIy3dT3H1pqqwlb5cqQSG7A+lPD8FsZPYL1xTSSYztYJzyw9P8aQCAeUoL/Mv8RxVeG784uSPLYNgQkZOPUmrMj7XAZSyjtjljTBEsZMm3LA498UDJOTEOzsOjdveiNWQ4aUlMfKMDI+tMSViUDRbnbIIU8D3+lKkhZkHC5JAz1osAXKebD5S5+c87epH1qF38kxb1cgPkuOrcYqy0ZyrqWJTr6VWurkG2kjUNMy/NlV+UGgFroIsiSTMmGEABDNjn8Kl0+ZJo5HgUxxsxChuuB3xWfZjzY4xJMYlJLHnjPpU+kzlbQRv5YPmNgYxtB/pSLkjSJxz7VmQWNrO80tzD5gLkKu4rhffFXrgSqqiD58/fB649qqSC4t5FWFml3fdxz06jFDJV+gltpFrBGwAkbcTgluMdhVHWrODT4Iri0V1VmKurNkDjORWjai6aSW5D8MuHVlwiY9K5XxTqoubbawkxCDggYVnPUgfShK7sa04uUrGNqd7LNI0kaoqYwQTyaq2msBJAI3KkevGBVG4uEl8pAxZCRnB5FZt8ypM0Z+eMdGxg1so9D1I0k1Y7XUL157czMQ4YDOea5y4tI5rkGPjIDH096qQXchxCrNtAx61JLcy26g8l1P5j6UowcdEKMeXQYZNQ07UTdzSbrMJsSAdxXfadN9psgzFUBX5QRlselcxo01tdb3nVcPwzHnHtWvpkgsWba3mRkHaW9KmSurNaozqJJ6EVzbyRszW8h2k4w1RW1xNFMkUqsUY43Hnv0+lXpiJ7cLn7xzkGp4YUjmiiWNWL45PYmnfuZSmupdNtPIgPlp5ZHBLZwPWnXDFisc8bqU4yDkEetWIbLFw0cLtC4PJzx/+qrE1hclSB5b7M/xDp61jfzM7pmY94skoVQGAGA0jE/hVK7hVtw82Eg8/Kvb0+tWLiGVG8vyHiByBhfvVR1Jpra3RDGo3rk8fNTt2NY+Rmx2aTTZWTcD6cba1gfsySABTwBu5Jrm47iTd+7V0YHJXpmnzS3ErAyswJx36D1wK1ab0ub8t9zSeWGUoXUmPsD3ata0gjUBuAJBznoorItJJ3IMUSyQRjbyOv0rTUidWWJG2oOR3qJbGMkjS0eYRXMsKybradxG4HGT0Bz6dq6IRx2UZjSLv82FySa88icvLK0RbC44B6g10mneKJWKW2pRqWTGLgKcke49fehq/mc1WDvdHSeUvzAlsentUSEqAHYbMYBIxkUlu8skAlEnmRSsSG6lcetMvArREMococoQcip0RhZ3EltCYkiV/3anO0jPHtT41MUzZbEBwoAOQMd6qiVLeGOKaWTMZyjDoR6ZqCXxBpsMhhhEk8xJ+RBhSfc01rsPldi88kjDCFETdtPPzfUU1kWWB4VKv3JJ549DTrZ3ubdZJYzCw7YyMHpj1qORoorlIvMwfLySV6nPTIo2YgkEDRvAqlgjAv7e2aIzbteIsUW2JQRz1J9/YVHdlkZXEoKn5MKOD+NTQQJEgVd2epIPXNJANR/8ASsKoBjU9+o+lCMzXYAZVbB3qvII7Z96m8qMH5Rt4xn2/rVSQDK/OUjR/mAHLfT2o2DRjLyVpIBIsT+XL91cfNjPWprWOWGTarM0aknGdwzjg/WoobK4jlmma9zB/CoU/uxnOM06WV7c/Id6HPOPv+9NWQMmuLbz9+/8Adtn5JVOWz70JBGJPO2gzgbQzdcdwKesvyxLJxIwyRSnrnqarYi42R2+6oI46+lSkfL7jvio2J3AqOAfm4pSG8wFWIA68cGkA8nfGSqhxgnBrm5bqSSW3llCmPbgALzjPSt+4YrESh2kHisrVJFurmNQoUrGAAPXrmlpzXNIbGlAI54bedQFVQR05P1NWSAemQO1VojttFCKwGcYPUEVIkm9dwBBxnFXczYOFibeDk96hdsNhRje2OeD9abdXCrGSMgAjLD+VSWkRUOZeT0XJ6CpWuo9iWKFUb5S2OhHY1HHBulMmVTDEADmo2uvKZgNpGc5HQU9CWZwiglTknpmjfUNUO2O0WUwZQeh7+1MV1Aj8xHDv2YdqkDgMXkPz4+6DyB9KWUSPs2MBkdevFMQ7gjaM49u1NQblJcZJPQ0DcZCwYjAxj2p28BjnIAXLf0ouIk5xwQOMAntSR7TAFwSAPmOep9KatwgJ3AqMZBanKA23bJ8ucjA6/WgCKCYTKzojIVOArdcU8B1jIdslh3/lTyxOWA5Bxk96RkzITIOCvBz3oGIJhtTd0PDP0C/Wln2Rk3BCll7nuDSBw5bO1zgkIR1FIZQIvLUglwQoP8qLAJNBLdFFbbGi8sATljS24+RVJ8tlJDJjgU5XEblZTywGWHbA6GoLVmneQSJ+7xghvQ9D/WpuUR3djmUujECXnaeg9xSPO1uoWJw7b+A6DJGKEjmjdj5qmNTtBJ+974qW7lQQfvFKXG4CMEZ3H1yO1FrjuWIpd4BI2jHLdRnvVSVJm1ONYNhl2+ZkcBV/xqSAeU7xGQBHO7aP4T7e1V2F0sxuIkUqMLweWX3o3FsZ19MZnkUzy+VuJKZwG9yKwdfgmjszJG2VUZAxxj0re1m9uJJI1VIyCxyqLyfqfas6/LtZy8fulUgk+vpQnazOilpK557cTRxl2L7R22jvRbWv9qSRLG4AH3sntVWW0DTOSyqobBJ/nUaFbWVZIXPmAjkenrXVbXR6nrPWOh1Z02G2ljWGRD8uCWHJ+lNuNPkjuf8ATY8sFBCqOKlsHFzFFJkeYrAkk8n2rbkEpYyzxfebOByfYVjexy+0s7mJpFjFcDaF8vk8H1qOacQM0TMPN3ZwOxrqvJij3SiMQPsHfv61y0sCSSHa3mkk7z70RldvsJS5nqbejX8EY3zqkjkYK10EkttJIhtiAGQ5BGMY6AV52d1pcIkRA74HQVrx3c6kgMPMAy3ofYVMoa3TInT7HT3sgLSyjAdRmQFuCKht9UYx/wCrA8zgJnLH3rIi1AyBlumCFvvH1qzps9oZYt0THy+men/66nlaWpi4nW2kkTyttVpFCg4z900+/wBNgvYZPtUKyyBCqcY2HsR71zem3zwaiuwHyycENznnpXUHUI3jeSJHLDgj39BUtGUrxehxE3hzyrlVu5HicgbsjI2nvxVhvC9yiEwrG8ePlZTnI7GtnUhJIYpZsIz7V8o9QB61tlo5JNkSjYVz8vandtbmjrSikcCsc2nFUlSSNm+6HXCn6HvV+1vEjd/3asexHBBrrbtFurVoLpVkiP8ACRkn3Hoa5u50F8PNZysY4z/qiPmK+oPc0Oz+IaqKe5gTvJZ3EnyIVI4IGM5qzZvHLOpu3ZMKdz449qExdELMfNjDfL/s/wD16WGxhZyfNkB5GOvHrVO3Xc2bTRo2CXMMrR2d15Uc4Ocn5T9R2NS6jNLp8aOGCqwYK65O71HNNGmwSgC3uZohtyruOHPoawNTJPy72ZVOMFuopXUnv+BlGCbK9408kg+1TPKDzgt09K6Hw8sUu0boYW6YA5JPoa45pBGxx+8k9jyv0qSO6VGRyXzngnsa1cbqxvKndWR6bJO1rJiYbFzjJb0Hp60FF8tJY0bLnjI6g/yrJ8J3kV0FW5eN5R9xs5Gf8a6BSLgs6nzIwdoKnPzd6ytZ2ZwTi4uxh3q3Et8sSuyrFjII4rWyW+YABScDHQ0y48x5CYgp+bYBnlveq32iS3lYMpeZxsWBejN2OT0pR7CeuxeJwuTnOOg5NQvEZp43icDjBQjp71YYtGULBQ7YB54B+tVvPV77AKMVwq7OnNO+pKQkkSGOVmYlwNzDOF4PcVEivMkMmdxwQqngKf8AGpxZgyq0iggZJ2n731p06g4bIGTnb2IpWHcht5N6iHYQwGQ3ripm2kMp4b0oLBiqtgj+FgMAVBc3MKyGN3/eoMJgdCabdidx9w6lPmJwCM4qwSDnI2+lVNpNuTIGDNncD3zSLLJHY4B3urBAccsM0X6BYdqGWswEUu5PHtWGySC7JuThFAIyMf5xXQCIRkgbmYnAJ7VgaxetdwNb/cEMu7zW6kDjaPale0jSO1jViujPI5ikVWJ7DiieUxMwJPljo49fQVl6VL5qzFF3CMDe6j7vtWrbFrqFJjzHGflQjBU+p96rlewmETgqkkhAYnj5c49/rT4DKpdpSGEg4x2PpVlUVOUGM8n3qNI9rHjj27mjqQyvPap5qFH8tWP7xR/Sp5pds8UanLTHAx3FLKAuHIGBwagkUfboJCMOBwV7ChOzSAI4pRqt9KigbkjRWboR3qe3RguQOV6jPf1pJdrFRG7O4bgdh9aTy5YpGYXHDc7SvU+1CHJ3JELBcAgsB09alMeVLI5jbrzyPoad5QB+bbt6ijBCncoYY6g9femkRcIxtjbzCCcnJI6D/ClGCOMbfUelG1mVQy44+bJpAoC7UOAvy5HahAJndwOBjIB/nTYZQ0SkcZOHJ5yKc4GMEEnsB1NMyflVlZSBgD196AHq7J5HPByASPuilI3w7HHykEcDnJ6Glm5ZQScMx57A04ZXaDjOOvrQGw1f9Ht2bIcopJbruNQ26yLIrsD5LLnk9ePSppdqxuoXBKHp05/lUFp50YwZFk8shFUdhQNbFe4leOJNqD5eR6MM9KlLiZGaQiNEGdvcH0pqlYZpJIwpJJw2eKW6YzzZwwIAyexqSieBCoLMoEg6H2p6ktuDJt57nOacVxHtTKgDGTzikVAuSRyRhv8AGmSY2twStqv+irt3xK5K9M9DVW4tWmsmRH3IThjgA5Pt9a2JSRcNKkZQxgL1zn8Khu4Hnt1bygHZsl14K4/pUm0ZWPJtX0qe1nmjm+6PvCshYHEymOLapIBDfzFena9os7IXZ0EyfM/O4MO2KyYPDn2mRWuvl4+UDv8AhXRGqmrs9GGIiomdoEAlvgXfyoz3PT6V1kJUxZLszFuF9B2plhoMttlpI0VUJAjccnNTGMW0Esq58wHknpj0rKUk3oc0pcz0LOpQRSyACQxoy4XeP0rlbwTW8zSKoZBkDaeMHua059SmnmDPjCnCA9Afb2ot12yOwRSuNw5zz/WpV47lR0OfkjDOpBCKeck5JqOGUzAtOrKg6sf0/OtmKK1hDRQ2qx7mMjFe7HqTUmrpGtpuQDd0K5wPrWnN0NFK+hnrjyS8ZLFecN39qs2THcZCMk9B/ez2PpWBFOI5SJCSWPJ64NdDp+2GHdPuKSHgD+f1okrBKOhrTW7EieJsSFQQuOVNb2jSC4SGRXQGI52g8kj2rn/mdS6FnBO4nPT2qsl7Lp85ktQxkPDYPJFQk3oYyjzI67xCUSO2lk4O/wCZj1INSWs7JAHSNZE3cjOGC+o9a5u78SRzGJr20k+XAAJ4z7CtlNZ082EbLMivFwOOcHkio1Su0ZODtY2EIfD5AH8I9KbNcJAC5Yb07Z5PsKwh4msIII7eTf5xJ7YAGeD70rSLqLiRUYRJwpYfNnrVNPsQqbWrMi8UR3s0iRGPcxcovTnvU9naJdFCshGclgTjOBV+8tHkslmaHCsdpycOfw9Kbb2eBuhIyg3gE4NHTU2501oQnZDBKs6lgPu5J+X8PSueIDSlUPz43YPAAro76Xzo5pzKxfjLZHzVjW8e5N7Bd4PA65oj1bLj3OcuomjnMiqyv6jmqAeRizqFB7BuhrptQiE8/mQk+Sw5UjGD3NZk2m/NggYJ3cHrWykup0xqpIj0lim5snJ6hOma7rw/I7+XbefLGcgqE7j3rmdPTGI3iVGyMHP3sV1Nvc77hJFXyiPvSZ6joQKio7vU5a1pamxGjKQZiyKrFkOetDRxCVJMPx/EzdfwomLWrqspBgZdwIG4kVBNJuIbcGQNnI9Ki5yWJ5EBkRmO5HYBWLdKoSeW+rBwQCzBWYYxkdxVth50boI8D1P8P0okgjO4sqB9uUOcZIpa3uHkXGGXHoD+FMdd33RXnVn8UNJl8YarpVxc29vp+m2nmSXTtgNKHAcD1xuAAHJIPWqp1fxH8QgY9A87QfDD8PqUq4ubpe/lL/Cp/vfr1FUY+0XTVmz4p8dQabf/ANi6BavrfiNuBaW5+WE/3pX6KB6dfXGc1W8N+DtUOq/2/wCLdQN9rW0iGGFyttbq3BRF78dz/MZrd8OeGtI8K6aLTSrNolbLPITmSbHVnbv/AJwBVm3v5I70WPltKfKMomI4/wB2pv26FRpSlrIvidPMMUYKBeWRjytM2i4UbpNiBweOMHtzUEMMk0bz3G0tg78Z3YHaq8uqxzW6wxRFWdfmdj8ue2Peld38zWxuZPr83Sop4IJImimijeNwc8dD6g1Ts2ugjSTzpjAxlfmq1JJGqoZJFjUnGW4yaqW2pKTTKdrarYwSwWiBYmw+d3JPvVeCWVp2kb/lp/Cp6/WqM48qd1t96xMcpk9qmiuJYxny43xzlhzmhO/vM0t0NPEsF2JJhmMDBIbgD1xV3bhshwV7AdKyrS/eQeXJCWz3DcitK3jHk/uvmyMnBzVLRGckJLJIrALGGV+OvSkZvJZskEEcH1peTNvz2xg0NFv6NgipsxBG5VHMeHb06VGHBGGJ4G4k9qia3VFnVpHMjHdkf4VLA7x4i2BkK9SP50LUZcxu+6c4HPvSgHy8HhQOw7U1dpjYqfqR60qhnVdxwe49qszHbt0S+aAGI5APAPbFIq7MjAwTkepNLkMDlCAPWmlOFYSMQD2HrQA5V+bPc9aQsH54ABADEdc0g3HJ6MeMn0oiURpFCeUORk+v+FNgStz8hH3eeR/KlwCCCPl96ij4XLfMQcHmnP8AOCi9T97nGB7UgEb5mULymPmx6088KSCoJHGfWo4l8tNhzxyCO9S5BIAA9qBleRNpKgEheuBzz3rLuNyfOzyeWeUTrkg9K1dnmzM5Zwi8D396qzoftEaycKxGB1zjqfakykxNR1P7NbRC1tzJfXRVLW3POSf4nx0Ud6uea2HRthkHyEDs3fHtUJtV+1NewxKt8qeWkjHOF9Pxqe1DKnmSDdM53Fic4HpS7f1/X/DjbVtDJ1GZrLdHAJC0kgLEDLHPbH170+IXpjaSeN4WD7QpwDwOSa1Ih5TyOSrMW4YjkU2Yyt5iIE3FCQzfrTSFzdDMu3kNugYA2zgg5Xkt6/hUNnCsR+0SeeQnOVQkAevvV6OONUWSUnaCPkBzj2+lXmuFVG2tnH8Ip2Hz20OdmmuNQ1LFszGNuPmBIA/vfWq+ppc211HbvBiJlA3ckOexFdUznll3Zx91RjNQSRfaImhcBE2+Zye/t6UrFxqHE3tlJBcMt2QsrdNvI/8ArVBHJLDJhWj29Ax9PUVsavp91BOWZN6L855yCvvWbJJ55Z3jyWPfimtdzpi1IUvHIv7ss7/3tvHvVLVJg0W0KF4xye/r9anQvGHeIBWPYGqF9bq8iMxyWB6dPxp8ppFJMx1ZWXbnDA8E46dK2bbTl0ywjlN4GQ9pGySSemO1UbvQhZMs5uE3MAQpOcVHPdRxsguyGlTnC+n0ptp/C9Ddx5tjpNPSeGAzedtxyFJzuBpYr37UoKooY5HpzXK/b5jL8ztsxuC56D/Cu78CSQXlvc2rCJ7pR5sLEZHHUVEotJyepjUg4K5hMki+c7nMQQ/UfSsMXDtOZbabYE+8hFbfiK9W3aSKQiOWRv8AVj/PSuUu0+xuGYkgnoO1XBXNqUeZanU2f71RcXGX7Akckd8e1dJperxaYTKh85T8vldAvp+NcBpesoskcWX5XLEf54rTfN0PLgHuW6Ck4dGRVpX3Otk8S/a4ZIogikqUMh5Kk9xVCzvpAVRSX28A96y4ojaHEiHOMZbgg10NjaC8tYpB8piUgMeN3fp60nFJX6GLjGKsjHvXkVTJDITLuJKjoB/jVCwF3PvwW3Z+6o7/ANa6Ce2to4i43K45O7qaisJIxPE6R7RnJK8fjQpaaIfN7uhagt7iyuN1xCrKq4dB7jofeifR4I7ZpQH8lI921QMpnp9RWnDbLdENvDITvYs+ee3HejUlSGVY0kHlOucHquO1Z67nPz6mXBZ2zQMCpZtm8Z5Ix/WseaWUR4XKqeqmurhtA1kskUrpuPRTw3rVS90iRyZHCwksAcHdn1NUpWepSn3MzT9Vlyn2iZpAo2KufuiusghLYknGS6AgEdKbYrptpZxRILdURf3jOnLk9yadYziZ5IkbcsfQg547U3ZvQxnK+wXM0On28lxctJ5QZQzAZ25OAfpzXHfFjxBqeheH3stDsri81m9UxwG1iaQxL3kIAPQHj3Psa7qSOOVHimQPFIpR1PIIPFZ2m20ttbJDdKzNAfLilL7jIg6E+npSsZtc0NHZnyx4c+Fvja4vYLuHSY4TG6yBr5o9uc5G5GySPbaa+ptBXVDpUA1yOyj1BV2yCzdmiOPTcAR9OfrU17K0M0coBRWGPl5IxVX+0SUjQM7NuP73GNwxwAPWlzGdPDqlqmTT232maF3chQuBz29xU0FttLNscHJ+XPBFUoZpLm6haV/mT92AmBuPoav3CFnxufze2x8fnQlZGrM2+vGsJXwxBdfmBHIB/rXPTtIgaKNPnAxhuwrc16EfY5JjGfNTCsxbP4571ixRS3t1bw5H7xgnmf3F7minG78zVNJGpZ38qKn2ry1kK4Enc49aWSea82Lcy+ZDEc4C8fX3qSTRUs7h5DOJI2JG4rjZ9aQzN5n2eRFdiMDGAHHahpX0FoMuwvlCSI75X+XGfuAVQWeWOFlb747+uelbkNnLGpmEiNcDkqRxgetRXOmSTQm4R4zKBu8rbgH2zTXu77ApIq2ExJ2sm4kAenX0q9exiweJ3dhGTtD56HHQ1TjgcMJUJQ7ht9Qa0bmRr20aOVE37wTnuR3FDSewpWuJb36KoFz92RuH/u/X2rSZSvHXjI9656/t0gaOVAeRzz1JqXRdYEbrYagUSH/lhOeNv+yf6GnH3l5mclY2PLAOcc5zUbmQyYfHPIP+NW5ImRuRleoYdCKpzxbpFY5IPDYPIqX5AvMnYHZhgoZmycVITuJDYKnpjg1EWViQmC+PvUpGSFxuUjI+tWQTRlchfm4+UZpF3biGwGY9B0pjgmF1LMrEcMOop0ZIKqTllAGfWgBAC7bnzwen9abMmE3N83OSCeg9qfLIE/hYknG0dajWMtOzuPlONi56H3ouMV3fDtCCZMcgDg4ot7hZYEZG3lAPOHdTU/Oc81l65HGkaNt2qwIJTg5p2HHXQ0ZCX43bRnnPWldgmTI3yjnJrJgv2RFE0QmjwAp/iAq4jxscqVd2+Uhz7daVxuDRKkzPJJmJ1iXATvkeuKYbhzJ/o6oFZgp8zgkHrUscwaEtJvXb8pUjGcd6R08wSIACzH5eOF96BEuzBYDHIwwz1pqsBsQlS23OQck1EruqnzFxJHw5HIHpmmskcUayRRhAhzuzkDPWlcLFk7WyAM+opAM5wBjpxVW9upYNPe5jETEY9Tx6/wD1qq6XNAbWHLN5zEmRpXyzHPX6elFxW0uaPyybdqhdpwB0OKgu5ygwqjIOcZ6H608Eo6AlgpfAz0p0WHWRkI3btpPqKL3HsAUo6mOQYP8AfOD0pYUZZCCQxKn/AFnb2FKsakxq4DEcg1Iyh1AlO884JOADSAhkQ+SJNyl4wRtJBzu4/GuSvdNaSV4SG3g4UHj8q65rZ/s8vmMhcgFMD7hrJ1OyuHYSTSSB1wQy9qLtO5vSlbQxLa0m3KJYim3qc5H406e1jhSaUEZBwqEZ3H/61aMF/cWkTRXNr58Wf9Yowx+tc5rt4rIWEUiNu+QE4wab5pOx0RvJnOapBPDqIcyMzuScdhXN3byw6k7zKzMDtY9hW5Kl7fTxCHd5g44571U1iyNjMBcNkyk4x0Y1vFu9up6NNxjpIjs7tlnEahd0in5u5r0HwE7Sa1DKuBsVg/bjb0NecSF4JULRqEC/ex/KvQPhdqFsbmYSj9/JGYkZh8qsTkVE9It+Rni/g0LnjzS4p7mz1t3QmIeUUA4I7E1xl8o/fCVt6vhlHc+oFepa1bQasjaepTGcNKBhUPr7/SuNudIaG/MF3iWOH5VK8Z9CDWcZW0b2/Loc9GrypXOOtIgsEpVGDD5Vz/Wuj027+wvF5kfmROByDmql1pVzDqIkiUvC53Ee1XHjWGFZEyQD8yn0rZ2fzOmclM0TqUFxOJFRsB+h5Ga39MuRLPEhYnJyueAD71x7bRODCwaNgDwO/wBa0YHaKFDExCseG9/es3FWOacVsb+rp5V0JEQBEbDKvzZ96y76RygSNWXuS3Bx7VraVcfaGi81FMikMCOhI61t64ftGmygqDKMNENucGoTta5zufK7GV4evII0WBo5HkkyV2LwDjvW7AWZQ0kaZI/iXn8a5oNJEqSxSNlF+aNByvrWvp+p/bYZJlwyIdrALjB/xovfUwmtboq37zW1xL9ghVASByPlz2wKl0eOZi0sxAmJJKkHC/nWoqMIiJkKkddw6elQufKJmZsQ5wxI60Ky3E5XGXVqJ7YxMAgb7zqMMMc4H1qqC/mGe1twFwEUk4zj+I1o3KttUxsF3d8549RRGm1FjbHHBPqKLdSbkrAnaDkHqcVHKpxk7tqgthaUphRhm3LwMnNUtQmdfKRH2F2IYg46dqJSshJXKuqzxNdWyvI0duycs3TOe3vUhECSrF+8U43OeufSudvR52pBCz7VQyDd9e1WCzOr3EkrLLwAPWhR0Ru4nRJHBKokWNPLX5V2/wA/rUsyBkIiHOQSw64rO0qPz7iRpDgquQAMZrTTAJPAOfmx0NVYwYr+Q0e2fY1uy4IboR3FYWiaf9mv8oVaOMtgMO2eCK0by9tLYss/Lr8wTbkc1mjV4dMfy5UklWUB0MeGPPY46VMZe9p1KSdjoCASwZcg9Qecj0qjcWUM0b5hUNF8y9gB3xUtveQzxggGFuyyEZP0ps10mWjjdWc9CORzQ7PbclXRQsbl4mKpiWJjhVYc+uf/AK9X2Y+U7GMuAu7zEPGPaoBYRT2zIDiPd/rEbIbB5ArQjVI0VLcBIwMBR6d6JJuLHdJmBaF7ueEK6pEpLE9yK070LhfsvMnHTvVaC3j0+8KovmJIpwjHO2rVsQqHcO38Pei6drDdyvqcLzQeUpC8AggfxCufntGlDBiCQcEe9dYrqkYLg8nr1rH1GNo7wvkOkuSCPUcGkvdloG6H6PNJDZkXMsgtoGBxnOBW4WBIMZ3hxnPtWPYxsx8r+8Rgda3m2hvlAGOAB6Vq7WuZ7DE24KqAR3AoCK6AkEY/CmCMFgWz8jZXHGDUm3DltuSRyc8fSkIUglePrUaJtkYryXHGafkKSxJzjp2FO+VkB6jGcCgBV65wN2OacPw21CS+CyYLA42sOtSPIEAZiQp56ZpASYORjHrzUMTG4jZZI08o5Ug9fwokcFCo6npnvRvfaQkZXHBLdM0DMa9As3kiKNsUZL+npn0qnpku+42xnGfm/D/GtyeVYlvknXzGmj2sdvGMYHNc3YRvBMpLHaoxkU90dMfejY66ZQYfLBO04yx7D1pgLrEzHkqBgqevpVO3vlulhgClJjJ+8UjIKjvntVqYpEjkOMgkjaeD7fSlcwaaeo2OKQxsGjRS65Y5+Y1EyxwStvLCGRfkQ8gGpiZUCxtIcyfMAByPYU3McsLxvGzOON46fX2pbghGUpaskiAo2CMcqKRUgt3ICIoI7DORT53WGOMksPm246qD64qOLE4wi5UMULdBmgBtyn2sjIYImQAT8r57mliAkuCI5AgHBxznFT+WQcZwgHbvUECRmQQR5Vx0bHX60mBOYvPIdxtVeOv3jVkAkDdgkHHAxTYHV03KcrnqOn4VJ0A6Y70yRoLMeAAM/nUF1OnlyAZ3rxgjp7/Sp96q20MNw52A81VuxH5iYZQ7DGD/AB0ropEbCJkiEkMiykZcjoQap6hoEN0HAUMpPIY5J+nvWvIhhJJbJU8HPX2pkbSAlsAt1HoP8aH3LjNxejPOLvTXtdQe3gLJ5RYblHf61teF4rC9hvIr23hmCjcpkGTgDt6c1r3Nm8sjxPIsiz/OV9D35rmrxJNHM0j4jVkOx0PHpzScm4tdTtU3OxwPieaOSZkgh8uDdkevtmoNHvZ7G9ijjYkMwIIOMVX1WWQyNKxRi5ySvaqdoxWaJwznBJPbFdCXQ9TlTp2Z9BaN9kurFQAw4yzE8E+tLd6TbGQSoWDnOwg/dx/jWD4Oje40KB2kKHccluATitK/a6h2gz8g8gHPHvXPL3Xa54sl7zsyDxBaJJDFfxYQYAfA+UN0OPrXP39vA0O6ENIcHcMY2mpbqe5lmkiaTfBnKpn5c+tVHkKW8Sow+R8HJ9auKaVrm0LpC2MsVsiCIRPLjDI3T8atT26LaPJ5gEhYkRKpOPoazr6zEMqzxrwcK3pmu60iwMmlxTX0e2Zvmi+b+H6U3ouZDqT5NzlbC6Y2yXEBIA59D+Vdsi5hdtyPIY0ZWVvugjr9aqtplgYmL+ZAxyWxgg8cVg217JHO6b1diSMqDyP6VLd3ZHPJ8+qOilt/LkN421ZkYHavUfX1rOvpxaXs6lomAbLKg4BbuBWlcx3jQh5khWTaHCp8xx7/AFrKurVniEiEGRjwduC34VHqTF9yfTdQEtwftF0ViGeQSfzp+sOz2Rf5xFnABYDP0FY6Wd7JcKfLYbgcuAACK049MnuXWOYMqgZZieq+x9apxvbUGorVDfC1/M0EkNyjy22/EUoGREe6k+ldH07DHbngimRSeXEsMEaRxKPlRBhcfSmZ8lBkAR5+ZQfu/Sqb1MHqxXYqvyLwvbvUF/DHd2ch3JGYh5u4jOzA5yKm8wFCQVK44zWbfQo8L3EW8yxqVZgflx7is5PoVBanPWayXUtzdZALLu56Y7f/AKqmtAJW3Pn2WpEEb2ziNCpfG6lsWjWcLtfbyPrWu97GsmbulqqrcgjEhK5LHGBVTUNft7ScR2zwXGBlyGyqt6VU1xjaIIZhvWcbtm7ofUmufEFvGrlgQD0OMgepqF7+70FGmt2a9vcPqk8weINJuL8ngjHb2FVrqxMLeZC3yn+EjpT7Fg8oW0CREryVq5GWvbhIArO5IBbso7k1VmnaIpOxWhR1RXcliOhzkirYuZLeFQpQg9M9RVy50mKFR9lmkfa2XDcbh7elWDZwSKhjjUSD7rkcke9J2e5NzP069a1lO1Ekhb78e7HPqPQ1pHVbQgD9+rEgEFMgH60y1Nm5NvLa26XK9Vx97HcetJPYbWlltzsQ4whOee+PShtk7klzKgcybwQg4x0PtmlhJeJWKmGTGcZ5NVPszgZQFifvJ1ApLi4MrBbiTZjBGRjpUpgXZFSRSVkwufmB7VlTsvnMSR8hwoB6CpncMjxo6lW5OB1rMcEEpCjEZxkDgH3oScnoO6SNfw43mX88hyRCmc44yeBWu/C++Kp6dDcWumeSSofqSvXNPtpJxB+8YFgcDd1rSbu7LZEWLJyEymDjmlJYoW4zgfhQdwdTwAOoHenE8nf0HPFBIqkMccZJ/OkYAZZRlgOlDlQpDZIpwYrkFWPPJH9aWwDXcZVl9ck45xTY23PgbgqnPI70+VMgleCevPWmLu3FW4PrTGL5akAsS2OxpSzxAEsZEB4bHJz0pQWjwckg9upzRHLvDlRtZTjDUgHNO0fy+W3zAk4+6PrWddxBrBmEOUVg7FR29RWiryfPlU2kcc9TiomY/YJo3wrrHsOP0plRdmc5HFGHkAlZAePl6YPUZrQvtQgtdOgitmUsoG6IL83FC6ZLEpZyrLLhWHdc9KqXunNDMyXBfd/yzIOc/U0ja8ZPU2rWRLyOO4U/MOqkfdNTyBGGSFHPHvWJoXmWLywzrITKwEZPABFbP2hY8LMNrk4AAyDRtoYyVmV5nZpxbo6KjDLHq2Pr6VPbiMRDywPLjYqFU8CoXiea8I3RJGBtJxk+9LE5tTh1G5VPyrxxnt60vMPIuALjtjt71RvoS1xujYguOc9AAMU26nvZUV7N0tUjmSSQvEJPMiB+aPnpu4+YdKlQzXVo4UodrEZB5Ht/9elvuCTQWsyRWwjY48oc8dRUs1wq7UiBeZ1yuOmT0qtAJ3s2mZUD7hs3cBh3p8czSyFbcbwGHmbQPlb09qbBIyrSC6e7a6n2x+VJhl/if1xWlfwwGWOecnczeXHg9B14FPkLTl3CrGBk/MeCQaS7iN/briRS5+QA8bQetItyu9RRdtIQoWNtqZ+91I9fep4mE1uh3bs9e3Peqf2aK1VI42DyRHBGOT7mrCTtDaSu0ZMUYLbs9Ae9GxLV9iR7eNrhZAMSYwDnqPTFZ+o6Xba40lvjy44UO0qB8zZ9KLae8uk8+3O5FbGW5xU8Ynhg3xkPsy2On4UalRfK7o8i8ReGZop3KQF4QcHB+YexHrRoGiSSypAloxOSTIw4+lexRpHGHWSKMvMm47hlsmomURPaxBCiR5UKOmMd/etFUdrWOv67LlsZ1tarZadFawzIWUZcDoT6fhWdezOScqQM4wB1rUvQj3iIWVtoC4Hy4PofWpkgtksZDISW6EA52k+lZebMebqzkBh8l8IQMlc1EsNuY1iRwWPzFm71vX+nA/IVVCvzDjkg96yV09JI5p0lVY1UlmJ9OtWpJ9TaMkVHnXy7eAb5RkcDnLZ7V3cNpdtHGLiQw7esQGWxj1rM0SwtbY2kweG8W4QMgHAUdsetdBcGRmVUO0k4yOcClK3Qwq1OZ2RGEiEqBlLKCNpcZrm4tLkutZuGtpVjiVzmVh8u329TXSJH5UTgyDIzjPIHpTbZfLtUZgchfmA5/KhaO5kpNLQVS6LtKbnQD51/jAps5jk3mVGIIBz2U/0oMrRy4AxIy/ICOCD0JqVQIYtjD5c8gc9etG6uTsR22zY0cIxFGccdKc8qRY3EKCcLn19Krl5reMkxxrGhKq2eq9s0p3OnmTR4fGVReQKW4Cos+1QXG4tyB0x6CnXTiGIkn5fTHJp4YuuQCOQQCOgqG6cCRVbDEdAR9002ugX1KX+okL3CkQsQVz3PpReQZhY2zYafPzDgH0HtWhIgkt3jOGyO479jWXDFcQF4XdA2DsJ+7/8AWqZaFxd9TMt4nH+rUnjPJBrV0m3R3eWQZdAAEx096qWJ8mKSG55lRsjHr/hTn1AiMJErieVwiPxtBz0NaJ66CldlfxZasbyyuFHyyKyNnsRWJqbBHRYldYY0+Zm/vH0Fa/iScSXISNJGe2+Vy56nvgVSspzK8rTbW4BVX6e+aVPZM2jdIuaVGFsrdyFDyJkMPT3rU0tyt0QQoB5B9ao3cpjumlgEflMq/cHAOOaqWWqAXYhuziBuC4GTH74pJuTbRDV2dLcblUGEK244bBzTo45WTLt04A9qrW0MNuy/Ztxt2YkDPLe9W2lIUkD5R+tK6WpnZ7EE9s8xQKU3KMb8dKJ4jHGFbMqdTg4I96fbNPIwLooyflwe3rU7LLu2DYc9z2HrTSstAuU5IreXYYJHV4x/CT096nkggnAS5T7QjdD6H1BrLuYAL9mgeVwo+6Oh+tSSXElvFlMR5/uDIpX0RTj2LEGno+dzsUOQe35VpqyrGY4QsaqACoHb39azrLUoJZvKiZSeoUnk+tO1hVa1R0UFvNHRsHH9RTcrJIjlZdyEHXoM0yCeO5iLxZK+pFQWty1zvhkiBMYwSG6ipLXKJIwwI85K46UPrzbCt2LKg7sDOOeacrAg5/E+tNye+OtIxUNy3OegqiQZhICCuQOuD1pwGBtV8EDnPUigFy+eAhFDNtC7uR/OgBTtVcPwfc00HMwPzDOAT2pRuIw4BB5HP6UIT5hBboM49qAFXaXLMFD9BzTv+Whb+9gHIqMwJK4d8cNuA9D60rO4OShYk846UWGSKQwO3kA8j0qtIjXKeYo2yZ24bjIFOASWVWTqfvYHp61KXwATzjnB4JoAgu900CxmMlXYBjn0p91D9rgMf+rbOQ3UrVFY7iFPO3O5B+YHvz6VdE8Lsh37STkAmlsMqreSMFSdVkeIYDHjNWl2GJg2XYdFB4x6VV1qCMxpJghgTyvpVXTbspKQcE7CE7Antmh6aovluro1ECmaMkEFxlh6U3VbRr2wliglEF3wYZj/AAMD39qr2d473AMi/JMMHYPukf0rQUll5HIOKEQ00zKFrc2cLrcuZ0flnj+6B6EUgX7smRGzfLhO47E1p3JIiwmWJ4x6e9QW9qs6oytsUHJwOciiyHcW5tybRUCOuw7uuevU4q2Avl7F27SMbl78dT71FbzGUO3PytjJ701DHA5jLqkZOUz3J60CJSqHYhA2Z6epqFvJEI83ywd3B9T/APWpZpSjKUXcQeF/vVXYI6iWEYkySVPJFK40iaLzWxtAyp+ViMEg9SaZ5KufKmBKFiWUn73pStI6RkfMQSMEjtSxCTekm/eDkDNAyzGkcSlY1CKT0XpSMu5QW5xyV7UyORX3gbsq205GOaarNDHIzgyEu5QZ5x/CKNRLViyzQqwDEOUHb+HNPUKYiGYDcCSw5+lUbFE+wGSdR5w9Dkj2q1ChVQxKtvGefWhIbMDUZXMiFwqFOCwHJ96uWLrdImcBgp5bqffFWL6FTfrJLGGRlG5M9/Wq6WkcVw0se1kPTefumpSNL6Ffy3j+1ic7Uj6MePlPpWNa3S2d2WdQYgdrL2YfSp/FOoSw+YjMJWkClivKgdh7VySXLOzYBB7MB1q6ceZXezOunTbjc9MjshLOlyJVXEi+UoXsOhrSGcEykA559qwtBd7rQ1O7bMqnIHG4dqtWEwigaHe8jD/V85JY/wAJqXpp2OOcdSe6uAY5lBwPL3KwPB56GljRYQF80FfLDBgfvnuKrXfkRRiS5V1n6Rp2BqtZ3X2nbCrqpyQmRgD2pIOR2uXyUQ/uy2CgQqOwz/KpFlaPMcmCVG4bj1HrTXU4Qy4EiLhkHSq2pPGsClS7Arxn+VNkpXJ5N80K7w6/vBJtAyrCp5ZOQzg4ByuOn41ErvFbRGYHcyjAHapGbC8OoH+1xmm9CRnmMh+Q/MwyAe5qvIXE5fILAbzHgnH40jbZ2DjcTkFT2xVhYxG7FWY7uCCciku49EJJLtkMo3MHHKCmy25kmDyFWG0gxnoTjjP0pmVilXzCW2/d+hqxBKlwrNESQDg56ihWYndGVNaiwjZ2XepHzAc/l6UzSbcTJ5qPgg/If7n/ANetC6je5ZViZTnqM9awrN3tpZ0ZiYwxDqG+79Kae5ottAvrB7i5kKyB5CcYbrIf8aZa+HryW6Xd+5i6O79AP9n+9XQW4LQq8bDy5AMnHQjv9amjmLEpIcMPXvVRfKS5t6HJ6jAbDVLi2MjPAFVo3IxkEf41m2lmHu5LgglF4UKcndWhrzyP4l1CMFZomSPbg42MByP61j6XJJoGnyG4/eL5hYMTkoM0qUvdu93Y3SR3kdrcQiLcVmkYBmYnGeOn5VMyl4FCrwc5X/D3rK0/xBFqekzTRrl4SB5meDnocVuwRslunmEbmAbg5HNK17o522tRkaE20YUbGA5B/lUSFg27cx3DGSOAaszRiQFWBI7Y4qFI2APmkcdMdqHu2Jdh0NzbvKsKSxiZ1J2dzTxGouCSo+7gZqiu1GScxq0rH5mC4ZR9atW7q671lLjoQOaa8watsZ2qaHHcyNc2n7u7XkIDtRz7+hrNSLU7Z1VjHJNFk/vuM+2RXVcdecUkvzJt2hgx5Bot0Gpvqc3a6rcRuzvprNEzfM0ZwVb+oq8811OHWHZDHIRgkZz/APWrZ5xg42jtVcBBIQMADqKGo32DmuShgGCF/mxke9NZFdjjORzmpCygJvPQ4BPWnAcAKe9XYyImU8MCVGORT1+6oPzADvTiMtyRgdQaUfeOeAO3rSsO41IyoJB4PQGpD68bscE0FuDkDPrSN3ZsH0oENPICtgKR0FLI6xxsXc4HUd/akaUKCevOcYpXO6NvL24deCRQMZbuXQuFCno3vSyK+cgKcDp60AGNFCdDxtNNVlJZUdl2nJBHIHrQAiyoMZY89sdaXyoQjysuQV6Dpj2pyyM2RtXyyMf73vUaRGIhAWaEnnPaiwJjSJobCVrVd0hUKEYZzmucktZVaWGWNo3jP3O5/GusLESDaeR/Ksm9WS11FZACYpeQx9e9HoawlYr6FEWSRxI8ZVtxZj39CK3JW/du4JJC5O2qX9mvbXbz2825WOWiYYBz15qzIC8WwELKTkY4xSJm7u4QMsrpkOdw6k9KREmjy0RDfNk84yP8acIRuyrfux/AO/1p+0o27LcYAB6YoJKssiyyxMY3SNJD5hz144/WnhUcDylkZC3Jxxn1FRzOkc4YA5U8qOlT25WL5d5Kvyqk/cPekUyYRKOTjeDnP9PpUclrE83msHBAJG1sVOpx1P44pR+HHOaZNyoFLIqiR84+6e/sakt0IRFzhlONp7VHGVkdySSzZVRnuO9SQlkZnI3jHJJ6YpXKKk+sW1pO8WoeZCQ4jV9u5WJ/lV5wWDCPD8ZDDoT7VxPiTF1PLNnEIHGDxk1o+HNdhtrFLK+ErYJMMiDIxjo3pQlpc2lR0ujYeMBm27lJ67TwT34qeCWE3EVlFMHlZPM29wPr6+1YsmtiKMsIljEmMlW3Mcdx6ZqlZ3lu2ox7TOhLBt6r90egqVdkum0rnUXcJlt2EYHmqQUJ/rWUJp3BEe2ExjLMwyCfQVuFw5DoMK3TmsXxHEy2wa2Ri7AqwTufU05K4U3rZnEazOZp5SuULScqOg9qz4YJGuo1+4sY5GODVm4illO1eEwN2OScdqvaVZF5Q6qWC46nk1ulyrU9HnUYnYeGAq6WXPIQYyPSrUEMRkmWDbKgQEDqcnvmhQWt1hG0HH0+tSwxpahvKfaXznIweP6Vg3d3PNk7syNTtp7iRQzOXI27QeEp9vpnlwOZJV80jO3HTHvV5W3XSSkhVY7W96ckUkzyOSBHnCKB0x3oT0siudpWKBnkjVRKWJyBux90e9PW1kv7pJnBSBDlQTnJq8WiSy2PKqqxw5bqWqW2l8yGNk27McEdCKIpJ6EOQTK0yOu4Z9/X2qpNI0nytzgAMSORV4ZwSRzUNwAURnxuLAMc8gUNCTGxpAj5t1A+XBJPQ01ix5yahzl2lhYqVbABGd49TUrvJG3MOF7kHOKLNiZVuMCTdIzBNu1ivUc1HboFu2aEyyoDkOxxk9xV+KFCN7oCW6j3p8SLHwgG5TkD/ChR5dwcrlecBI4ViVoyXwT7HqKgudLi+/ATHMDgnGQavTvsiJPP8VV7WcMSHkRs/MpovqCbWqKyS3iyLBMmJOzZG1gKtX0N3LalbQol0Pmi3fdYj+E+x6ZqcqJkUnsdyn3pSBKrfMAo4IHUGhrsHNrc5CXOoPNqGn2rh1AW5tW4kt5ehBHcehHBrHvrfUr+2lKWczKFwVKfN+VegRRrHevcvHGJniEbSY+ZlHQE+lW1YlBvOWYYyKpKK2Ro6iueYeGtCu4XFiqeVd3B+VZWwoHf/wDVXpltbC1tIrdX3hFwWPQn1rHuobmK58wRxynaQpzh/qK09MuJJUZJo9pVQQSeTVuo6m4quuqJJnkAKqoLYyBmq5EzYLnaW4HoParzMB8x7d6gkmWWJlAJ4zx2rKyuZ3A2qsQSWIHBUUxIFWeTYu0HnI4xSDzi3mBSGcDLZ4qUAyKAGx647mmrgwZyqkKAxHQHgUSOwXKIThu/p60w7ZTIm/LDgrnmpl+aLscccetCV1cCMTszYCcnoe1KRgkuv1oUhGZdwUAcH3pHEhw7yDpgr2PvQ/ICeSMM6lsttBAHY0oByCTx3FFFaEDgQABjqad7Ajjj6UUUAIeAwxgYpG+ZAAcdhiiikA4Nhgcc46+lM5yCfoT60UU7AKxA4cgE9KQAgYYhyRjdnoKKKi40Nkk2yiNQxbZvzjjHTrT0IZMZKhhxntRRV2AhhIQF3JO44BJp9xGrpiVtqJ8w9BRRStrYaIykjRMzvu7D5sCp1UFFAGB+uaKKlMGI8YbIOQcg5BxUdtGYmdS0kik/KCeFooouCRFPEjkMYmKEnkHBzSiJYbRmQsyZ3BH4P50UU3ohltMYBXlSMj/CiVgilnbC57d6KKTEii6SGYRD7r88joT6UapFtsTIrFSDh1PII6cUUUktC1uYV/CjRmPbgAgrnoaoYMTOrYD4PCj5VoopxXQ7IPQijg8wqyoxLJyT3rT0HT7i3u42mffEx/Ad+KKKpvdE1ptKx0yEqPvl2PzYIpSN+xXGQetFFS9zk8ytcaTpru8htUWbtg4/SnzW6NblBHGmQMso59sGiihO+5Tkxbe3aFyHLMT6/wA6TUUZoo0RQwMmST/CMUUVM9EJblcKjSALCyxsVDHtkdxVuVhbnJ3JCTjcOcGiim1bQGQW8CoxUoSzc5Izz6+1TWxCwqu4Ap8uB2oooXcGS9ePyqlIY5buJhklCTtJ4PpRRSe4JDRKUct5YVHOSDxj/wCtT5ZZ2RnjMYB+XHp7iiijpcHvYtY4xxn19fekdN2D0I7+lFFUQRyRb8GRsEZ5H9RWfCfJXy7xI9ygrvjGVdT0x6UUVL3sWtizHKphPlFlZMBgRSRs0UzC4dJN43Axjp9aKKPtIXQmmyygKwyTx9asKuQCQPX6UUVSEytfQq0ZfOHXlfrWbazuNSM0hfdj5wB0H0ooqVpJlwV1Zmmlzb3DExyDjjkYxTYRO+6X5Y0PTj71FFVa12S9CZZDsGTluhIFKoCghWBPXAoopoliPEhk3qMSYzmoZYpQS0LBdx+YelFFCSdmwuTogVAr4YdSx9ae6Bl5AJHQ0UUXEf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Bart Currie, Microbiology Department, Royal Darwin Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_19_28980=[""].join("\n");
var outline_f28_19_28980=null;
var title_f28_19_28981="What's new in neurology";
var content_f28_19_28981=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   What's new in neurology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/19/28981/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/19/28981/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/19/28981/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/19/28981/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/19/28981/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CEREBROVASCULAR DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Updated guidelines for early management of acute ischemic stroke",
"    </span>",
"   </p>",
"   <p>",
"    The American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association has&nbsp;published updated guidelines&nbsp;for the early management of acute ischemic stroke. One important change is that a&nbsp;number of conditions previously considered strict exclusions for the use&nbsp;of intravenous thrombolysis are now considered relative exclusions (",
"    <a class=\"graphic graphic_table graphicRef71462 \" href=\"UTD.htm?31/40/32397\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28981/abstract/1\">",
"     1",
"    </a>",
"    ]. These include minor or rapidly improving stroke symptoms, major surgery or serious trauma in the previous 14 days, gastrointestinal or urinary tract bleeding in the previous 21 days, myocardial infarction in the previous three months, and seizure at the onset of stroke with postictal neurologic impairments. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=see_link&amp;anchor=H209963#H209963\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\", section on 'Role of eligibility criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Genetics of ischemic stroke",
"    </span>",
"   </p>",
"   <p>",
"    Despite the publication of multiple genome-wide association studies (GWAS) of stroke genetics through 2011, no single locus for ischemic stroke had been confirmed at a genome-wide level of significance. However, a 2012 meta-analysis of GWAS that analyzed data from over 12,000 subjects of European ancestry with ischemic stroke and 60,000 controls identified three loci (PITX2, ZFHX3, and HDAC9) with genome-wide significance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28981/abstract/2\">",
"     2",
"    </a>",
"    ]. Importantly, each locus was associated with a specific stroke subtype: PITX2 and ZFHX3 were associated with cardioembolic stroke, while HDAC9 was associated with large vessel ischemic stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/15/249?source=see_link&amp;anchor=H21816556#H21816556\">",
"     \"Pathophysiology of ischemic stroke\", section on 'Genetics of stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DEMENTIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Discontinuing antipsychotic agents in patients with dementia",
"    </span>",
"   </p>",
"   <p>",
"    Because antipsychotic agents are associated with an increased risk of mortality in patients with dementia, it has been recommended that discontinuation of these agents should be attempted at regular intervals. One trial showed that this is not always possible. Among 180 patients with Alzheimer disease and psychosis or agitation who had initially responded to treatment with a 16 week course of risperidone, those randomly assigned to immediate drug discontinuation had an increased risk of relapse of psychosis or agitation over 16 weeks of followup (60 versus 33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28981/abstract/3\">",
"     3",
"    </a>",
"    ]. Those who were assigned to drug discontinuation after an additional 16 weeks of treatment also had a higher rate of relapse over the ensuing 16 weeks compared to those who continued treatment throughout (48 versus 15 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of behavioral symptoms related to dementia\", section on 'Antipsychotic drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DEMYELINATING DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Disease modifying therapy for multiple sclerosis",
"    </span>",
"   </p>",
"   <p>",
"    Phase 3 randomized controlled trials have demonstrated that dimethyl fumarate (BG-12) and alemtuzumab are effective for the treatment of relapsing-remitting multiple sclerosis in adults:",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fumarates may have neuroprotective and immunomodulatory properties. In two randomized trials (CONFIRM and DEFINE), an oral formulation of dimethyl fumarate (BG-12), compared to placebo, significantly reduced relapse rates and the development of new brain lesions on MRI in patients with active multiple sclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28981/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. Results from the DEFINE trial suggest that BG-12 reduces the rate of disability progression [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28981/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link&amp;anchor=H26#H26\">",
"       \"Treatment of relapsing-remitting multiple sclerosis in adults\", section on 'Fumarate (BG-12)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alemtuzumab, currently used to treat leukemia, is a humanized monoclonal antibody that causes depletion of CD52-expressing T cells, natural killer cells, and monocytes. In two randomized trials (CARE-MS I and CARE-MS II), alemtuzumab was more effective than interferon beta-1a for reducing the rate of multiple sclerosis relapses in treatment-na&iuml;ve patients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28981/abstract/6\">",
"       6",
"      </a>",
"      ] and in patients who had received disease-modifying therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28981/abstract/7\">",
"       7",
"      </a>",
"      ]. In addition, the alemtuzumab group in the CARE-MS II trial had a significantly lower rate of sustained accumulation of disability compared with the interferon beta-1a group [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28981/abstract/7\">",
"       7",
"      </a>",
"      ]. Alemtuzumab is associated with a small increased risk of potentially serious infections and autoimmune disorders, including immune thrombocytopenic purpura. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link&amp;anchor=H20#H20\">",
"       \"Treatment of relapsing-remitting multiple sclerosis in adults\", section on 'Alemtuzumab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EPILEPSY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Perampanel approved for adjunctive treatment of partial-onset seizures",
"    </span>",
"   </p>",
"   <p>",
"    Perampanel, an orally active, noncompetitive AMPA-type glutamate receptor antagonist, was recently approved in the United States by the Food and Drug Administration for adjunctive treatment of partial-onset seizures in patients aged 12 years and older. In&nbsp;randomized trials, adjunctive therapy with once daily perampanel (4 mg to 12 mg per day) resulted in a &gt;50 percent reduction in seizure frequency in 29 to 36 percent of patients with refractory partial epilepsy, compared with 14 to 26 percent in placebo patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28981/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. The most common side effects of perampanel were dizziness, somnolence, fatigue, irritability, gait disturbance, falls, nausea and weight gain. Perampanel is the first glutamate antagonist to be approved for the treatment of epilepsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H1668575#H1668575\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Perampanel'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MOVEMENT DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pathogenesis of Parkinson disease",
"    </span>",
"   </p>",
"   <p>",
"    Alpha-synuclein protein misfolding, aggregation, and toxicity appears to play an important role in the pathogenesis of Parkinson disease (PD). An aggregated and insoluble form of alpha-synuclein is a major component of Lewy bodies, the intracellular inclusions that are the pathologic hallmark of PD. Furthermore, a number of observations in mice and in humans suggest that misfolded forms of alpha-synuclein can be transmitted from diseased neurons to healthy ones, although the mechanism for transmission remains uncertain. In normal mice, a single injection of synthetic misfolded alpha-synuclein fibrils into the striatum leads to cell-to-cell transmission of pathologic alpha-synuclein and Lewy body-like pathology with progressive loss of dopaminergic neurons in the substantia nigra pars compacta and impaired motor coordination [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28981/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36970?source=see_link&amp;anchor=H9#H9\">",
"     \"Etiology and pathogenesis of Parkinson disease\", section on 'Protein misfolding, aggregation, and toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NEUROMUSCULAR DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Rituximab for myasthenia gravis",
"    </span>",
"   </p>",
"   <p>",
"    There is no randomized trial evidence regarding the effectiveness of rituximab for the treatment of myasthenia gravis. A recent retrospective study involving 20 patients treated with rituximab found improvement in disability scores in both refractory and nonrefractory patients, and complete withdrawal of glucocorticoid therapy in 11 patients within one year. This study adds to the growing number of case series that support the use of rituximab for patients with refractory myasthenia gravis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28981/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=see_link&amp;anchor=H5661854#H5661854\">",
"     \"Chronic immunomodulating therapies for myasthenia gravis\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     NEUROONCOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Risk of meningioma from dental x-ray exposure",
"    </span>",
"   </p>",
"   <p>",
"    Exposure to ionizing radiation is the only established environmental risk factor for the development of meningioma. Most studies have focused on relatively high-dose exposure from therapeutic radiation or atomic bomb fallout, but small studies have also suggested risk from medical imaging such as dental x-rays. In a recent population-based case-control study including over 2500 patients, meningioma cases were twice as likely as controls to report ever having had a bitewing dental x-ray [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28981/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients who reported having at least one panorex film before the age of ten had a 4.9 times increased risk of meningioma. This study suggests that dental x-rays, even in the modern era, may be a potentially modifiable risk factor for meningioma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/54/20328?source=see_link&amp;anchor=H627075228#H627075228\">",
"     \"Meningioma: Epidemiology, risk factors, and pathology\", section on 'Incidental radiation exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PEDIATRIC NEUROLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Narcolepsy following adjuvanted 2009 pandemic H1N1 influenza vaccination",
"    </span>",
"   </p>",
"   <p>",
"    Individuals in several countries in Europe have developed narcolepsy after receiving Pandemrix, an AS03 (oil-in-water emulsion)-adjuvanted 2009 pandemic H1N1 influenza vaccine. Pandemrix was used in certain countries during the 2009-2010 H1N1 influenza pandemic, but it was not used in the United States. This association was first reported among&nbsp;children and adolescents in Finland and Sweden in 2010&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28981/abstract/15\">",
"     15",
"    </a>",
"    ]. These findings have been confirmed in a subsequent large retrospective database review that included six countries in Europe over a 10-year period; increased narcolepsy rates were observed in Sweden, Finland, and Denmark after the initiation of Pandemrix vaccination campaigns, primarily in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28981/abstract/16\">",
"     16",
"    </a>",
"    ].&nbsp;An increased risk of narcolepsy was also observed in children and adolescents who received Pandemrix&nbsp;in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28981/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=see_link&amp;anchor=H592844613#H592844613\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\", section on 'Narcolepsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Modified Atkins diet for refractory epilepsy in children",
"    </span>",
"   </p>",
"   <p>",
"    The ketogenic diet is an effective treatment for&nbsp;children with refractory epilepsy, but it generally requires an inpatient hospital admission for initiation and some patients&nbsp;have difficulty&nbsp;adhering to the diet.&nbsp;Observational studies have suggested that the modified Atkins diet, an alternative, less-restrictive&nbsp;dietary therapy, is also effective in reducing seizures.&nbsp;In the&nbsp;first randomized trial to date, 102 children ages 2 to 14 with refractory epilepsy were assigned to receive a modified Atkins diet or no dietary intervention for three months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28981/abstract/18\">",
"     18",
"    </a>",
"    ]. Treatment with the diet was associated with decreased mean seizure frequency as a percentage of baseline (59 versus 100 percent) and increased proportion of patients with &gt;50 percent reduction in seizure frequency (52 versus 12 percent). These results are similar to those reported for the ketogenic diet and&nbsp;lend further support to the use of dietary therapies in children with refractory epilepsy.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15850?source=see_link&amp;anchor=H21468923#H21468923\">",
"     \"The ketogenic diet\", section on 'Modifed Atkins diet'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vagus nerve stimulation therapy for epilepsy in children",
"    </span>",
"   </p>",
"   <p>",
"    Vagus nerve stimulation (VNS) is approved by the US Food and Drug Administration (FDA) for adjunctive treatment of refractory partial-onset epilepsy in patients older than age 12, but its use in younger children has not been studied in randomized trials. In a recent randomized controlled trial of 41 patients with medically refractory epilepsy (mean age 11 years, range 3 to 17 years), there was no difference in seizure control between the high-stimulation (treatment) group and the low-stimulation (control) group as measured by the number of patients achieving 50 percent or greater reduction in seizure frequency at 20 weeks (16 percent versus 21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28981/abstract/19\">",
"     19",
"    </a>",
"    ]. These results contrast with many prior observational studies that suggested that VNS was similarly effective in children compared with adolescents and adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19578?source=see_link&amp;anchor=H6#H6\">",
"     \"Vagus nerve stimulation therapy for the treatment of epilepsy\", section on 'Other seizure types and patient populations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Everolimus for the treatment of tuberous sclerosis",
"    </span>",
"   </p>",
"   <p>",
"    Accumulating evidence suggests that everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is effective for the treatment of brain tumors in patients with tuberous sclerosis complex. The most extensive experience comes from the multicenter EXIST-1 trial of children and adults (median age 9.5 years) with tuberous sclerosis complex and growing subependymal giant cell tumors (SGCTs) who were randomly assigned to treatment with everolimus (n = 78) or placebo (n = 39) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28981/abstract/20\">",
"     20",
"    </a>",
"    ]. At a median follow-up of approximately 10 months, the proportion of patients experiencing a &ge;50 percent reduction in volume of SGCTs was significantly greater for the everolimus group compared with placebo (35 versus 0 percent). In addition, the proportion of subjects with SGCT progression was significantly lower for the everolimus group (0 versus 15 percent). Everolimus treatment was generally well-tolerated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32328?source=see_link&amp;anchor=H140858574#H140858574\">",
"     \"Tuberous sclerosis complex: Management\", section on 'Everolimus and mTOR inhibitors'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28981/abstract/1\">",
"      Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2013; 44:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28981/abstract/2\">",
"      Traylor M, Farrall M, Holliday EG, et al. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol 2012; 11:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28981/abstract/3\">",
"      Devanand DP, Mintzer J, Schultz SK, et al. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med 2012; 367:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28981/abstract/4\">",
"      Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28981/abstract/5\">",
"      Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28981/abstract/6\">",
"      Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28981/abstract/7\">",
"      Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28981/abstract/8\">",
"      French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012; 79:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28981/abstract/9\">",
"      Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012; 78:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28981/abstract/10\">",
"      French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2013; 54:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28981/abstract/11\">",
"      Luk KC, Kehm V, Carroll J, et al. Pathological &alpha;-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28981/abstract/12\">",
"      Luk KC, Kehm VM, Zhang B, et al. Intracerebral inoculation of pathological &alpha;-synuclein initiates a rapidly progressive neurodegenerative &alpha;-synucleinopathy in mice. J Exp Med 2012; 209:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28981/abstract/13\">",
"      Collongues N, Casez O, Lacour A, et al. Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. Muscle Nerve 2012; 46:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28981/abstract/14\">",
"      Claus EB, Calvocoressi L, Bondy ML, et al. Dental x-rays and risk of meningioma. Cancer 2012; 118:4530.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Global Advisory Committee on Vaccine Safety. Statement on narcolepsy and vaccination, 21 April 2011. file://www.who.int/vaccine_safety/topics/influenza/pandemic/h1n1_safety_assessing/narcolepsy_statement/en/index.html (Accessed on June 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28981/abstract/16\">",
"      Wijnans L, Lecomte C, de Vries C, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013; 31:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28981/abstract/17\">",
"      Miller E, Andrews N, Stellitano L, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013; 346:f794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28981/abstract/18\">",
"      Sharma S, Sankhyan N, Gulati S, Agarwala A. Use of the modified Atkins diet for treatment of refractory childhood epilepsy: A randomized controlled trial. Epilepsia 2013; 54:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28981/abstract/19\">",
"      Klinkenberg S, Aalbers MW, Vles JS, et al. Vagus nerve stimulation in children with intractable epilepsy: a randomized controlled trial. Dev Med Child Neurol 2012; 54:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28981/abstract/20\">",
"      Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381:125.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8362 Version 2375.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-41.78.124.10-00EF7A87C0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_19_28981=[""].join("\n");
var outline_f28_19_28981=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CEREBROVASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Updated guidelines for early management of acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Genetics of ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DEMENTIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Discontinuing antipsychotic agents in patients with dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DEMYELINATING DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Disease modifying therapy for multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EPILEPSY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Perampanel approved for adjunctive treatment of partial-onset seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MOVEMENT DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pathogenesis of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NEUROMUSCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Rituximab for myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      NEUROONCOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Risk of meningioma from dental x-ray exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PEDIATRIC NEUROLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Narcolepsy following adjuvanted 2009 pandemic H1N1 influenza vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Modified Atkins diet for refractory epilepsy in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vagus nerve stimulation therapy for epilepsy in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Everolimus for the treatment of tuberous sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/8362\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/8362|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/40/32397\" title=\"table 1\">",
"      Criteria for treating acute stroke with tPA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=related_link\">",
"      Chronic immunomodulating therapies for myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36970?source=related_link\">",
"      Etiology and pathogenesis of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=related_link\">",
"      Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/54/20328?source=related_link\">",
"      Meningioma: Epidemiology, risk factors, and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/15/249?source=related_link\">",
"      Pathophysiology of ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15850?source=related_link\">",
"      The ketogenic diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=related_link\">",
"      Treatment and prevention of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=related_link\">",
"      Treatment of relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32328?source=related_link\">",
"      Tuberous sclerosis complex: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19578?source=related_link\">",
"      Vagus nerve stimulation therapy for the treatment of epilepsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_19_28982="Roseola infantum (exanthem subitum)";
var content_f28_19_28982=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Roseola infantum (exanthem subitum)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/19/28982/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/19/28982/contributors\">",
"     Cecile Tremblay, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/19/28982/contributors\">",
"     Michael T Brady, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/19/28982/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/19/28982/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/19/28982/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/19/28982/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/19/28982/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/19/28982/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Roseola infantum (also known as exanthem subitum, sixth disease, pseudorubella, exanthem criticum, and three-day fever) is a clinical syndrome characterized by three to five days of high fever (may exceed 40&ordm;C [104&ordm;F]) that resolves abruptly and is followed by development of a rash (",
"    <a class=\"graphic graphic_picture graphicRef81967 \" href=\"UTD.htm?9/7/9329\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Roseola usually is caused by human herpesvirus 6 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of roseola infantum will be reviewed here. The virology, pathogenesis, epidemiology, and other clinical manifestations of human herpesvirus 6 in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40167?source=see_link\">",
"     \"Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31577?source=see_link\">",
"     \"Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human herpesvirus 6 (HHV-6) is the most frequent cause of roseola [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/1\">",
"     1",
"    </a>",
"    ]. Other causes include human herpesvirus 7 (HHV-7), enteroviruses (coxsackieviruses A and B, echoviruses), adenoviruses, and parainfluenza virus type 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of roseola is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/1\">",
"     1",
"    </a>",
"    ]. In a prospective study of 38 children with roseola, HHV-6 viremia was detected in all of the children during the first two days of illness (before the onset of the rash) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/3\">",
"     3",
"    </a>",
"    ]. By days five to seven, only 7 percent of children were viremic. HHV-6 antibody was first detected on day three of illness, and present in all patients by day eight of illness. This pattern of viremia preceding rash, and rash coincident with development of antibody, suggests that the rash may result from antigen-antibody complexes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Roseola is an illness of young children, with a peak prevalence between 7 and 13 months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/6\">",
"     6",
"    </a>",
"    ]. Ninety percent of cases occur in children younger than two years. Roseola occurs equally in boys and girls [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. It occurs throughout the year, although cases may occur in groups according to season [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of roseola occur sporadically, without known exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/1,6,8\">",
"     1,6,8",
"    </a>",
"    ]. However, secondary cases and horizontal transmission have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/1,9,10\">",
"     1,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The modes of transmission, duration of shedding, and incubation periods vary depending upon the etiologic agent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/4\">",
"     4",
"    </a>",
"    ]. HHV-6 most likely is transmitted by asymptomatic shedding of virus in secretions of close contacts [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. The duration of shedding for HHV-6 is not known but is thought to be lifelong [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/12\">",
"     12",
"    </a>",
"    ]. The mean incubation period for HHV-6 is 9 to 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40167?source=see_link&amp;anchor=H9#H9\">",
"     \"Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection\", section on 'Incubation period and transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The modes of transmission, duration of shedding, and incubation periods of less common causes of roseola are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14201?source=see_link\">",
"     \"Human herpesvirus 7 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41383?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology, pathogenesis, treatment, and prevention of enterovirus and parechovirus infections\", section on 'Transmission'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39257?source=see_link\">",
"     \"Epidemiology and clinical manifestations of adenovirus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=see_link&amp;anchor=H6#H6\">",
"     \"Parainfluenza viruses in children\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of roseola is characteristic: three to five days of fever that resolves abruptly and is followed by development of a rash.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classical roseola begins with a fever that may exceed 40&ordm;C (104&ordm;F) and lasts for three to five days (mean 3.8 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/6-8,13,14\">",
"     6-8,13,14",
"    </a>",
"    ]. The fever often is accompanied by irritability, although most children with roseola are otherwise well-appearing, active, and alert [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/1,6,8\">",
"     1,6,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other clinical manifestations may include malaise, palpebral conjunctivitis, edematous eyelids, inflammation of the tympanic membranes, uvulopalatoglossal junctional macules or ulcers (sometimes called Nagayama spots), upper and lower respiratory symptoms, vomiting, diarrhea, and a bulging fontanelle [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/1,14,15\">",
"     1,14,15",
"    </a>",
"    ]. Cervical, postauricular,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    occipital lymphadenopathy are common, but later, findings [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/8,14,16\">",
"     8,14,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series of 80 children with roseola, associated findings included [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lymphadenopathy &ndash; 98 percent",
"     </li>",
"     <li>",
"      Erythematous tympanic membranes &ndash; 93 percent",
"     </li>",
"     <li>",
"      Irritability &ndash; 92 percent",
"     </li>",
"     <li>",
"      Nagayama spots &ndash; 87 percent",
"     </li>",
"     <li>",
"      Anorexia &ndash; 80 percent",
"     </li>",
"     <li>",
"      Upper respiratory tract symptoms &ndash; 25 percent",
"     </li>",
"     <li>",
"      Diarrhea &ndash; 15 percent",
"     </li>",
"     <li>",
"      Cough &ndash; 11 percent",
"     </li>",
"     <li>",
"      Convulsions &ndash; 4 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During the febrile phase, a diagnosis of acute otitis media is common [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/17\">",
"     17",
"    </a>",
"    ]. The combination of high fever and bulging fontanelle, which occurs in as many as 26 percent of infants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/7\">",
"     7",
"    </a>",
"    ], frequently results in an evaluation for possible meningitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the child's fever abates, a blanching macular or maculopapular rash develops, starting on the neck and trunk and spreading to the face and extremities (",
"    <a class=\"graphic graphic_picture graphicRef81967 \" href=\"UTD.htm?9/7/9329\">",
"     picture 1",
"    </a>",
"    ). Occasionally the rash is vesicular. It is generally nonpruritic [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/14\">",
"     14",
"    </a>",
"    ]. The rash typically persists for one to two days, but occasionally may come and go within two to four hours [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/1,6,18\">",
"     1,6,18",
"    </a>",
"    ]. In children receiving antibiotics, the later onset of the rash frequently is misinterpreted as a drug allergy. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laboratory features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory investigation is seldom necessary for patients with classic roseola. However, it may be undertaken in children with atypical features (eg, simultaneous fever and rash) or as part of the evaluation of fever. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link\">",
"     \"Fever without a source in children 3 to 36 months of age\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory features of roseola include relative neutropenia and mild atypical lymphocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/1,6,19-21\">",
"     1,6,19-21",
"    </a>",
"    ]. Early in the febrile period, the white blood cell (WBC) count may be elevated, but reaches its nadir (frequently in the range of 3000",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    by day three to six of illness, then gradually returns to normal over the following 7 to 10 days. Children with roseola also may have thrombocytopenia, which is thought to be caused by bone marrow suppression rather than immune-mediated peripheral consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Roseola is usually a benign, self-limited illness. Complications may include seizures, aseptic meningitis, encephalitis, and thrombocytopenic purpura. Seizures generally are related to fever. The frequency of seizures in case series ranges from 0 to 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/6,9,22\">",
"     6,9,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31577?source=see_link&amp;anchor=H2#H2\">",
"     \"Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Roseola is diagnosed clinically based on the characteristic features: fever for three to five days followed by abrupt defervescence and development of a rash [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory evaluation is seldom necessary. In most patients with roseola caused by HHV-6, by the time the rash appears, viremia has resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Virologic studies may be warranted in immunocompromised patients and those with an atypical presentation or complications. The diagnostic approach for potential pathogens is discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HHV-6 (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31577?source=see_link&amp;anchor=H11#H11\">",
"       \"Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      HHV-7 (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14201?source=see_link&amp;anchor=H15#H15\">",
"       \"Human herpesvirus 7 infection\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Enterovirus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=see_link&amp;anchor=H18#H18\">",
"       \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\", section on 'Laboratory diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Adenovirus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37513?source=see_link\">",
"       \"Diagnosis and treatment of adenovirus infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Parainfluenza virus type 1 (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=see_link&amp;anchor=H11#H11\">",
"       \"Parainfluenza viruses in children\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of roseola includes several other infectious exanthems and drug allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/6\">",
"     6",
"    </a>",
"    ]. Roseola generally can be distinguished from these conditions by epidemiologic or clinical features (eg, age group, temporal relation between fever and rash).",
"   </p>",
"   <p>",
"    The infectious exanthems include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rubella, in which the rash (",
"      <a class=\"graphic graphic_picture graphicRef61263 \" href=\"UTD.htm?10/17/10513\">",
"       picture 2",
"      </a>",
"      ) and fever occur simultaneously. The rash classically begins on the face and spreads down the body. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26855?source=see_link\">",
"       \"Rubella\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rubeola (measles) (",
"      <a class=\"graphic graphic_picture graphicRef57093 \" href=\"UTD.htm?4/26/4512\">",
"       picture 3",
"      </a>",
"      ), which is distinguished by a prodrome of coryza, cough, and Koplik spots (",
"      <a class=\"graphic graphic_picture graphicRef57571 \" href=\"UTD.htm?40/6/41070\">",
"       picture 4",
"      </a>",
"      ). The rash classically begins on the face and spreads down the body. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=see_link\">",
"       \"Clinical presentation and diagnosis of measles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Enteroviral infections, which usually occur in epidemics in the summer and fall and occur in children of all ages, not just young children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=see_link&amp;anchor=H18#H18\">",
"       \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\", section on 'Laboratory diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Erythema infectiosum, in which the rash is prominent on the cheeks (",
"      <a class=\"graphic graphic_picture graphicRef71737 \" href=\"UTD.htm?26/16/26895\">",
"       picture 5",
"      </a>",
"      ), and which usually affects school-age children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=see_link\">",
"       \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Scarlet fever, in which the rash may be confluent (",
"      <a class=\"graphic graphic_picture graphicRef63234 \" href=\"UTD.htm?8/55/9080\">",
"       picture 6",
"      </a>",
"      ), and which may be preceded by pharyngitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27110?source=see_link&amp;anchor=H4#H4\">",
"       \"Complications of streptococcal tonsillopharyngitis\", section on 'Scarlet fever'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Drug allergy is another consideration in children with fever who are treated with antibiotics and then develop a rash (",
"    <a class=\"graphic graphic_picture graphicRef70062 \" href=\"UTD.htm?31/30/32239\">",
"     picture 7",
"    </a>",
"    ). Clinical features that help to distinguish drug allergy from roseola include the duration of rash (longer in drug allergy than in roseola), and pruritus (present in drug allergy, not in roseola) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, roseola is a benign and self-limited disease. Treatment is supportive [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/4\">",
"     4",
"    </a>",
"    ]. Fever can be controlled with antipyretics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ). The rash resolves without treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with roseola recover spontaneously without sequelae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hygiene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Roseola may be caused by several viruses. Transmission of HHV-6, the most common cause, probably results from asymptomatic shedding of virus in secretions of close contacts, which is difficult to prevent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/11\">",
"     11",
"    </a>",
"    ]. The other viruses that cause roseola typically are spread through respiratory secretions or the fecal-oral route. Simple hygienic measures, such as handwashing, may help to prevent spread. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41383?source=see_link\">",
"     \"Epidemiology, pathogenesis, treatment, and prevention of enterovirus and parechovirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37513?source=see_link&amp;anchor=H21#H21\">",
"     \"Diagnosis and treatment of adenovirus infection\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Child care",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no recommended period of exclusion from out-of-home child care for children with roseola [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/23\">",
"     23",
"    </a>",
"    ]. Children with sporadic cases of roseola are not considered to be contagious [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28982/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/31/1522?source=see_link\">",
"       \"Patient information: Roseola (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human herpesvirus 6 (HHV-6) is the most frequent cause of roseola. Other causes include HHV-7, enteroviruses, adenovirus, and parainfluenza virus type 1. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Roseola is an illness of young children, with a peak prevalence between 7 and 13 months. It occurs throughout the year. Most cases occur sporadically, without known exposure. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Roseola classically begins with three to five days of fever that may exceed 40&ordm;C (104&ordm;F); as the fever abates, a blanching macular or maculopapular rash develops, starting on the neck and trunk and spreading to the face and extremities (",
"      <a class=\"graphic graphic_picture graphicRef81967 \" href=\"UTD.htm?9/7/9329\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory investigation is seldom necessary for patients with classic roseola. However, it may be undertaken in children with atypical features or as part of the evaluation of fever. Laboratory features of roseola include relative neutropenia and mild atypical lymphocytosis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Laboratory features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Roseola is diagnosed clinically based on the characteristic features: fever for three to five days followed by abrupt defervescence and development of a rash (",
"      <a class=\"graphic graphic_picture graphicRef81967 \" href=\"UTD.htm?9/7/9329\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of roseola includes several other infectious exanthems and drug allergy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Roseola is usually a benign self-limited disease. Treatment is supportive. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard hygienic measures, such as handwashing, may help to prevent spread of the viral pathogens that cause roseola. There is no recommended period of exclusion from out-of-home child care for children with roseola. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Cherry JD. Roseola infantum (Exanthem subitum).. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.780.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/2\">",
"      Hall CB. Herpes and the rash of roses: a new virus, HHV-6, as a cause of an old childhood disease, roseola. Pediatr Ann 1990; 19:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/3\">",
"      Asano Y, Yoshikawa T, Suga S, et al. Viremia and neutralizing antibody response in infants with exanthem subitum. J Pediatr 1989; 114:535.",
"     </a>",
"    </li>",
"    <li>",
"     Jenista JA. Human herpesvirus-6 and human herpesvirus-7 infections. In: Textbook of Pediatric Care, McInerny TK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/5\">",
"      Tanaka K, Kondo T, Torigoe S, et al. Human herpesvirus 7: another causal agent for roseola (exanthem subitum). J Pediatr 1994; 125:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/6\">",
"      JURETIC M. Exanthema subitum a review of 243 cases. Helv Paediatr Acta 1963; 18:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/7\">",
"      Asano Y, Yoshikawa T, Suga S, et al. Clinical features of infants with primary human herpesvirus 6 infection (exanthem subitum, roseola infantum). Pediatrics 1994; 93:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/8\">",
"      Meade RH 3rd. Exanthem subitum (roseola infantum). Clin Dermatol 1989; 7:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/9\">",
"      Breese BB. Roseola infantum (exanthem subitum). N Y State J Med 1941; 41:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/10\">",
"      Barenberg LH, Greenspan L. Exanthema subitum (roseola infantum). Am J Dis Child 1939; 58:983.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Human herpesvirus 6 (including roseola) and 7. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, American Academy of Pediatrics, Elk Grove Village, IL 2012. p.414.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/12\">",
"      Harnett GB, Farr TJ, Pietroboni GR, Bucens MR. Frequent shedding of human herpesvirus 6 in saliva. J Med Virol 1990; 30:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/13\">",
"      Stoeckle MY. The spectrum of human herpesvirus 6 infection: from roseola infantum to adult disease. Annu Rev Med 2000; 51:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/14\">",
"      Clemens HH. Exanthem subitum (roseola infantum): report of 80 cases. J Pediatr 1945; 26:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/15\">",
"      BERLINER BC. A physical sign useful in diagnosis of roseola infantum before the rash. Pediatrics 1960; 25:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/16\">",
"      McEnery JT. Postoccipital lymphadenopathy as a diagnostic sign in roseola infantum (exanthem subitum). Clin Pediatr (Phila) 1970; 9:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/17\">",
"      Pruksananonda P, Hall CB, Insel RA, et al. Primary human herpesvirus 6 infection in young children. N Engl J Med 1992; 326:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/18\">",
"      BERENBERG W, WRIGHT S, JANEWAY CA. Roseola infantum (exanthem subitum). N Engl J Med 1949; 241:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/19\">",
"      Caserta MT, Hall CB, Schnabel K, et al. Primary human herpesvirus 7 infection: a comparison of human herpesvirus 7 and human herpesvirus 6 infections in children. J Pediatr 1998; 133:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/20\">",
"      LETCHNER A. Roseola infantum; a review of fifty cases. Lancet 1955; 269:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/21\">",
"      Hashimoto H, Maruyama H, Fujimoto K, et al. Hematologic findings associated with thrombocytopenia during the acute phase of exanthem subitum confirmed by primary human herpesvirus-6 infection. J Pediatr Hematol Oncol 2002; 24:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/22\">",
"      Greenthal RM. Roseola infantum (exanthum subitum). Wisc Med J 1941; 40:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28982/abstract/23\">",
"      Richardson M, Elliman D, Maguire H, et al. Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools. Pediatr Infect Dis J 2001; 20:380.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6035 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-D8E5382BBA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_19_28982=[""].join("\n");
var outline_f28_19_28982=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laboratory features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hygiene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Child care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6035\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6035|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/7/9329\" title=\"picture 1\">",
"      Roseola rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/17/10513\" title=\"picture 2\">",
"      Rubella rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/26/4512\" title=\"picture 3\">",
"      Truncal rash in measles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/6/41070\" title=\"picture 4\">",
"      Kopliks spots in measles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/16/26895\" title=\"picture 5\">",
"      Slapped cheek rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/55/9080\" title=\"picture 6\">",
"      Scarlet fever rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/30/32239\" title=\"picture 7\">",
"      Morbilliform eruption 2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=related_link\">",
"      Clinical presentation and diagnosis of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27110?source=related_link\">",
"      Complications of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37513?source=related_link\">",
"      Diagnosis and treatment of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39257?source=related_link\">",
"      Epidemiology and clinical manifestations of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41383?source=related_link\">",
"      Epidemiology, pathogenesis, treatment, and prevention of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=related_link\">",
"      Fever without a source in children 3 to 36 months of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31577?source=related_link\">",
"      Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14201?source=related_link\">",
"      Human herpesvirus 7 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=related_link\">",
"      Parainfluenza viruses in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/31/1522?source=related_link\">",
"      Patient information: Roseola (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26855?source=related_link\">",
"      Rubella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40167?source=related_link\">",
"      Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_19_28983="Molluscum pathology";
var content_f28_19_28983=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molluscum bodies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 292px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEkAaIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDqJWt76Seyv9O1JEJURTPbh4J+5O/OAawPEOlaXYSXUt2wg0tgRJIJG3xSqw2YAzgEnGR+Nb2tebJ9ml06NljeRcEnBbONuM+vTHvWTeR6hbaDJYX0bxTR3EkRZwudr5znP8QyBzkdK+4w8mmmpWv0v+P5d/u0PTi2loei/CLZdeHbh1uprhTKyfP/AMsyCQQD3JxnI7EetW/iZcrY+HRCVdbPYcrAPm47L74rG+B6Pp1je6RLL521luRISMksBuz+n5VR+MupXl7B9h05VVraVSWAy+Pb344FeM6HPmrin7t738ujOZwlLFXfr+B5lBpsZ0lXlur6/tFHnpDN+5csThY368k9+9dd4fVDdafaaqg/ti4idlSJQRBGOdrEHgcY471j6PYTanDIuo/aI4/MEnmXLBQ+Oi4z0HUV0i28NnrFrcXKw2+oPbYSUy8LFuxn2HBNe/iqvNeDeuu3p/V9L7HfN2VrmX4vF1LDCunypGUkAdSm7crDlt3QDoMda1lsLqwS1sZYJrmz8srNqEMvmMGIJKPGcEAHo2TWrpslyL8W8s9jcaYgJtpIORLk9fqee/UGm63DdPcLMrTMmAoAODwenHXr+NcDrt8tLS39emq8zLnvZEfhCGWynvSZ7cxiL5Ylk+dnDrtDLjAOCehro7yB1KgMIw+5mZsqCVBIBHr71yl3aeIH1GUabayrGmMOHw0RIwfl7noQc12Ntqsl3ZKt6B9thj+cOuA7AYOR78j8a4sVzcyqJp33127HNWvzcyM2BLa6lit4Z5heDlo5k65HQEHj8etWJZYLK2mmu5HEUKlmGCztj+FQKoafpnk+I4rz7QQskSrzGQOME7z7AHBzWnvju3up5LVSiLJNCkjf3WyGwp5GDnB9KzqNXWt0Ke6RVIk1LSnubWCWFgSPJl/1iY7nFP1O58q5t5oA32Z4IpVdHKFeqsjHtjB/OszyfEFn4lju7kQjRrmAl5fPjHkzAZ+9xkHqQemauBlvIdgaUSFdwZcKMnlXRlO2RDz09DVOCTTumvJ3tfo/S39XHZXsZ2sXEp8VabPC7RQW6qrqW3ISc8n6hutdUkQubuRJXEQgQAF/l5cZ6/hWJNAgtIZbmKVjCUhKxqSWIYc/rnn3rR1y+iN7H5ls+N2x8/dfHIyR0/8Ar1FT3+WMVsmgnrZIgePyyyecR5YCEFS27OACH/PrnNY+py3t9HBZaeklvPcXCxsquNxXqSO2Mde1bZl2W4c2vneWCxifID/Qjmq8tzDaanb3EMbmQSHy8sG2ZGDhsZPX2qqcmne1309RJ2KyWd9Dr7XAu1W2MTQiBWIjbAzhh0wCc7hyM+lNTV/OvW0t4fI1GHEjRT5YPH3eJh97H6Gr9zJvmAUtFtGYgF3DOemB6066tRdz2DvBEZrcyeWSoBAcbWGfQ96OdO3Oun/DevmU5uduZEt1EssMUpZEdc+WGbl2B6Y9KLFobqBWc4UvuQrzgY6ZI5x6VFDJDFExjnV4UKoQhPl535O0fXv6VK/2m1treGxhtriC+dmRbkGOWGQkkquAe+Dz2J57Vi7pW8yNTQ1o/aIolcN5zAswLFdqAYAz6msW9ntNMsbIXMr2UFyxSAsjhW3fw+ZjarnAI3Yz2rX1rY8623lTRvHBlkckswJ5Oe/ANYCarqmoalcWOq2sb+H5UKYOCkqZ6k9c4xjH1ow8W4p9Fq9bfdv/AF1KpxbjoS6f4fhsHlu7iZnMJby0iULjd3c9se3pVi6ksX8xbzUIngidfLhlt9vzAcbTwcd8/wA6p2Nnd3Ehf5obGOMwTmaP5mb155JHSsvxPb6heQxPBay+XboqbmjzvHUke3btXRGLqVLTnr8tP+D6dzbk55Wkza16yTxFps9m009skqIFaBgShA6e4JByPStWyijgS1tjeJf3kEe14/KVSox1OBgH2qkr3NlaWO3yJLlkbdayQjYEJUrkAjB4bGM8Hmpr971tNvBpkcq3SIUQsFKQtjcu8ZyQeACM461zyu0qd/dv/wAC/f8AzMZX2WxoCB4yMKjDOAvBBz6+1ZD6Vplw8t3Dq1nO9s22RFjG6EnjkZz2A5rIh1ae3tbd9XCW9woKTeWc7mxnjHUYNFzL5mk4syVup5A/yR/Mp67mA/rWkaFSD3t5rb9TWNKaejNe3g0953e0hgVFA8xEkaTd/tEHgZqePT5YEE7TaZBpQhclR8sgkOQAoXAHODnkmvPL+z17QNUs7zSoN8cs6pcOEydpI557eor0K7ke0uHvIYYWKMEhlk3MiOSBnCjqegPQVdek4crjLmUvv7fLy/IK1OzVncpXVnNdtFHYa9pJnjQf6OQVL49+p59KtaVZXSsDczj93wBE25V9duemagvNW1O6tUh1JLZ5VzmJY8yQspyT359MHp1re06xaBEvY2inju4/LRriEIySEfKXC/w5G3HUcVhVnKELSt/XnZf13M5ylGNmR2rLaTGaPCnLKvGd/rms4yNDN59vulZpMOh6gZ5bnsPSkiXU2tANat4rG/OVPkoHRW7MoB6H65qwRbLb3DaheCKeJcxoxA3+47nnjFQkovv6a/8ADkofLMGZxAzAjgE/xe49qoTXAa5aJZY2VE2NGFBZWzknPUH26VR8N22sxrLPrd9v3yb7YSIqlI+2QPz5q1Jb3Usk1xZQNJNLICcKRF2yeO+K19nGEnG6duvT8R8tnYVQLi8YJbMJsZV1Gd/PT24zzRd3EthZ7riy1C4jGSZIAH2D1x1I+lSwG9tLt2NmZoZI2jYxy/Ogbg4HX8an0+V7GMqZrqUFNgS4JL9c5z3PYH0pOVul16/1YG32uYGq6iy3ulLYxvK0gdpQq9EC5Bx25wMd81Na3E9zBdo9zbxzgCMfZZ95HGTuAyFYHtVCTxF/xUEWnSWk7FgZHCwqNp3cHeDjZtBPPOTV7SlSws4baKcXdzM7FGKpE0jFiccccdK6pwcIK8df+C3fsdU6bhBJorXehDVLGC11p5rho5Nx8hvLWZQflSQfxD1xitPULhNGs5jDEZoVQeRZwYHCjhATx3rVfSL42UbSyCKTGSFYZU9xg8VXudIWKLfBK0N2XG6Q5JcD2B61h9ZjNqMndX26f8D5HNzxOXtrnXNQsS1rpa6XJKBLKTd42Y6Ns5LHHBIA4OOai1fQtQ8QWMEltd2suntLsuPKY+ZBIOjNE4GV6ZGQcHNdVZwm3+1ap4liijNtL5cEtumGMbfd3Z6AH8K0Gntb5VvbbfIr4Tc+G3LjIIYdR29q0eLdOfNTilbruvS736enYbrtO0TjtX0TSp9GmD6lY2jW1sIEe4K7YLjI2klgSFJz16imLHa6RZST3O26QhEZkiUpuICu6j+7nnHp0rT1XQtOGqz6xscSyQCO9hCiSC5i7mRMZLDggj0pjXdtc2zrbTxXUcPCpHEwyvYDpxW0arlFJNtdfLbS/wDX5lwm+5h3ckyXiwwLLbWptmjWSOHagc9fLPuvUZ5xWS0UNvbtYvp9/cy28QlR9qrDIwH3Rn+IgnmtGz0y6hvNQP225ks2YTG2kYFIM8gqpz05HHSugisQ2nywXN7DcSSg+XGsewYPQAf1rqdaNKyTvt3OjnUTyrU7S11LUIZP7Ju4JprYohLBkgK8YJHXp+tT2uraLp9vd2jT3MFgGMcdnLAs5aYY3HPGVPv0966LULVLS8hs7W+kguHTzVtzHlGQd1PYnB+tYN5bma6juf3Cy+WY5opIh84zu3Kw6H/DBr04VY1YqMr8vTV/qn6X/HVm/wAWzETxGioqxvqkaAYVEldQo9AOwHpRUDpqm9vL1iVEz8qnPA9OlFaeypPt97/yL5TsvFEcN3YT6bPIyu0SXDBBl0G75WX3yOvakhD6td3sWtMXhmWERvcSjaUAKsHDdWb5Tu65qxIZbi0vEMk0ySoUjbaP3annAI5IGentWLPBZWOgQabqVxaSlDteaYO0IYnIXI+ZcA9exry6avHkW9+mr6Xa+5aHCo6X6nT/AAkt4rHxRPaxRNCnkyKsZk3hVD8EHJ681jfEa5s9S8RyRXSSvapKHxGDubsOB1xWn4X1T7J4x0aOaC2iM7tbRfZZ0lQ74jtcFeq5Xoeec9q37Ww02WctexyXFwZNwwvyoBxu+n1rlnU9jiniJptuK2fm+vyFzxhP2j7I4C9jt5kDMjNBFmVVlQrsA5J45/OozAdQtJNUtrZrt4tkQBU4Ku204B6KBnmtuPS41tNQN7dx30iea7tzHuVclVI7E8cVbhg+16Fc/Zm8mSeHZDscqbbacrIp78gcV1uuopW7/Lz8/wCu5cqitoR6FbRWP9nJp0sUmlozwyxq24LkluM/MTk9/Q1ev76yZ5LeO8T7TG/z28ikpImOVJGcHPOatafJKmimZLRYdRk2Ney2yr+8k6F1ToBzk+5JqeWxstVs4JrmFHuiFw2QWU5x1AGa8+dROo5T9On3v/Pf5nO5Lm94z7BrF4bM6fLutIJCWi3kDOOrA/e79f6Vq6rexm8t3jgM7SuA7AfKo6Z/z6VXGkadb6g1pNeSWkgi89yoYMybiDjg46D8MVR1TQLPxRZmy0bVdUtLmMb/ACfPAS4IOQDgZHI4bpUXpTmpSbS7tdH/AF/mS+Vu6Zqagu5xIjrG+eQTgHA4/SptFIleRlRI5QPvIOGB6nH0rnbWS4EAWaGRnjQBkBO5QDjknvW9omoWl4DLYucKQrKxAIPp65qKtNxg1uOdNxiYuu6cDb6hbalZ/abO5UCOJmLKjDuMfgfwqwL+zuNEEmuWDXRgMEVrExxt2KTuLJ0B6ccV1KG3mTa0hbd0DNjJ9MVU1LTIp08lsIdnyeY21SM8jP6fiKlYlSSjNNW82u233akqomrSINP1ey1Lw7qM13JcRWokQQyJG0kkZb7vbnacjPTHWqcczT3CLM5ScIfMhJwruvTZ6cjoeenNXdKuGs4LpAi+SiCO5McfyxqoPJx6A9RViePSLtoYItbt4tUnhWWGHzVAnUj5SM/ez6g1F4wlKydvvtovL+tNibqEnfYzU2vfvJHcSKpUo8JXK7h0dT2OevrVgbVCbVSbbzsD4De2R0pmn3FhPE1tDdRS3cBImhQgPE2SCrqeatytFGkPlFVZWBwODgdaJt3tYb1ehBhWQzRW7W8bdY2cOV/EcYpIgFlZjkMV5cnoOuM1chRZCC0sG4jbtJHOe5x3qtPcxQ2shlkdo1OGEcW6Uc4+77kjr2yalNvREp30E1W2Fxo8sMr7zLgkkgHn1496yba5itLCzhjkxLbMWZjJzuPygAjOCFB98mrmnLqcety291Ck1r5eFXlWJI4znt3rVS3bTpFmtxDJcRgDcYhgnPzHAx1yeT9avmVNcjd+pd7aMbrUjLa6O80rSTNErOzEksGYHBI7da53Xb2x028iIKh4t277MoBlkds7RzgbRnk49Kv6LqsPiHWmt7We6bKtHKpUMj7cg4PYDtWOdLuNbutOgu1t59IFqkMksR2SxSx7snJHzbsgcc1rQpqm7VdLav53/wCDp+prSSjpIuDWk1TTFk08TFAxJkcZdW2nHPccdai0W51WRZLy6umjW2+c713rGo5JwPT05/Styx07T/DkBeKKVUk+UIzb2Cng57DNU9VsU1RJ1jXfA26K4jDtFlSPusAQQe/uM0KpTbcYr3e7KU4u6S07lDWpLW7sNGltzDKt75jRHGdmDtwpA7nnJ6EVrWd09zeyyqhcjbFuYgsAo7+/XiqVvp1jaWtvGs8VhFaxCIF2wqRZJ7nrk/U5qzby26CQWe+TDAja+wNwQN3sc55pTcXHljd2vv5v/KxMtY2Ramht78QK9rBLsX5S3BX6VHd6UjxSpBzIY8Foyp2HsfmIBOQawtLu9Yt7zUTq1l5dtAT5DxdZVB6gg8jGPxo1jUluLBVljkMcsqKZI8fu26LuB6DoMjnJFNUKkZqMXp96KjGV0k9AOmw6bfvqF1HqvmC3a3VLh0FvlvvOAnVvQHjv1Fbmkhb5kibKs7+ZGwfIAIwRn9awNDv7kJcafqQkmt3DLuc988cdiDzzXQ2ttbaXA8kUZhTb5o+bcASRzn1PoO1GI5l7svi6W2HVjy6Pcfcta2+sTw5lPkkK+Ryxxk9PbjNT/ao7uOKVGldYXU+a7FchTkJs7nPc1mPplvr8Ud9a6rHCgz5iyKSSR34NTXLNpXh97qGybUphtY28E/luE3csoOeVyDyRWDjF2SfvaLt+dl+Ji1Gy11NN7hL+aQBSCPn2tx16GoJY3Sb/AEhoVx90hS23gVLYvDpdrExgiQtCbuc+eAY9xJVQgyWJ5yeB1xVJ9QhuLJbhZt0Uu1lkWFiwyMgY6gY5yexrOMXe0VoZLyLZMMYKpGxlcjJfkn6e1QNd3DyKbV5YyqtHvG5MZwTjsaixJ51oqW0lzBIT5kqSr+76YJBPII9KsyQPPcMJLqJYgwwgOdvcA47/AP1qdorcPUzbnV722vVS7ljlSVv3QERU7R1yxb5j9PypddW91DSLyxhkjtpLmF4vOAJ8sMOuOucVekubW3lmtor1J5kIZ4VAPlE9CV5xTILBbyNponla6EZeGVUC/N1ClgcMp9+laKUYtTta3l+haaWpylx4XWJdHWYRE28SwRztLthusHIUgZOQTnJ9cc1vJdXNrfMsulwpFGu9JEm37n7g9voR/wDWrNubu8vtMkmgs3nsN6S+RMq+ZbzoxDDb26dfetixlklhjkaNog6n90/UdcD24xXTVnOUf3lnv1+ff/gGtSpOaSm9iys5mcSW82bedt3lgh9jd+2BinXEDzxoxLgE7lcZXJXrz6VVbMAleK1ComW3Ix3kemOh+tWbdXmtIWvo5bQsD5kJKsyD1+Un8utcjXLqjDYYt1fvM0QdoI9vFwNjqx7gDPUe4ptzHN9nEQvNsjch5o8DGewUYFM06xNpA8cdxJcEsxEsp688dAOgp0r3lnp7XC2pvpyclVkCoozzlm7VWnNaNvy/Mduw+aRprrZbARw/dHIJOB1I60iRq1y9sY2DqrOGKkAAdSTjHWrKC5DBnhLDaSVXp+HHNUrlPJsLn7N57C5P7wPMxPPYc4H4Uou+iBdipBGweWKG5llhC42SgHGeoDYyRVHVYbmOe1ntpUiWIkSq8IlEqY5XHb6jpWvo2i2+nrNMqMiSEFkaVnHA9TTtQlSYpDBEPLDZcjKbx/dyOg561vGqlU93VeiNVJXsjOsLqCa1uJsTPEQqRor7lwvHyj+H+tZ+oW8Gr2JutMKwOse2cHakbqCcOcgENkdehrUnF3o8Wnf2VBDypa6835VHqM9eBjFYmp6zZeJbtdMtLmOXYPMnieNlLovYHPPJrelFuXPBad97Jaar8tTSL968TnjojgkNZ6qG7hJk2j6e1FdCmsLAixeReL5Y2YKNkY4oru+sV+39fedHPLsYM2oJc3OqaFqlj9oTzyQkDGJuDwyEdCK0tOsI5dS3xrMyMojQSZwMDHP1x+JFJqn2NIre5glFmMQsZt2ViY8kbuuOg59aZeWdxB4mnuUm8tzalZYFf91P1ZSMcA5Pb2IpuSlG0fd0/HS/9ffoZtroa3gHSbXQvEF9fXLCaaV2iiiZ1bySMEMuB8uQSB/Orb6tGtzcWi219LczAyBYrYlHY/w7+i+vtWV4f1hYzY3N68of7TGhW6jGfmIXYXHDckbW/OtTxO7wz3dnaLfPC7vGTaxq023dyOeBzkZ61x1YylXbqatrfpp/X/BMJK++5Hc7YJb3V9Rhja78hY4YbaYETkcDnGMjPIPNSWUcl1YIqTLaTtEV80jKxtjOMdxkYrOTWLGC1h0u1hntI0UIsLwlWLHnBJ6Y5z607QluYpJ4L1mMDkujE/KB/n0olCSi29Lbenp/w4JOzZs6PfXupaeo1C1tLa/QFCUYyRSrj72DgjJ/h7VbhtZWsfs8ptoAF2hbZPLA4xVOylgjLq02WbKrz/D6/TNW13ucLJwSFHp+tctRWk+VWRjJWdkV7FPLv7ebXUlupo7d7NDCWHmRsVIVxnJGR1HfPan2EXh+S+MmkxbJIZNsiCcl0PXAzyOT09veppdFhupkk+0Xou0bKNFcERn2KEdKg+xXkd2WgvIrk7tuWxhTnkE9z1pc0ZXtJp29F93/AAwJrozG1nVrzU/Edzp+h6rfWosnJnC2cbxhj1AkbkNz09arLbCPxLBfRy+RJHG/mQgZErkAAkY4Pc461rR20s920ayvFHG7OTFGSMk9SQMZ9Ceavz6dDZWn2oSPOySBXjSFpHZW4zweOeST2zXR7aFNKEV0ttvfu7dfPbua80YKxPdTaW2lxPaS2tprCKEFxcrkA9xx6846darQ2ktzp3l3scKMZCrwooMfTIdeSOf84qO5sY3nIS3/AHbD5mXofqDx+lSWWmefeSWsFxtuI4luDERhth43D16Cub3YRupeeutv+AR7qW4lvdajaXISyuCF+UMkkYZSBxyR8xGM1c8J6LNp6Q2UQjntEneS2F2it9k3ZJEZGCF9BVefwzqqSpc2V4G2kP5ZCnOPr+NRarp63lzp99qVnK01sw8qRWdQhzwWCnDKD37Z54pSlCa5YyVnvZa36dglaWkWjY1bSobPWJr0xQyXzxFWnVcPtPYnuOO+alT7LeLIvlxhoiA5VjuTIz8w6cj0rOaeaSKWSe4jYR/KqM2JSfRl6/lwetMDKs25YoncLsWbBDbfTrj9KxUJOKUnqjNxfVmmYWRQtvKPm65FLbaYoyXdETksQC38+tY1tLeLKySzK0ecptBDpnsw6H1zWxdMLOyhmlttVv2m3BVsId+0KOdx6DPbNTOMo+6nuEk49Rbe4ikvporaeT7QihnE8DqSpOAdx+nSsnxbdi1sidOvLOaBMec27O87iHGR0YYHWtGW9tYba3+1z3FmbjAjguyUlyeMbeufpSXWqypLFOsgjkhjYOyjaCuRuJGPYHpTppxmpWuvP/hv+GHC90zJ0pYyJZrNF8tQFeSIFQ27gc/U1b022lhIKI8zwLsykaoEjzwD64/Or1pfT3tqyyQxxQKBNhFx5vPX8+o9xUUNq97hFt4nKyb3aWUKoYf3VP3sdz2NVKo3fm0/r5Fyk3e5z+tnU7/VPL0TW7NLyNA8lpLIoOw8BipGfyyOexNaHhi4ltra4SaeO7uyqQmZF2oQuSeT97BOKjjks9WkuFktWW5XzLVmfAkiPfbng5GGHtisbVtH1B51uLHU1Qx8/Z5gUVuMcMAVI46V1pRnH2M7R+X6robxSkuSWhsX2mW2o27xsyRyD55HkTcGOflLH+6Ooo0nT/sgcS363c5KnEUe1AQcn5jy3bjp9aXToVs9NvLy/Eyr5B8zyyS2f9kHgjrj0JrnfBus3l9bTyol3eOJjNAjglgo7ZPABAxx1J4ojCpKnLlfuq39X/rQrlk4tJ6I6ee0u5IobaBrRbITk3MTg/NEFx8hHQgnPv7Vc0qysrWwk8xUaDGcyYOV7AD14/Oq8t66+Hn1Ka6WNVi86ZCoQKD/AAjvkdOSa5ey1+a51B4NoaEoWVcFSh64xjr1rONKpWi0tlv/AF3IjTnKLS6HUXVp9ognOmQ20c0kPMkzEjPPXvye/vVDSoLu30NLLxLe2895IGDGL5flzwvYE9QCAOAKluZ7hZ1a2GyGSNSMqCD3yeew9KyYNQM+rPYxhDbzgo0jDcWGDkEnofTFVThNxa6b+enmEacmtTo7KDQNAtBoRBTUmXdPIFYlehwCPY4wPQ1LapPfrCWc/vE3SyAYyvXA9jxS36SXFrb3EkzNd3EKRny2K/7JY+pI6fWr8MESRb3wGjI8tllIyAMbNo4wPf1rjnPTmbbk/nr5eX+Rg3ZX6kN4JLiaORIIxGqbQY4gZXC/dVT7HOMnvUe/yBNHOGO8Aybzh93r9R0/Cr0AaeSNV+VYxy4/pWbdtC93vaaREDcYIBcf4VMHf3exHkPaSOG2SOGUwtGPljRRsC46j296xfDuqXGqte3Wnp5Njayr/pMkRK3THqiDI5PBz271sSiyMdz58AvVNpKUtx8rP8v3cgZAPIz6kVR0e8lm0LS4Rpn9nQW8IUWbSF9p7kkgEtj1561vC3I9NdNXb8t3+SNYpKLfX5DtE0mDSrSZrRTI80zy3DS8SSu3J3FsfQVeeYgottg5PK5wQMdabDNGI3DxoqKw4LZBz0HNT+TISySArIVydoxgdRWc5OUnKerM3q9SvbQfZmVURm3EsZDOQQx6krj5ifX0qZlBkT5ZMLgFgp2+wz0rPWaRLyaSUGG2VAFHmB2kPqFHTP5/Sp9VvINNVNQvWmEMEKMTnDYdwgUrnB5xz1wKbjJyS3bDle5LcWqIJCpbk78g9P8A61SWEkVxbebHOkqZKlkYEZHUZFY3h/VDqWqy211ZyJDGSUkVvkVcZzkfQnn0rUH2zUR5dsYniiGWIIU4PqAOp96KkJQ92ZUouLsyvMJpVIiBdR2B4p15Frh0o2+mXsVpcOwPmTRGRYR6qnRm7jOQPStWGGOFfKiwXUYZuCQe4FZ+rXq28eZizZPCxnoB/n8KUJuUkopP1V/wJT5naxJHp7tOrR3VxJMQFZ3Y/Me5PbnripHspIyXKtcMh4WIbmY+wPHHc1Ba2VteaaWvor6CKRirFrkx+WOPmTHXFMeRtJ0ZJr6+As1HDO2GfnjC/Slq3ZPXbb/IHduyLMqu8EZmLxzZO+JmUhF7dO/tmqz39tYxeZMSqx92Bx+Xr+FVrHUbTUoFuLOeJ4CfvoNxb/8AVVWGW7kkngurdPIkXcjSwMzAg9Ac8lh9K1jStdT6dNilHuaWl6odVCz20kc1qGKlFj2lT6c9TU93BcXC+VY2sCQIQXkZV+Qe3HJ9qe8EWlae4tbV7iQfMYY+WY4+6o4rOvdB1qYxXU12LcJh0iJwRzkcDgH/ACahODldNJdL/wCSEuW+j0OekttMaRi09uCSSR864/Dt9KK7b7fd/wAclmW7kwqeaK3+tz/p/wDANfav+n/wDy/V7LUIYzbva2aXZZWaaEPh1Vsq7Bs9+4PGOanezTUr43N9qtnd2WwRtD5QO3ju6n157Vf1a5H23TFEkk1nDcPb3BR84YjOwr129OfWrOmJGunzwzQW4izsCFdu4HOVI7gjHPSvSdWSgpdf8357bfItydkzj9fsoNNjtDpoOpRtcIYHWUuiHcCoZvXIIUn6dq9A1JE1HXLp13PNZuZJYgwwNxwcjoeQcVz+i+GrzV9DvlmtbPTdPvHGyB3ZpFZW4cHopyDxgggmm6fZwW2pajOLhopFt47aSMNuzsztlxnOOqn3HvRWlGppzXlG/nvbe3zWhu3CcEk/eX/ANPxDeS3umS6Tc3tq169u0sUCgiReRtY9kGfz/Csm7aWPToYnuo47u3h8vzHDNH5hHHQZIz3p0cBvrqO5huZEiLLuEUJVpQOzsecemK0L2+hubyBJQERWPnSerbTtRe+c+lRFKnaMV5vyf3HPCDhpYu6DpyaXpkULPJeXEhM8kkwAJkYDdx6ZHHoK0Lq58uWNJEw553cHB44JpukzJHYh7i1E80jApHJuARdvPueasXUsd1cxlY1iiQYMakEjjt7ZrgnJyqNyV/M527y1K0s1wICttNscuMSMdgUdyTg/yp0dvdTRGa5SF7iRv3joMq+OAegycd8Vc85YVAETE+46Gq0d9I8si2d0qXKkK6h9uD1wfepTbXuoWvRBP50zQR+dPEIckeVIy7hjGGA4IqWFoS0yhiLhYw7KvI2HPXHTODj6VXvJ2uLq2nuLYpC+d8W8oyNnqdvX8PWrFm88SxKzS7uec9cng8d8YBNJp8oNaA80DSRfvULSgFI2bJAxnpS/bWhu47q0mBaNHt3i+baVOOnuCKrTT2tnFLeC0H2qUtG1yeWC8gjBx0wRycZNMO428csk0gR490TBPvL2BGTtz+lCgnvtt/X9XBK+5K+oSrfkxyMECJGDv44JOdvY81pQysyeVJMo3thdzbQT6ZrGtrRWmLvFbMcAoxb5+nIHbA9uat3MPnJFKzFSjKximG5MqfvAdmHYilOMHZIcrdCxc71QkwiZ4+GQY3be+D7dabbtHgEMzgkbcjBA9+31FSsRJPksC25d5J6DpR9jWK4RTtMZkU8N8pBPXNZXSVmLQILWKS5LFlXdjbk4H41E11Pp2tJpiPeJLIpfz4Lc/Z+BnG7oSO/T8ak1IyR3Uu4cp90QfMCT2yevH86y7q6m2FrIsWckMJVEG444Bbkc9MmqhFz32aKjFyItR8iHXLbVr+3S6um/0eKWZ+g6/L6H3q8t4NSkWaefy5QDsaLJdeTwAB82QBkHOeKR7xoitrIIXJRS6lVZQf5ceorTgtTO6RCF5JJQf3T/ACrt7n1A9xVzklFcy22fkW5JLVFKExJpUkdkxYzEpH5iGE5/2s8rzWE017Yz280t0ftRTACv5gY55Y56DJ6itPX7siTyDEw+yr5SQoh2jPGV9eePwpmtWjwq9wqJJBMo/eDrGBjkrx09KulZfF9r+vyNKS197qSGI3Fyt2qBZHVZARhDJkYDdMbuOh7AU7RtVtr+xluNOMgSNzFJHKu2SKQHBV1HQ9/Q5Fc3r95Np2uFrCXZCvIjwW3joMnpx2qxoZtNJ0+6kt7Yg3RJZFU7pDn5pD37gfyrWVC9JSfW1v1TNJULxUhv/CZRR61NYytdRzAgZYg7/UBTxgVqaVqVpfWj+Uj2twjkcAqhC9ge3WhEsJIFu7yFg0RBEotw5HHTJwehp2pzXFzp5Oh3C2N0gPkyS24Kj8Ohz6nNKfs5WjGNvO+n5bfkOajtFWM6z0Um4mtbzYmnl1kXq4Xbz8oOcEnufena5pyaXbS31pJLeqAHaVwCuT0HHbjn3q1E2pLpC/brh7yWMYNyYwgJxwSFHAzmiyRLxlW6j3HjzImQgMD3HYEfrVe0mpczd0t7df11/wCHBSknzN6FbwnfSarZO0kUckySLLmMqoYZw+e2cbTj61szWNkHWRrYJLy0jrwXXOSD79vzpbi0RJbCWNxElq7yJEIkwWPG4uMHG0kY759qTVBklZ5buOOXDrPZ4fCnPUjPBK7eOckVhOanO8NE+n9b9zGVRSleOiNOFvLW61Bo4pZFUR26Fdynu23324FPnZzBHJMgTK4THG7uefQcVIpZLGOFi6jHzR9PmJzz+dU7e0W3e6LTPMjSmRfMyAoIA2qM8AY/M1xqzu2c+7uTSRvaQBPNXfIASc54P/1qzhYOJVAVZGYhRhcfrmpAbqa6fzArRkAAljwe+O2OmMUy3nMN7NHgtxtZmIO0EZGMevTmtYqUU7PUtRHW8Bt5bqBzGJJJBiZR94AcKD1IXnk4+YnA4zSuypFK7yTBVBLELksBjGR3Pvip5rlWIjYRblXAyQrYx29fSnRwRARLMWEJYBsA85PTj/IpOXWQm7u7II7WOZES5jidInDsqYbcRyCD2/nWvIhuPMmeWJSoAMaH7q9hVRVkmkaK1tVWBDlUjQA/Tjk1XvVuktH+ytGrDG5DgZPvnrUO82tbEbsrWl7Cmprp9xBJA8rl4jcWgKyAcsyMeM0zUjayPMl5bwXSeYuI3BlWUKQykkcghh+h4wavG7unsF05WkdEC/aJmA2RKP4RxksfyArKvnuHu7iNpbe3sGiBjuVdi+7gMhA6Z4x2xW8FeV9vn+Pf5b9TSMbvUsXSHUUubKyXTtPEnz3UcBAmnB6pwMLnv1P0rJEMFkNTnshcQQXBE12DK21toAPAII4HrU+l2sOmwA2we5uwpMeFCBM8FuvTHYnmn2aIBJIph+Zdh8w/w98jOAOvXk1snyXUXp+f9W0v+hrypXC5v7OytoHldLe3fCxqrkgg9AOeTjmrq35gsxcaYls4Cl/OESszDuRtOPzqpqa6fLY2n7hIrmAssTPGdm3the44rN0SVtPu5nknW5VQciOLCgH+AAYGMcUezjOHNbVdH1CNNONxPEusarF9ilktbm+SQjDLjbGDzkKOpx+NQ+KN+pItqLWS43xgui8Ac8DPX649a1tNt7uHTYUk8gQgBRCZCHIPr69qLKzlMstxdzxyWasdtsLZVKnPPzjnHbFaxqQptOKXu+uv9fL1KUowei2H6RpWn6V4XWOS6t9LDyZlYDkLtwFUD1OT9QK1tD0UW8jJYSTXMMfLu7lgpP8ACM85747VRjLSXHm5EMez5Sr4ZRk7tw7DGMe5qC7uk1HWl0hTrFgbBBLHcWVy0MU6scnOAd31781zS9pUctd9X/W/luc83KVzZ1XWodCsGv7oXJhRwJDaw75ME9h2Xpk1iW51DVLhdW0vWzPokshHmrIcsP7jAgFT2wRW41yImJkc7wOvUn86rvdT3EglnZ3Vc7Qe/vgVlTtCOi17vt6W387/ACJirdA8mY8rG+O3zAUU3zPVZPzoo97+v+HCxwMenix1u7ls7aG3tbiTd5QX7jYHKnPc7vzrTmlfe0bqBKJQoKDIYYOMnIIBGc5p8cN3qRaBIGVXCEM/yjsSB9BjP1qvcu7TmXSriwuoINyXaS5dY/U59cd+cY4r2HJzfvbr+lf8jpk9EuppXmv2NlcnTY7yzMzopUODuXIBwSOAayvKtZ7HUNjBtRRpTNK2NygvuIXHO0n9fSpdM0rS/wC2pJ7or9obmBTJgbdvzZx94nnFKulrZaqJbd9qyJJE3HJDYZSffP8AOoSpw0i3fR+r/r8SqKjdpbnEXctrp0iOss8t55eNrbuFOfmbb1PpXb+H9HiOmWUl1HJGUXcHKFuTznGePx5qa0EaSO1pJHN5LGKT5QuWzggYyc9PvV1kqK0YBCQqrBcucgZHU+n+TRi8Y7KKVvP/AIFiK1a2iMm2jaK0jUkSYYqGCYJ/Dn647U+3iZiSTkNgrkdR7GlTTFFoI5JJHkVgWDOVw4PUY6D271LcyJcXUkUc6maL5XCHBTIB5A6VwuV27HPfUSSd5SG8zaeSEPOR9TTTK8yMjSqQq4GUXaAOoJ9Prmow1ijLLMyF7fCESqQBuH3l/vDqPxNK+m6XZwyy2cCESNkInOcnoQeMUe6tLP7g0J0E6Bfs6RmDqx3jAGOwHYnPJxVW1xbuxH3iSSCxIPTk8n0xxxUl1aJqKPE7SQyyRYHlp83Aztz6e1UdPsjbWMDLIpMC/wARJXkc5HfvTjbld3qWl3NaC+tr7y1JDKFOdnYeqjuM1Tkght4WKurIRgKTyR/hUUkkcbC8YpCijcREcR9MZOen8q04oGuriQpYxkScxMZgxB/u4HGOfrUtKnqtidYlWzRXkGQik4GT0Qev0qzcSQyKDG++MHAb+8B3FBmukdI4Il2ZbfGy4IbPBB9MZyPpRFYsDulOyMEsqRjGT1PPvUNq92F7u7K2/MkoWKR4403MINqmRsgADcQo555I6VZW9RZEtpbC41COUrGPIceZCpODIFHDAEgkgkj0NYkeorb6ubWSRWLpsWNoCAme/J+Y+9aqpqO+3YTRSabZkmRg43ROWAUKMA55POfrWk6drc36oucLbkxxFCLa8cqVOPMUHa3/AOuqN1JAZNsMjYHUkYrXim+12wkiinjVyGCTgGRRzww6ds/iKoi0EV3NMLmZ1lUD7O+Nikd14z1561nCWrvuEGupXjiWO6WZwkmSPkJ5A/Kp9Wnu4rOzS1lmLqrq0itszu7DH3fw9KmgAaVd/Yd+OamuooZ1Cndlemw8/nTc1zJtbDunJNmXYXMt5ocz3Cu1xaOqrLI2WcDovrn3qxas0NsrSytNh8skhJB4688+mahWK30+F5XYIgbBJboMZJP5VT13Vks3sr3TkaSzWAzs7qGZiGxnH19M1qo+0lywWjf9I0Ued2Q3UdBvpLcT6PY/aXWQiSGIopQ9R8rEcfietRS6W2nafPdX1oltqDLiWMuCHxyGOCQNoOM+9GreIXtp4NSsJENvdQF5EK4k8wFctnpyM8cYNRu0kFrDfW+pz6lbvIQyXaq7REg9OBlCCV2tW8fbcq5rW+d/R9DeHtNL7HN6VNHqrvKl01jqEbmOSMMVS6iYYwynrweD1GK1dN+2QTAESbAu7ZIwJGDzyOvTrVnT9E8O3M0l2YJba7JARUf9yoJHJBycjJ6Vcsdatnv7i2vNElhRJ3t+EbBEbFQQx7HGfTGa6K1XmuqcW0u9tPTXU1nUV2oorf23c2+otbLv4PzKGZQ3POOcY/pW5pmopqVhJsMkTJKbf5hsBZefx47cCmnRNMvU8wm9A3sYmVgAq545xk//AFqg1Lw3NdRoNIuWCq7MwlkyeRjGK4pToTsvhfcwnKlPTZmvbQ3F5ZS3UURmeIEAKyp84H3SG469c00RC5kiuTCUaRoty7NuwLnhgOM5J59hVWy0++tSbQSswyrlB8obACkn64rTmQwWLIjgSIuMBjgn04688c1yyaTtF3/yOaVk9Ca5vUuL+4hCOjQvsZ2Jwx2hhgY6dBnJoeJZplRJUSWQZRXfG5uuB79ay726/wBPihtLmK6uyhL28rmMsRztQYwR171dtHgkEZ2CybO9o5mysTjrz7Vm6fLFNf1+pLjyog85Q7QzQyrIwILgDauD0Pp7VVW3uZZZJbWMuBz8gfbn1brgfT3NbskUwkO9RIzLuV48EMPUVngX17fmM3EsZtSHj+z5hIXurHo4PeqhU3aEpdUWrGHMSZVHmwXLk/JEP94/zp10WmH2TT9QjttQkUmKSSHzFGOOVyDg0/cttGGJtX6ZVjkfjXOa9LpsNxJqupgl1O1fL6DHUAdTx6VNODqT/LS+voEYuTNdrCFYLeXWr+X+0NPlEnmWMjJHK4wcFR1zjlTnGTWBYeIbnWPFBltrRZF81kQP8oDY/hPPTuSKuzGSfRI7RbiR7aaXzYDJH5fkqRkIGxnjPfmsGbxFoWlwQadYTwEyBkmvI1yXXPzIvU7c8Z712UKTkpK3M9UuyXX/AIY2pQunpdm74i1CWGwn1SAGVZpsxRZIV0B2q2fcDP0NU9AlurhZby5YhFGUiER++TgAOTyOtFzex3X2SS6YTRRkmJVyqlccgt3A7Ul3eXk92twbuGOxSMrHBH8oLseT6scd85qowtDkt8/0/qxooWjaxpMx8sl5MxcbmZMgH1J7D2rF8Qa1DpWnziAxm4Xb5URIJyerOOeT2Hao/wCxribVTdw6lcxq42PHFgoBxhRu+709CTU8sGk+GL2+1YWdzcX11tMkYkPkluo+XkgZz0NVCFOMkvifZd+z/wAwUUmluWvDGv6hr2jX51vyZrWOIksYyGWToozgDJ4I9qy9X1a1s1mW2tWfarMLeBcSS4HLe/oKtaHrWpanew6hq1uG03zPLgtokIiUnp8vfHes+20q5uPFjXsIaK2+YF2Xah7sVPYfSrhThCpJzSSWtk9PT1KjBRk76FzRb27vdNtriaKG1eT70NySZQOwwOjdOK0Zmksm8lSPNY7dp546ksOn/wBeq2l5sIZtWvDBK1tv8gDnfIWOzJxwADuyeelXtPjaGyaXUC/m3MWW3DDAE/LnA4NZVWuZtLS+39diJ7lq5tJRbSgOsm4hmZyIjtHr69c/hRo0M627m4bZGTlV4Ib0qxZiMRQ3GpTNcSnMcKynyy5A5zgcYAP1qnq0Ul/JbiB5rcK+9vJcAnn7pyPu/TFcybfuPbv/AF/kc97+6XWdfN3GMuBzyKJ9REkhDQrGg4Ugcj61S1R5o7VvssTPPuwqjGTzTJrZ7W1ja6E01xIoDRwkFuffpSVOLs2JRW7JGuIVJAZiBxkMtFVhaIoACtgcc7Sf50VpywK07k18G0y40xbNDK9zuzMzAKgQjOc9c9eKhvj5t/LDBb2cbzJmMW0RDsu0lmfHpkdKqLqcwi+w3s8Qk27kEo4kIH5bvyzVGWRLTV7C7aeVGu2Fr5jsVSMN1Leg4A/Kt4Updd7P59SVB9TcsbEgQrCtosYAJknj8wOP7uOvvkVl+I5BYahapCd4keNTuTZtLNjPPPTH44q3rbXenSSxhJJ9hUDZ90jGeP8A69Ys8sepWCSXsC26gNG8cmVK4+YPk+hAINVRi21Ubuv6+ZvhU/aKT2JNWun068gCiCG2kZpbydwN20YwFHuc5PtXQt9lisYPtqG6R5vNhKQhhG2MBuecnOPas+Sxn1W1tW2LeSGASRRs6puA6sQeqnOee+KzNN8L6nZa/earqN2LUXaqpt8iRscfgo4Bqn7OcbSlZr73+v8Aw1iKiWzZ1ENxsVmiIKFSVI/iP0745qSWSGa5a4FtGtxLF5W/G2R1HOP61zkmqWMOsDTm1jSzEwEQTzsXSsck4UZBzmtebThLHmOdYsYBYpksOwJ68VzzpKDTlpf1MOVF43lqkIjm8prYhlaORchySO547Y59agllEEciwpJHbIP9VInCjthiMYrP1aW0sLS4ur4vNFFGXMYYjIxyMjnkdap3HiuO10SHUbhbhUuF2xafG24bMYUCPOAuB/k0Qw8pWcE3d/j/AF1LjSl9lXNNtMkultNSnuZba5szcPDEeBuaFk3H2G7INPhvbeeSHRJ3mlv47OLzpuCrkKM5PYnrz17VyUep3uo+D7+CWZ47rUoHWIyN90kYA45AOME+9QaB4TuryeTWJpNR06W4WENDBLg2ZTKlHJJDJhVYd+cGup4ZKMnXnbl0X3/lq/6aNvZcr9460288EsjROnlkAIuDhfXPqKSScafF9puFPlIS7C0UsRz/AAr1zz1olZY7VpJruMKh+bzHCk+pPYZ9Kr310ZxbxWyI8f8AEO7k+nr+dYRTk7PYlq7NdEnvbGZ7a4eCUkL9pZCxiycknHTIGM9s1pXEUVpbQK0vmPHGfMYLtMnB3HHYZIxnkVk6daWttcyTxLIbqCFokdWxCgcDOV9Rjj6mtG2hVbeJrqdYIpFPkxuCSwHU56ZPpXJUtfR6en9MxlozPn0Ww1OSK71OAzzRJ+7IlZAvucdT+lRabqltd6pHaTXUtxCuEBiYKISAWDOPQAda0r6GG5ga3kLLbOD5nkgIWPGPcjg/nWdpOhWWnuHs7aafuyOu0Mfp3H1rSM4uD5279PL/ACNYtOPvMbPq5tYrG4MSO06q0pZ5MvvznJxtAX6/1rTsbmzvY/Mjt5oGJIIlbcqn2xnNQPBN5LLcW9zBCr7iwIy3fOO4+hqYm8hsJhaCQt5bNE/lEbmx14qZ8jVo7+pMkuhE91HHfvF9klcIBmV54hFJn0AO4H2Iq2jjkRKig9TjoPSuXudRury/gtrCEpEq/M6xnduIxkEjk5GTmukjmN5b2xS1VJgN0+JAqTFcggegJFOrScEmypwcErmNr2pW9k0ct0bhbYfu0W1YeYMjlumB7Cie40zWZInNxqF4ixskLpGolQehGAGB+lF9p2m3V28rspmC52SrvVQeuR0Jxxkcmsa38SWdvrttp+lWUdzaSx/NdrKLfyJMnhYsbSPbGT611U6XPG9NPmS9F+P+evZm0Y6JxTuE2iW9tbtF5F9ElxHvywRJIgf4GjB2nODkg+lJomivHOIbWVJomziPyygJ9XJJxgCtnT7iG+aViWfPL/eJHH6VdidESW3G1FljKrj5jhsgjAGRx3NOeIqJOL3K9rJJp7nM3WqRQyzRW0lrcKDhNileAPvY6kA56YzWpY6kdSeK31JLaSZNpQSz+W0mVyu3jDHAPB9KyNW0NHt1S1tH1GWLaqfZ7mOI7fqeM+tb2nwtb6f5U2xJ2ASYRMWG0Z2oXIHPXJHerq+y5E47/j66a/giqnJyrl3NeWNri0ZEDKWAIPciuUW9u7bX4dPmsbxLnGBcKH2EdmV+nHcHNaLeJLpblI2tFSDgr+7w5GfX19q3be4a58uVomiVxuVpOA4HXH+RXJHmoJ88bp+f9fcY+9SXvLRliFVluS8kjRYjO4xjcx47CqV1FcS2KSWj2zxPgBZpRE7KehOejdOKsXd5FaWL3M1lJqFptLDySMMOhIbIHAz3Fcnf6JFNr9tfpcKli0IAVXYyHPQNjgsOhxnIrKhBSd5O3yvt07mVNJvU0ZbeyjcXd9Jax4AAEzY2P/ez3P0q2GZwFt7k3MkjnaioA27H8IJz2+lVdW0XTr22msb21+2Q7wVGMMDgZZe69aLu21K10VYdJFjHc5SKWS74DW6qRtDjOGzjPqOla+7NLXXz2/zNG0+poq66dHFBJbyWhYFwmVGCT144GT271pJcXUlvhJ7ho3yABEGB+hH9a5nT4Ln7StxfalZyXRAUoke4IO5QseM/StK7vTEi/ZUVRkJ5rTs2ST/dBGetY1KV5WWr/ruZyp30RoW9ncyQSNe2kdsgx8rTIWAJIB44HQfnTfsVkrK11drIcY2iPAI9+5/Csy/jubS3QlP38u9owVJkUKRkhST69e1Y9jJPaXDTXHnz3DkFLcEAj05JwOeP5CnCi5pyUvu/4Nxxptpu51Xmafbbh9pncufnGDsBxjO08ZriNX0nQbnW7VXsruGaRCkc8kDRQcDjnByOwwD6VtQ3kGpQgzK8LNgkMeFYdj6dKNVzsSy06NUn2lozc3REjgnorMcAei8cVvQUqM92m/OxdLmpysnYyluorZfKk+ztIMr5BLBh77cDPQ1Ff6pDYWltqLuz5zGgVAQMjJ2+mMDn8O9c+za3a6iYr62fehLYXG6P8QSB9a682dtq+hRvqsM7wBgDGq72IzncACpHvg8121IQpOMpap9nc7KkYwtKWqOW8K391rOrySX4umto+kSHBxn72SMDpjnmtu+1qJrqO3uo43CHYu5ju/3c960SLe38u2sb6F7KcZUxW3k+W3Tay9s9s81VbSY5NXNwNtug2gs6AsOMZ57Up1ac5uTVlbTcj2kJO70XQ6DTJfMsWkeJYYoQFjVj8qgd9o96zrV4pEd7RSFl3Bn2lSWLZJAPTOO1QXOoSW8Ti3UzoMhIt4BcDpnsSevp2p/hHUr6/wBNlfVNPksZUkby1kTyy6c84PI6YrkdKUYSqdLrr+hhKLinIuiIeXDbzrmBZhOI0Tccge3U8cCrWnQvdr9sntntbo/vvJnn/fKnQM0YOFBH8J59elNS6FjfqGQtJtDqfT/dqzpmmLapcXSvcT3M6jz7m5cM7gdBgADviuepO0ddP61MZSaQsUQkuEMpLRIuAvYe9RPcRI0iRZGT1Ap8g2Rhyw2jLZRS2B6nHaoIGBCvEpMeey/e+oqUr6shdx17FK0bPCv7wKRuIyUyPvfWpVMjuryPmQjJOME8cn9M1W1G2up5IXJuRbq7M4LEKSRjBA6+2elTzXT28bh1QQyADc6ZK+6ntTtdJLViMl004u2bm4Bz2l/+vRWj5kP8UsZPc7FP9KK29o/P+vkO7OVvRFOsZuQixxuuCx79BV5ZYZ7PU7bXLBFIOLWaNfNSbjowHTnHWsi6uY9Ut23wfZELblWUh8DHJ5H1rY0uVLhrZbQrO2PlRD94LwTnOD2rtqJqKv0/Drvt6m0lor6EE95Ba7GuMWsKhdzSIQAp7cH+nSq2pQJqkaQQ3EM8U7KrycMhjLqCPrt3Zrpo7Se4WUCWJC4+QuB8v0H44rC1O1/sp0jYIjbTIVjXABzjj8azp1IuXu/EXhppzt1Ksdvc2XiqeS6na408q8VupA4TcPkBHQDbn6mtuS5hxI8joqdRk8kZ6motL0yO/wBLjn82QSRzs0gdduc9x2IPTPqKtWOiaFFJLf2sEkt+Dj58ZPrgMcY6VNWrBv3t1pov6t6mU5xWj6GRdWJMn2yKwWKQsCbhYBls+jYya0ItH1y5aXz5LdiGH7qFsssefvH/AAqzc3bHcqQtDCo3jY/D+2PX1qhbTXP9pQETbLqclIT2bPZh3/Olz1JR0srd9Rc0mroil0y7EV8bmC5hlhZVXzUBVgXA+U8ZyuSR1FVPsrnVprq7fePL8mICPDLFjp745ro9Vll1Lw3aRTXbPeQXG93AKl1JI+X6ZwRWNOuIpCzPKwfa3mMwwM854OB7YqqVSTTvvt+X5mtGtJJofp2nQwyTSu9sUCL5QDMXB7bgcAc+hrY0y9Rfs1qkaIJJC7r1IPcfnn8qpabHLLDOPLzGg+UE5O33/pirVmk4haVmA5ILjHpWNV81+ZmU3zbszolFq2prMY44opm+dwWBjIzjnqBk8Uxngt4xh4oFdtoYKF5xwB9a2LZZLhhHIsH2faSz3ExbJGOAOpz9eKbe6jpdmCbyK1nY8CN4/kXA4OKftG5Wtd+RUZNuyVx6xJYulsEhhVAHlMi75HJHLZzwAcdM9KfLJDcGRWvZ4Y+vmrtLD6Kcj9KgWa3vkW5uFjPmN5hcIC8mOig9l9qnlilKJ5Sww20K5WONAHk4/iOP5GsGtfe3IcX13M4SW1vatbW13eXUROHnvH2MwOSUUqM8+tWJYraKKSCEizDv87pIZAgIxlR1yPwqvNZpdKTexk7XB8pWHIx1J9P14qktkPI22dxu8t/UfNkknHc+mK6Eovr/AF+X4GsIpu1yfRdNGnawLi61lL5SuEWLo2eu7cfkbjt1rclFwLiOLTIrm5nPLJEhSKIZ6GUsOcHpznFcRaWsOoauumNBNdh43c3vlYjglQfMMjg9QCemRiorK41LSNQ8qyuZGhMgVtjP8p9ctjPHbpWtTDupK7l71uqsvw/4DNZUXU2eqOzki+zyvIxkjdjtfB6HuDigPPHBdee1k8KQ7oFi3NMjAc57BetWbUyXkY8wAzYO8gbdwBIyAeo4qECWOUtHEoCsFEjzLHknoF9TXEnfR7nO33OGU3dxr72iI0VsyAtgkKfcH39qv6Z4es1v3mhJa6QABueo4yOBz710dhqljeSzwrEBLCf3m6MrjjOckYP4VX1e9lt4LOeG2k+zzbjG68FgCMkZ7d8dxXa8RUb5Irl0t6/8OdXtZSfKlYty6docDrPcvqCXax7GihnPkkkcgKflI7cise8ja6vlEDsoTLYikKlV/wBrtjHrV11ij0xNQv1MULYZCxyGz6jrg1npfSanHK1sryWhJl2QA5JA/iz09s1nSUviu3bS729CaULXZp2qtdCGK1kiinjACuzfKQR/ERyR3xW1IskRitL/AFKye/kzshhUkuB0wOufzrgbGfxLfzia3snt7bcSDKyJuXofvdT9Olb13rdlb6fbJqlpZzOkvnxlogDG3QOPXPPzAYxzmprYeXMkmn5KzaJq0ZX93Uv3D6fZTBLmZknJwcI6nPvzwaulJbi1QW0kbrCrBVndlMeRzwAWJ9DzXB3+lQ6lDcTy3eoeRdu9yBBIsoORyFO3JXgHHXNaehFY7FIbR9Sj/dIInnlgJA9WQncRjGBxTnhkoKSld9b7BOl7t76nQ22oHSdUSzuEijmlcJFF5hkEzkZG3gENjJIIHHWprC/it9K/s5tUluZ97TGXUSruSxJ2DaMKM8DrgVi5FxbQXl1FE0tpveK7tkEcsRKkF1U4D5HB2sfTmk0TT83u/wDtWG4aQmQCSBomXPUkE89enFZSow5W5br81f16d/8AIzVKLTcuhrz3lhDbXT3JnnSJQ8KiPlwR2JGDhuP51m6ZqFjqtrDBdwytFP8AJ+8iXeMHpk/KfTI9aVtThjuGsobmG8FurEwyk7z/AHuScDpVy5j0eDy5ryV7ebbuQIoPljGMr9MnmlyqCs07vb/hvxG4qKtZ3Zn6jcaHdQxWdvqkkDQ/KiyZkl2Z5BwehPQHioWsoLmcRRFkiHzDzoRh1B7EY2kHvWVdaJp+nzG8Qvcl+jBtoYfQe3oa0bq7jl0OO62QyW+N+1ZfmyvPBB9uldXIopezbafe2/8AXc2aUUuVg12tvqjXerXl1eXMq+RGQojiiQHOxB1POCT34rYuFMqxDNpE0h/dR3TfO5+8AoIxn5cgE54qikli1lZ39/DBaLMiyBlVXmXdyBubp+HrTrLV7VoCttLLcIrgAz/NLEWyQFz2PTPBBI/DGcXLWK208vw0M5xvrFEMs8O+3tbeIu1ySF+X5mbvn3Gc1U1COzvriVbjT7VAqhPtU7bmJXgjAxiqp0u38SyWep6ZNeW17ps5O1FBLBTnbgkYPHBzj1rV8OG0TTZtd162T7erO0Vq8W0CTLYB5+Y8de2a3ly0lzJvmWlut29Plpvsa3Udt/1KP9nQxGKGGWK2LfwtCWWQe4zkc45596tXFxHOIVvpRHMThooWKjI4+8MY/KsmF7261eC7lt2WVyQxDKMZH8WeBWofsUyyQ3F3FsyURWB2sTyQW705pprmd/T+v68i5R2bItdvWsLaIbVMFzOI4PPIfL4z5ZxjkgHaT1PFZtleyPdtI8JjIcrtU4zjqu05wR7VbsreKawvtM15FvrB+BDlg2VOQ24cjA759KlGmqt7ZXyuD5AAmEkg3yAZ2k5I3HplsEmri6cIuD379H2/4P8AVhOMU4tE97ozm7leJ/3K7QTxhgRxgdc+tXLYGORH3SuFBDwBCXLdgMknH1p+r28t2WAmKQjL4Vc7h1qp4tt4IdNj09p5RcXW0NJbyBZtwx+8Pv0BGRXNGTqcsJPcw5nNJM0Y5hZ6jbx3EEjpIQFVSHEe7+LPp06VtT7ooCDIQpO3g8D/ABrnftNppOmQvfSXEpjG1FQ5llIz94+g7n8Kp6PcXWsX4uWh1CxjUKq26y5imAHTBHXnORisZUHNc+yXXv8A1/w5lKF9TXjFxBDNb2lzKvmFmlkkfczZA/AYxjjAxT5dWkk1BZbqdLQhQhkWFmX3OenOeMnipxcNcSXdtbgNcWqjPmErE0hBIUsByo74zXKvc31jFNHf6rJq99LIJpdy7YYgeixIT9we/wCVOnT9o3da/jr8rff8hRjz6WNxXj8yVNMu5mEuN6yTAI4HO7YD1z6Yz3zUD6Xqs2r6W1teWyWcaSveLsBZyPuryceuCPxrNm8SarqEMNlpOkQancl9km5F8qKNfvMSOOc4AreN3Z6ZDB9vhuJS0qQxWUUZaSVyeFC/3QPmOeMD8KqUalLoru+mje1r/wCW3foEoyhoUv7euxwmgzuvZvNiGR60VfuPEvlzyI1tq6srEEJbShRz246UVKi3/wAuvxf+YuR/ynMajFHMPLD7mKqRIi4Oc9cZOB2wa0tOjtrSSIWarG1ujKGQ9F75+p/WsjxBaxXunx3umXBCxTgM8bKyynPIyPTHI61v6pem4ihezhijnjj2l7dyCT1x07Yz3rqndxjFdb38vUJO6SQ6O5uXG/T5FI6ZYgrjPTnGOPfrXP8AieCWW6sCI9s6mRGBYkSIy/d69mANadxLd3llE42vKzbnWccMhGADjoQee9ZeuQzvr9lIZB9nW0YL5fAWUuoYjPsBinh48s76Lf8AIqgmqhJpYhjvbmW7vS7xHyUIyFRSMlVGcdT1Fa5KIzSrEm+NdqnJxg88+tWLSJhbNZosMDgl0cIG3HHRgOQM8moLoKYk+ZWLEl5CpKhQO2OhPqazlU55ENpvUoXV1ds1t9hjgZQx81SuSv0549eh/CpZDBnNwUBjYSb1GfLYYOeOeMCkgtCFAtnYRu+8kNnIPvVkQSQXAMczjgFY8jYCM4YL689e9U5RWiLdugl5OYDNOLczysvmskWN0hPU4PX1wOazNO1J7y8jjhjlSKUr5kCkI8fPdT1Oe2c81euLSV/mVJJmDciL5j1556A1r6daiEzrFPsiDHdIMBpD35/wqXOEIbXYXjFeZFJaQpfOyyqHTEZdgeRnOAB3pt5Mli0TSxORPNHAisygKXbauT7+nNM1CMxyPMYWe3DLGqIMlifX0znj+dKJNVtGRpLS2Z4XLs7LvZuykN0BX6dqxSvZ3v8AOwlEqXerXN3q9tZaf9hgso5Fac3C8kbsELz14PP0rAmieS5vGdomhIMaSyEDa4Y5BHXd9MitPWNPa+ktFt7L7QrynyWlwP3jc/Lg9Ac5z05qXV9KlsJo0vLiOeZLaJQ0XIU8hx7ZIB9SK66cqdOyju/v3/r/AIJ1UnCNlHqZt9rgk0yNUO2UOS8qk7ZFxjG3+HnFNtDNLbxpY3BeV3BeLcxwhBBJHXBPTb/dOaqyappl3fLa2lkZIkZjLK52KWBGfunoBk/hWpPqMUVoqWDKI2UiOaE8heAzBvXHH4+1byhyJRUbX7m0o3jyxWpLpF7NpkE41ueOe5Egf7Pao072y4wA+wHH4nvTr3XbHU7dbbStVghuCQ24QM2MgjuMA1mx+J71rmOysLa3tIEO2KONDtx64HUnuTzVManbWkN0skzqsrSI6qRsEhbB2kjIHHQmp+rNy55R18rW+6z/AD+ZCw0nK7WpuXMEslhbWFiwazsAhhhUAmAgYz0z83PPOcmud0uwh8PasLnUridxMGHlSK2zI5yx7Y6+lRtFz9u0y4khnRTsRD8ofGVI574wR0Oa2dRMa2Ru7yQ3F00ZREaLfEkjL8+FyCR9TWqTprkvpLfvf+uppyumuRdSKDxnLNEl5b/aUt5FLwhVC4HTPz5yD1x39q7DTb2DVtNhvW2h3IhnUAKC3Y/Q/wCNeY2Ewu7O2tb3T4i1mwh/0fftYBcK65AYKc9MdvSuu0ueFIJ2sHljnsFW9dHK/KFOCAB17545yM881jjMNBL3FZ/p0Ir0Y+zTSszqb2OVZBbEJIoQFhuLeWM4AOP5VGkEUUcynzDG7ZCO5ZUYcbkB+7x6cGsi88T2slkdRtokVHPmSeX8oBOCWbPYA5NW7C51FpkF1HFJFJykiLjaDyvfB45yPWvPdGpGN5aHG4SS94l1jQrLVraBDcssUTbgquF7YxwM1n6xrOmeHtGg04vdwtFn5YFXcxOSGYnrnuDmtW4nd1Edu6qTlQVxXI+KXi/tD7LBHPcy24H2iYIGiifshOPvcj9M1rhoOrJQqO8VrY2oR5pKM9iDT9XfV9Vs7fULcC1kjaSOSOQ5RgpHzrjoSRyD2weKkm0K0vLtr2ZftLIoEjvONkgHAwBz+HAxXKW8i3GoMZoy0nEcrxPtdYSfmUUW2qIb64gSCOKB2IFuudgQcBTnkgDv1r2HhpRd6Ttp/XX+rHqfVpKT5NDsLi5mstFvW+x3EahCkYdGBkPTaCMYyemKn0Xw/DYyXl1PcLJEIvNuFtnGT8ufKx1ViSBgj1rnhK4ZTBN5sEQEZCSltm3GFxn7wwOPQCrNlHLYtI1mLd57wMsMikKjknJd2/iA6/XA4rnlTai4xdr/ANfKxjODitHa5DceJ9R1YXlozSGWIBokB2pGwPG1f7oHHH9as+HtSvorZrjX44raSOfy4uNpx0BOfXp71Qkd7bUJ7CGPTVCRi4N3GjsfvY2E54z14IrpPDN/b3lsNPu5VljYMJlwNjc9dhqq6hCn7kNNPX+n2FNR5LxjobEqW0UTzRRQBJc+fugDbvUdDjP41zP2pZvDFteM48u5jkMcmSSEDlQo64wKs29zHYxJZtHIkLO/kSRSAGALnaSCdzAjGSM7RjPFS20X9mfbYp5/OsVlL7CoSMSyLuKtlfvH72BgY69a5YR5Frq739Vt/luc0Vyy7kEMCad4Ttbmxs1a6e4kkdpi2I1DFCirxwAM/jmjTtQmgtJtUtJHikjwMxqCHDHGMHjjrmor/U72xtJLrS5JZYZnDHe5Yg9s9gRjp6Y61CNZ1DXNJmtt1tCzMsxOxV8wo2fLfGMA+oweBWvs5STlJKzet307WNvZvlvJXVy83iC2u7a2sJbGHbFkgI3IPbAxxj+tTpJNZXC3dhplzNbwjfJdLtYqc9ME547gZqhaaLpr3BlgunhuQnnbDMHDjvtOM8dzWdq9neie3vrk6hBCqqyQpcFo4SD3TkZP+NCp0pS5Y6Lzv1+YOEZe7T/E7S5uyI57sm2SF13vK6L8x7lhgZAx3qCyubLWluDp1ytysy4miAyPqFI4P0rI1PV/JNmkFlI6tuklWSLMQRMblPrksD+FYGr+P799UjiF7cfZ423RhGVfLPboOcehrOlgqlRe4v69LfqjKGHnL4UdReeHhGJ5UlmVXT92HclVbI546E847ViaXY+I7LUVt/tUtzbMu/yEQz70zzleqjPHOPaumvtQvI7axSaxiv7xo/NuPn8mWCNh8pBA2lm5bacYx61hNep4l0290jU9Hu4JBL5sRMm9bgA8YYYywHO08VVGdVxfPZx67O3S6V7/ANX8whOaVmrm9ZywxQTQalFc2UkCtuQx4do8ZG0E89wD7e1Y+meK7tYWX+xbW1jV/wDRtzsXCkcmQ4+b1yMVuRWN0yWz6pMiwWjI0MjIvmIACNuCwGME9+/FQ2WkXM10Idj/ALsnbLyVVQflJbnP4k1gpUbS59fm7fL+vL1iLhd82poaE7tDP5pnbqY/3ZOfUZ6D2BqC/wBJe1SO6vLWErJ84ViCh/3mOBu+uBUsOql9Q8m1sVawT5Jb67uDAkhxg+VGAWcDpvOBzVbUFudRs5bUtdSq2CUimADDPAcEcrxg4ArFKand6J/18vnqYrm5r7DrcWeqx+ZcI4iDjydoC7Qf7xHVe/19at+IPEKaZG0cYeOKJA7OELlVzgYUd+nHWrF285njl1CSw8yGMqoQ+XFEDjJJOeeOnanWGp2c8qxQ3dnNKV3L5UxDDHT7wA+nSsm02pON0ul9Py/Qhu+rV0Z0N6bi0hudQa5jlmTcYJkCMqnoGAJxnrjqPrVWC9jbRkaS0s4dRErB/spLIcZCkbsnkEZHr1rS1K3+0bWM8iKgOFPy59zjnOfWnadDBHu8648xwOA/PP1q+aCje3y/QpNJXMKKO4023kmu9yofncJhMDqR6DjqRVDTPiBbDWoorNBJN5gy5Gc54xnsOla3ibRItQiMt1JJcWUEeVt8bS0hPfHb3NZOiWNgzRxro1ihGGyrMJEPqSf68V2U/YVKblUV35aJGyUJRvLU72TW75pGI06wIJJybsjNFYix6ZIofz7Zt3O5XQg57g56UV53saa+z+f+ZzctP+r/AOZFqc4RY4RtD+bwFUKpJ6kAcAVS1mK5XSJl02My3P3gM7Sc9cGrWoK8uo2YiAYbS7HYcEexPX8OlTRSfvCryKFcZ2qo+nXvnjrXZF8ii16kJ2SsVrXyhbebbRzC2KZVZsgxjAyCc9Ac9ayrvUbP/hILS0mE32p4jMs+/MaxZAIC92J5DelbVwA5CJmSQ5HJIC8d8fhxXIXtqZfHf7ufdtVFkjI4hymcA59s49TW+HjGbk5dm/6/rU68LBVJSu7WTOpiuI0uEaGcxBOI0k52d+/UH0/KnTzRxox8sZdizDJKknkkHqB147dqzYNI2T+Yl1Mzt99WOeO2M8j8KvxgxKruhZcYJDYIPqc9gKzlGKejuYOKRLDqIs4AhjzIx6cgZPv1pLrUAZUKLnGeey/SrKqd2BEJWbIUYzkdeKoRaXqOpa3ayWOoz6c20gQRxq6OQchmJ6cZGB1rOKp3cpaf15AuXct2LZiZzLcSxhSS7uoyT0+7x9B6VuNB9i05ZbxliiVM7x0PrzUF0bezm8qW4tbso6yTRo42jB5Vhzyc4A/GozYWdpapZ6Vo32fRonN1OZJQyxvt3hgjE5GTwF4z7CuaclOz2/rza17aamc5Xsye71C2sliZPK4VBJdPgk57KPQZ61ialqG62mWLTLW8R5vLaaSfy0WPqzHnJOOlY/iy2nnWKGaYJPKPMjhX55NnU5x93HocdMis+yn0+3sbYTyLPDDjzYY5OrZyN/oPz5rto4SKgprV/P8AzX+R106CcOZas6mXVrM3cU7faHKqI4IbcAKOMDAP19ecmuP1O+m1WyaLw55WlW4ZxAgA8ySQPhiyj5QDg4yc8e/Goljorzm7+2vHbov2lkZNzYXk8jvx1xn0rn5ZJbpkutOI+ysNyEHA2kkjk4JznvXXhqUIu8elt9vTs/8AhzenQg3o9USW+kS6NpccEwlvdyyPshXbLPJIRt2r2wB34yaf4UtbrUtFjS3tmRosw7Q4JBHzHOT74781o21w2s3UdnYvM1zDnz2VG220iBZI3Ddsk4x/9eoNf8U2/wBnknjuLe2cTqJ1jYIZpAf3hUgDAyR164Nbc9ap7lvebv6fLz1/4YIzmpcqNJLSPRlTzLdormXcWaZxtAA52henXrWZFptrqN3Mxlt2VlyptwzKxPcggYxx71tWuoabq9pJpkmob5oVaWOR/maMp3B6nGfyrOsdKttKk+23F5C0bc/NcpHknnOWxjI9a54TlHm5m1P8/vLjUtdydmZ9roKXGqaboFxcXFpHfzSJLLDLhgqKTwT0y2PcjNc29pqjXsd3Cy3aWrNbo8TlgQjFSwB7MRnPTBxXod7Ok1rGyWZiRJtzuzhiyH+JH+pxkdM1ztpdrbK1vGLqS3Q5VZHaRVBPCD07YUV10MRUs3a/l99381ZfI0pSnObqdCvc/abq1tS0bx3hby40kKx7xg5A3EA4OMfWtjwf4c1bR55NXvoLuG3syGeJ0Ctco3DoqnqAOeRg8AUzWmtIby3s9b0dLe+vk/dQCfMqoc/PIowQoweD9KdpWo7bwQWkaQwQp5YAOVIxgAj+lZ1J1JUnGCsn+Xk7/IJVJ1oNQtY0dO0YxxSlP3thI7NHCyAsqFiCpz1OO3p2qWaWKW7tYpre4EYeQwxibAi7Hb6kjpngdqrw3k9xq5uNODG0vrXzhvB2xTRsVdSfwFS3lnDPCLqWJz9peSFIw/8AG2SpDdemec9RXI7816j/AK/r+tTBav3yLWbm10aFJ4He5iUoIFGC7dPl9mHf6Gq0twixT3Vos0Ucc8puIcFHB+XLMM8k5B546VUn0+w0XVtPtn0y+WaGIiGaZo/KkO3qAG+/nn5+Tz7Vn69qkVv4gg0y2sliiZWfUJ40zKwxu2ccAfLn6H3rppUVOyjd6N301X3/ANN2NaaTsy1dw2sUM8l7PIt5vR0a1cJnIP8ArOO3XA68GpILSzuLktpl2pmaIukUgBY/N1Ujrxn6Gqmp79WW6ksNrxySonzR8kiNevHXBqtps8w1x4I7O23w2W7dImTAS23hTjr1wfStlBuF769vuOlXUbp6ljXtMmurKO1CGGV58EIQHEeOWZvr26n6V0HhTSLew0y1sIbyeGcb4ozIFcMrNwpHoSfzNQtcXdrYG91U2Jijcb5YB5flhiAAY8/rnpWJqJki1CWc3XnLDtZDGe5zg+w4NZ3nWh7K9l9+v9PqZcntdNmbEGj29r5sdtCsYlZ2JwwOQcFSGwc8YA7VSu7J7C/sHitnmEsu3spXrnJz2AOfwqZdZaXSZ9SuRJtG2Lg535IC8/UnntUur21wbkyXdzZmYQ7F8qbd8v8AE2BjDYwD+nWpi5xlab7r+vvFecXytlCS/tYLtbqY3F7EpkijhtYcmSR/lPJ6HaMYHqa62aKz8Q6Otpa3KJMreZHFcPtMgwAVYfwuuBjI5HQ1zujRWd3pzC2Zo7i1ikZYyoRZF437Dn5X4GAevI6nNQaVayWurxyXU0cBXc8DuGKsUVnGV6gcYPapqwjLWLalH+tv669tJnC/vXs0a+m+G0OlPca1I0f34sROQTtOFPPBbGT2wDgmnyQ2lnZG2sZVnlliBdSvVRxuOPw4qa5vItc0WKbSwy2l384juH8swvn95GQffkHoc1mWRSwnhWWfZIZD5MijLxnu3sFz16VivaTu5vW+39dv0Ji5STlJ/Ir/ANqxaIyX08z+WqhfLij3FgeMAHqa2LPXGfS7aSX57e4DcSLhlXnK49v8im6h4ZutSMckWpxS32MNcByPNIzhu4BIx7Zp2kf8I7ZQXOnazM121k4S4kUFAkrhWI/3ecA+uac5UakLpOUlvbt+HX7+wpTptJ7vsVIvFFve2Uw04CZLaQwvvyrHK8kf7Pbmo9Et/D94tnNqPhhH1EviX7LcMqMSeDtY8jHYd+K1xo2jxRmXTJZntXYDyJcZ2lvXPPPNH9pQaVplzLoKQG5BWNSW+dBjp7EHqB7VLnCzjQTV/Nr77WJ5otcsL3+77yvrEc0+p3uoM1zeAz5KQqJCo3ECPhgRjpjoMVqaRphVllhlIlSQsI2GB3Az1I6fpXJeFNOgX7R5EOEmkMtykjnjHXA646mpNZi1eLxHqFxPDFNp7uI4XV2MiRhRtIOenfHr71U6V26MZWsvLy0tcUoSv7NM7iCGaFQ15DJdyFgqKoLBASM5YAgDHbqa0biGUadJHbtneXAjZwqseWAJPQNjGfeuc8PXFytltmM8aFN6sWI5B9M8g8da27OcXNu0hiO3hdmwgMD1IB49q8utCUZejOKpFqRydr4e1WW4a81khLlgqosr48rJ7c4wPX06VJdSaPd6nY2Wq2c9vgN5F9Bdywz5z94kH5snkZ6egrpbkSq7SKNi5IIAyp9B7fUVh3OhG9voprtYzKwJjmJG7r0PY+ldUMRzvmqO3a2ljRTU/jLniTSkuNjxzNJF5YYSSMASM9WHdtwGcdR9KyfD+hzxyCQ2flweYfMZiAAw6Akn9R/SuriaGKWOHNveTxjLozB2x3+X2qlqFjBc3Z1B0dzAu6KMv+6Qj+IL03c9e1Y08RKMfZvb+vQiNVpcoXMfn3+3EjbOVMYzlgPmAPQ//Wrl7jxLepKsNvbocsFJWM4znkZ61cfUriO6eWMM8rEMAcsMgYBABxjHXGKv2/iPWWi/0azguFKkJm3UKe+C2ePyreFNwWsU15uxoouK1Vx2lppMtlBeX4vpNQ3Oq27ys4U9QNo4xju1bNvaQwwxPqKrBbzqW8lSThR3cDkjOKoW2pNduZJBujOVaVUCKvrxxVrWDbSQQPeT+QCyx9f9af4QuQQD9RiuSpzOXK7q/wA7eSOebd7MRreEsTDrnhuOLPyI9ipZR2BPmDmimx+GBKiyC8swHAbDuCRn1xxmip54L7f/AJKv8idP5jKt4bmHTjapNK7I7PH9rYyEEn5txGM8dAOlWg5eEM6J5inl1BAkHY7ex9fXrVW1uhclbi2Sdw4YhcZYjjOQelRXTFkja5SaCRDnbux3IIODg9DwciutxbeouXUu3WoNYJHiC4nEpOxI4x8vHOWPT6d65O8L/wDCx7dJYWGntYfaHOzhJBkBicZ6DGK6eG1uLu1802kiwg7kJbDL79ee/aquGfxLDDDLutRZOsig/wDLUMpXJ7fKfxzWlCUYc1t7O/8AXcuk+Vvl8xpjeK5M6yPJDjcCF7H8OePSp4y87wuGh8jb0dTvJzwQQceo5znNTagbPzm0xRIbpIllOY28pQQflyCO3p+dNhZoJUhSQOUCGV2ibYVIJAVuhP0PFRzcyv1/QOa6uT3Eb3NoBHtikjJyU6c8bT7mpre0hvbS5tJ0nmZ0MbfeVWJ42qwIPXuDUU+onSvCdxd6pFEPKYyhIhyyjkYY8lj9OtaNlE4HnR7mGUdNxKnrwPyrnk5RjfbXR/cTfQ4qTTYNNuLPSbLSz5crnbHCWHlnIBL9T75LdK6LxjeFI7f7FzHA0cAfblJ2XcSM/wB1eT7kVoa3ceTqSeXBDM4UO0JGRLI7YAPTIAVjz9e1cx4jna8lOoWNsF0yOYNOqtt2p91pAvcHOcjHQHpXRTm8ROEpfi92/wDP+tTaDdRxb2MGz1S9/t14sM7XW7zPNYqSSpGSewBxz2qtHoEWnebcXLXf2KZOVSIMQzfdAJIzlvw9639SW3hnbyrdx84K3AyV+XoCPf1rndKtdauppINQWVYpt0JikUgKD/EvoBwfwr06c7xcovlVlfz9D04O6vHTQ3dGuLCykk0qVpLW7jA+0W1xHgjIBVgRldpxwQayNYvl0fUYpRdX1wSVnjM05kjYsM7tp4xyAOKn8Sajo2u314bO5u31SIhbmWOErBlUVcFicFNyswA/vcd6VdJudV0aG2mltne0gEUTOrI5jJJRCACG53YOQcYz1pQio2qVbq+6f9bfoZUraVKnXcx9e1rU77TWhsL2e3mlkVJre3iGZg3BbcvO4D8MDtWtezaZZWEdnpls9jDFHgFgsoORgkA9T3OfpWX4x0+bwzoEsNzcx/bHCxMy8FVPLYPqQMH2osGVdJs7xZWnWYiPddQfK7noo456Z9ABnvXTyQlTjKHw3drddvv8rm16fNeOwaPpEOk29nqejSy3ssN2pEc0KxM6NkSRrjtgg85A4rav7Ww1m8uQZbC7hL+WtvuG7aoHdsHIBHT2rB1y4jvmsHjnNnYwyRQXawocxxNIBIy/QenWm39lDFbQWdzaQFYruWWLyCyovzncRuyQpxnBJpuMptTlJ8zv/n5euncSpt1NDY17U7axvrXTDaXEd+MRosaZDRkYC5xkZI6Akd8GrGqPMJrIaZaPZXcILLei4Ro0lKkZMWNxxnKkE8jkVb/s+KOWCe5upWuI4FZIFJDWbO28Ek8ZIIBHUA8VnS6X9tlU6bLexSYO6NkGAM/3jjOe2D6dK5Yyp6eW7d7f8N63Xy3mKi7qRkac9pc6rZJZC61T7Esj3EgA+0SZUh2y3JJOTgn27V1114ei0rSrXUrq+Wxd5oClmG8x5G3qSruCcALknbwPWsvQ7DT4pL5l077Pf3kTRSTi5RwWAPRQx25IAP1qZoYltLM6hFBHtI3/ADK6IMYON3HGfT86defPNKDaS9G31723v0v6ESlKekHZGhc2twsN0Lq1mWU3M8y7MHCyOTjI9hnistZry30hba6YLb2rmRHKZbdsO0H6f1rT0aW4Xw8Jre6cpHGEy7b1lkjDJleeAMAnBxnpVezluLsxW2sPDdTwwCRpEyqkONg68nGGHoc1hFtXTs0n/X9eYoNpctjn7vVLy+v4rSa4eF1KyRbsfeC/KWB6j1HWm37Xt/FBdPaLNqFuAghidsoWOX2gHkkAYBHIFRXTW9hrV7bX1xcedpYhW3ns9sclykiblL7wyoyghTgc+1Z+vQwa7p7JNFJJfROGWdZTC7+xVTjOOAxH6V6cIK8WlZaa+v3aNNX1v+J2Nc8OanE6B7hrfQrPNrLp9yys1xalDHIHLYBZeoLAA/SqtpJahILi4WGO9u3cBtxUvtXPzdj6DPeofDhfQ/C1zdi0aSxkC3Xl3bGSRWVME7wMjPNdBpOg6jra/wBoNpmm2ryoqwWMmoAyopHJKFeCR2LD6CsKjjS5uZ2V97pfLfp89tyfa8kUpbma0MuoalaW32pEtdjNPbk4aZeyn2q3dxWiyyQ2lokUMLMqh1XI7EZHrjOOma5LWfEElnr0dtZQCe0SRYfmOAz52sikdVDDt157V30mnX2n3dpFrh06Nr9vknhl/diQ5Ow54GR0PTilXjKkouWl1ovzF7WHNe4ybTbPUNPSSeZ7GGEo0UCR71bKjc5OcsdwI9gcVxcniPR4daNtPZ3sErh0NwoH71A/BweFBx61tw+Za+INTt3g82HCRBriOQKMBiTGQR/EeexwKTUfDK63GlvpwsknkiaaOTmNnYYBTHI5J5JI7U6LhTdqrfK9ulrq/wDw9yoWW70J9DvbGO0uW0crc6jLhSkkecIOWCep4B7cCtq6aO9hs0mQKtxnzSpIB/uhue/5V5r4I8KeJZPGttaDTrqNYLlDcyMpEcaBgWJfp93PQ89q7vT/ABdbTTavHf6DZGSO8kVPtMJWeSDd+7Yg8g4xzgZqcZh1Cp+5fO9Ho1dX0X/AIruMqnLT1ZRvYryWCxgtIZTAkYwEjYHd/EGPrnPWuh8LxsPE13a6zZr9qsrNbi1jbazndwQSemewPXGaztXvtTe4sH05ZirSAhFumii2DkiRhwVzjggkjpircK2M2orrE4dLuKYhpLYhkkUDBGf7vPI9ga56rcqdmt09t73/AF2ZlUcnHltYv319qOtadJZrfxaXds+FmlXdgA542gDqMVpRfZLTT72a9WBze8SPGgVpyOCM91x0B5FVN9o9y8cdxkMCRb7wG4GduCcflVbUdUifTUt0t7xL8fvYndFIaUMNoOTjoCCOmORXFyOVoRVlf+vO2hyySulFD9G1zQELRbzGpGUXaFC46nb3P0+tEHhbTil7c6dHbG3u186R7t/KQSnnHqTjrjGOK559XtoZ2lK2aOzfNGLeMsxPDEfLwD6itzUdFm8U6BpyWUMqG2meFgpXy8Mdwbn0zjOK2nTdGSlzOKlu29P0NatPkale1zS0y3sDbrLaR6e7wKN0sUu9MY7nAI565+tVr+y1OWWGSG9SNHXLJcIeAf4lOMMDxjgcdak8MeGI9JtWgiminV1w/kzZidmyAD69O2Kq+IrZItT083eoi2aVmVraS+eM3GGCHaeikHHQ/hWEZRdZqEr+quYqS59GaMTRyWt0wdMWKLP5qR/Idv3168BsYxVq2vpJJ0EsU8Czx+cplQNtB6KSMc84A7AUxoY4SsMj78oIZRkEthtw3ep7H61halYrc6k9ybe4kj+6CJDkc5xgdvSs4xjUbT/r+tyFFTep0j3SEBM7kODuAODk4A9ifeqGuawdGsEgtE3XUgP7x257nao7YqW3lNqiMLaGGWRxlAS7uy5xkDrx6Vm6vHpF5qaC8v76GZmXbCIlwzDPHcjvn2pUqcef3ldff+QQjHm1Whm/DS31OHUbhi8KicluB5agjncSO2OtdrqMotJWMctvIHUlJI2DISTyOOnXpVO0sRBDPHGC0U8Xlt85Xah/ukHgnPUVVbTTZ2ix2Fp9nt4RnbGu1SeTwfUdzRXnHEVXN6f1/XQmpJVKlzB1DUZp2aO0tdqoxUtHEyEn1zgdeR6UaVrE92L7TLK2+z21kQks+8rvkPJj49MjJq1b+IboSyJMryqMgMr54zyPb1rahvIZLSLzI4omlXc3PzEZ6n/Oa6Zy5I8rh6a/ibVG4qzRmaZLPCY8wmUn72SWDnPvW28eoXFpeNZpCbxYWeBbkbolkGMbj6dRzxnBpguLe0ngigtFkaQgMZwykrz9339AMetXr68gtoZIGFwltckxhvKLhGHI3kZwvbn2riqTcpJqJyzlzPYrqiTqJpcQySDe0ZJyhPJHBxx7cUVz50zxLn9xdWKxfwAbThe38IorT2Mf+fi+/wD4BfL/AHkaKgS2jSxugUqUJX0IPBHbpVZAlq8cLLISRu3k/Lu/2h1Of6e9WYbwZeSZlZ3IVi3BZsYJPqSMHiqM0joqtHh1znk/e57VcE72Zkk+pYdna4jdVck8gYOee+eg4zxVV7GLT9fudQuCrRTQx74y+wAqMA5z6Uoa+klhayuLSOxXmRpZGJ5HQIoJP04HSnfanl1S6huELeS4WKRRw6FVYcdTjJBFWuZXS2tr9/8AXmVHqT6jNMEb7JIhjZgrL9/5T/ukHOM454zmpbKQxQIJkuZIoZFEaqQSuehO44wO+OTVW4YJIAkZJcZ+VdvPYnjr2GTT7ORLVGEskiozp8ioeXOe3YYGcmpcfctYFHQtpJBqN1LZXDrM0cZfyW9Bzjp0962bYu81qtqiLvctGkYI+VR9459zisXR9Mt4bq5kimV5RCZGkMKq+05YKcdeepPX0pL6SVVsnhvHtTFcQyybDgvErM7RDuAzYz6gYrnnBTlyxehEknoi3q1sZ7e4jSRRMRiRm6L821eRyBjcPoa4rRtOuRql5b311Z3P21zbPFEZS5BJDAjAAG0NzXYXgP27V2N7NDCsrbIQPlclE2nd0G1gx59aL9DOfMkMrzGLzd7sMklyCOMfLgAfQ4rajVdOHL3/AA2NaVRxVu5wklpcXV/KEkumhtbqeC4jhYF3iBIVlGRuK5Xng81kR3v2GQQX2pSwyQ/IYy7Eqf7hx3xjIrpYft1vd3Ftos0Noqs8SyMUMkjk5LHd0I6KORVHw60+h2x0m9SSZ3lLJPN85O5hlsHJ3jJz+devGp7rvZ7WXXrrs/69DvpuUVe1yC805pYbZLx5S0sYeMW42t5QAUFwRgdMc8msW71G0h1C5WayFxcQRiCxleVs2xwTvxja5JxnPpxWz4yvZJ9SkFj5UduSY2jJKynB4dTnkc9KrXcVzqGgT6dPI9u52qszLgJg7snHJOM8e9b0XaMZT2fna33fiuvzsdkE3BORkSeIbm3lMMq6PfXUqIojmXhcA8AtnGeTj/Gt7Rbe21G8jurhW/dRlFiEq4iBj+8o+6OR09M1m3NjCul3WgWKWk9vqUXGpT2uZomVgdi4PpyCcdSK5+2106CLzTdThu7uILiSaCLBUE7ehHPPXP4V0eyVaD9irP8AFra/l2tv95lJWu2rLodSsAgtJbeGC3nnuV4QsWXOOCQOnqB3xVz+0prayOoarZyyxxspkiY7QAvbB4G7A/DtVTS5LBYrKWx1CKUqXKGJTHM7quWUqRwQpxzke9T+KZbq6xpuoaW13YW8Rnd01FFC8Z5Vcln75PXOABXM1zTUZL1vo/ldryE613aw/RNWbWtLu9Rkk3ys7PKiqAsIY5AyOw6AnJzmm6ReGW0uHvj9ittjf66UL8hOCRk5Gfb8Khh1A2UNppOgPaSzF1a18tUQTxSfN+/dgAOOPyxzU2r6vfaNrOmw3Vz4a1yeQ7G062td4t5AdqBGAO7BIyCQ3B4pOneTjCO+qXWy+Vl6vTpuS63KuWxZiudI0/VGuYYbNtThgRLS2gicLaWgUhSWIxk5zlsklvwqF7+31zwzcxapbxwQyFIY5oZPKfOGIQnBGDjkdSKNK0y9fT0kvbCOHWGab+0Fe4803GTlSqjhMHJ2g8Y461HpumxyQyXeuW0qWmlzQi0t43IaSVlZ2kbjJ4Cqo7ZPpUtU0273atre70dlbXZv8Hd6hFR9ntqdMlnHD4fsrG0RRBbQiCVokBKnb852g9c5Jx3b1rF8RKYtPi1Czha0QP8AYljjTY+CCR75BUnBz1JqnDqSw6h4cuoN0Vvc3xguLZyAp3KVG4jGcbv8aNWt7jUfEVnpmmEFAtxceXICQwVCCoJ78thu1Z06UoTvJ6at3+d7mkIum7djF/s671s3FwllcuZyjW8vB8xFQRsGOQQSybl4wQfpVH+1rbSmMN3DIby1VvMDrjYuflViedxJOBXdC0m1G1tNQ0ZSYZVB2K5UqMY256BlIIIOOlQ+LNAtvEU1lHNiW7t0kXdKw8qRnHGWA3Hb2Y55PQiumni4cyhUXu/ird/68/I19tKEOWP/AAxzuv8Ai2DURJo1ncqpSCNmkEgEaSEjKMw64HboSMVqzJfaZetcyg+XHibap3NJ3BUjrnFSaHpwsNMtJzYW15qWqJHcT5tVOcphQo9lA5HJOTUp1G5hvGtBcAtHcJbzxxKuEGPlQZ6H2HPWplKHwUlot/Pa7/yIpSaV3bUZFrV/azwxiyNjABNegQAB/MdvmDEccA8MMGsu41G/1XTjBbWt2rXF0DdxBcqVUhtxcDABPT8a3tWkt4YDZTzWcF1cRNJm5bZgBgPkPOWY8Y7jNWpUtdN0zULa8fEESYlkMjRqrN8oHXjnAGayjUhG0lDVvT79/vYvcS91anMaLcTR3TXs813e2d7cE3UENlIzWZ2sWYnbghWI4UncD0FdgksF3a3Oi6XN5stiWLPJhPNEhBBVMk7RtAJ75rnLePVE0iWwkunubvydq3TvtwwHyqvovABPen3ujte6jDbyPayXIRGZA4ZmYLuAAPJxg8+lOsoVJXbtb9OtrLpp+ZMabW8vM1U1zVn0e7RLqRrVMQRopG12Vcsykc4O7HtisXVtQnH9kzxXyKZrd4RLcMWMZwCrbsEgZyCDwOtT+Gb611Kw1C50y4uNkkgVreZ1EUJVcA4bGGwMfLnjHFYS6hPqustp8MNrHBBv8iFslmAPLkAblz2yB19OaulQUZy91Ll3+7+vzKgobPQ6rQZb2+v2s766tEvUtTA0Ky5Scgg+bEejAqeQOQcHoasS6NPBp0yIvlIzBHYEA4JHGCfXB461kzWGq2l1Hd6e9hPPbybI41YCUq4ChUJHBBJHFaen3r6jp3laoxjeyJMn3Q5JJBD4zz2yPeuaommp02raXX/A+4hKUdnocxr7z6FH5Cwm+kddxuXQ4hOQEIbpuHYHpWzb+I5l0+G31wfaYj1GDHMj4xgMeOh6Y71pX4lgt4JdMkt5IreZJWS4jLhmBypPqBknPrip9RtLDWNOmvNQYAJmZzCuAwB5ZVbv+P0q5VoTjH2keu/X/gfILpu81oTWWmaI8H2pLeSaU/vG819pA9MDg+mQR9KsRasrGUQSI4BZZYTuVj0z29KxLCS+068K3T20dlLH5pAbe4z0VlB54AJxxmte3sLW7864t1mjuAwDySABec/dG7OD9K46sUneo7rp1/r5GMknrJtok07w8y3vn2kckFs6bVxISEJ5BGOPzrV8Q6SL19MikSKZoboSq80fmlTtI3jJ+939MgZHFZFv4y07SvEVzo135kciSJEW8tjGyGMP5m7GAATg8j1rsZIjuPzBpFXCsxxn0P4iuOvOvTnGc1a6uvNM4qk5c12cZqGoaZDfR28jNbtC+FEafeP8O9j175Pv3rrrK7025kW3cywmeMNHMXUIW6FQpPJBxn61xOt+GdUk1yB4I0+xMuTcPhssOi8c5xgc4ru9GgTTbJkSOI4w6gruVG/2c0sX7JU4uErv1Ctyci5WYmv/AG23gaexXEzPsaRGwUULz9Mnv7YrC8N+HLmad554HfzcmS5YlXVhnO317V0HiWwl1OzhjtLp7W9hdZYZOcF1J+8v8SkEgj3ojTXH0FLS3uLS01VyN00eUjUbvm28HnHbvTp1nGjaLSbdn/n6f1YqNRxp2W4zT7MWmq39xLJO8l2VC20n+rtgoADD3Nak4iDMHkdg4AKkkj8qg1O9awt/NmeK72KIVe4OJJCoOZMAY5OR04wPWuXGryrePvEb2xUHyzjAGfU9unPFRGnOv7/9aExhKp7xpaze6fo1rJO9uwEMTS4iQdB2HGM/WruoWovtOgfR2fypoVnPzBW+YA8kZJOD/OkEUItmLQA28ynfDIflOR646Gq+kz/uY7KwtI7a2jGxI4+AFHTJzmn9lSjuu+wPuuhg2elTQXFxGJ7uK5lDRr5sm7ZkY3HdyeCeeOa2Z5i+nQ26Xmp2ycfv7Z1TfjsxcHHrTPEzWmlzR3E4mlkiTChPm+dgRge+OrHOOwrPsriK+tWYwlHHIV13Zx/EM9R+VdLcqsVVexp8a5mjUj0TR3RW+z+JXyM7jcN83v8AeornTY6ixLbC2edxlXJ9/u0VXspf8/fx/wCCP2b/AJzZvIzcG4kjaa3eXad8UgSRAG6A9QM8ZA9qkltZjGZJA7eYfm74z2+vv3qSJY0MuyczRSxsYxIm10z1RvXBqOcY3PCS2/nO7A/+tWak9kcqb6FJZJPtTWpTzxx8x+/uHTgD07mmWVxJP4k1K3lXbHZ+SI/RkZNwOPYgg49BVxZmSLGQ+35VOCW6dsYJxmo7m5Waa2w6lkVyy5Bc7tuGI+oYVqnurbr+n+FvmXHVtWJZmXzsLt3RgEKSSQD6r3z7Zp9igkdWkBzznBKgj3H+NVnlJxJEqkAfNvyuCT1Pr+FI885CjzguA2xVXLFcck/3iT+lTyu1kCTN6K5KxSJGBvlX53P8IHJH48VVmeNYQZBuCJudI3G7p/T0qCJJomEZy3mj7rtlwCeM46EjnFWdjtPHLIgd4/ldSwClQQTxXPyqLISS1LN4kklpf3HlGKKWSMBH4OMjqO9OvU8tp5I1GCse0HoASc/nVTymkjvAkjPHPOjrg8KoI4H4nqeanm1CE3cto25Qf3as3Cs4UnAJ7/4VCi9l/WwK/wDXyPNPENlDZ6vcS6pLPELq9dbd4YDIEBUNxtGWGQcgDINTWd1PYRwMuoRXExIkh8kbvMjX72/I+Ve3rnirevXUlhqNrq1jcMZNMjaNgjYVVk+WUjPRxkMD/s4NNiRH1YWsrxOY2IjnlyZA3c57hvy5r3lPmpx5tVb8vK3a19dfU9Wk5OPLLYz7yNFja9s9WZJzKec4Ck8gjIxjPGKtia4v7ZYNQht5LlGy5jAUsCMdRwCep9xVG0FlrF/DZQxTpqCBpHgNs0gCKTkMM4GD0PSnS3bcWK2s+nSRDNtFfIYzLFkkspHAYMWJB55FW4t2j1XfdL9V/XQ6FKN0k9SaDQrKC8ZpdRuE2uB9nkjw/IyDkHGOetY2tX9nY6pfHVY5At/cJMY7HK7lC7YxuP8AdAJxkgnrV7XQl9NbmEpDIqAbW+XcB/GPxzkDpxVXxPpN9fWcEDQ3HlwqiCcxHHl7i2Nw5wSx5962o25ourLf5W/p/wDDjnBzjvqaVrpbTR2upW87huZrSSS1WNdrjgMOcjGeaboXiGLWvD62uu+FbWYLM8AuEfyjcFWwI0VSGx90bmO0Yb6VJfR6RZNYtd3hsXto1QQn940ir91lGc7cYHoMVl2eof2jrxtrSVNlotxLbQldrMjYzn0YnPHQAVCj7WLbW2qeqta+zX/DGEqSlbWxOLSza/N1q+jW881wcyxEZWHaR+7Xtt2gDjnHNWjo1pYeIEk0y1KvE+23iTnaufuj1OOM9TSaBOdVuxBdTvD5jgPKwyqdgCB2zgZ96nmv77XtcuhpGhahNIskcCszbWdAuwyktjB+Tgd80pSqKTi3ZJa66dlu/wCkbScaUkn2Ev4LjUNbt1SVrWVduyJsK4OfTPB7VdtdZa7e7TUE22iv5DFjmQRpnLn/AGh8xB7dO5qjFDd+GBNqer6Zc2bI2Flu0CoXPyqN2SSB149O1Mi05IpWtIZLYRSoQWDKNy4yzA57jP51m1CUbbpbP8/0L9yezVkS6VLY63FbWtqGTThclTNO3lPcyKVdMrkmNR2I6857Cq3iDWJ/+Fi39vbMiCCw2wbMjcGYMTx1z+uKp2GoS395dSojW1mp3QK8ZUsmPLZvVScH3+UelV/iDZSWnjXSLmyuBHcGyWZnZXYGNQcKyqM/NyK3p0l7fkl1T0310evn0/Ax2kp7jYYEutf0TURvglNxJFcxwuyk4TIJ7H+IdK7ayT7VcEzzFYAwLyb0j8td3J5PHpXNJqXh/UtQs4vD8E51GB1n3rcghJGUllKsuWjCjDdMZHJrU1eGO6hmSV5xps6lriGSYs8APLAHHbHB7issReTipJx0677+v3F8yqN8qMu21K40zTNR0i7uZrRLGee2t5IpCJ4olf5S5PDY3DhTnH4VlxeD2Wy019I0udwzfvr8zq4kkxlsKTjbjuwBqPw5eSeILK907SLBbXTjI7z6pMTIIIyx24X/AJ6EDAJOfTpmujvZtE8P2lpeWE7fZbdltbiFVOJgY22yc9SMfiOK6JSnRm4QXvN6rvp1s9L9E7+fcwjsnHp1LJ8OW0mjCwvr1lNmvmW+9fMVXzliSo3YJ9OwqxbXFtqVpbyTXkz3GnXCuwaZTl8ArNtAwyEHKn096peHbiPWIbm5E9wjWuxGz8ofcTjI6nhatTJHJband6XpTXeoJGkYRCqO656ZxgY5JrinzczhN6p+Ss3/AJlzit29Opa1nxPPqN1ZaJItuLmeY+XPbL96RPmCkk8M2ACO+aytUS/8O6VdajqmEcr5Vmu4edJIeApycqoGSSeOMDrWBYQHWr1L9YvsNrbXZu5YLv8Af+Ww2l0jHRwN67c46GuturmdNXminfzGc5Z5IwpcYx8y4wOP0q3SjQcYQStu18++3rv5d0qKunGnoiroujSBIHglguLO5/0grMwjVPlGCB7DvyD70y70rTtO1yfxAb8RWU0RinzGFRWxtDgjkAkcgjNVjYy+GnuL3Rra71KwuD5sgtoxM0D45jIByFAGRxgA1a1zSrnXdH0ZntIbPQbmbfLFHIXuQTwu8kbVwM/L2JGaOZ8/M5+7LRvS/dq3fsKc7JK+pY8O2/8AaemPqGnyRXywMzQLFMFfzlzjGce5Htg1X0PTpNQ0e/xJZWl1NcLG0d1NsYhU7kDHUng1uaaLJpV0qC1xYrtUhSeEyPT+I4zn1rk7BdMs73ULGKVzbw3s3lSq43Tc4BDfQdfriohJzc+XTZrTp562/A0Upydi1qeof8IXb2lpawtqeorOnnpCS6Qg8hCf4nYchew61P4vt4L3XPsi6hL9qi2/6J+8eO3LDcCwXsPXp24rU0C20vShJqtpp9ncSSTH7SzM1z5TYAwvJ2t1yeTVdr26tARfXrG6SZvKuI0iEksXVNzbMgjJ4555pKp7/NBe8r3b3bflrovvs/UwkqkpXW5J4gtmFrqepS29qLO2Tb9qSdjIzAKCfLxgnJ5GRWPpdvcxpeQtqlnOfIDqtplpmjbq4U4+UA59c10VrM2r2swluZts7bp14UTAADc4XAJ7ZAGe44rJ1PRpI/EEOt6ReOzWluZY4omB87YcFNvTGM5zz6VNGaSdKbs/w0tZa/P/ACEpzinCTNfRI7vV/h5Nax3O64gHkrKpLefGoB3AdeRx7GuyRpI7XT2limETWqK8xHyqwxt3H8xmuUVLPUrOWGyZLG9s7pbqJ7YFBh0WRXK+jKwBHQnNbUuvSXCfY4rwq3lCEwMoKHcxBPHOcHvwOPevNxEZVJe6urdu1ziqRctYo02Khz5eyNFxwi4+Ynqcde/51JA5GY7kkKg83Pque1ZdrNLbXZhhWS5KGSJkiiIMRi2j72cMOevHINaEcMdr5FvGQqRpuUq24EOckgj39K4pxtoY2Mq1vIhctFbRFIlb7obecdcsx5/AVuSwArM7Txrs+6rcBj9elUYogL2SSdS7jcY2APyeuexpt/C9zZxoyyJcH97tZeoxjpVTtKStoXK0mraGOs9pJqK2rXG5ny7Ro25FGeg54P6UmpTadpsTsuEQrj5V3Mcds8kYrBg0G9j1n7XFMqFDn91mRnPddoHHTvXZXmkR3bJ/aieVcspc/u9oLMcnGeOvpXbV9nTlH3rrqdE+SDWt0cpp+qzalLbPpshtoELearKZfOGOjFumOvFdXp2osfkaKOMZ4VDnntUcWl2FjG6yxvHGw2+Yh5/P3qyEhW3MlhaxW9mD/wAfFxJjzDjoB1J/Ssa9SnU0jHTp/wAP1M6s4T2Rl60s17c3cDWN1FDawBjqSlfK8w9I8Hkrg8t2NUNIh0eK8jS5luLy9JAHlyGKPvxxktwO5wa3Z9a8oy2U0dhPFKn72NM5Bxxz0z+FZekpoUOqmW3Gpx3jRsohWOMbgRg7WHJFXCUlTcWmtNLf1dfkEebkaYsXi6/kjR7bwD4jkgYAxuMDcvY9PSit7/hI7xfli1BYIxwsT6a7Mg7KSGwSOmaKz93/AJ8r76hz8j7fmZaoqyywKWHziSAuS2VI9frxVKeQSRKwbyk4BwRwc4wcgjmtIwGJFBGYc7cnojZ9e3pWbeRvb3DQywQyI4G6OYZDc5GR6gitabTZUdRoNzOyrFDbiHBLvIC5HJ4VR14qneW0Y1bT7i08uNZIJFjmCbcqhBK/T5yR7g4rXMQaMNF5RkPz5eMMu7vgH3qHU7Q3D2l7JMCbYuNoTClGQDGfTIBAxWkKiUuy1/IqMnzWRW05o7hTJDJDMifKzKjAsR65PNLFErOAZ3SSWTaYy3Hrkd8jHY4FTWFvDawSPBIjCZi2F3HB/Gp7e3AKzxliRL99sfkB6+tKU0m7D5iaBFadvKXCq2DxgkYzu+mCKv2qlboJuVFmJBYpnao2nJbPA9u+etJZAiXUGkKu7qg3E8AZ55+gAqvqEMryCaMRyPJmMqgwu3aWGOevGPeuVvmdn/Whlu7Fm3EqW4N9JbyXH72N5bdNiOUcBCF7Haw/KuWuNShttR+yXMvlQl3kDMDK2/gluTwARgD1zWkYDNYwGObYpd5iHBJcZQDbjueP8K4y/wBdkn1/ZbWtlc2uVeQEFZY+MHYWOGPXjjkV24ShzuXz8rfodVCmm3fUmGo2l5p/9pqzTRX8zrIzrsAAfG5x24x+dPv7ZZns202SKO5EeUVxsjZMHBU4JB9Ac+vTFWrbRbVLWK2tbW1ubB2kaUyShXQsT98E579B61li8trK5stOYGPzpJrNJ3JDMFbbGd5HIwoUHJyK7ouMm/ZX0v8Adrv6JHWr3STMnSheC/1SOCC5tLy5hDETbojL82So3feHp1qWznvLm7Wym3rLGx24G1ie64/X9a1vDd/eXdzLpepW4u7BsrLDImRtAOeex7g8HjNY9t4oaw8OtqOl+JJ5IHBtlju7ZXuYWwflEn0OM+mK6/fnKUVFX07vfRapPt1+825/Ze7a5ZuzBL4gtLvUbm3jsYUleHcwGMREB2J+8RIyDHQjjvWkiX0IOmC3vorWIGFJLRW/d8dQcEY7+lZ/hWDTtQ0eALbxy6wqiGddRbCqc8AZ45HJHrWxBZatp9/Pc6pK0VgFRUg+0Hy41HLCNQfmz6HpWFaSi+R7x0s+tno0vn8xJq7aOR13R7i6k08ajcPcakJJY9qP8zrldrcEbd3II/GrWiaZOddN7DYWvnT2zPayiRVWcBzHJt3HOFIwCeSOeho1/wANx3rvqLySRvO4Ihxzkn5fnHTA68e9XdM8O6bFZC7mkkllWV0DuciNUOGZRkYLMefU8n0rqlXj7FLm8rW7623X/DfgJNSTRuXEc1poOoNPawacRbOFuBJHJIH/AIQoBI3FsAd+eMV5zo8t94cvNOuDdTL9sXMyknIPJA7liMZ4Heuh1bydQ1DT1sLa42QuS1x5iJsI/wCmYGTx3qfxL4es7+xv47SSfzUGRJNg5KnO5MfTgcHnFRh5RpLkqbT3026d2/P9O9uLvdkF3qJ8SJMZ5o7mKOeNTBN0kwep6E4HbPOfwrnrK4e48TX+madZwW/2iREiMQAMBYbcLjAwdxIA4FbMbaJZ2umtY3RuY3VCbeFDJO7gfMpAGQ2eBmm+CNa/tjWbm5aG3gvRG7xyn935brny8tjIC+vtW8f3dOcoR91Lrpb5fIU1C147iR3F1plg8un25kv0ht7Pz1YGPzVkeMHGOclfxzmtLQZ7+8sNT1Uqr67JeG3kkBO0CNRhE9uSfes/xPZzjw/pmrR3kn7mNo7dOOPLy5kPqzOTj2rT8MXY0zS4zYTWVxeDTnvr4CXzISSpdRIMff3duCpyAccVlVtKk5xSbb/Lo/LT7yIy5bEcelQX2pLqUNx9g1VrRgFCgxTksCVl28/MARnqO+elaGl2dxapcymdTG8LbCreYoGOQD3GeOeaqy3epT6ZHPqVmkTuxeBba22NMjYOEA6scYwT2z1rnbvVni8G3jRRR22qi8EL21zGxbd646E4Az255rONOpVXLfql3/Ht+R0XUU336G54VuLS5jjt47OGKPS7XyLq7ifatxli0SkKOWAzk+tWtfstJ1+yimZpBFaJtMFuuQ7MQu9gW6qSO446VyfgbVrXSotR0nVEew+0soN0EZ41KqxL7RhihB5wMqQp9a9B1qOCxE1oUjWBbVFBVNpbauS7EHO4n5jn1A7UsSnRxHu3XVPuuv5v0+454OLfJqcXa6ZqWjawlhpkNxdWF9JGY54STHLtVlYEnlGGD17A9a6CDVtAhu4bCTxBLaXtzcJaBIoHeYOW4bcMYUlSCQM8g45rT0G3tNO/sj7V5UVyJkuriaZiAu4Yzk8YCkcdOc96h8S6Ra6d8WrS/tbS1lvI7cqJ5AdqyMDtkwD8zbAQOgBIPas54iNabhO9+Vu6tq13vddv8uhnVlUS9nTf/DDNX+yXkWo2+leII766ErkWc1swUkHDeXKVzjjrnGR6Zp3hjVNVvdHMl9pEkOoW83leTOjeYkWAARkZ4INSLqX2ZmsvmdHBTIfkIw6fr2rmLHS9RsNW8u51OaF7iVU3x3TeYPlDkO2cgNgBR3IOcZGVCnGdNwl6q+/ntb8r+ZfsnTaTOtvvIeySDVrcCe6yITE4jliAGfMDZDLjHuDWVpFpqMd7p11cx6b58KSILzyy7S5Od7gYUlh365GTVwQR6kxeMwrcScTGU7WYD1Y5rRh8m00O3tJrhblPOe5a8hBCg4wyKc8oAMZ6E5rHn5I8q3f+T/rz/JzUU9dyGfVobuS7W4juIUtpQjOr4jkOM7VAHT1AqndWemeTtaCMQSYZEAKhB/8AW6euODmtC7trpvPS5ZV0mMQzW4Vty5IO9mAHGeMHpjpRevpJuEjuDdtcISDGIQArDj7x6/QZxWcZKNuS/wAvT+vTYcGla34GVpWiwW+rajeaTe3Njb2yxvc28DCQzFgcsUbGwAD73PXirl7ZxXMEqXM/2qN5BLBuAjfYRwpYcZzwGPX0rm7mWdPH811ZwsLeLT0gKZ3pJubOJB3yM+nTjpXR6Qmlu32i6t5rCZH3EWgBWQD2cn3x0rorKcbVJO+i7X26vf8A4ewe8ryK0F8U0NIFh+yyxMfOQN5jCQE4DMByQOP1pmuyta+D44rBttwZGC8BnjjcENke5IweoqVbjTrVNS1WTT5rF7+8LCCZgzgAD5iPfOSO3qazLjTXvEtNT0KURxRzRrJnnfukC7CMAEnJP0FOCjzqTVlfrtft166dQveN2jpLdWt7Od4g8tziK1ji4DybI1UfUACoPC8KXdy+65eZ4nVZHKHylw4LIJON5GO3FdJcNaw2yXESRyy3hcxzBwqmMscNuyDwOw6/hRomlwW13bNJIIrbcBDEcAMAM4X27/rXnPEJU5X0f+RyuquRjPiHcQpZ3Nl5bBL355WaYxgRE5KgjBwSSSO/eqHw5vpDbS2yhvIt0ZYos5VFAOAvt7ZqxqKanqN1PbxXL+VCdoRlDZXsR7DmtTRNKXT7aYQNGJGCgb2JHq3TH6elZOUKeG9lLVvX/g/cYvkhS5XuPurm4ihAltpLYM33nBwSOR071m6V5pvndpmkYuWJClQBtxwp6HPX1rYVD5FxHNJJNHLIriNnLBMdwTVW1vQsrgo0cQyAxjKnIOD1Gfx6HtWEXaLSRlGXutJGXrr6o9yIdMvbeKLYGW3acIzKR6Htx/OrXgnTZ/D2m3ommlW0lfzE0+Z/M2MRjEZJPyknNFzb2lxd+bHDJIxUkMpZlCjsc9DnPAODRpp8lpWSJAg/2MHGPWtZSbo+zWi0vp/X+ZTfNCyLuyGaZIrpXlWMqzq6YBI5+UZ5x60y2hn13SNNvvEEv2O4j3h7S3hICHcQAGPTjHPvWbrVxLol/ZSW81tPYzxGR4RGwaWVuWdpD/COgVSD61fn1Ce80aOBboTQGRWLQp90g5wc8+/4VDhJRjKPXr23T6f1pqRyy0aLMP2e5vV0+yhWyh4G/ZzJ+Pf6nrWL4xtobaQ2WpwLJbMAIkZckNn7wYHK1Okd4bpnidJ1U5UxOvA7Zwf0NPfxRDM/2XVrK3Z1/dAzRAKM/U5GfTGKqnGcJqUNUt9dfUtRkneOqCG/u0hjVFARVAG6AZx70VcXUNqgJBYKgGAuJDgenWioe/wE/IRHkWCe3JEkYwwU90+tV7zbtRWJeSLKkEkMy9QwP9OlTqhdo3t5CPMQ7VB+6e6/T2qtcsktgvmWyQ3UDKplVsgY7nPOSM8dDVR3MluV4rswyANHmNwd7K4ATjj3ye2B1p9rq1tfXDwRC4LRruLSphWA4zzzn69aeVTa0mctgOr5AUgjII7kYIrM0ywjs9anl+0TzXEoCyqHxHGP93PX3+tbKMJJt7l+7e5ffdlzAx5+Xk4wPanqjNIQB+7IHzHsc54pZPlZ2lMagcKzEAjn6cg/nSBwiyEyYVFyFCAYOc7t2eRjjFRfTQct7GiigRMWkjj8xdql8hc/Xt2qoJopEuUuYEQqittjGxgwJGc9M/4irNxbvGiR3AkRXIZNjjkjqrdfyqFE/wBJikZlYFR8zEE57gj61lG1rkR6kU1ru0pVmjdw5CoroBnJGRge4GfpXIre2yXivc2NtdXNszGN5VIlQ5zhgMZAPqK7y4gjTzSVDxSN5jOxOeg79hj0rEkmtXuzJdNBdGb92slxEA2f7u8YyT2JHUdjXTh6uj0v+B1Yepa90crDq7294yS2sEzf6yNpVyJAfvZ9ep/EU02k2rf242tzTGCa2W5FoRwskZXZJEei7gMEDrWpq1tPbzzRWljFf2lqjzLaTDknbkeW/VT+n40muXH9l6diRbaS1EKvHFAd7vI+MJnHABJAzngE16EZptezWrt67p/Lp/nudMpRk1Zasxr1ZBdWlhJqgJn3W6QuCWkznAyBz0xyegrmdRtF0Ozlu7aK01C1iwJ7UJtG8NlX6ckZI9cGr2j3VjcajealrtlI9jHuS1uo5QGsXjBwQuQH4xkH6CrOmrptxbw3Quri1kl+9DLETG3OD/T869CN6OjvbS+mjfy10/B+VjeCUm4yNRxHrWlouleS80iZuYJSEkDnGSjvgMRkDPtVb+wm01bbzrq5DXebdYNQugyb1w3BPAY9hnnBq7ZXulXaLZwajbo8DvGsQ4cqOc7Oq9+3pWV4hn0m512y82K6jeElEWVHEErlflYnJAdcd8fezXNTc+b2aTS1e2vl2G5ctrD/ABhpGs3XhXUbdk3yOqlI7ZzJK2Dk5VRwMZOTx71p+ELZbbQDpV8W+xylJbKQKcwrJ8zREH5iFYnBPXP0rHtIZdR1SeGO0ukRkH2kR3Dxxsg7sVOMY4ya2rBZIdBij0mVdQa3d4Z2ktk+0xoD+6BAGSNuCJOpzzinVclSVJtbp+mm/XtbXe/noVKb9omxINKg09XkWJrh2DFM5CqAfvOPp0HT1p/2+PTtl9eyQRFXBBkO0uOMADGW7cDms03Wpavdz2niW5mNtJFsVrVRCxwQcykdQDjjnrWZpGgWlpNJqE2pZEMbRr9ubckRYj51bsD938c0Kmmn7aV35a3v5/8AANfe2kvmbGgrd6RplzNoeoJb303mTs7RKI2PuTzn3PGe3FYNhodrbyxWl7dNeapqN/A+pCIHEcJkDOA3TJBGfTPpW1cLaGxuNO0e5trnUZT5VzMuQsKn+EDqfyGa6Uf2ZHplzZWUcs0draOxlYAMXQZ3Nx1JAzntkUpYiVO7V/efaz02u+3ZGNSEVrFGDoUa33hqS2lJmt1NzNArnlo9+E3HHf8A9lrPx9muvD9pEsMKTXkasIkCrIx3YOD2JwD6kVH4K1nPiW28PwQybra0lhBTkXEwOcdsgDcAfWm+LtFu5LaGK+i+yfaybZI7nKsmDuVl/wCBcZ9615XCs6c3ZPVfO+tvxKglZrqampXFyBcjUpZWKyh1DqV2yc4wOgI5NY8Gjwal4k0rVLl1ED3ltbzRFcAZ3AHd0J4789qp6Fca8+t/2d4jnS8WC0eTbebix2jJIwQS4A6nPy5rXSKbxNfW+mRQQLYJIGjtLOJlXzSNoZmJLdzznjJNVyuhdJpaatbWfb+vmdCSqQ2t+hP4i8P2msanCNSAja2usKEJDHGdyMP4c4PPeui+0W2q6CImtori4htzFbzSgpIuF2gSEdQB374rznXPFPia48PXEDGyvZYr9IUuBCHvBtY7AWX75+U84ORn1rtdEMOu6aHtLmLS9Qu4Q27pEshOQ2edoyB17Mawr0akKcXVez0s72/Wz/Q5U1O7atJDU1C+m8i3v9NluJmYvJ9nKTBIdny5QMOOMZJAPviobQyiefUdZWXR/JbzFnkKyqY/4WAXPzYONp9QKw/AtyqeNtW0e+tZLXXLbfLDbvdOu+ZRt+zgHKlBlpEPqcc8GuuimiltLi2vbbzZ5WKkS8gL0JY+tTWj7KXIlo0tuz7atW/AijUlUTa9B+hXsOrW9xJfaKttcw3Dwl2chnYAFjgHA4IJGTgniszWYtYOvyXHhyCGG3kKrJFPc+bbSpkbmnibByAOCnPQDmtHw15HhqyutNubklGvJFRtwWT5woxluoOAQT0II9K2LC0gsbK5MtzbyOjDzAHDt7bh2OOxrmlUVKpKUVdPRXu0/lcicbq0vkZ+p6BMvhm6vdNtNMg1uRGERtzPiRjnGxGZlU9MZzWJ4ObWtO0yaHVkuLuRcBo5yFaFmJG7aAcAYB9DkV1F/qUdxHDZ2chQXAkO/BwpQjAYds5J98VQt2uL+1nga7a2vYYWSOaJjlTg42nuMk+3NKnUn7JxqK6bvre6X52EoSa5pO/qRWv9vG5kup7hBZSTKojkg+6gGSiEdjj7p9zxVma1S21C51G/a3kXcFQhQPmxk7xnkjIAI4xXI6D4htbCzk0rxFqF9He2zNefa5FaaN1boQUBIweDxjg81safd6d4r0qaWO9liSS8cwgwfvHhXaqvjP8AFtbPp07VrVozpy95WjtdLS3r/XmaKUea23oaaWllYy+bphAW+hJuWb5ijxfMrAngcE59h6CqVhrLXusJbxRTXMu7y2CWw2qCecgHnp14q2ft51Kwj8N20hms2MouLnCxTsylPLAz0wxyTz6etZ+oN4mnuJ9Onnh0tY4trGBADuyAVAJztweuTUQipfE1e3V6r5Wb2sEWrtDby6sIoL69l1Kx1C2a9YW+lyxFrpRkK/CnKjq3PB4H8VHijQvE+oWNlu+y6bZqh/c52fZt3BY/3mCkj2zgdzVvQtJW3t2vLuCJrlp4FVwqqWKyBuNv+6T+FP1dJrjU7cSXAe2kYoi3DhW5PTPPHqeKpVeSovZtO3Vq/TotF83q/wACFF3cW9CSTRzH4L0q31BPt8tu4gs1SUETYyQMdvlznPatqyv49S02aZ7CTT76JQY4Xk3qq8c+3QDA6VkW1xJdX1rPa3Vld2+ms9nIYBuCGUY3txjbwFBBPOTWpEq+WsNqpa4bCSNtyUBPPA/D371yVrvSe979dLvttqrP5mMoq2psG+EFyhhj/wBZjJC5JY4AX19q0HXy5JEmAMiNg4/OqVjcKDA5KpIAcE7dy9goI649ferV06RRIA+JJcjnua8ua1SSOJq7K1/j7MxjdipPY9e2DXNPHdqXmguLm3iDDc27GPVST1x6V06bUsN0+ArZxu7g1nalaC8gCwkmReQM59+K3oT5dGbUZKLszLt9ViD+U5VyDy2ecnvwMfhXRa/Gi6BYy2W77RnDBQMMvQj8657TvD0j3O8g25bKu5OO/Yf4V10qKln5KswQgfcOCCO9PEShGcXAKzgpLkMm0bdZG1uEE0JH3JhkBs5yp6gVPDb2scp8tYbcEg/Kcsx/GqWu6iYrkW9vsNw6ksqnDKcA/N+dYGmalqF1qLQG1tTErhXZvnL+oz1GKqFGdSLmtFuHs5SXNsdXcRWlnp63F1HNNcXUhRY45BFwCeTjnpzWRqNrfreRSWmi3AtJk2favtA85Pfa2QR+RFWtalsLSxmudRulgiEojgSTlZGK5Kqf4ScHB6Vn6Zrlrcym0WdBFvHyqScg9DnoPenSjPl50r/fb8Gtv+HJjB2uiw8MZdjJPucn5jt6mirUkEKSMrTXYKkg4RT+uaKFP+v6QEkWREoQlXU/Ifcfd6/iDSXix3NqzxsAWGyTP8PORn/GnTh4L24SMExb1khJYn5T05PJzjg/zqG/VJkk3ZjmB3rgZBPdD7dxjr0qI6tMyW6Y2XPllCNsgTC4Pyn0/nUtvHkhpSnnYzuHc1Wt43jluAsiS2rEmPb2HBwR2PsPT3psE48iOZmZGZsKHQqeenBGatptaFW00HhEuLu6ij8zfbeXK6kY+WTODn6qfoaa+JkmiGAQQCUcHPfHrU99PbadpOqauxKzQWXkv1Csu8EKw9QW4I6ZNRsiR5t9u4nO8rk9/XoKcXfXp/klf+vMfM7kmjkW80kpkE6yb3HzErvbgsPQDsPen/6qYo0ZZtpwu3OeODnt/WoXlIkKQoDsxkgjv0yO3T9KmL5aGYRtNGc8jO3IHfPb61LWt+4mi/p08cdvG0qplGQFSOW5+brwRjvWVqOi20t1LJDNFNZTOWdJ4TlSD0weDjsau3KSt5n2WElV2MUiXcQTgcD07nHTmneXI1vIYVMm0BgqnkEnBxn05NZxk4Pmi7XFCTi7pmffx/ZrdJTLtkUAB0zkjqNw+n6VhzPp0lmUe08xy4k8pW25cHkgevOakTxhJY3txZNpfmjcd0ksZcSA8ct71W8RaXHcSWjwFomutxUR5ONvJHqSOcd676VOUGlV0vqn+PQ7aUbNKZm32m6Xa2t7qkduheC1klS0mUHMmBlwfUKMY5FYfgy+vdSluZ4HTzprYR2/lIFCsrHCY6bmVsg9yDWtLps+r6feQLeB08tthb5mRyMAnoQpGRx65rnrLSbPUZWP2W5tNSs5Fb7A7FW8oDKsmMeYM7uByODzXrUuV0pRm7v77L8NL/8AB6HUl71rnUXbtFYW95cqlrrqOIEnlHlyvGeGUnqQGCnPbJptlqWsTXcMWsXU0xZvLOZ/mB2naAB9CDx0znNUtZk0S/sjrF6NTSaMFPIm/wBIWQEYKg9Vbk7e2RyO9PbS7KyuojbXVokM2NsUkEiSycZUtuXIOBnOQayUY8lpLXXpt5J/0jWPLrGS19Ch4hl+3atosFvqeywumKSWayH7Oyp6op+oB9atx6ppcsz3Yu3s2Td5az2kkbsoycqQpyDgkAHPtUItdPstHgjmsInvN7SSSqfMPJ42SDB/z071Nqx1pNDjfw3qmp2ZkB3RG7bepHdWPOMYyM+nrW3uyUYLRbX0S/Jg4zguaBcu7221ax0m6gsLt2uS0ST7wCw/hkZTyoI3fkCawdSstRttQt5LjTwdMtZTK8STRS+ayjcm7kLjdtznOOuKhuJItHgXUZ4rmW+uY4vNSaR3nU8qSrNzg4U/8C/CtnSNR1C805hp4tzJLcn5W2gQL/AFD5K5+8WIyT06U1CVFXgvd1Wv/D9PT0FBOUORvco6djS4tRv9UtjZJLPEEiMg87P3mMhGdoyWIZuoOBW/feK9PaO4tdIvZLvU9V3W6RzxsDawsvzO+Rj7pO0DPUHtWH4hS6utMaGGVL6USia9nRmdEjj5IYn7xzg/hxVzw5ocesavqWuaQX/sqFPs9o825pLhlxllXGVzwOfX8KmpGlKPtq3T7uiSd9dd+7s+hNSPLaLehhaPBb3Ja8SK4gWOCSMyRgbyM/eQ9n25Az357U3xE9hqlnpd3pdzqJ1eBpDNNeyNNO6B90DHJOQAdvHHHI5Fd7YeUlvdRCGH7IkqK45PmswIyfYde2azZoootK0vVLW1FvPp04RExmJi2T0PJIIUgdMiiOLvU5rPR6a909H/AF5+RbipSXl+p5/awprHipdQa7+yXUSebby2i5iSYn5W2uOY/VT0BI7YrSutTW78Uafpjpa6Feea0WoLDcyrEWAPyqCdio5HGCc7hyBVLW7hbW+bU5Lgq19K298crL13YA4B78dhTjNoOq2hfWrqC0vbeEoOCWuCPuhcDBP9e9d8lzWm07Wtprbp816+uhvUwsYx5lKzW/n2OsuNOjXT9TupIobGeC+hjia2AicMI92TjnjPPrUOn3V3bGCIWa3QYGZxGQq7By+0HlyBzt61haYG8NpPbeJozfWNyyu0Yk/eQzKCAw9Rg7T6/hW3p+o6Ne6ZdWkGj3chuFcKkbAiPaRiTLHIPoPrniuSdNxT05o9+m3rfQesYvTUz/Evg7WdT1mHXbCzljnuVS4DKdjRYA27T16Yx71veHfEGo6ve3On63bW8OpacfLmu5GEPnsRwZB2YDq1Zul+I7rQ9KFxZatbXXlxOscFzIQwKnhVPJUr/dOAQBis3wLZTXekjWtQ3yjUZJGkkLMG3BsFmbH1P50VIylSarWtHSLs7+n3L+mjCKUpqOx2BF9aRTWet2kUou5PNNqXjkjYEDDq5BDZA+nHODWDpVtL4buptL07R11TR7wPeRE3DWsts4wGidvmQgdjg5z17Det9Qs7m2tLJ4LVpmlNvHNMw81X3HaFPG0EAcdDmp7LT7211OT7bAIkRWhPnkBShIyGGemRn1H41yKpyKUZq1+m17bNWd/xv3CdNSs27NfK47To9PvFM+qWypcKMQPYXDMIIx0Q7vvHuWwOayNR1u9txLa+H7b7aba7itZ570MoaeQEJGuMHCglmY9ew7nR8OazoViZL3SrS+uNsjwt9qKCHK5BAAJLjp9ah/srRtUul1PULnUIdRkl85okuVWGOQAKCFPOSoA46AVMbQm3UT5el9dfS9/x/ExnCT+C/KYmq+HLee4hl1R5bvUWJWVIS0cBXOQoAOSucnkjmuimsINMQrbT2ltbv/y7RyqJMkcIIid2eOAOOK5/xNrN5pX22HTNHurq4iX5pRGfkRv48qOfTg1B4G0TTde0yaS/sb/7bODE11PNuVQOuFGCCeB1x710yU3SVSrL3V6PfyurfmXJxj8C16nUn7XcNHNC5ittoba68gEY5Hbp6Vq6fewX9pc2KJGziJ4zObbMiNgfMHzu69Melc14AsINI0q60uWCC9hE7O7zjaULYXh92SNqnIxn+da2qgWsA0/RRYaVNdsYEubVGkbcV5XczfIWAOHGcc9DzXDWhFzdNdNn09Xu/wADKpK6s1qixbRtctoul273V0z2TTEiQbwztw7PnBG1W47A1Uubex02+u7OWC9uiqrHdRryuWHyqW6tuHYenNactvbQ6Q39g6glsbGRE+0uoO0JHgKM/eG0kHPUGmrpzyXDYvhLdugnuJowMyMQFUhRwFwoAWsY1Fdu9l8073vd+WunW9jCE2t9jY00yXtimniKGCKQFtkacQR5BwM98jitWGA25dwF8uMFlJ6s/qayNHv9Ps7C+ktIbsmzZRdbYmnlLEcfKOWyB64HtU+l+I9N1BEkhnvh5hZXtLyFUeMD+LA6DnjmvPqwqNycYu3+ev5HNPmk3yrQhupwszwxxSzTlsmVQGC5HVvoP51eNnFqS2y3aKzRqeTkdRzUf9mxNqIcKpJwM5OCnXp075zVrxBJJp8TNh1Z1I3rglWOAualyTcYw3CUk2lHch1LU209ZJ4okfy/3cAboB3b/PpUui30mp2qXskaJK27cFxjA4BrjovEEbXH2a7Esjqx2kJk+mcY/wAa7NLR30S4jtvLS6I/1Ur7d2e/Pb2qq1FUYpSVm+vkFSChGz3FhcGMvcTIshA7khyT29hxzUqurMMspXOOOlYFraTwxRtdktKB8wKk4+h7+nFaVpOEVlaN1ZmO1D14+vNZzppXs7kSglsyDVtMsb29i1CXS7Ke6g+VLh3eOQjGNu6PBYdhuzUtsrwIGn8wRSEAmNgUz2DYwc/Wq15bPOWW3WVo3HCxkcZ6jB61j+H5J77UG+y6hYT2MUpWWJoZBKuOxyevqelbRg5U9ZaL10/yKUfdvc6jXbDStdg/svVbIeTGPMim3EkSDpwOfWsyx8HadYP5+6SZyPkDIfl+hJ/pW1ezX8MEY0/y4nJBLSgkFfXjnjtnirtxqJktZGKBYo497CNcliB8xUent1rmjWrQgoQl7r6X/rcwVScVaL0MJ45N7fI78/eMpBPvRVuG5s5Ykkjlt2R1DKwnXBB6Giq52tLDuzl/DpVNMsJJGcCN2t5BnIEfmEDP0U8f7tbtxG0bSxTbnMZKt6qezD69a5+zhFrqH2i4dGkmaSMpyqZGDtx6gfzNb998sNpKOfLC4z/y0j/ut9OOa7K+s7rqbVVeehSdZFMZt3fz+yDoSDyKS5ZJFkCxuWYl2G8rtbofp7ip7qG6sLiMTeV5blniaJsqcc456HBH6ioJYmYvI0rGQsG2Km7eCMFSexzg59BUxadmSmnqSQNFJo+qQzrJLaSWzh/LizkKMkqp64GfrViKMuYma5ikRgrFoGyjttHI9iCGweme9SWF5Pb6hbTM6+UjjfjqRnBxiqvhHT/s+veJ9CuY/s6zXTahpf8AdMeFV9h9AduR7iok7KUu2v5J/do/T0Ik2isVAnuIt+QW3eXIeAQO3PSr0RjWAD7RvndQ7IoOME46+vtSXURimMcq7XX7+Bn9fSooMo26CMCRSWweN3r9Ooqm+ZFbosKChZpDIrAYODtOKWO5ChckuhTggcnPQ/oKrWEs/wBnjVgpZBsK7txA9yeppXa+U+abSU2o2gTMVAYeoAyfzxUuOtmO2upELcRGa83m7RF3f6MiIxf/AJ5rHwd+eMnI9xU5W51e3gv7qye0urYMtvHMys8fqSyfKM9OKlZ/MYO23djAYKFYe2aSJmM5DSsVbr82TQ5Pfqv6t8/QfM9+xhXFnpqzJcXct3Z3JY74hAH3k9AuMVlSyDU0v4XixFEMW86S7JI3UAbuQCCOMkd84yK9CngjuLd0k8tx/Cc8iuQ8RaPcNZl9NnCXiqBuA5IHaunDYiMnaTs/wR1Uayk7SPONH8XX/hu4uV8WS3X2vcgtpDbISYxn94HxuZwcAE5GMg44NbVxfLe2RvG160itL1SqSThmd2PYJyS/0796nx/aWk3dr4tt7dLxEIjuGJJUgZVkxwPw/GvPdL0q8mdJbRAYo5fNCzR5hVgDkjsoPP8AnFfQwpUqzc7cslva3K/TQ7YRlG7R6DP4g0iTTkt9Is9SuLoR4ha5j2bkBx5uEznPPB4/lUN/IbvSZIG1AKwYsqS/KoDkA7COnK9APasqBTpdnfXOl2WBeqd5E+WBA+6o2/KAT0/wrf8AAT293a3T3MVquqgbfNZt0Hl7R+6Uj7hyST1yT1rnqQjRi6kU7J903/wPkClyas5Px9p+qzaDaR29jdPGrjChTuC46jIyc4H5V5/s1V7qOVZJzJO6RM7Od4HTnvgCvoJpbG4vYZLjTIfMh+4yXMgbGeMHt71xvi1J18QXkSW6Q/KNyhSSpx1JzncQefXANdOCxr/hONt3/W5bSqSu7pljUroWejS2umSf6PJEEigjXZtO3ksMkH/e5r0LTHlsPDnh200iKFbWKBBMWK/JJ/HkE5ySc9K4HTdMTUmW4uUeOFV+6gUZOcY49s/55reuYb590dtEEXIVpg2CFz0A65/lXnYqMZ2p32d3f0sOvFTa8hEks7qFVtr1AGKysrIxG5WxwFHXBJ/Kq2tpf36xxZVbUBXiEsY3LzjIx3xg4PpVuwiS2LRtaBAfmzub5e2Fz2q3cwrNER5pU5BBGTt6jANZ86hO6/EiMrSuzyrxALiSTfMwSOAYMhjx5mONoHHB9axofDN5LHaMDEL0D/UswHyscqQTwDz3r1LUNNhliCXbPMofnfj5T3wPw/Wq+xEPZWC4Vhn7v1xx2r1qeOtFKC2O5clX4jFn8R2t3eBtZIs9StyonR4x85A5cY4OetdppkXhux05dcuLrZbEtO4XGWI5CqPU9CO1efahotmGLyAkof3XzbWLMc4BOQR7dKtRRQ3FiybYoHLAyrgjYT146dB196zrUIVIpQk0utu39eopU5VI8rdrdjY1DQ7LVPDOlW9xbpBLdqt/LcRR/eMxLYPqADgY6Yrn/Ch1LSY73TYE+028j5exlcoUYHG6Nd2CcdQev5Guy8Ka1bWWgQ6Xe2cd5a2zukbSneVUnJUEfUEVV199JhvotRsNpaR1XY0Zwxzg4JHJx1HoOKzhWqJyozjdNtrqt/vX6EUoe9yzj8zlvEfiLRc6ZawFnuvtOL2Sa18poY/7p5POfTpzzXV6HetbW8UUaC4t352s+OD6N15HOa4/xPZ2XifUrq506KeC9gjAeNkyJgODsPc+386paTdSeHNNEk885RnbCMA8YH8KhfvKc55zj2rplQjUoqK37Pz9PwsXGnNX9orrv2Or8QaOb/yFsb1NOLTOds4Ux5woHKnrnrx79atQXeizW0d3qstxprRqqOjQrJBJIOC0L5yy9Dg5YZrNj1KG/kgaFg++PzI5U4UjqwOehz1B9KLayh1K3lsryaOVFdrnzCwIUBcsCoGegJyoPuKx5XypVG0l23/r1Llh2lzqR0/9p2F9CZ4NUjt9MU7FNwChz16dCD65H0rl7648QaVqM09wQtpqU/mWyQXCrMU67kXJyhU5JIx9KxfEdxoSGG3sbuS/sVifz3tVdYWPGxVDgZbPU44B61q6LpWnz6SdS0nTbh44UZbmJJEdwSOQrNyRtzkAVcKEKMedrR9192t1Zv0+65585LRxeh0Vu8tnqxt5LUQ2Mi/fDGbzc/3Tjk9yfapYpdOuPEKW1oqNLGgcDZgAgHJJ/Ecd6m0K9sZNHhl0/URLbWyj7rAGJOAoI69iOfwq3qgUW13fxYNxJbG1RkiLSEMwJPGTwOwrz5StNxaae3XfzFKTa0Lf9naXb6CbbVJGYiYXEjIxB88nO4Y6YAGBV/RdQjugXsrd4YvMG18YZsZPTpxWZp2mQSeGbU6hcMsccjGQyJIfmBwARjJPTqKdd6PqWp6dbf2ReRCEjMbNIqsqk9WGdwPHbPpXFNQleM5dXq9jn9xqzZevHSG2v7W61J4ZLmT7RLdAZaQ4CgMemAABjpWP4X0mznuUfTruO6aRfnkDEN154PTvyc9OKs+HNKnW6WxvD57NHIXG4sJM8YwfcZzW/pehJpNu6WsElvMDxIhG/r6/0qZ1Y0YyhGWr9LdvUznJU04pm3JKkVxbC3eKWMLs3oc4Po2R7U7ULq3m1NIplleeWCWfyRJtWREKqxz0GNw56+lc9p9sralaJdyyyL525yAI0ZucB/Uc9eprX8VQtCzXQt4pbyNJIki3ABIn2lhz64B+tea6cY1IxvumcUoJSSH5uZbGMqbu0glbC/dd8egbHBxzk1BaafDpdhJa6Z+6iw0geZy5DHksS2ckmsbwxcNqEzWzXEm6PJCjMgA9c9x+VdBdq5adJeY9qlH7Nngqfpj9aupF05ezv5/5eo5rldmURqEFrYOJ77zRG7XDHp5a46KQPujGazvMnmuFmhzcQSAPHlh5bdwVce2Oau2ml+Xfw3AjExwdqOmVkBBUg+o7c1d8L+G49CtpbYzvNE+I7eEr8sK5JwT3POPwFU6lKmm07v8Aq/pYfPCC0M2e5ks93mOSH+cdGZSefx/rVf8AtO4WRZY42ml24VmQAhepAOcc+9aevXmoWN9ZxRraC2mdUfz1Jxk/e6dvT3rWaxjBeJAhiKB1/unPXGfcUvaRjFSktxOoktUUE1HzZIJZlUfuwpXOD/u5/rUyyF7u2ijIE7PtAVhjHXp6D1qpPaB3ZRhAp5CjrVe8iFqqsgzK42g9Dj0PtUqEXoiOVN6F54rYu263tSc8/uaKyvteo9pYAOw54oqvZS7l+zl3Od0C7L+ILKyvNPCxzW29U1FdxG0YyjHgSjO3ce2D3rdLXdtthaMyWkTGFv3wZkb1HqMYyemTXEeE7qfV4WV9QMmqouZ7OVwz28+B++hPG6F14dByucjtXa6Zdi5tfN3AR3IIds7ijDjk457jPcYNeni6fJPbbff7/u++2mhrUi072LjlWtIg7jEY3BhnG09T7dMYqlHNGhVt4G7HXIwCe57Z960EhaNUA3Hy8AhX2kqDkMD/ABD1HcGs1IZPKk+QFmDRCXk4Q4JG3oc469RzXJCzuZx6k6M4nl3l+QFiU4wPU8fhU2vltQ8Mrqtu6W2p6Sy39vcM2zbg7ZRn0ZeCDwc81FCZhtM8DxxqPklJG2UY9PpTND1Jbea7mvo2uYYi+YguTJGy8oA3DAgHjpkYocXfnjuvx8vn1G11XQ6fxCUubG21W3xHFIMSjg4PbnpjOefpXJwzNEYBFulR5x5sqqCDGq8KPTk5yOuK7jSbXTDo8FlZusuj3kQNqxcsDkZwCeenOPY1zT20kCvbyQI0gJQqpIXb/U1yYapFJ0+3ft/mjCnJax6FSZWZT+8CEuMHJHB7Z7GnbtsgV/lJOBz98+ntUdzAkothJKsTSOyRpkxnAwTgY7cU6+jkaaCRYXkaP5A3mbUX3bnnoK6lbRG6dyeWYW8TPLlEx15bj6DpVWSWLln3bRhsqOHyOmfT34rQeG7Y58tGjGCCgwQe+exBqlBbX6+Jb9po2XR/JRYI8ghX75AGQKUHGzd/x9PxJ5rF62kwiqykgjHTBz3pgljJA34XPHHWq6XktqUhnjEpYk8H7qgnB6fpVqKJWd2hkkbJw0bx7doGcnPpk1Djy6sL2IZtPjn2i4jQMeSP61Sn8MwsuV3dOx6D26j860+HhaQo9yibsxmM5bHUKOtFmwitgLeNoIs/LGSTtH49PpVKpUivdZrGrNbM5fUdIktvLid9kAxmfLO2B7dGP1qxpml2aBr22iVLyHbtMvzhgBj51PAOD0HSte/tDdxNHJKFBI2tndiq1rpE8MuZL22ZOqCMli3rnNdHt3KFnKz/ADOhV7x1ephaiNN0u/S5vdMFzeSsSkVvK5TjoT2A7VesdFW6nutSvkH2q7YSMT0AwAFC9gMVu29qLeTMaoSw5BAA+pqaUHymfOXb06H6VMsS7JR373/DyRMq76Gc0cAiCKAqgABVGAR9Kr/ZVeQyKXiwc5B4z6c1ctryB4JF8hZVkAYPjDe2O2OtNKNLaARkOMjf3OPw71Kco76CU2ipPYSznJnIQnJVTgH2NE1qIYkAJdQeD6E9D/8AWrRjLQW8ZlfeSpztGSQO+KWedXhB2I20hhkdPSj2ktug1N30MCaziaVZGhjDYw4RdnPcgZNRSWiSKSoUjrwc/l3rXmG5Q2AM8DHY1nuWLqVwScgshBCEDow9fp+NdEJyfU6YVGii1j5i8RxOOcq5HOMHp35x+lc/rmkzTqrWsQXu785A/DrXWzWzuNwkRTjGSOcex7UyR47dFDMME7R3LEjoK6KVeUHeJvCtKLPLtT0XVdLlEssbS202W82JeVxween9azbq7vZbvS0zI1rHIJQkrYVmXjt0OCa9UUyGOQRFzG7AuhOAfqPWue1HS1C5JdDyfnPBGehz2r1aONUtKiVzrjV548sihPa28P2a6SZLIN/BNKwyQeobkZHofwzUeo6DqupWkN9o1nNqVhdoSWhh3hHBO5ePQj8setUdfc2mmTQxrv3ja6yqcLgcAD175o8M3Oo6HbRPa3jW8kqhpYG+aJ89mU8f1Fa8k1Hng9el9mvz/M7OerL3af4i6boWr6ZFBHqNk9vEWIPnIUYA/wCyedo9fzrUjsdR0++tpUtbp2Vt6uYz8rA9j0rG8R+JNU1HUEjuI4YvJPyxwqQrbgAeScnPv0q/bvf6fd29vLq6+V3imy2wD/8AV0pyjVcU52u+mpKqSUeVrYf4T8NGXUdaEkSzvAI7hYn4IjbPzbTyQDxx04rpNE0ezl0u7gmhd47WT7R5jRDK46jPcf8A164mxuLrRPF6aheX8zG4nbyp1j5kCjG0g8YOcY6eldw97cXuuMmqywnTpAo+zRLs+Qg/wjhsd8dzXNi/at35tGk9L9NGl/SPLqNu8baDtYXQdOsIJ7eCWK18xkQ2qq7zcZGASBgZODyQK14hqE0cdxbQtpWn2kfmSNdzqGLMOSWGMk4AwOmKqapoNpczxzLqk3l2f+rtTl0cNnhMdB9T7VPfeFtRijtb61VoJI1CG0upPPjCHuVOdp6V50qlKUYpy113v/W3XW1zl9pypL8y54Vu5pGn03UVWFruMThFbK5PO3PqRip/EDvb5hs7NHmVQzSKgLoD39T3q4wisbYXH7v7dIVVoshSFxltvPZeQPQZ9aLyOS41NNskVvOxAEuDkLnOcgjjBP51wuadTntp+v8AkcylefNYj8KXF091bzY+YSZLAHHA5+ldPf2sb2GIldPLmMuYmCkE9/fFS6NAkqRyysMAkFxyPTOfSrFqbxdKl/tJohcPKSkcZ3KmG4wcZIwM8+tedXrc1TmirWOWtV5p3RBFDEwyEDyuQSTgqB16fXvVfUIBOoaSHzZw5/ehiCR7/pV4v5YIXAduvtVUXTLKqhDgfe9xWUXK90Zpu9yNIZ3XY8xjRSdoZ1RSAePmwGNSLbXATbJFCIWGAytvQ+1RagkV3CizoJFByPMj8xQe1JpscFhbxR2kCJCh3GONNie+B9c1evLfr6A3c04EW3CRptVI0EaIowEUdAKp37yXCOoyrx85U8Eeo9/aks7mZob2O+WMsZA1u8ZOdvcH0+lVzOjyRkNlT94H8enr2qIwaldkpW1LVxO89hst2iW9xtjubiIOUb1C5wf61UtjeQWyjUb6W9lHytL5QUKPQKvQfWqd7ZySX6sJ90KjiNc8856dM579ccVbbW4dMsrqa4VtiDc7EHCjgc47c9e1a8jslBXv5a/f+hVtNC5KhGnyzWt40F+qlolwDHJ7HIP6c1S1IG7srJ7loor9Y08541PlmXHO0elPvUmgs2i2xiV4GMTI+9TkYByPSq/hr7UNNjF9lpf48nr+dKKtHnT2f9fIErLmD+zZ+8S59jRWjJMwkbaqgZOMg5oo9pMfOz51ubyCcxTwoIZopFbMeRgjoQe3TH5V2/g3XNqTC7YyR+c7XEgwSiNykxHcHlWx35rh7jRbu00kX4MUtlcP5SXELhkDj+Bu6NjnBAq3pnnWrJPG8ZeKMxNCx4nU87Djv1I/LvX2lenTr0uVP+v6/wCCfVY3DwnDmge07Iri1Uwuk8YIeKUNkY7rVIhot4CsFlJOGYsVPp9PTtXOabfx3kUep6bcGykY+Rc2xl5VghALo3RSQACo6Y5GDXRCG7Fq00ojWNnVEUMSc4z1IAB6jA+tfOypOk7SZ8448rsxWtijCZHbese0RYwoHXeCPyIqheRrHOIrR3gY43sq/Jyeh9OTnFaOZ55XjtUjGwDEZbGVyMnp97r69qjktg0rvLGrHcdrqoBXqP8AOKmMmnqCMjQ0vIPh+2n34dYEu5xHNbktJZusm4MV6gBufofQ13F7ate6ZbXUkgaVl2zGMZDOBzgdqr+H9SSRE44tpsPheWTBU5/+vU+l6/Fqmtx2ZszY3MtjFdtGWznfuyCMYyu0DPfd7YrmxFSpOcpqNrNt/MxlGXM2l5ma0Lb0gVd3krlSece+frTtNs5XRozcMZS5OeVAX0HfFdCllG0gdcgE5K4xz3+tc/r3iC10fUrmG8gljgiVW84DOckfpyKiFSVV8lNXY4Xn7sTbsXWMbH3qo4DAZqS7+zmBpXVpSg3DamSR6VzV/e/a7BjYyKgmQmNvQeufSsnw5rZttIRHv0nkimeGVwcAOMZXt0zQsJOS51vfYv2DlqdZqMlpHpvnvC43qRDGRhpWxnaoPfrwfSsqGzvEs0ns1dIZgsi5Q7sHqGU/yrHvLjUL7XrK+smilNrcKoEc4CmE/f8AMU53dOOhz0r0Ox1CG/a4tZFKSRHI3dGB6GiopYeCtrfV+X9f5hUi6UV17nKJqBlvijk7Y+CyyfOp/wB09BjoehqxcjduMbSyknO9hhiMdCBxVvxJpyRobppxbRRAu8gIwAOufT1qjdQ3McURtSs0Lpu81CMYx7cc1UZQmlKOhMWnqhjKyRnzM/LgE5Gc1CXK52Q75G5woHzAd8VLaC3uLmVRGQ6rnnnIz65qWSGOJgyp5bLzuDFgPfParuk7MvmKRuXe3WSdGjB4KsPm9h+PHXpTjKWhY4ZECbsb8tn6+3qPSrgjk3yNM6SJkFSQd3vu9/pTZYYlQIsZLk/Kd2Ao7kn0p88ew7oqwlDDLPM0jPIQAz9cY4/rTUlMcf7lUYEgltoOfxPSpS0flIiscjgOV4JqFGZM7lQEZAwSB+OelVuaJDboicjzQSy4bcItyqR0JP8AXtTU3LHtZSS2Mj0HYUyby7oqFV9yjeoZSoz0zzz7Zp4Z2jbcjDjBx161eysaRGJEwbaUOwtgnPCmke2lYsrJgEfe/ve2aspHtEbuNuMg44zVllJ3SSSEJ6Z46UnUsw57GM+GUomd4H3e4xWXcwyOpO4xjccMTn6dh+VbMcljfSlRJLG+CzeWQD6ZOaa9xDI+xW4A2gA5Y57kdq3hNxexrCpZmfplubZwjBmyOWc5yRRe2hknRpEAO4bG2nrn/wDVxWnFp58xHiMowDncRg59qsxK6EAFiAMH0odb3uZDlVs7o47WvDP21HMkETy9drHAyPQ1kappchlGyMb0UDY45HHOK9Dumh8nCyBCSSDnqage0a8jWPyIURR91SMtzkgDsTiuiljZxS5tkb08ZOG+x41qdk91qUcVrbBplVkaTGQMj5Sc9Bk4zXoGjatfrZpbeI9BhuptgL3CKpYjGA2COWwOStb9rb2V5dWq3WnMqpIzSn7pACnHI98cVlrpE+4/ZLuTy926NJHJK8n1/LNdNXGQrxUJxtb+t0/60HPEKq/e0ZzXi6Gy8R6fF9r22CRySCzHzKseNuMrj5i5HX8hXT6fo+mSwWH2iV7W5tWETx+Xuafj5cfN8vUcnjOau2+lzqVjvTGY5BjaOWB9eePWr9tocFlMt8GdpiNgkySEGDhvwz+dc1XFpQVOMmrXtbXf+vPvuYTqxWkWR6rGLLUYbj7KZAQG4YYQLkgEe5wePemxapLe3NzKxkCHngDAPsevc9agj0pL7Udxgul38ylX8wYHGV9M4PrWjbaCIoYw3nYABKu3Jxnr+lckpU4xSk9f68zJyhFavU130qS7sYCZVibIDMc9Np5yORj+tPuoDNeQOsDfZ3DeaygfIBxu/wDrVmw60sGpQadFFeXM2dks0cJMURxnaz9CfYVtiZJo5DC+4KSGIyMMOCD+PFcM1Ug05bdPn/WhwycosSW+WwK2u6OKIJuLsCFx6A96t3l7K81tDaWFu9uwKSytLiRXxwBjr269jWbq8X2mzhniVj5AKzKo+ZQOcn0HHJqPSc/ZIdnzq8e9SrK2RuOOR361l7OLjz9SHFNc3UtRTLNLIkTqxRjG3PRh1FPdJYmxIjZIyAf5+9R4QCSfBJI3nPcd/wAaqNK81oU+1SzAfdkdhlR6fKB7dRn601G+2wtSwXlZFKEgnBG3jjOeh7GnTyiaMNDJHnI3gnAXjkjiqUN7IYoADvJ+U7jj8s1OFZvMEMp3hdo3KflGf1/nzVONnqK1i3bzLI0m4KrBcggYGf7vuMVVAtLQqg8iA3MuI1J5kc9lHvTVjmHBTeQpIKjGfUYqPTwJZor53dTbkyRiTH7vIw3FCild30/qwEl3ILZAXgd2QH5EHzcdQBTpjdWV4jBI9kiJmLzACnuD0PHUUzUUMkj3NyQIwN7swOc9OMdRz6e9QXWnw6jawzs7o0chQhh0YD9eKqPLZc23UFbqTpZ28E1y9rAsZmJMgUBQ3qcdAarz2cV1a2SJI22G6SZw53rIAeRjuMdjTzA2EBabaqYBbo49x6frToII47YGLEYzvUIMKVPbHYfrTTa1vqO9jrDr9pk4t5iO3y0Vz2+DtMMdvmori+rU+zM/ZxPmpZpbC48q2ldYrhcSx5yrjJABHQ47elVyzeYBvYbTxg9MNRRX6XFK9z9FSSbaOx0Q7rlpXG559M+0sT2kMrISPTIUEj1J9a9Ps5WutNtZJCRvUHaCdoJ6kDsaKK+bzH4l/XQ+Sxa95+rJZCyzwKGIBbB9eDUd4SlrFKp+fcI+QCNvORz6+tFFefFao4ZBoKta3iTRySFi6rhmyOcknHrzV3w2xg8R+JbNMGC3EdxAGGTE0i5cKeykjOPWiis8R/y89F/6VH/Niqdf66nYAYlODgFun4V418T3ePxpBKHLGSxYsrAFTjjp796KKWSJPEP/AAsWD/iI0iGYQyrI6eXBhUU4XpXOXMSjUpVBISNPNCA8Fm6kjvRRXrYf9D0qW5r6IxFqJl+WRlD5HY1sXV3K1rfhjk+UULdypbpRRXLWXv8AzKmry+Z0PhTUJdY8OtLeJFzLJEUVMKVU4Ax9BWOLeW98Raq5vr2BLSWCKKKCXYm3GeVxiiiuPDxSq1F/W6POS95mvq8n2OJJ4I0EjsAxx1qOLEkTu6qSCoxjg96KKwj8FyFsF7I0JaNTlWTdz1BqKdilgVU9cHJ5NFFaJbepUehnXsQtIkliZizqD85yBg449KkgRJ0uXlQMQCo68ev8hRRW8m+W5rf3biWlvGks7AHceSc0ruUyFwNpwOKKKT1lqadR0Kee1uJCfn5OKmYCK5niI8xI8gb+4K8g0UUp9TOZBDBFEpijjVF8pfujBwe30p1lbRCMsVzsQtg9/b6UUU23ytl30ZLob+el+zhR5cmEVVAAzn8+nep9RtYI1jYxq5Vgy7uxx1/WiisZtqpp/Whlf3h/h6wguopfNVssxyVYg8N0yOcU59kJxFEijfgDGcZooqJyftGrkSb52jO0jF3qt0JVG1LjywF44wP15qz4t0seHby0TT7y8Md/5qOs7iTy9qlgUYjcvPGM4x2oorqp61uV7W/Qu/7xIz7i8kt9MW4iEYlimi52j5wzgFW9iCff3rqoPD9hJeujLII3jbcgkO3PUEDsR6iiiubEScY3i7b/AKGdVtPQ5i5aWIX9tDPLGIpvlkRtrngYyR1xn/8AXXReHrybVtC0q8vmD3M0LB3AwWKtgHjvRRVYqK9kpdb/AKMuulypkGFeOC4KKJVlMeQMAgkgkj1q637q9l2E5VeCTk49KKK5pf5nPIhsAl3cvFPFG8UzeTIhHDKVzz+eKbb2kNpJHb28axwpuCqigAbenA+tFFJt3a6W/wAxX1LWlwpdebHLnawY8cYOeorMWFHySMF1w2ABnB60UU4P3n8hrdmY7eW8IIDgnGHGcd8j0NaW4/YRcjiYD736UUV0VOg5dBLKV7m2SaRiJEcYK8dxUtvcMbmaPC7Qr5GOuDRRWc0tSGEQV3g3IpDRkY9sdPpTre3iUCJF2xKd4QHjJ60UVF2JEF4xG9uuZBwenSiWQ/arS3wPLnidn656jgfnRRWnb+uhSOZ/t24T5RBa4HAzHn+tFFFdvJHsWf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Eosinophilic cytoplasmic inclusion bodies are visualized on hematoxylin and eosin staining of a molluscum contagiosum lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_19_28983=[""].join("\n");
var outline_f28_19_28983=null;
var title_f28_19_28984="Porphyrias: An overview";
var content_f28_19_28984=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Porphyrias: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/19/28984/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/19/28984/contributors\">",
"     Karl E Anderson, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/19/28984/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/19/28984/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/19/28984/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/19/28984/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/19/28984/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The porphyrias are metabolic disorders caused by altered activities of enzymes within the heme biosynthetic pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The alteration in enzyme activity is usually due to an inherited mutation in the gene for that enzyme. However, in porphyria cutanea tarda (PCT), the most common of the porphyrias, acquired inhibition of the fifth enzyme in the pathway, uroporphyrin decarboxylase (UROD), develops during life, specifically in the liver.",
"   </p>",
"   <p>",
"    This overview of the porphyrias will emphasize what physicians in any specialty should know about these fascinating diseases, and how they are classified, recognized, and distinguished from one another.",
"   </p>",
"   <p>",
"    Other topic reviews within UpToDate should be consulted when one of the specific types of porphyria is suspected or diagnosed, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5656?source=see_link\">",
"       \"ALA dehydratase porphyria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40198?source=see_link\">",
"       \"Etiology and pathogenesis of acute intermittent porphyria\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute intermittent porphyria\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3398?source=see_link\">",
"       \"Management of acute intermittent porphyria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5801?source=see_link\">",
"       \"Congenital erythropoietic porphyria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=see_link\">",
"       \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41687?source=see_link\">",
"       \"Hereditary coproporphyria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/51/825?source=see_link\">",
"       \"Variegate porphyria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15834?source=see_link\">",
"       \"Erythropoietic protoporphyria\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mutations of the erythroid-specific form of the first enzyme in this pathway (delta-aminolevulinate synthase, ALAS2), which lead to X-linked sideroblastic anemia, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36441?source=see_link\">",
"     \"Causes of congenital and acquired sideroblastic anemias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6138?source=see_link\">",
"     \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35750?source=see_link\">",
"     \"Pathophysiology of the sideroblastic anemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE HEME BIOSYNTHETIC PATHWAY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heme biosynthesis and its regulation will be briefly described here, emphasizing aspects that are especially important in the porphyrias.",
"   </p>",
"   <p>",
"    Heme is made in all tissues, but the bone marrow and liver are the most active organs involved in overall heme synthesis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The bone marrow accounts for &gt;80 percent of daily heme synthesis. Almost all of the synthesized heme is utilized as the prosthetic group for hemoglobin.",
"     </li>",
"     <li>",
"      The liver accounts for most of the rest of overall heme synthesis. In the liver, heme is utilized primarily for the production of the various cytochrome P450 enzymes (CYPs). These are especially abundant and inducible in the liver and have high rates of turnover.",
"     </li>",
"     <li>",
"      Other important heme-containing proteins (eg, myoglobin, respiratory cytochromes, catalase, nitric oxide synthase) are present in various tissues, usually in smaller amounts, and most turn over more slowly than the CYPs [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Enzymes and intermediates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eight enzymes and intermediates that comprise the heme synthetic pathway are shown in the figures and the important features of these enzymes are summarized in the table (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"UTD.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57890 \" href=\"UTD.htm?34/50/35617\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54358 \" href=\"UTD.htm?0/9/155\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The first enzyme in this pathway, delta-aminolevulinate synthase (ALAS, 5-aminolevulinic acid synthase), is a mitochondrial enzyme that requires pyridoxal-5'-phosphate as a cofactor. It catalyzes the conversion of two simple molecules, glycine and succinyl-coenzyme A to form delta-aminolevulinic acid (ALA), an amino acid committed exclusively to the synthesis of heme.",
"   </p>",
"   <p>",
"    Importantly, ALAS occurs in two forms that are encoded by different genes found on different chromosomes (",
"    <a class=\"graphic graphic_table graphicRef54358 \" href=\"UTD.htm?0/9/155\">",
"     table 1",
"    </a>",
"    ). The housekeeping form, which is found in all tissues, is termed ALAS1 (or ALAS-N). The erythroid-specific form, termed ALAS2 (or ALAS-E), is transcribed only in bone marrow erythroblasts.",
"   </p>",
"   <p>",
"    The enzymes that follow in the heme synthetic pathway catalyze, in the following order, formation of the pyrrole porphobilinogen (PBG), a linear tetrapyrrole hydroxymethylbilane (HMB), a series of porphyrins (cyclic tetrapyrroles) that undergo stepwise decarboxylations, and finally the insertion of an iron atom into the cyclic tetrapyrrole protoporphyrin to form heme (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"UTD.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57890 \" href=\"UTD.htm?34/50/35617\">",
"     figure 2",
"    </a>",
"    ). With the exception of protoporphyrin, all of the porphyrin intermediates are in their reduced forms, which are termed porphyrinogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Regulation of heme synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALAS1 has a key regulatory role especially in the liver, where it is the rate limiting enzyme for heme synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/1\">",
"     1",
"    </a>",
"    ]. The human gene encoding this enzyme is localized to chromosome 3p21 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. A regulatory heme pool controls the synthesis of hepatic ALAS1 and its transport into mitochondria. This provides a sensitive feedback mechanism whereby ALAS1 is up-regulated when the need for heme in the liver is increased, and down-regulated when the heme supply is sufficient.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since most of the heme synthesized in liver is used for the production of CYPs, it is understandable that induction of CYPs by drugs and other factors would also lead to induction of ALAS1 through this feedback mechanism [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/5\">",
"       5",
"      </a>",
"      ]. In addition, the ALAS1 gene and certain CYP genes share upstream enhancer elements that respond to inducing chemicals and interact with the pregnane X receptor (PXR), an additional mechanism for coordinated induction of ALAS1 and hepatic CYPs [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The regulatory heme pool may also be depleted, and hepatic ALAS1 induced, following induction of hepatic heme oxygenase, which enzymatically degrades heme.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These feedback mechanisms are important in the acute porphyrias, which are exacerbated when hepatic ALAS1 is induced [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. Accordingly, the acute porphyrias may be treated with exogenous heme, which is taken up primarily in hepatocytes, where it repletes the regulatory heme pool, down-regulates ALAS1, and ameliorates the acute attack [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heme synthesis in the bone marrow is regulated differently from that in the liver, in order to provide heme in amounts required for hemoglobin synthesis. The gene encoding ALAS2 is localized to chromosome Xp11.21 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/10\">",
"     10",
"    </a>",
"    ]. Unlike ALAS1, whose expression is regulated by the liver heme concentration and inhibited when the free heme concentration is adequate, ALAS2 activity is constitutively expressed in erythroid cells and is upregulated by heme [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/11\">",
"     11",
"    </a>",
"    ], and by iron [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/12\">",
"     12",
"    </a>",
"    ]. The upregulation by iron is due to the presence of a functional iron responsive element in ALAS2 mRNA, which is not present in ALAS1 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/13\">",
"     13",
"    </a>",
"    ]. Other enzymes in the heme synthetic pathway are also up-regulated in the bone marrow when hemoglobin synthesis is active.",
"   </p>",
"   <p>",
"    The subsequent enzymes in the heme synthetic pathway are described in greater detail in the topic reviews covering each of the individual porphyrias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DISEASES ASSOCIATED WITH ALTERATIONS IN HEME BIOSYNTHETIC PATHWAY ENZYMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     ALA synthase 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations of ALAS1 have not been described. However, upregulation of hepatic ALAS1 is an important feature during exacerbations of the acute hepatic porphyrias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     ALA synthase 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALAS2 mutations are present in many cases of X-linked sideroblastic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/1,14\">",
"     1,14",
"    </a>",
"    ], and gain of function ALAS2 mutations have been described in a variant form of erythropoietic protoporphyria (EPP) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36441?source=see_link&amp;anchor=H2#H2\">",
"     \"Causes of congenital and acquired sideroblastic anemias\", section on 'Congenital sideroblastic anemias'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15834?source=see_link&amp;anchor=H3912210#H3912210\">",
"     \"Erythropoietic protoporphyria\", section on 'Molecular pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Subsequent enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the subsequent enzymes in the heme synthetic pathway is deficient in a specific type of porphyria (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"UTD.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54358 \" href=\"UTD.htm?0/9/155\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many different mutations have been identified in each type of porphyria. The disease-causing mutation in a particular family is often private or shared with only a few other families.",
"     </li>",
"     <li>",
"      The hepatic enzyme deficiency in PCT (uroporphyrinogen decarboxylase, UROD) is mostly acquired, although approximately 20 percent of patients with PCT are also heterozygous for a mutation of UROD. Homozygosity or compound heterozygosity for UROD mutations is the cause for the rare condition hepatoerythropoietic porphyria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These enzyme deficiencies lead to accumulation of pathway intermediates and diverse clinical manifestations that are either neurological or cutaneous. These excess intermediates or their derivatives can be measured in urine, feces, plasma and erythrocytes (",
"    <a class=\"graphic graphic_table graphicRef80601 \" href=\"UTD.htm?31/63/32765\">",
"     table 2",
"    </a>",
"    ) in order to establish a diagnosis of porphyria [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/1\">",
"     1",
"    </a>",
"    ]. Detection of the responsible mutation is useful for confirmation of the diagnosis as well as for family studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Laboratory diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Environmental and metabolic influences",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to mutations affecting enzymatic activity, heme pathway enzymes may also be affected by environmental and metabolic factors. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ALA dehydratase (ALAD), the second enzyme in the heme synthetic pathway, is inhibited in lead poisoning and hereditary tyrosinemia type 1. Lead displaces zinc from its binding sites on the enzyme, and succinylacetone (4,6-dioxoheptanoic acid), a metabolite that accumulates in tyrosinemia, is structurally similar to ALA and is a potent inhibitor of the enzymatic activity of ALAD [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/17-21\">",
"       17-21",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Accordingly, both lead poisoning and tyrosinemia are associated with accumulation of ALA and other heme pathway intermediates, along with symptoms that resemble the acute porphyrias. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link&amp;anchor=H4#H4\">",
"       \"Adult lead poisoning\", section on 'Biological basis for disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=see_link&amp;anchor=H4#H4\">",
"       \"Disorders of tyrosine metabolism\", section on 'Hereditary tyrosinemia type 1'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drugs, hormones, and nutritional alterations are important in precipitating attacks of neurovisceral symptoms in the acute porphyrias. If these inducing stimuli are intermittent or cyclic, as in the hormonal changes associated with the luteal phase of the menstrual cycle, attacks may occur on an intermittent or cyclic basis. A table of drugs that commonly exacerbate the acute porphyrias can be found elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40198?source=see_link&amp;anchor=H6#H6\">",
"       \"Etiology and pathogenesis of acute intermittent porphyria\", section on 'Exacerbating factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A largely different set of susceptibility factors act in combination with iron to lead to inhibition of hepatic uroporphyrinogen decarboxylase (UROD) in porphyria cutanea tarda (PCT). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=see_link&amp;anchor=H4527395#H4527395\">",
"       \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\", section on 'Susceptibility factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF THE PORPHYRIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As shown in the table, the porphyrias are classified as either hepatic or erythropoietic, depending on whether the site of initial production and accumulation of pathway intermediates is the liver or the bone marrow (",
"    <a class=\"graphic graphic_table graphicRef80601 \" href=\"UTD.htm?31/63/32765\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/22\">",
"     22",
"    </a>",
"    ]. They are also classified as either acute or cutaneous, reflecting the primary clinical manifestations. These classifications are not completely distinct and, in some instances, overlap.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Acute porphyrias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute porphyrias present with a variety of nonspecific neurovisceral symptoms (eg, abdominal pain, psychiatric disorders, neurologic symptoms), the most common of which is abdominal pain. These can include potentially life-threatening neurological effects (eg, seizures, coma, bulbar paralysis) and are associated with elevations in the porphyrin precursors delta-aminolevulinic acid (ALA) and porphobilinogen (PBG), and often with red or brownish colored urine. Symptoms usually occur as acute attacks, but are sometimes chronic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of acute intermittent porphyria\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cutaneous porphyrias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous porphyrias are associated with photosensitivity due to activation of porphyrins in the skin by visible and long wave ultraviolet light (also known as UV-A). Most cutaneous porphyrias are manifested by chronic blistering skin lesions on sun-exposed areas of the skin, particularly the backs of the hands. If severe, these may become infected and mutilating. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=see_link&amp;anchor=H4530124#H4530124\">",
"     \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\", section on 'Skin findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5801?source=see_link\">",
"     \"Congenital erythropoietic porphyria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The acute, nonblistering photosensitivity seen in erythropoietic protoporphyria (EPP) is distinctly different from other cutaneous porphyrias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15834?source=see_link&amp;anchor=H3912160#H3912160\">",
"     \"Erythropoietic protoporphyria\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In erythropoietic porphyrias (CEP, HEP and EPP), increases in porphyrins and photosensitivity are first noted in early childhood; these are usually quite constant throughout life. Rare late onset cases of CEP and EPP are usually in association with an underlying bone marrow disorder and expansion of a clone of erythroid cells that harbors a mutation in a heme pathway enzyme.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     The three most common porphyrias",
"    </span>",
"    &nbsp;&mdash;&nbsp;An appreciation that the different porphyrias display great diversity in their clinical manifestations is key to understanding these disorders. Indeed, the three most common porphyrias, porphyria cutanea tarda (PCT), acute intermittent porphyria (AIP), and erythropoietic protoporphyria (EPP), share no common clinical features. The table contrasts the clinical presentations, factors that determine severity, methods for diagnosis and approaches to treatment of these three distinct disorders (",
"    <a class=\"graphic graphic_table graphicRef51232 \" href=\"UTD.htm?7/35/7740\">",
"     table 3",
"    </a>",
"    ). Thus, anything understood about one of these three conditions will not apply to the other two.",
"   </p>",
"   <p>",
"    PCT and AIP can be considered prototypic, in that they share features with the other less common porphyrias. However, the nonblistering photosensitivity and many other features of EPP are unique to that disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LABORATORY DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the porphyrin precursors ALA and PBG, as well as porphyrins in urine, plasma, erythrocytes, and feces is important for the diagnosis of the various porphyrias. However, for screening purposes, reliance should be placed on a few first-line tests that can rapidly establish or exclude a diagnosis of porphyria. Additional testing is appropriate if a screening test is positive [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/16,23,24\">",
"     16,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acute porphyrias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute porphyrias should be part of the differential diagnosis in patients presenting with neurovisceral symptoms, such as abdominal pain, especially when initial clinical evaluation does not suggest another cause. A high index of suspicion can lead to early diagnosis and treatment of these disorders and avoid progression of symptoms. The recommended approach to laboratory diagnosis is shown in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef61709 \" href=\"UTD.htm?26/12/26831\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis is readily established in patients presenting with severe symptoms by finding a substantial elevation of urinary PBG, or excluded by the finding of a normal level. Rapid qualitative testing for urinary PBG should be available in-house at all major medical facilities. Spot (single void) urine specimens are preferred, because substantial increases are expected, and a 24-hour collection can unnecessarily delay diagnosis.",
"   </p>",
"   <p>",
"    The same urine specimen should be saved for quantitative determination of ALA, PBG, and total porphyrins, to confirm the qualitative PBG result, and because urinary porphyrins may remain increased longer than the porphyrin precursors ALA and PGB in hereditary coproporphyria (HCP) and variegate porphyria (VP). This will also detect very rare cases of ALA dehydratase porphyria (ADP), in which PBG is not significantly increased but ALA is markedly increased (",
"    <a class=\"graphic graphic_algorithm graphicRef61709 \" href=\"UTD.htm?26/12/26831\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PBG is a colorless pyrrole and its measurement relies on formation of a violet pigment with para-dimethylaminobenzaldehyde (Ehrlich's aldehyde reagent). PBG must be separated from other urinary substances, principally urobilinogen, that also react with Ehrlich's aldehyde reagent. A kit for semiquantitative screening for elevated levels of PBG (Trace&reg; PBG kit, Thermo Fischer Scientific) is reliable [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/25\">",
"     25",
"    </a>",
"    ]. The Watson-Schwartz [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/26\">",
"     26",
"    </a>",
"    ] and Hoesch tests [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/27\">",
"     27",
"    </a>",
"    ], which involve initial addition of Ehrlich's reagent to urine, are less objective and less reliable, especially in inexperienced hands.",
"   </p>",
"   <p>",
"    PBG can also be measured in serum or plasma, which is essential if acute porphyria is suspected in a patient with advanced renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, in patients with acute porphyria and normal kidney function, PBG concentrations are higher in urine, and urinary measurements are preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Delta-aminolevulinic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal urinary excretion of delta-aminolevulinic acid (ALA) is &lt;7",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hours (53",
"    <span class=\"nowrap\">",
"     micromoles/24",
"    </span>",
"    hours). In an attack of AIP, urinary ALA excretion is markedly elevated, with typical values being several or sometimes more than 10 times the upper limit of normal (eg, 25 to 100",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Porphobilinogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal",
"    urinary excretion of PBG is less than 2 to 4",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hours (less than 9 to 18",
"    <span class=\"nowrap\">",
"     micromoles/24",
"    </span>",
"    hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/16\">",
"     16",
"    </a>",
"    ]. In an attack of AIP, urinary PBG excretion is markedly elevated, with typical values being at least 5 to 10 times the upper limit of normal (eg, 50 to 200",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    220 to 880",
"    <span class=\"nowrap\">",
"     micromoles/day).",
"    </span>",
"    In severe cases of AIP, the urine may develop a red or brown color, due to a high concentration of porphobilin, a brownish auto-oxidation product of PBG, and porphyrins, which are reddish.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Subsequent testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a substantial elevation of urinary PBG is found, further second-line testing is needed in order to differentiate AIP, HCP and VP using the same spot urine sample along with samples of plasma, whole blood, and feces. However, treatment of an acute porphyric attack with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    can be started after these samples are obtained and before the results are available [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3398?source=see_link&amp;anchor=H5#H5\">",
"     \"Management of acute intermittent porphyria\", section on 'Intravenous hemin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The three porphyrias that cause increases in PBG (ie, acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), variegate porphyria (VP)) can be differentiated from each other by measuring erythrocyte PBG deaminase (PBGD), urinary porphyrins, fecal porphyrins, plasma porphyrins (",
"    <a class=\"graphic graphic_table graphicRef60572 \" href=\"UTD.htm?4/23/4477\">",
"     table 4",
"    </a>",
"    ), and by mutation detection. Further diagnostic details for these conditions are covered in the topic reviews covering these types of porphyria [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Blistering cutaneous porphyrias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total plasma porphyrins are always increased in patients with active, blistering skin lesions due to porphyria [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/30\">",
"     30",
"    </a>",
"    ]. Normal levels are less than approximately 1",
"    <span class=\"nowrap\">",
"     microg/dL.",
"    </span>",
"    Measurements of porphyrins in urine, feces, plasma, and erythrocytes are important in differentiating the various porphyrias that cause such lesions (ie, PCT, HCP, VP, HEP, CEP) (",
"    <a class=\"graphic graphic_table graphicRef80601 \" href=\"UTD.htm?31/63/32765\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51232 \" href=\"UTD.htm?7/35/7740\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60572 \" href=\"UTD.htm?4/23/4477\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75386 \" href=\"UTD.htm?29/55/30588\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A simple and direct fluorometric method first described by Poh-Fitzpatrick [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/31-34\">",
"     31-34",
"    </a>",
"    ] rapidly differentiates VP from PCT and other porphyrias that produce identical cutaneous manifestations. The plasma porphyrins in VP are mostly covalently linked to plasma proteins and are readily detected by this method but may not be detected by HPLC (",
"    <a class=\"graphic graphic_table graphicRef60572 \" href=\"UTD.htm?4/23/4477\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/35\">",
"     35",
"    </a>",
"    ]. The normal range for plasma porphyrins is higher in patients with end-stage renal disease than in normals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/36\">",
"     36",
"    </a>",
"    ]. The individual topic reviews should be consulted for further details on distinguishing these porphyrias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Nonblistering cutaneous porphyria",
"    </span>",
"    &nbsp;&mdash;&nbsp;EPP is unique among the porphyrias, because it presents with nonblistering photosensitivity experienced shortly after sunlight exposure. Urine porphyrins are not increased in this disease. A total plasma porphyrin determination will detect most patients with this condition, but an erythrocyte protoporphyrin determination is more sensitive. Normal total erythrocyte protoporphyrin is up to approximately 80",
"    <span class=\"nowrap\">",
"     microg/dL,",
"    </span>",
"    with some variation related to age.",
"   </p>",
"   <p>",
"    The increase in EPP is primarily in free protoporphyrin, whereas in other conditions associated with increased erythrocyte protoporphyrin (eg, iron deficiency, lead poisoning, hemolytic and bone marrow disorders) it is primarily zinc protoporphyrin. Therefore, in screening for EPP it is important to measure either total erythrocyte protoporphyrin or free protoporphyrin, rather than only zinc protoporphyrin (",
"    <a class=\"graphic graphic_table graphicRef60572 \" href=\"UTD.htm?4/23/4477\">",
"     table 4",
"    </a>",
"    ). Laboratory reports may be misleading and not specify which of these was measured. For example, some methods reported to measure \"free erythrocyte protoporphyrin\" actually measure only zinc protoporphyrin. In EPP, total erythrocyte protoporphyrin is usually increased to &gt;500",
"    <span class=\"nowrap\">",
"     microg/dL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Patients in remission and asymptomatic relatives",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     The acute porphyrias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute porphyrias becomes more challenging in patients without symptoms, because levels of porphyrin precursors and porphyrins may be normal in asymptomatic, affected subjects. Levels of some intermediates generally remain elevated between attacks unless separated by a long interval.",
"   </p>",
"   <p>",
"    However, it is difficult to \"rule out\" acute porphyria when symptoms were present months or years previously. In these instances, it is important to obtain the previous laboratory reports and determine if the original diagnosis was well founded. Comprehensive testing, to include urinary ALA, PBG, and porphyrins, fecal and plasma porphyrins, and erythrocyte PBG deaminase may still show significant abnormalities and establish a diagnosis even in asymptomatic patients.",
"   </p>",
"   <p>",
"    Sequencing of the relevant genes for AIP, HCP, and VP (ie, PBGD, CPO, and PPO, respectively) is an option, and can provide more definitive evidence against the presence of an acute porphyria if biochemical testing is negative (",
"    <a class=\"graphic graphic_table graphicRef54358 \" href=\"UTD.htm?0/9/155\">",
"     table 1",
"    </a>",
"    ). Consultation with a specialist laboratory and physician is useful in planning these evaluations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Porphyria cutanea tarda",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of PCT is highly effective, and may leave no biochemical abnormalities in the treated patient. Therefore, it may be impossible to document that a patient had PCT in the past, unless the prior laboratory reports can be reviewed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Erythropoietic porphyrias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms and porphyrin levels are usually quite constant throughout life in the erythropoietic porphyrias. Biochemical and DNA testing of unaffected relatives may be useful for genetic counseling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Studies of the index case in a family",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before studying family members, the diagnosis of porphyria should be firmly established in a propositus or index case, and the laboratory results from that individual obtained to guide the choice of tests for other family members. Retesting the propositus or another family member with confirmed porphyria may be necessary. Identification of a disease-causing mutation in an index case greatly facilitates detection of additional gene carriers within the family [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28984/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/25/27025?source=see_link\">",
"       \"Patient information: Porphyrias (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Suspecting the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the porphyrias should be considered in the following clinical settings:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     The acute porphyrias",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the acute porphyrias should be considered in patients presenting with otherwise unexplained nonspecific neurovisceral complaints (eg, abdominal pain, vomiting, constipation, motor neuropathies, respiratory paralysis), the most common of which is abdominal pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of acute intermittent porphyria\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     The cutaneous porphyrias",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of several cutaneous porphyrias should be considered in patients presenting with blistering cutaneous lesions on sun-exposed areas (especially the backs of the hands). This occurs most commonly in PCT, but also in HCP, VP, HEP, and CEP. Nonblistering and immediate cutaneous photosensitivity, with pain, itching and swelling that is often transient should suggest a diagnosis of EPP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15834?source=see_link&amp;anchor=H3912160#H3912160\">",
"     \"Erythropoietic protoporphyria\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=see_link&amp;anchor=H4530124#H4530124\">",
"     \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\", section on 'Skin findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5801?source=see_link\">",
"     \"Congenital erythropoietic porphyria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Making the diagnosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Acute porphyria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of an acute porphyria is readily established in patients presenting with severe symptoms by finding a substantial elevation of urinary porphobilinogen (PBG), or excluded by the finding of a normal level (",
"    <a class=\"graphic graphic_algorithm graphicRef61709 \" href=\"UTD.htm?26/12/26831\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Rapid qualitative testing for urinary PBG should be available in-house at all major medical facilities. Spot (single void) urine specimens are preferred, because substantial increases are expected, and a 24-hour collection can unnecessarily delay diagnosis. The same urine specimen should be saved for quantitative determination of ALA, PBG, and total porphyrins, to confirm the qualitative PBG result and also to detect cases of ADP (in whom ALA is increased but PBG is not), or HCP and VP (in whom porphyrins may remain elevated after ALA and PBG become normal) (",
"    <a class=\"graphic graphic_table graphicRef80601 \" href=\"UTD.htm?31/63/32765\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51232 \" href=\"UTD.htm?7/35/7740\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60572 \" href=\"UTD.htm?4/23/4477\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75386 \" href=\"UTD.htm?29/55/30588\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Laboratory diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If such screening is positive, measurements of urinary, fecal, and plasma porphyrins and erythrocyte PBGD on samples obtained before treatment will define the type of acute porphyria as either AIP, HCP, VP, or very rarely ADP. Identification of the specific mutation will facilitate detection of other at-risk family members.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Cutaneous porphyria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of total plasma porphyrins is preferred as a screening test for porphyrias in patients with active, blistering skin lesions. Urine porphyrins are also elevated in these conditions, but in many other medical conditions as well.",
"   </p>",
"   <p>",
"    If total plasma porphyrins are increased, measurements of porphyrins, ALA and PBG in urine, and total porphyrins in feces, plasma, and erythrocytes are important in differentiating the various porphyrias that cause such lesions (",
"    <a class=\"graphic graphic_table graphicRef80601 \" href=\"UTD.htm?31/63/32765\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51232 \" href=\"UTD.htm?7/35/7740\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60572 \" href=\"UTD.htm?4/23/4477\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75386 \" href=\"UTD.htm?29/55/30588\">",
"     table 5",
"    </a>",
"    ). EPP is readily detected in patients with nonblistering photosensitivity by measuring total erythrocyte protoporphyrin, and then demonstrating that the elevation is primarily in free protoporphyrin rather than zinc protoporphyrin. Plasma and fecal porphyrins are not always increased in EPP, and urine porphyrins are normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of each of the porphyrias is discussed separately (see individual topic reviews). This is especially true as the acute porphyrias, PCT, and EPP are treated very differently.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attacks of the acute porphyrias should be treated URGENTLY with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"       hemin",
"      </a>",
"      or glucose to avoid prolonged illness and fatal complications. When a substantial PBG increase is found, spot samples of urine, blood, and feces are collected for later testing to establish the type of acute porphyria, while treatment is started immediately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3398?source=see_link&amp;anchor=H2#H2\">",
"       \"Management of acute intermittent porphyria\", section on 'Treatment of the acute attack'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      PCT responds readily to treatment by iron reduction (eg, repeated phlebotomy) or a low-dose regimen of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      , following specific guidelines and targets.",
"     </li>",
"     <li>",
"      Avoidance of sunlight is important in CEP and EPP, and in those patients with VP and HCP who have skin blistering.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       Beta-carotene",
"      </a>",
"      may improve sunlight tolerance in EPP.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemias and the porphyrias. In: The Metabolic and Molecular Basis of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, et al. (Eds), McGraw-Hill, New York 2001. p.2991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/2\">",
"      Puy H, Gouya L, Deybach JC. Porphyrias. Lancet 2010; 375:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/3\">",
"      Sutherland GR, Baker E, Callen DF, et al. 5-Aminolevulinate synthase is at 3p21 and thus not the primary defect in X-linked sideroblastic anemia. Am J Hum Genet 1988; 43:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/4\">",
"      Bishop DF, Henderson AS, Astrin KH. Human delta-aminolevulinate synthase: assignment of the housekeeping gene to 3p21 and the erythroid-specific gene to the X chromosome. Genomics 1990; 7:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/5\">",
"      Anderson KE, Freddara U, Kappas A. Induction of hepatic cytochrome P-450 by natural steroids: relationship to the induction of delta-aminolevulinate synthase and porphyrin accumulation in the avian embryo. Arch Biochem Biophys 1982; 217:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/6\">",
"      Podvinec M, Handschin C, Looser R, Meyer UA. Identification of the xenosensors regulating human 5-aminolevulinate synthase. Proc Natl Acad Sci U S A 2004; 101:9127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/7\">",
"      TSCHUDY DP, PERLROTH MG, MARVER HS, et al. ACUTE INTERMITTENT PORPHYRIA: THE FIRST \"OVERPRODUCTION DISEASE\" LOCALIZED TO A SPECIFIC ENZYME. Proc Natl Acad Sci U S A 1965; 53:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/8\">",
"      Bonkowsky, HL, Tschudy, DP, Collins, A, et al. Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusions of hematin. Proc Natl Acad Sci USA 1971; 8:2725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/9\">",
"      Mustajoki P, Nordmann Y. Early administration of heme arginate for acute porphyric attacks. Arch Intern Med 1993; 153:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/10\">",
"      Cox TC, Bawden MJ, Abraham NG, et al. Erythroid 5-aminolevulinate synthase is located on the X chromosome. Am J Hum Genet 1990; 46:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/11\">",
"      Fujita H, Yamamoto M, Yamagami T, et al. Erythroleukemia differentiation. Distinctive responses of the erythroid-specific and the nonspecific delta-aminolevulinate synthase mRNA. J Biol Chem 1991; 266:17494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/12\">",
"      Cox TC, Bawden MJ, Martin A, May BK. Human erythroid 5-aminolevulinate synthase: promoter analysis and identification of an iron-responsive element in the mRNA. EMBO J 1991; 10:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/13\">",
"      Melefors O, Hentze MW. Iron regulatory factor--the conductor of cellular iron regulation. Blood Rev 1993; 7:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/14\">",
"      Camaschella C. Recent advances in the understanding of inherited sideroblastic anaemia. Br J Haematol 2008; 143:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/15\">",
"      Whatley SD, Ducamp S, Gouya L, et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 2008; 83:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/16\">",
"      Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005; 142:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/17\">",
"      Ebert PS, Hess RA, Frykholm BC, Tschudy DP. Succinylacetone, a potent inhibitor of heme biosynthesis: effect on cell growth, heme content and delta-aminolevulinic acid dehydratase activity of malignant murine erythroleukemia cells. Biochem Biophys Res Commun 1979; 88:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/18\">",
"      Tschudy DP, Hess RA, Frykholm BC. Inhibition of delta-aminolevulinic acid dehydrase by 4,6-dioxoheptanoic acid. J Biol Chem 1981; 256:9915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/19\">",
"      Schierbeek H, Beukeveld GJ, van Faassen H, et al. Hereditary tyrosinaemia type I: a long-term study of the relationship between the urinary excretions of succinylacetone and delta-aminolevulinic acid. J Inherit Metab Dis 1993; 16:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/20\">",
"      Granick JL, Sassa S, Granick S, et al. Studies in lead poisoning. II. Correlation between the ratio of activated to inactivated delta-aminolevulinic acid dehydratase of whole blood and the blood lead level. Biochem Med 1973; 8:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/21\">",
"      Bergdahl IA, Grubb A, Sch&uuml;tz A, et al. Lead binding to delta-aminolevulinic acid dehydratase (ALAD) in human erythrocytes. Pharmacol Toxicol 1997; 81:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/22\">",
"      SCHMID R, SCHWARTZ S, WATSON CJ. Porphyrin content of bone marrow and liver in the various forms of porphyria. AMA Arch Intern Med 1954; 93:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/23\">",
"      Deacon AC, Elder GH. ACP Best Practice No 165: front line tests for the investigation of suspected porphyria. J Clin Pathol 2001; 54:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/24\">",
"      Chemmanur AT, Bonkovsky HL. Hepatic porphyrias: diagnosis and management. Clin Liver Dis 2004; 8:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/25\">",
"      Deacon AC, Peters TJ. Identification of acute porphyria: evaluation of a commercial screening test for urinary porphobilinogen. Ann Clin Biochem 1998; 35 ( Pt 6):726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/26\">",
"      WATSON CJ, TADDEINI L, BOSSENMAIER I. PRESENT STATUS OF THE EHRLICH ALDEHYDE REACTION FOR URINARY PORPHOBILINOGEN. JAMA 1964; 190:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/27\">",
"      Lamon J, With TK, Redeker AG. The Hoesch test: bedside screening for urinary porphobilinogen in patients with suspected porphyria. Clin Chem 1974; 20:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/28\">",
"      Sardh E, Andersson DE, Henrichson A, Harper P. Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes. Cell Mol Biol (Noisy-le-grand) 2009; 55:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/29\">",
"      Sardh E, Harper P, Andersson DE, Floderus Y. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks. Eur J Intern Med 2009; 20:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/30\">",
"      Kalb RE, Grossman ME, Poh-Fitzpatrick MB. Correlation of serum and urinary porphyrin levels in porphyria cutanea tarda. Arch Dermatol 1985; 121:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/31\">",
"      Poh-Fitzpatrick MB, Lamola AA. Direct spectrofluorometry of diluted erythrocytes and plasma: a rapid diagnostic method in primary and secondary porphyrinemias. J Lab Clin Med 1976; 87:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/32\">",
"      Poh-Fitzpatrick MB. A plasma porphyrin fluorescence marker for variegate porphyria. Arch Dermatol 1980; 116:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/33\">",
"      Longas MO, Poh-Fitzpatrick MB. A tightly bound protein-porphyrin complex isolated from the plasma of a patient with variegate porphyria. Clin Chim Acta 1982; 118:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/34\">",
"      Enriquez de Salamanca R, Sepulveda P, Moran MJ, et al. Clinical utility of fluorometric scanning of plasma porphyrins for the diagnosis and typing of porphyrias. Clin Exp Dermatol 1993; 18:128.",
"     </a>",
"    </li>",
"    <li>",
"     Blake, D, Ratnaike, S. Plasma: all you need for the diagnosis of porphyria with current dermatological symptoms. In: Porphyrins, Porphyrias and Photodynamic Therapy (Conference Proceedings), Blake, D, McManus, J, Ratnaike, S, et al. (Eds), Melbourne, Australia 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28984/abstract/36\">",
"      Poh-Fitzpatrick MB, Sosin AE, Bemis J. Porphyrin levels in plasma and erythrocytes of chronic hemodialysis patients. J Am Acad Dermatol 1982; 7:100.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7101 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-FE4A772EBF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_19_28984=[""].join("\n");
var outline_f28_19_28984=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE HEME BIOSYNTHETIC PATHWAY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Enzymes and intermediates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Regulation of heme synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DISEASES ASSOCIATED WITH ALTERATIONS IN HEME BIOSYNTHETIC PATHWAY ENZYMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ALA synthase 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ALA synthase 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Subsequent enzymes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Environmental and metabolic influences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLASSIFICATION OF THE PORPHYRIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Acute porphyrias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cutaneous porphyrias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      The three most common porphyrias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LABORATORY DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acute porphyrias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Delta-aminolevulinic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Porphobilinogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Subsequent testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Blistering cutaneous porphyrias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Nonblistering cutaneous porphyria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Patients in remission and asymptomatic relatives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - The acute porphyrias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Porphyria cutanea tarda",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Erythropoietic porphyrias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Studies of the index case in a family",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Suspecting the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - The acute porphyrias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - The cutaneous porphyrias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Making the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Acute porphyria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Cutaneous porphyria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7101\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7101|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?26/12/26831\" title=\"algorithm 1\">",
"      Diagnosis acute porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7101|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/31/25077\" title=\"figure 1\">",
"      Heme synthesis and porphyria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/50/35617\" title=\"figure 2\">",
"      Heme biosynthetic pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7101|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/9/155\" title=\"table 1\">",
"      Heme pathway enzymes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/63/32765\" title=\"table 2\">",
"      Classification porphyrias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/35/7740\" title=\"table 3\">",
"      Three common porphyrias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/23/4477\" title=\"table 4\">",
"      Excretion patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/55/30588\" title=\"table 5\">",
"      Heme intermediates",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5656?source=related_link\">",
"      ALA dehydratase porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=related_link\">",
"      Adult lead poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36441?source=related_link\">",
"      Causes of congenital and acquired sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6138?source=related_link\">",
"      Clinical aspects, diagnosis, and treatment of the sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=related_link\">",
"      Clinical manifestations and diagnosis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5801?source=related_link\">",
"      Congenital erythropoietic porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=related_link\">",
"      Disorders of tyrosine metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15834?source=related_link\">",
"      Erythropoietic protoporphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40198?source=related_link\">",
"      Etiology and pathogenesis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41687?source=related_link\">",
"      Hereditary coproporphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3398?source=related_link\">",
"      Management of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35750?source=related_link\">",
"      Pathophysiology of the sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/25/27025?source=related_link\">",
"      Patient information: Porphyrias (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=related_link\">",
"      Porphyria cutanea tarda and hepatoerythropoietic porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/51/825?source=related_link\">",
"      Variegate porphyria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_19_28985="Atopic dermatitis infantile I";
var content_f28_19_28985=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F77457%7EALLRG%2F56461%7EDERM%2F77386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F77457%7EALLRG%2F56461%7EDERM%2F77386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atopic dermatitis: infantile",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 419px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Confluent erythema, microvesiculation, scaling, and crusting on the face, with similar involvement (to a lesser degree) on the trunk and arms. The facial involvement is more severe due to easier access to scratching; the baby is squeezing the breast skin to relieve the intense pruritus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fitzpatrick, TB, Johnson, RA, Wolff, K, et al (Eds). Color Atlas and Synopsis of Clinical Dermatology, 3rd ed, McGraw-Hill, New York, 1997. Copyright &copy; McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atopic dermatitis: infantile",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 447px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Confluent erythema, mircovesiculation, papules, crust, and scale of a young Asian infant; the shoulders are relatively spared, being protected from scratching by clothing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fitzpatrick, TB, Johnson, RA, Wolff, K, et al (Eds). Color Atlas and Synopsis of Clinical Dermatology, 3rd ed, McGraw-Hill, New York, 1997. Copyright &copy; McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atopic dermatitis - infantile",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperpigmented patches are present on the face of this infant with atopic dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_19_28985=[""].join("\n");
var outline_f28_19_28985=null;
var title_f28_19_28986="Management of persistent hyperglycemia in type 2 diabetes mellitus";
var content_f28_19_28986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of persistent hyperglycemia in type 2 diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/19/28986/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/19/28986/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/19/28986/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/19/28986/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/19/28986/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/19/28986/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/19/28986/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment of patients with type 2 diabetes mellitus includes education, with emphasis on lifestyle changes including diet, exercise, and weight reduction when appropriate. Monotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    is indicated for most patients and insulin may be indicated for initial treatment for some [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/1\">",
"     1",
"    </a>",
"    ]. Although several studies have noted remissions of type 2 diabetes mellitus that may last several years, most patients probably require continuous treatment in order to maintain normal or near-normal glycemia. Regardless of the initial response to therapy, the natural history of most patients with type 2 diabetes is for blood glucose concentrations to rise gradually with time.",
"   </p>",
"   <p>",
"    Treatment for hyperglycemia that fails to respond to initial monotherapy and long-term pharmacologic therapy in type 2 diabetes are reviewed here. Options for initial therapy and other therapeutic issues in diabetes management, such as the frequency of monitoring and evaluation for microvascular and macrovascular complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link\">",
"     \"Overview of medical care in adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR A SECOND AGENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a successful initial response to oral therapy, patients fail to maintain target A1C levels (&lt;7 percent) at a rate of 5 to 10 percent per year (",
"    <a class=\"graphic graphic_figure graphicRef81706 \" href=\"UTD.htm?17/5/17502\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. An analysis from the United Kingdom Prospective Diabetes Study (UKPDS) found that 50 percent of patients originally controlled with a single drug required the addition of a second drug after three years; by nine years 75 percent of patients needed multiple therapies to achieve the target hemoglobin A1C (HbA1c) value [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the factors that can contribute to worsening glycemic control are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased compliance with diet, exercise, or the medical regimen, or weight gain.",
"     </li>",
"     <li>",
"      An intercurrent illness or the ingestion of drugs that can increase insulin resistance, interfere with insulin release, or increase hepatic glucose production (",
"      <a class=\"graphic graphic_table graphicRef67257 \" href=\"UTD.htm?10/40/10891\">",
"       table 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/6\">",
"       6",
"      </a>",
"      ]. The latter factor is particularly important in elderly patients who are taking multiple drugs.",
"     </li>",
"     <li>",
"      Progression of the underlying disease process including insulin resistance and deficient insulin secretion causing type 2 diabetes.",
"     </li>",
"     <li>",
"      The patient may have type 1 diabetes with gradual destruction of the pancreatic beta-cells, sometimes referred to as \"latent autoimmune diabetes in adults\" (LADA) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=see_link&amp;anchor=H247196672#H247196672\">",
"       \"Classification of diabetes mellitus and genetic diabetic syndromes\", section on 'Latent autoimmune diabetes in adults (LADA)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient's health care team may not have made appropriate changes in therapy often enough or at all (\"therapeutic inertia\") [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/8-11\">",
"       8-11",
"      </a>",
"      ]. A population-based study of over 7200 patients with type 2 diabetes demonstrated that many patients remain with A1C levels higher than ideal for years because changes in therapy to improve glycemic control were not made or were only made slowly [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/8\">",
"       8",
"      </a>",
"      ]. Adherence to algorithms that dictate changes in treatment at designated intervals and computerized decision aids may improve A1C more efficiently than standard care [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/10,12,13\">",
"       10,12,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) consensus guideline for pharmacotherapy to control hyperglycemia in type 2 diabetes recommends testing A1C levels every three months and addition of a second medication when the treatment goal of A1C &lt;7 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    plus lifestyle intervention is not achieved within three months (",
"    <a class=\"graphic graphic_algorithm graphicRef70606 \" href=\"UTD.htm?7/63/8176\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. In order to achieve the A1C goal, the glucose goals below are usually necessary:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fasting glucose 70 to 130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.89 to 7.22",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Postprandial glucose (90 to 120 minutes after a meal) &lt;180",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (10",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic options for patients who fail initial therapy with lifestyle intervention and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    are to add a second oral or injectable agent, including insulin, or to switch to insulin (",
"    <a class=\"graphic graphic_table graphicRef56876 \" href=\"UTD.htm?3/22/3437\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. In a meta-analysis of 140 trials and 26 observational studies evaluating the effects of oral or injectable diabetes medications as monotherapy and in combination with other oral agents or insulin on intermediate outcomes (A1C, body weight, lipid profiles), combination therapy decreased A1C levels more than monotherapy by approximately one percentage point [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/16\">",
"     16",
"    </a>",
"    ]. Most combinations similarly reduced A1C, but there was weak evidence favoring metformin plus a GLP-1 agonist over metformin plus a DPP-IV inhibitor for reducing A1C levels.",
"   </p>",
"   <p>",
"    We favor insulin or sulfonylurea as the second step, and insulin is preferred for patients whose A1C is further from target (&gt;8.5 percent) or who have symptoms related to hyperglycemia. For those close to target, we prefer to add a shorter-duration sulfonylurea (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    , to reduce the risk of hypoglycemia compared with longer-acting sulfonylureas), rather than insulin. Another reasonable alternative is the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/25/4503?source=see_link\">",
"     repaglinide",
"    </a>",
"    , which can be considered in individuals who do not reach glycemic goals with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , if there are contraindications to sulfonylureas or patient preference limits the use of insulin.",
"   </p>",
"   <p>",
"    If target A1C is not achieved with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , and sulfonylurea or basal insulin, we suggest starting or intensifying insulin therapy. In patients on sulfonylureas and metformin who are starting insulin therapy, sulfonylureas are generally tapered and discontinued. This selection of drugs is based upon clinical trial evidence and clinical experience in achieving glycemic targets, with the recognition that there is a paucity of many high quality head to head drug comparison trials.",
"   </p>",
"   <p>",
"    Thiazolidinediones (TZDs) are not considered first choice agents due to the risk of CHF and fractures and expense. However, in certain clinical settings, such as especially high risk for hypoglycemia or intolerance of or contraindications to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    or sulfonylureas, a TZD may be considered. As an example, in a patient who would be at particularly high risk if hypoglycemia occurred (eg, a construction worker) and inadequate glycemic control on metformin (A1C &gt;7 but &lt;8.5 percent),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    could be used. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    is not recommended because of the greater concern about its atherogenic lipid profiles and a potential increased risk for cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. Because of these risks, rosiglitazone was removed from the market in Europe, and its use in the United States is restricted. Subsequently, in 2011, the French and German Medicines Agencies suspended the use of pioglitazone because of the potential increased risk of bladder cancer and the concern that the overall risks of pioglitazone exceed its benefits. The European Medicines Agency, the US Food and Drug Administration, and Japanese regulators withheld action pending results of ongoing review of the data. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link&amp;anchor=H17#H17\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Summary'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link&amp;anchor=H12774482#H12774482\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Bladder cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucagon-like peptide-1 (GLP-1) analogs may be appropriate to use in certain clinical settings, eg, when weight loss or avoidance of hypoglycemia is a primary consideration and the A1C level is close to target. DPP-IV inhibitors can be considered as add-on drug therapy for patients who are inadequately controlled on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , a thiazolidinedione, or a sulfonylurea. However, the modest glucose lowering effectiveness, expense, and limited clinical experience may temper enthusiasm for these drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38298?source=see_link\">",
"     \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFICACY OF COMBINATION THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Combination with metformin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several agents can be used as add-on therapy when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    monotherapy fails (",
"    <a class=\"graphic graphic_table graphicRef56876 \" href=\"UTD.htm?3/22/3437\">",
"     table 2",
"    </a>",
"    ). In meta-analyses of placebo controlled trials evaluating different drugs (sulfonylureas, TZDs, meglitinides, alpha-glucosidase inhibitors, GLP-1 analogs, DPP-IV inhibitors) as add-on therapy to metformin, reductions in A1C with different classes of drugs ranged from 0.42 to 1.0 percentage points [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In one analysis, the reduction in A1C with sulfonylureas compared with placebo was greater than that of TZDs compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/17\">",
"     17",
"    </a>",
"    ]. However, these trials did not directly compare different agents in combination with metformin. As expected, the use of TZDs, sulfonylureas, and meglitinides was associated with weight gain, while GLP-1 analogs, alpha-glucosidase inhibitors, and DPP-IV inhibitors were associated with weight loss or no change [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/18\">",
"     18",
"    </a>",
"    ]. Sulfonylureas and glinides were associated with higher rates of hypoglycemia than placebo.",
"   </p>",
"   <p>",
"    Insulin was not included in one meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/18\">",
"     18",
"    </a>",
"    ], although it is clearly the most effective and one of the least expensive of the anti-diabetic medications available. As an example, in a 24-week trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/31/5622?source=see_link\">",
"     sitagliptin",
"    </a>",
"    in 515 patients with type 2 diabetes inadequately controlled with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    monotherapy, there was a greater reduction in A1C in patients randomly assigned to glargine (-1.72 versus -1.13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These results demonstrate that add-on therapy in general is effective and, therefore, the choice of a second agent depends upon additional factors, such as safety and cost. Insulin or sulfonylureas are the preferred second-line agents because of efficacy, side effect profile, long-term safety, and relative cost (",
"    <a class=\"graphic graphic_algorithm graphicRef70606 \" href=\"UTD.htm?7/63/8176\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Combination oral and insulin therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Metformin plus sulfonylureas",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    has an additive glycemic effect when given in combination with a sulfonylurea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. In the US Multicenter Metformin Study, patients who were not well controlled on diet or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    alone were randomly assigned to metformin monotherapy, the addition of metformin to glyburide, or continuation of glyburide alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/22\">",
"     22",
"    </a>",
"    ]. Treatment with metformin plus glyburide resulted in lower A1C levels than glyburide alone (7.1 versus 8.7 percent, respectively).",
"   </p>",
"   <p>",
"    A sub-study within the UKPDS suggested that early addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    to sulfonylurea therapy might increase the risk of diabetes-related death [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/23\">",
"     23",
"    </a>",
"    ]. This finding was attributed by the investigators to be due to chance. These results require further study before firm conclusions can be made. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link&amp;anchor=H16#H16\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Metformin therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Shorter acting sulfonylureas, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    , are less likely to cause hypoglycemia than the older, long-acting sulfonylureas, and therefore are the preferred sulfonylureas, especially in older patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=see_link&amp;anchor=H5#H5\">",
"     \"Sulfonylureas and meglitinides in the treatment of diabetes mellitus\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Combination tablets of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and sulfonylureas are available in several doses. For patients who are doing well on these particular doses, the combination tablets offer the convenience of taking fewer pills. However, if the patient needs the dose of either drug to be changed independent of the other drug, then a fixed combination is unhelpful. In addition, the cost of this brand name combination is substantially greater than taking the generic components individually.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Metformin plus thiazolidinediones",
"    </span>",
"    &nbsp;&mdash;&nbsp;TZDs lower glycemic levels when given in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    . As an example, in a study of patients with inadequate glycemic control on metformin monotherapy, the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    (30 mg daily) versus placebo resulted in significant improvement in A1C, fasting blood glucose values, and in measures of insulin sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/24\">",
"     24",
"    </a>",
"    ]. Specifically, the mean A1C values decreased by 0.6 percentage points in patients receiving metformin plus pioglitazone and increased by 0.2 percentage points in patients receiving metformin-placebo.",
"   </p>",
"   <p>",
"    Combination tablets of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    are available in several doses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The early addition of a TZD to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    to achieve glycemic goals is favored by some [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/26,27\">",
"     26,27",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/28\">",
"     28",
"    </a>",
"    ], and is not included as a first tier option in the",
"    <span class=\"nowrap\">",
"     ADA/EASD",
"    </span>",
"    consensus algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef70606 \" href=\"UTD.htm?7/63/8176\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. If a TZD is to be used in combination with metformin (or a sulfonylurea),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    is recommended because of the greater concern about atherogenic lipid profiles and a potential increased risk for cardiovascular events with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link&amp;anchor=H8#H8\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Cardiovascular Effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Metformin plus meglitinides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meglitinides may also be given in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , resulting in superior glycemic control than with either agent used as monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. A randomized two-year study of initial diabetic treatment comparing",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/21/11606?source=see_link\">",
"      nateglinide",
"     </a>",
"     /metformin",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"      glyburide",
"     </a>",
"     /metformin",
"    </span>",
"    concluded that both regimens had similar efficacy in lowering A1C, but hypoglycemic events were more common in patients treated with",
"    <span class=\"nowrap\">",
"     glyburide/metformin",
"    </span>",
"    (17.7 percent of patients versus 8.2 percent for",
"    <span class=\"nowrap\">",
"     nateglinide/metformin)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/31\">",
"     31",
"    </a>",
"    ]. Meglitinides are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=see_link&amp;anchor=H7#H7\">",
"     \"Sulfonylureas and meglitinides in the treatment of diabetes mellitus\", section on 'Meglitinides'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Meglitinides were not recommended by the",
"    <span class=\"nowrap\">",
"     ADA/EASD",
"    </span>",
"    guidelines because of higher costs (currently only available as brand name drugs), compared with sulfonylureas, and more limited clinical data [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/25/4503?source=see_link\">",
"     repaglinide",
"    </a>",
"    is principally metabolized by the liver, with less than 10 percent renally excreted. Thus, it can be used safely in patients with chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7865?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of hyperglycemia in diabetics with end-stage renal disease\", section on 'Meglitinides'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Other metformin combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    can also be given in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    (requiring twice daily injections),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/47/21238?source=see_link\">",
"     liraglutide",
"    </a>",
"    (once daily injection), or with DPP-IV inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38298?source=see_link\">",
"     \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\"",
"    </a>",
"    .) However, these combinations are generally not recommended unless patients are intolerant of or have contraindications to sulfonylureas and insulin. The GLP-1-based therapies are more expensive and long-term safety has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Sulfonylureas and thiazolidinediones",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TZDs have been studied in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , sulfonylureas, and insulin (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Insulin'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7\">",
"     'Metformin plus thiazolidinediones'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. The glycemic efficacy of TZDs in combination with a sulfonylurea is illustrated by the findings from a 16-week study of 560 patients with type 2 diabetes who had A1C values &gt;8.0 percent despite sulfonylurea therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/33\">",
"     33",
"    </a>",
"    ]. Those receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    (15 or 30 mg) plus the sulfonylurea had significant decreases in A1C values compared with those receiving placebo plus the sulfonylurea (0.9 and 1.3 percentage points for the lower and higher dose of pioglitazone, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/33\">",
"     33",
"    </a>",
"    ]. Fasting plasma glucose concentrations also decreased significantly in the patients given pioglitazone.",
"   </p>",
"   <p>",
"    Combination tablets of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8823?source=see_link\">",
"     glimepiride",
"    </a>",
"    are available in several doses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/25\">",
"     25",
"    </a>",
"    ]. Although combination therapy may be more convenient than taking the drugs individually, the fixed-dose combinations offer less dosing flexibility, and are generally more expensive than using generic agents, when available, as separate pills. While these combinations result in short-term improvements in glycemic control, long-term trials demonstrating improved outcomes are lacking.",
"   </p>",
"   <p>",
"    If a TZD is to be used in combination with a sulfonylurea,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    is preferred. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Metformin plus thiazolidinediones'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Combination with alpha-glucosidase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     Acarbose",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/0/3077?source=see_link\">",
"     miglitol",
"    </a>",
"    can reduce A1C values slightly (0.5 to 1.0 percentage points) when taken in conjunction with any other form of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. They act predominantly by lowering glucose concentrations after meals but may be poorly tolerated because of flatulence and other GI side effects. The",
"    <span class=\"nowrap\">",
"     ADA/EASD",
"    </span>",
"    consensus guidelines do not recommend these drugs as preferred second-line medications because of lower efficacy, poorer tolerance, and increased cost compared with the alternatives above [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=see_link\">",
"     \"Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INSULIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both patients and providers are often reluctant to initiate insulin therapy, despite its proven efficacy and cost advantage compared with many newer agents. Self-blame; concerns about life-restriction, weight gain, and hypoglycemia; and the patient's perception that insulin therapy is associated with worsening of diabetes are factors contributing to patient reluctance. An international survey of over 3600 nurses and doctors in 13 countries revealed that clinicians who delay initiating insulin therapy have also delayed initiating oral medication, and that specialists and opinion leaders are less likely to delay starting insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Insulin is a reasonable choice for initial therapy in patients who present with symptomatic or poorly controlled diabetes, and is the preferred second-line medication for patients with A1C &gt;8.5 percent or with symptoms of hyperglycemia despite initial therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and lifestyle intervention. The",
"    <span class=\"nowrap\">",
"     ADA/EASD",
"    </span>",
"    have developed a flow diagram for initiating and titrating insulin in the management of type 2 diabetes (",
"    <a class=\"graphic graphic_algorithm graphicRef73793 \" href=\"UTD.htm?19/63/20467\">",
"     algorithm 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/1\">",
"     1",
"    </a>",
"    ]. The dose of insulin may be adjusted every three to four days, until glycemic targets are achieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Combination oral and insulin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with persistent hyperglycemia despite oral hypoglycemic therapy may add insulin to oral medication, or may stop the oral drug and begin insulin. Part of the rationale for combination oral hypoglycemic drug and insulin therapy is that by suppressing hepatic glucose production, the patient can retain the convenience of oral agents, while minimizing total insulin requirements and, therefore, the degree of hyperinsulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/38\">",
"     38",
"    </a>",
"    ]. In several studies of patients inadequately controlled with drugs alone, combination oral-insulin therapy resulted in equivalent glycemic control with less or no weight gain compared with several daily insulin injections (",
"    <a class=\"graphic graphic_figure graphicRef80026 \" href=\"UTD.htm?6/49/6928\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/39-42\">",
"     39-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While NPH has been used commonly at bedtime to supplement oral hypoglycemic drug therapy, longer-acting insulins, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    (once daily) and detemir (once or twice daily), added to oral agents are similarly effective for reducing A1C values and may cause less nocturnal hypoglycemia, with the important disadvantages of higher cost and fewer long-term safety data. Combination oral agent and glargine therapy does not appear to reduce or increase cardiovascular outcomes, compared with oral agent(s) only, as illustrated by the findings of the ORIGIN trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/43\">",
"     43",
"    </a>",
"    ]. In this trial, over 12,500 patients with cardiovascular risk factors plus type 2 diabetes or prediabetes were randomly assigned to an evening dose of glargine or to standard care. Approximately 60 percent of the patients with prior diabetes were using oral glucose lowering agents (predominantly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    or sulfonylurea). The glargine was titrated to achieve a fasting glucose level of &lt;95",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.3",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    After a median follow-up of six years, the achieved median fasting blood glucose levels were 94 and 123",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (5.2 and 6.8",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    respectively. The rates of incident cardiovascular outcomes were similar in the glargine and standard care groups (2.94 and 2.85 per 100 person-years). Only 11 percent of the patients in the standard therapy group received insulin. A1C values were similar at baseline (6.4) and at study end (6.2 and 6.5). Approximately 60 percent of patients in both groups were treated with statins and 75 percent with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link&amp;anchor=H4#H4\">",
"     \"General principles of insulin therapy in diabetes mellitus\", section on 'Human versus analogs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link&amp;anchor=H6#H6\">",
"     \"Insulin therapy in type 2 diabetes mellitus\", section on 'Choice of insulin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Sulfonylureas and insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfonylureas are the oldest class of oral hypoglycemic agents. Data from the UKPDS and meta-analyses of several randomized placebo-controlled trials report modest but consistent benefits of combination sulfonylurea and insulin therapy compared with insulin monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. However, the combination of sulfonylurea and insulin is less efficacious and results in more weight gain than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and insulin (",
"    <a class=\"graphic graphic_figure graphicRef80026 \" href=\"UTD.htm?6/49/6928\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/39\">",
"     39",
"    </a>",
"    ]. Furthermore, insulin plus sulfonylurea have a similar mechanism of action (providing more insulin), and the same glucose lowering effect can usually be achieved, and at a lower cost, with a modestly higher dose of insulin alone. Thus, we prefer not to use combination sulfonylurea and insulin therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=see_link&amp;anchor=H7#H7\">",
"     \"Metformin in the treatment of diabetes mellitus\", section on 'Lactic acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Metformin and insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several trials and a meta-analysis, glycemic control was better with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    -insulin combinations than with insulin monotherapy or with sulfonylurea-insulin combinations (",
"    <a class=\"graphic graphic_figure graphicRef80026 \" href=\"UTD.htm?6/49/6928\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/39,48,49\">",
"     39,48,49",
"    </a>",
"    ]. In the UKPDS, the combination of insulin with metformin was also associated with significantly less weight gain than seen with twice daily insulin injections or insulin combined with sulfonylureas [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/23\">",
"     23",
"    </a>",
"    ]. This is consistent with other observations that metformin alone does not usually produce hyperinsulinemia or weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/3\">",
"     3",
"    </a>",
"    ]. However, there are few trials with clinically important outcomes, such as cardiovascular or all cause mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/49\">",
"     49",
"    </a>",
"    ]. Based upon the available evidence, we prefer combination metformin-insulin therapy to sulfonylurea-insulin therapy in individuals without contraindications to metformin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=see_link&amp;anchor=H7#H7\">",
"     \"Metformin in the treatment of diabetes mellitus\", section on 'Lactic acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Thiazolidinediones and insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of a TZD to insulin improves glycemic control compared with insulin monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/50\">",
"     50",
"    </a>",
"    ]. However, the combination of insulin plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    causes an increased incidence of heart failure and should be avoided in patients with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/51\">",
"     51",
"    </a>",
"    ]. In addition, both available TZDs have been associated with bone loss, and rosiglitazone may be associated with other cardiovascular risks, as described above. TZDs are also more expensive than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Insulin versus triple oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who are not well-controlled on two oral agents, switching to insulin is usually less expensive than adding a third oral agent. This was demonstrated in a study of 188 type 2 diabetic patients with inadequate glycemic control on two oral agents who were randomly assigned to receive a third oral agent or be switched to twice daily insulin along with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/52\">",
"     52",
"    </a>",
"    ]. Patients on three oral agents (a sulfonylurea, metformin and a TZD) had similar glycemic control, but more side effects, a more atherogenic profile, and substantially higher costs than patients on twice daily insulin along with metformin.",
"   </p>",
"   <p>",
"    Three oral agents can be considered in patients with A1C values that are not too far from goal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. This was illustrated in a study of 217 patients inadequately controlled on dual therapy with sulfonylureas and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , who were randomly assigned to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/53\">",
"     53",
"    </a>",
"    ]. At study end (24 weeks), improvements in A1C (approximately 1.5 percentage points) were similar in both groups. However, insulin glargine was superior in reducing A1C values when baseline A1C values were &gt;9.5 percent. Although insulin glargine was associated with more hypoglycemic events, there were fewer overall adverse events, significant improvements in the serum lipid profile, and it was less expensive. Subjects treated with insulin glargine also reported greater improvements in several health-related quality of life measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings, combined with the greater concern about adverse cardiovascular events with TZDs, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    , favor the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    over rosiglitazone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link&amp;anchor=H8#H8\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Cardiovascular Effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ADA/EASD",
"    </span>",
"    guidelines recommend rapid addition of medications and transition to new regimens to achieve target glycemic goals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/1\">",
"     1",
"    </a>",
"    ]. In general this means the addition of insulin in patients who are not meeting goals with two oral agents. However, it is reasonable to try a third oral agent before starting insulin in patients who are close to glycemic goals and who prefer not to start insulin. In this situation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    is preferred because of the greater concern about atherogenic lipid profiles and a potential increased risk for cardiovascular events with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link&amp;anchor=H8#H8\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Cardiovascular Effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Insulin intensification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diet and exercise patterns should be reviewed in patients whose glycemic control is poor despite initial insulin therapy. Insulin doses should then be adjusted to achieve target glycemic control. This will usually entail additional injections, often including short or rapid-acting insulin based on postprandial glucose readings (",
"    <a class=\"graphic graphic_algorithm graphicRef73793 \" href=\"UTD.htm?19/63/20467\">",
"     algorithm 2",
"    </a>",
"    ). Daily insulin doses typically exceed 65 to 100 units per day, and may sometimes be much higher, for obese type 2 diabetic patients to achieve near-normal glycemia. Patients should measure blood glucose two to four times daily and should only reduce their insulin dose if hypoglycemia develops.",
"   </p>",
"   <p>",
"    Use of an intensive insulin regimen (similar to that used in type 1 diabetes) results in higher serum insulin concentrations and better glycemic control than that achieved with either an oral drug or conventional insulin therapy (basal insulin only) alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/3\">",
"     3",
"    </a>",
"    ]. This regimen may require large doses of insulin to overcome insulin resistance and can be associated with significant weight gain (averaging 8.7 kg in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/38\">",
"     38",
"    </a>",
"    ]. In addition to the directly deleterious effects of worsening obesity, it can also lead to partial noncompliance with therapy, particularly in women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/18/14634?source=see_link\">",
"     \"Nutritional considerations in type 2 diabetes mellitus\"",
"    </a>",
"    .) Insulin therapy is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link\">",
"     \"Insulin therapy in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link\">",
"     \"General principles of insulin therapy in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OTHER MEDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Exenatide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14375?source=see_link\">",
"     Exenatide",
"    </a>",
"    is a GLP-1 analog used as adjunctive therapy for patients with type 2 diabetes who are inadequately controlled on oral agents. The drug is administered subcutaneously twice daily or once weekly and thus, like insulin, requires injections.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14375?source=see_link\">",
"     Exenatide",
"    </a>",
"    does not cause hypoglycemia unless it is administered with unadjusted doses of other diabetes medications. Unlike insulin, exenatide promotes weight loss but has a high rate of gastrointestinal side effects including nausea, vomiting, and diarrhea. It is more expensive than insulin therapy. Exenatide use may be most appropriate for an overweight patient who is experiencing weight gain on oral agents. However, the long-term safety and efficacy of this therapy are not yet established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38298?source=see_link&amp;anchor=H4#H4\">",
"     \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\", section on 'Exenatide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Liraglutide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/47/21238?source=see_link\">",
"     Liraglutide",
"    </a>",
"    is a GLP-1 analog that has been modified to non-covalently bind to serum albumin through a lipid side chain, resulting in slower degradation and allowing for once-daily subcutaneous dosing. It is available for use as monotherapy as an adjunct to diet and exercise or in combination with oral agents in adults with type 2 diabetes. It is not considered a first-line therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38298?source=see_link&amp;anchor=H10#H10\">",
"     \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\", section on 'Liraglutide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/47/21238?source=see_link\">",
"     Liraglutide",
"    </a>",
"    does not cause hypoglycemia unless it is administered with unadjusted doses of other diabetes medications that can cause hypoglycemia, such as sulfonylureas or insulin. Unlike insulin, liraglutide promotes weight loss, in part probably because of its high rate of gastrointestinal side effects including nausea, vomiting, and diarrhea. It is more expensive than insulin therapy. The long-term safety and efficacy of this therapy are not yet established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38298?source=see_link&amp;anchor=H10#H10\">",
"     \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\", section on 'Liraglutide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     DPP-IV inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dipeptidyl peptidase IV (DPP-IV) is a ubiquitous enzyme that deactivates a variety of other bioactive peptides, including glucagon-like peptide-1 and gastric inhibitory peptide; therefore, its inhibition could potentially affect glucose regulation through multiple effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38298?source=see_link&amp;anchor=H13#H13\">",
"     \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\", section on 'DPP-4 inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of high cost, relatively weak effects on A1C, and limited clinical data, DPP-IV inhibitors cannot currently be recommended for routine use. They may have a role as a third agent in those who cannot or will not take insulin when full doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and a sulfonylurea have not produced satisfactory metabolic control. However, the modest glucose lowering effectiveness, expense, and limited clinical experience with DPP-IV inhibitors may temper enthusiasm for these drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38298?source=see_link&amp;anchor=H13#H13\">",
"     \"Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus\", section on 'DPP-4 inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H457895\">",
"    <span class=\"h2\">",
"     Pramlintide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amylin (also known as islet amyloid polypeptide) is a peptide hormone secreted by pancreatic beta cells in conjunction with insulin in response to nutrient stimuli. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link\">",
"     \"Pathogenesis of type 2 diabetes mellitus\"",
"    </a>",
"    .)&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"     Pramlintide",
"    </a>",
"    is a synthetic analog of human amylin that slows gastric emptying, reduces postprandial rises in blood glucose concentrations, and modestly improves A1C concentrations in patients with type 1 and type 2 diabetes when injected subcutaneously three times per day.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/22/13669?source=see_link\">",
"     Pramlintide",
"    </a>",
"    is only approved for use in patients also taking insulin. It may be considered for patients with type 2 diabetes inadequately controlled on insulin who are overweight or experience weight gain refractory to lifestyle measures. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15734?source=see_link\">",
"     \"Amylin analogs for the treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H457938\">",
"    <span class=\"h2\">",
"     SGLT2 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the absence of long-term efficacy and safety data, we do not recommend sodium-glucose co-transporter 2 (SGLT2) inhibitors for routine use in patients with type 2 diabetes. SGLT2 inhibitors may play a role as a third line agent in patients with inadequate glycemic control on two oral agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and sulfonylurea) if for some reason combination metformin and insulin is not a therapeutic option.",
"   </p>",
"   <p>",
"    The sodium-glucose co-transporter 2 (SGLT2) is expressed in the proximal tubule and mediates reabsorption of approximately 90 percent of the filtered glucose load. SGLT2 inhibitors promote the renal excretion of glucose and thereby modestly lower elevated blood glucose levels in patients with type 2 diabetes. The ability to lower blood glucose and A1C levels is limited by the filtered load of glucose and the osmotic diuresis that is caused by this therapy. The glucose lowering effect is independent of insulin (beta cell function and insulin sensitivity). SGLT2 inhibitors have been studied as monotherapy and in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , sulfonylureas,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    , and insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Dapagliflozin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42832?source=see_link\">",
"     canagliflozin",
"    </a>",
"    are available in Europe and the US [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/58\">",
"     58",
"    </a>",
"    ], respectively, and other SGLT2 inhibitors are in development. In meta-analyses of clinical trials, SGLT2 inhibitors reduced A1C by approximately 0.5 to 0.7 percentage points, making them relatively weak glucose-lowering agents, similar in potency to the DPP-4 inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 24 week trial, 597 patients with type 2 diabetes inadequately controlled with sulfonylureas (A1C 7 to 10 percent) were randomly assigned to dapagliflozin (2.5, 5, or 10 mg) or placebo once daily [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/59\">",
"       59",
"      </a>",
"      ]. The mean change in A1C from baseline was greater with dapagliflozin (-0.58, -0.63, and -0.82 percentage points for the three doses of dapagliflozin, respectively, versus -0.13 percentage points with placebo). Dapagliflozin reduced weight (-1.18 to -2.26 kg compared with -0.72 kg in the placebo group).",
"     </li>",
"     <li>",
"      In a 52 week trial, 814 patients with type 2 diabetes inadequately controlled with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      (mean A1C 7.7 percent) were randomly assigned to dapagliflozin or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"       glipizide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/60\">",
"       60",
"      </a>",
"      ]. The mean reduction in A1C was similar in both groups (-0.52 percentage points). Dapagliflozin reduced weight (-3.2 versus +1.2 kg with glipizide) and produced less hypoglycemia (3.5 versus 40.8 percent with glipizide).",
"     </li>",
"     <li>",
"      In another trial, 808 patients with type 2 diabetes mellitus inadequately controlled with insulin and up to two oral agents were randomly assigned to dapagliflozin (2.5, 5, or 10 mg once daily) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/61\">",
"       61",
"      </a>",
"      ]. After 24 weeks, A1C decreased by 0.79 to 0.96 percentage points with dapagliflozin compared with 0.39 percentage points with placebo (mean difference -0.40 to -0.57 percent in the 2.5 to 10 mg groups). Daily insulin dose decreased by 0.63 to 1.95 units with dapagliflozin and increased by 5.65 units with placebo. Dapagliflozin reduced weight (-0.92 to 1.61 versus + 0.43 kg with placebo). The rate of hypoglycemic episodes was higher in the dapagliflozin group (56.6 versus 51.8 percent).",
"     </li>",
"     <li>",
"      In a 12 week trial, 451 patients with type 2 diabetes were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42832?source=see_link\">",
"       canagliflozin",
"      </a>",
"      (several doses),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/31/5622?source=see_link\">",
"       sitagliptin",
"      </a>",
"      100 mg daily, or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/62\">",
"       62",
"      </a>",
"      ]. The reduction in A1C from baseline ranged from -0.7 to -0.95 percentage points in the canagliflozin group versus -0.74 and -0.22 percentage points for sitagliptin and placebo, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The overall benefits of SGLT2 inhibitors include a decrease in blood pressure and weight, and a low incidence of hypoglycemia when used as monotherapy or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/56\">",
"     56",
"    </a>",
"    ]. In a systematic review of dapagliflozin trials, there was a reduction in systolic blood pressure at all doses (-1.3 to -7.3 mm Hg compared with +0.2 to -0.11 mm Hg in the control groups) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/56\">",
"     56",
"    </a>",
"    ]. In 12 week trials of dapagliflozin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42832?source=see_link\">",
"     canagliflozin",
"    </a>",
"    , and emapagliflozin, weight loss of 2 to 3 kg was reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/56,63\">",
"     56,63",
"    </a>",
"    ]. The weight loss appears to be sustained over time. In a meta-analysis of three longer-term trials (48 to 52 weeks) comparing dapagliflozin (10 mg daily) versus placebo, there was a significant reduction in weight in the dapagliflozin group (mean difference -2.36 kg, 95% CI -2.85 to -1.88) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects of SGLT2 inhibitors include an increased incidence of vulvovaginal candidiasis and genital infection, the latter reported in 11.7 to 14.6 percent of patients in a 24-week trial with a long-term (102 weeks) extension [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. In meta-analyses of dapagliflozin trials (10 mg), there was also a higher rate of genital tract infections (9.5 versus 2.6 percent in the control groups) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In addition, there was a small but significant increase in the rate of urinary tract infections (8.8 verus 6.1 percent). There are no long-term safety data with regard to the effects of chronic glucosuria on the urinary tract. In addition, there are no data on microvascular or cardiovascular outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Inhaled insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inhaled form of rapid-acting insulin was available for a short time but was discontinued in 2007 for commercial reasons. Other inhaled insulin preparations are in clinical trials but are not currently available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link&amp;anchor=H10#H10\">",
"     \"General principles of insulin therapy in diabetes mellitus\", section on 'Inhaled insulin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Colesevelam",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the modest glucose lowering effectiveness, expense, and limited clinical experience, we typically do not recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35734?source=see_link\">",
"     colesevelam",
"    </a>",
"    to improve glycemic control in patients with type 2 diabetes.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35734?source=see_link\">",
"     Colesevelam",
"    </a>",
"    is a bile acid sequestrant that lowers LDL cholesterol in patients with primary hypercholesterolemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link&amp;anchor=H2#H2\">",
"     \"Lipid lowering with drugs other than statins and fibrates\", section on 'Bile acid sequestrants'",
"    </a>",
"    .) Colesevelam's mechanism of action to improve glycemic control is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/66\">",
"     66",
"    </a>",
"    ]. One possibility is that bile acid sequestrants act in the gastrointestinal tract to reduce glucose absorption.",
"   </p>",
"   <p>",
"    In a meta-analysis of five short-term trials (16 to 26 weeks) in patients with type 2 diabetes inadequately treated with oral agents or insulin, the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35734?source=see_link\">",
"     colesevelam",
"    </a>",
"    compared with placebo modestly reduced A1C levels (mean difference 0.5 percentage points [95% CI -0.6 to -0.4]) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/67\">",
"     67",
"    </a>",
"    ]. The meta-analysis was limited by the high or unclear risk of bias in the individual trials.",
"   </p>",
"   <p>",
"    Side effects can include constipation, nausea, and dyspepsia. In contrast to its effects on LDL cholesterol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35734?source=see_link\">",
"     colesevelam",
"    </a>",
"    increases triglyceride concentrations by approximately 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. The clinical implications of this increase are unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=see_link&amp;anchor=H20#H20\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\", section on 'Triglyceride rich lipoproteins and apo C-III'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24159710\">",
"    <span class=\"h2\">",
"     Bromocriptine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given its modest glucose lowering effect, very frequent GI side effects, and the availability of more effective drugs, we do not recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    for the treatment of type 2 diabetes.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     Bromocriptine",
"    </a>",
"    is an ergot-derived dopamine agonist that has been used for over two decades for the treatment of hyperprolactinemia and Parkinson disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\", section on 'Dopamine agonists'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=see_link&amp;anchor=H14#H14\">",
"     \"Pharmacologic treatment of Parkinson disease\", section on 'Dopamine agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A new quick release formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    (Cycloset) was approved by the US Food and Drug Administration for the treatment of type 2 diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/70\">",
"     70",
"    </a>",
"    ]. In short-term clinical trials in patients with type 2 diabetes mellitus, bromocriptine (up to 4.8 mg daily) as monotherapy or as adjunctive therapy to sulfonylureas was minimally effective in reducing A1C compared with placebo (mean difference 0.4 to 0.5 percentage points) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Common side effects include nausea, vomiting, dizziness, and headache [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/72\">",
"     72",
"    </a>",
"    ]. The mechanism of action in reducing blood sugar is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1665282\">",
"    <span class=\"h1\">",
"     SURGICAL TREATMENT OF OBESITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical treatment of obese patients with diabetes results in the largest degree of sustained weight loss and, in parallel, the largest improvements in blood glucose control. There are a growing number of trials comparing bariatric surgery with medical therapy for the treatment of type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a two-year study of 60 obese patients (BMI 30 to 40) with a history of type 2 diabetes diagnosed within the previous two years, subjects randomly assigned to laparoscopic banding with conventional therapy versus conventional therapy alone (education, lifestyle modification, pharmacologic therapy) experienced greater weight loss (20 versus 1.4 percent, respectively) and remission rates of diabetes (73 versus 13 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an unblinded trial, 72 patients with obesity (BMI &gt;35) and type 2 diabetes for at least five years were randomly assigned to gastric bypass, biliopancreatic diversion, or medical therapy (pharmacologic therapy, education, lifestyle modification) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/74\">",
"       74",
"      </a>",
"      ]. In the group assigned to conventional medical therapy, oral agents",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      insulin were titrated to achieve an A1C of &lt;7 percent. At two years, diabetes remission occurred in a greater proportion of patients in the surgical groups (75, 95, and 0 percent for gastric bypass, biliopancreatic diversion, and medical therapy, respectively). The average time to normalization of fasting glucose and A1C levels for bypass and biliopancreatic diversion was 10 and 4 months respectively. The reduction in average body weight was 33, 34, and 5 percent, respectively. However, there was no correlation between degree of weight loss and normalization of fasting glucose levels.",
"     </li>",
"     <li>",
"      In another unblinded trial, 150 obese (BMI 27 to 43) patients with type 2 diabetes (mean duration approximately eight years) were randomly assigned to gastric bypass, sleeve gastrectomy, or intensive medical therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/75\">",
"       75",
"      </a>",
"      ]. After 12 months, the proportion of patients with A1C &le;6 percent (the primary endpoint) was higher in the surgical groups (42 and 31 percent compared with 12 percent in the medical group). The mean percentage weight loss was 28, 25, and 5 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these impressive results, concerns remain about the rigorousness of the lifestyle modification and application of &ldquo;intensive therapy&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?28/19/28986/abstract/76\">",
"     76",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\", section on 'Intensive lifestyle modification'",
"    </a>",
"    ), long-term success rates in maintaining weight loss, and reproducibility of the results in patients with an extensive history of diabetes or with a different surgical team. Thus, longer-term follow-up is required before laparoscopic banding or other bariatric surgery procedures can be routinely recommended for the treatment of recent onset, obesity-related type 2 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link&amp;anchor=H7#H7\">",
"     \"Surgical management of severe obesity\", section on 'Effectiveness of bariatric surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       \"Patient information: Type 2 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/49/16147?source=see_link\">",
"       \"Patient information: Treatment for type 2 diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/37/36436?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"       \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"       \"Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Glycemic goals",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of contraindications,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      is usually the initial therapy for most patients with type 2 diabetes. Initial management is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"       \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      After a successful initial response to oral therapy, the majority of patients fail to maintain target A1C levels. We recommend the addition of a second medication to achieve a treatment goal A1C of &lt;7 percent (",
"      <a class=\"graphic graphic_algorithm graphicRef70606 \" href=\"UTD.htm?7/63/8176\">",
"       algorithm 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This decision is typically made after two to three months of initial therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for a second agent'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We are aware that this goal is not appropriate for all patients, especially the elderly and those with comorbid conditions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"       \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"      </a>",
"      .) In addition, the goal is not practical for all patients due to patient preferences regarding combination therapy, particularly insulin therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Metformin monotherapy failure",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with inadequate glycemic control on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      and A1C &gt;8.5 percent, we suggest adding insulin (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Metformin and insulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with inadequate glycemic control on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      (A1C &gt;7.0 percent), with A1C close to target (&le;8.5 percent), we suggest adding a short-acting sulfonylurea, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"       glipizide",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Metformin plus sulfonylureas'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/25/4503?source=see_link\">",
"       repaglinide",
"      </a>",
"      is an alternative option, which can be considered in individuals who do not reach glycemic goals with metformin, if there are contraindications to sulfonylureas or patient preference limits the use of insulin. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Metformin plus meglitinides'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"       pioglitazone",
"      </a>",
"      is also an option in individuals without risk factors for heart failure or fracture, who do not reach glycemic goals with metformin alone, if there are contraindications to sulfonylureas or patient preference limits the use of sulfonylureas or insulin (",
"      <a class=\"graphic graphic_algorithm graphicRef70606 \" href=\"UTD.htm?7/63/8176\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Metformin plus thiazolidinediones'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Contraindications to metformin and sulfonylurea monotherapy failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In individuals with contraindications to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , sulfonylureas are often first-line therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\", section on 'Sulfonylureas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with inadequate glycemic control on sulfonylureas, with A1C &gt;8.5 percent, we suggest switching to insulin (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Sulfonylureas and insulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with inadequate glycemic control on sulfonylureas (A1C &gt;7 percent), with A1C close to target (&le;8.5 percent), we suggest adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"       pioglitazone",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, the expense, side effects, and limited data on long-term safety make us cautious about suggesting its use. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Metformin plus thiazolidinediones'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      DPP-IV inhibitors can be considered as add-on drug therapy to sulfonylureas in patients who have contraindications to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      and pioglitazone. However, the modest glucose lowering effectiveness, expense, and limited clinical experience with DPP-IV inhibitors temper our enthusiasm for these drugs. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'DPP-IV inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Dual oral agent failure",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In individuals with inadequate glycemic control (A1C &gt;7 percent) on two oral agents (usually",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      and sulfonylurea), we suggest switching to insulin (discontinue sulfonylurea and continue metformin) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Metformin and insulin'",
"      </a>",
"      above.) An alternative that is less likely to work is three oral agents.",
"      <br/>",
"      <br/>",
"      However, three oral agents (metformin, sulfonylurea,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"       pioglitazone",
"      </a>",
"      ) can be considered in patients with A1C values that are not too far from goal (A1C &le;8.5 percent). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Insulin versus triple oral therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      A GLP-1 analog could also be considered as an add-on drug for overweight patients who are poorly controlled on maximal doses of two oral agents. However, long-term safety has not been established. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Exenatide'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Liraglutide'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      A DPP-IV inhibitor may have a role as a third agent in those who cannot or will not take insulin when full doses of metformin and a sulfonylurea have not produced satisfactory metabolic control, and there are contraindications to pioglitazone. However, long-term safety has not been established. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'DPP-IV inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/1\">",
"      Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/2\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/3\">",
"      United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/4\">",
"      U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/5\">",
"      Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/6\">",
"      Bressler, P, DeFronzo, RA. Drugs and diabetes. Diabetes Reviews 1994; 2:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/7\">",
"      Kobayashi T, Itoh T, Kosaka K, et al. Time course of islet cell antibodies and beta-cell function in non-insulin-dependent stage of type I diabetes. Diabetes 1987; 36:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/8\">",
"      Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004; 27:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/9\">",
"      Shah BR, Hux JE, Laupacis A, et al. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 2005; 28:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/10\">",
"      Ziemer DC, Doyle JP, Barnes CS, et al. An intervention to overcome clinical inertia and improve diabetes mellitus control in a primary care setting: Improving Primary Care of African Americans with Diabetes (IPCAAD) 8. Arch Intern Med 2006; 166:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/11\">",
"      Grant RW, Buse JB, Meigs JB, University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care 2005; 28:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/12\">",
"      Fanning EL, Selwyn BJ, Larme AC, DeFronzo RA. Improving efficacy of diabetes management using treatment algorithms in a mainly Hispanic population. Diabetes Care 2004; 27:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/13\">",
"      Grant RW, Cagliero E, Sullivan CM, et al. A controlled trial of population management: diabetes mellitus: putting evidence into practice (DM-PEP). Diabetes Care 2004; 27:2299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/14\">",
"      Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones. Diabetologia 2008; 51:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/15\">",
"      Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/16\">",
"      Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/17\">",
"      Monami M, Lamanna C, Marchionni N, Mannucci E. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008; 79:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/18\">",
"      Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 303:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/19\">",
"      Aschner P, Chan J, Owens DR, et al. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet 2012; 379:2262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/20\">",
"      Hermann LS, Scherst&eacute;n B, Bitz&eacute;n PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994; 17:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/21\">",
"      Jeppesen J, Zhou MY, Chen YD, Reaven GM. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 1994; 17:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/22\">",
"      DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/23\">",
"      Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/24\">",
"      Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000; 22:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/25\">",
"      Pioglitazone/Glimepiride (Duetact) for diabetes. The Medical Letter 2007; 49:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/26\">",
"      Goldstein BJ. Clinical translation of \"a diabetes outcome progression trial\": ADOPT appropriate combination oral therapies in type 2 diabetes. J Clin Endocrinol Metab 2007; 92:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/27\">",
"      Kahn SE, Zinman B. Point: Recent long-term clinical studies support an enhanced role for thiazolidinediones in the management of type 2 diabetes. Diabetes Care 2007; 30:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/28\">",
"      Al-Ozairi E, Sibal L, Home P. Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): good for sulfonylureas? Diabetes Care 2007; 30:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/29\">",
"      Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/30\">",
"      Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000; 23:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/31\">",
"      Gerich J, Raskin P, Jean-Louis L, et al. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 2005; 28:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/32\">",
"      Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/33\">",
"      Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001; 111:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/34\">",
"      Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005; 48:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/35\">",
"      Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994; 121:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/36\">",
"      Johnston PS, Feig PU, Coniff RF, et al. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients. Diabetes Care 1998; 21:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/37\">",
"      Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005; 28:2673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/38\">",
"      Henry RR, Gumbiner B, Ditzler T, et al. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care 1993; 16:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/39\">",
"      Yki-J&auml;rvinen H, Ryysy L, Nikkil&auml; K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999; 130:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/40\">",
"      Abraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care 1995; 18:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/41\">",
"      Yki-J&auml;rvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/42\">",
"      Chow CC, Tsang LW, Sorensen JP, Cockram CS. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 1995; 18:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/43\">",
"      ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/44\">",
"      Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 1996; 156:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/45\">",
"      Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/46\">",
"      Pugh JA, Wagner ML, Sawyer J, et al. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Diabetes Care 1992; 15:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/47\">",
"      Landstedt-Hallin L, Adamson U, Arner P, et al. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 1995; 18:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/48\">",
"      Wulffel&eacute; MG, Kooy A, Lehert P, et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002; 25:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/49\">",
"      Hemmingsen B, Christensen LL, Wetterslev J, et al. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ 2012; 344:e1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/50\">",
"      Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24:1226.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. MedWatch the FDA Safety Information and Adverse Event Reporting Program - Avandia (rosiglitazone), April 2002. file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154468.htm (Accessed on June 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/52\">",
"      Schwartz S, Sievers R, Strange P, et al. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care 2003; 26:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/53\">",
"      Rosenstock J, Sugimoto D, Strange P, et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006; 29:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/54\">",
"      Lingvay I, Legendre JL, Kaloyanova PF, et al. Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? Diabetes Care 2009; 32:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/55\">",
"      Vinik AI, Zhang Q. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes. Diabetes Care 2007; 30:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/56\">",
"      Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012; 2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/57\">",
"      Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012; 44:375.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA News Release: FDA approves Invokana to treat type 2 diabetes, March 2013. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm (Accessed on April 10, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/59\">",
"      Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/60\">",
"      Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/61\">",
"      Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012; 156:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/62\">",
"      Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/63\">",
"      Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res 2012; 9:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/64\">",
"      Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012; 28:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/65\">",
"      Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 2013; 11:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/66\">",
"      In Brief: A new indication for colesevelam. Med Lett Drugs Ther 2008; 50:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/67\">",
"      Ooi CP, Loke SC. Colesevelam for type 2 diabetes mellitus. Cochrane Database Syst Rev 2012; 12:CD009361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/68\">",
"      Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008; 31:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/69\">",
"      Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008; 168:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/70\">",
"      Bromocriptine (Cycloset) for Type 2 Diabetes. Med Lett Drugs Ther 2010; 52:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/71\">",
"      Cincotta AH, Meier AH. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 1999; 8:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/72\">",
"      Gaziano JM, Cincotta AH, O'Connor CM, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010; 33:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/73\">",
"      Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008; 299:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/74\">",
"      Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/75\">",
"      Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/19/28986/abstract/76\">",
"      Ludwig DS, Ebbeling CB, Livingston EH. Surgical vs lifestyle treatment for type 2 diabetes. JAMA 2012; 308:981.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1790 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_19_28986=[""].join("\n");
var outline_f28_19_28986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR A SECOND AGENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFICACY OF COMBINATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Combination with metformin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Metformin plus sulfonylureas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Metformin plus thiazolidinediones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Metformin plus meglitinides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Other metformin combinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Sulfonylureas and thiazolidinediones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Combination with alpha-glucosidase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INSULIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Combination oral and insulin therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Sulfonylureas and insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Metformin and insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Thiazolidinediones and insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Insulin versus triple oral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Insulin intensification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OTHER MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Exenatide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Liraglutide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DPP-IV inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H457895\">",
"      Pramlintide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H457938\">",
"      SGLT2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Inhaled insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Colesevelam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24159710\">",
"      Bromocriptine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1665282\">",
"      SURGICAL TREATMENT OF OBESITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Glycemic goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Metformin monotherapy failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Contraindications to metformin and sulfonylurea monotherapy failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Dual oral agent failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1790\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1790|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?7/63/8176\" title=\"algorithm 1\">",
"      Management type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?19/63/20467\" title=\"algorithm 2\">",
"      Insulin titration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1790|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/5/17502\" title=\"figure 1\">",
"      HbA1c with intensive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/49/6928\" title=\"figure 2\">",
"      Insulin plus oral hypoglycemics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1790|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/40/10891\" title=\"table 1\">",
"      Drug induced diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/22/3437\" title=\"table 2\">",
"      Options for diabetes Tx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=related_link\">",
"      Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15734?source=related_link\">",
"      Amylin analogs for the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=related_link\">",
"      General principles of insulin therapy in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38298?source=related_link\">",
"      Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=related_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7865?source=related_link\">",
"      Management of hyperglycemia in diabetics with end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=related_link\">",
"      Metformin in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/18/14634?source=related_link\">",
"      Nutritional considerations in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=related_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/37/36436?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=related_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/49/16147?source=related_link\">",
"      Patient information: Treatment for type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=related_link\">",
"      Pharmacologic treatment of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=related_link\">",
"      Sulfonylureas and meglitinides in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=related_link\">",
"      Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_19_28987="Concepts regarding evaluation of fever after travel";
var content_f28_19_28987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Key concepts in the evaluation of fever after travel",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Diseases unrelated to travel can appear after exotic travel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infections can be acquired en route or on brief layovers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever related to tropical exposures usually begins during travel or shortly after return, but can rarely be delayed for months or years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Defining the range of relevant incubation periods can help limit the differential diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malaria is still possible even if an initial malaria smear is negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with acute falciparum malaria may have a normal physical examination and no fever when first seen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early symptoms of self-limited infections and life-threatening infections may be indistinguishable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risks for infectious diseases and manifestations of infections in local residents and in visitors to a geographic region may differ widely",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risks for infectious diseases vary from one tropical area to another and may vary depending upon the season and year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familiar infectious diseases acquired in a tropical, developing area may have an unusual resistance pattern or may be acquired during an unexpected time of year (eg, influenza in July)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_19_28987=[""].join("\n");
var outline_f28_19_28987=null;
var title_f28_19_28988="PPI recommended doses";
var content_f28_19_28988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for PPI doses in the treatment of acid-related disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose (adult) oral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Active and maintenance therapy of gastroduodenal ulcers*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dexlansoprazole",
"       </td>",
"       <td>",
"        30 to 60 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Esomeprazole",
"       </td>",
"       <td>",
"        20 to 40 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lansoprazole",
"       </td>",
"       <td>",
"        15 to 30 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Omeprazole",
"       </td>",
"       <td>",
"        20 to 40 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pantoprazole",
"       </td>",
"       <td>",
"        20 to 40 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rabeprazole",
"       </td>",
"       <td>",
"        20 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        All administered daily before breakfast",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Primary and secondary prevention of NSAID-induced ulcers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        All PPIs as above",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Treatment of erosive or nonerosive gastroesophageal reflux disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dexlansoprazole",
"       </td>",
"       <td>",
"        30 mg daily or 30 mg twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Esomeprazole",
"       </td>",
"       <td>",
"        20 or 40 mg daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lansoprazole",
"       </td>",
"       <td>",
"        30 mg daily or 30 mg twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Omeprazole",
"       </td>",
"       <td>",
"        20 to 40 mg daily or 20 mg twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pantoprazole",
"       </td>",
"       <td>",
"        40 mg daily or 40 mg twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rabeprazole",
"       </td>",
"       <td>",
"        20 mg daily or 20 mg twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        All administered daily before breakfast, second dose if necessary should be given before evening meal",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PPI: proton pump inhibitor; NSAID: nonsteroidal antiinflammatory drug.",
"     <br/>",
"     * As a general rule, active duodenal ulcers should be treated for four weeks and gastric ulcers for eight weeks.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Meals should ideally contain protein to enhance parietal cell stimulation.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Wolfe MM, Sachs G. Acid suppression: Optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118:S9.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_19_28988=[""].join("\n");
var outline_f28_19_28988=null;
var title_f28_19_28989="Morgan lens close up";
var content_f28_19_28989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Morgan&reg; lens",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 170px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Morgan&reg; lens provides a simple and effective means for irrigating eyes exposed to toxic chemicals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: MorTan, Inc. Copyright &copy; 2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_19_28989=[""].join("\n");
var outline_f28_19_28989=null;
var title_f28_19_28990="History of C trachomatis";
var content_f28_19_28990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Natural history of C. trachomatis infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 327px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Repeated episodes of infection cause recurrent conjunctival inflammation, leading to eyelid scarring, trichiasis (ingrown eyelashes), corneal opacification and subsequent blindness.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_19_28990=[""].join("\n");
var outline_f28_19_28990=null;
var title_f28_19_28991="Healing transverse fracture of little toe";
var content_f28_19_28991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Healing transverse fracture of little toe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AXQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDlvGWsM8rjfnk8VxR1F9x59+tW/E0pa6k+prnS3PWgDYGpse9OGqMBjdWLmjJoA3Bqjf3zTv7Vfj52/OsLJoyfegDoBq75+9TxrEgHDn865zcc0u73oA6NdakHWQj8akTXJB1c1y+4+tKGI7mgDqv7ckz/AKxvzqQa9KOkh/OuR3t6ml8w+tAHZL4imH/LT9alTxLMP4z+dcR5jetL5rep/OgDul8TzcfP+tWF8VTr1kb868+EzDqaUTsOmKAPR08XTjGHb86nTxjOMfvT+deZfaH9aetxIcEZoA9PTxnOD80p/Op08bSg/wCtNeWCZ8ZBNDXLqepoA9ci8czY++atR+PJhj5zn614yL1s+1L9ub1NAHtkXj+Ufxmuj0Px400RBkOQcda+chqEn97H0rU0bV3inZS5GR0zQB9MW/jQkgCWrv7Uf/JCfE3/AG6/+lUVfPtvrbLtO819L/Huyg1D4Ta9bXYYwuISwU4PE8ZHP1AoA/OuiurvtGsoZWVEfH+/Vb+y7X+63H+11oA0opmEaDJHyjt7U/zz/eNVlAVQB0AxS0hXLHnns1BnOOtV6KAuWfPPqaUzkgDfVWigLlsXDD+Kl+0t/eNU+nI60pNAXLf2lv7xpftL+v61S60GgLl77U+Ov60oun/vc1QzRQFzQ+2Sf3j+dOF7J6n86zc0uaANL7dIO5pft8nZsVmZPrRuPrTA1hqEg53Gl/tKT1rJ3H1pyb29cUDN6DV5EjA3UVmxW+5ATRQBoa+c3Ln/AGjWL36Vq62264f/AHqyCeegoAfRSZGKWgAoNAIpCcNQAZo74pu7BzxSMx745oAdnt3oHIzTCeMUZ45oAeWAOO9GeKjJzx2oBxQIkz+VGcg46iowc/SlzlWB6UDHkkY7Z/GlHPSkGcipY0z04FAAiZOB1qwq4FOjToBVyK1yAWP4DmgCltI7Ux0zzjNaDRAcAEMO3WoHQA8UAZku5D7UzzGq5Om5ORVA8Z9qAJDJz0qWCQiRW71W706P7w5pCOht3JAGTX2R8cOPhbrn+7F/6OSvjWxO6NTX2T8cuPhZrn0h/wDRyUxnxBqRzK31qpVm/OZm+tVqQgooooAKKKKACiiigAooooAUD8aCMYpOlKTn8KAEooooAKKKKACij+dOTqKAJI48HpzVhE6EiiMcZNToCT70xlq1T90M+tFaVhbBrYEnuaKAMbVjm4b61lE9a0dUb/SG+tZpGQfrQA4gcU8UxSfpjtQc9cGgAOexppPPNDdqT1AoAd1HQU3OOlJk+tJSEOzRmkooAKKB0pcH0oASlU5ApDkdRQKAJ0HAzVqJeMd6giHQCr0C55PWmMntY8tn2rQWMhsYxj0qOxTc6jpzmtER5Z88c0CKj24XcTnOMrWfIhDnIroEYGN1fA3L9cVlTQ4znqKBmZImRWVOhWQ1uyLjg1lX4wScUCKdAPIPpRR6e9IDe01swrX2X8dePhVrv0h/9HR18Xac21VA4r7Q+O//ACSjXfpD/wCj46Yz4fvTmY/Wq9T3h/emoKQgooooAKM5NFFAAfal7YpKKACiiigAooooAKKKcsbMaAG0VL5NNaMjpyKAGUq/eFJRQBoRDK/jViEdqq2jZXB61diGAMdTTGdFphjFrhjzk0VJpkSNagsWzk9KKAOP1I/vm+tZ4Ofzq7qLfvnPvVFaTEx/T8aTp2pCcdaQ59TQAoNJ3oooAKKKKACigZJqdI84yKAI0jPU1OI2NTJHgDNTKhPQUxlIwk9qheNk5IrV8s9xiopE4wwoAr2x3Edq04hj8azkXy5xnpWpECSOKAL9kuxlJ5+laaszj5ecjmqNmokbPQD0rXtkOxQowKAHJbDZ83p1HNZd7C0TNu71tRuA59apamrFT5g57UAYTruwDWRqSYJz3rdcdT2rI1MBlJ70AY1PhXe4FIylfpVuwiJyxHFIRYhG0jnFfaXx5OPhPrv0h/8AR8dfGaKAV4r7K+Pn/JJde+kH/o+OmM+ILr/WmoaluP8AWtUVIQUUUUAFFFFABRRRQAUUUUAFFFPjXJ9qAHRJkZNWEQmkiXJq/bR8qcUDK3lf7JprR8cDBrWMO4DHXPrxVSaP5vcdaYGTNGVbNRVoTx5U8c1n4wSKQie2bB+hrZgG4KRisKNtrex61s2DjauaAOq0rcLQc9zRUuk/8ea8dzRTGcBfffb61UBxVm9/1jfWqtJiFz1pKKKACiiigAoopVGWAoAliTvVxFxjiooR7VbiXI5pgPjTIwepqzFbMwyRilgiLMCa04UEZBRTkHBJ5oGZjQYAI+771Ay9ciuhKSSLgpkHoSKzbiHaDkCkBj3MXGQORVyxffCBn5hSOoIPtVS2kMU7DpTEdJpieYWRevXpWurBgmMiM5rI0p8OHUnPetSQjgjoRQMmTBBYD/H8qLxFuLfZzuAyDVQ3Ocso+Y1YimA27h165NAHPT5Ryp7dqyb352IFbGrFUupAv51llCXBNAFEW5Y4P3avRxhFwo4qdIAB7U5YyBjvQIiiGXGBX2H8ff8AkkmvfSD/ANHx18jwRDeBivrf4/8A/JI9f+kH/o+OgZ8Pz8yk0ynzH94aZSEFFFFABRRRQAUUUUAFFOVCe3FSeVxxmgCGp4xwPpUbxsvapIj8o5xQBbhHArTtY9wOOwrPiySOa1bLKg5PB4xTGTooTgjOetQ3VvucsmAp6A1ejiGcnuOnrT5bZ3jJVeBQBgSJ8pBrJu49j5robhNxbI5FZGophMjpQBnCtHT5PlGTjHes5RngVet1PUcUCO30iVRYrkjqaKq6VGxs1+UmigZx1395ifWqtT3RyT9agpMQUUUUAFFFFABSqcMDSUUAXoSCKvRDj61lWsgBwa14TkKaYF62O8qo+9Wou7B6ZBrJRtpUjjBq9EzFd2fvUDLBlxjsBVWZgQeM5qR2UjHeoiR9KAMz+9ms5/8Aj7PvzWpdKVdsZwayZP8AXK3vQBtaVcGG4TdwrcGtqaTGV6Y6Y5Fc7EOcjoOcVsWTiYqCcH07UAOAOeDU8YL/AP16kW0f5iR+VWLGBjJjGfrQBh3ql5yWHOKrLCFIOM1r6pHsumBGMiqoHtQBEqcEU4IByOtPC0oHt9KBDrVB5o4r6p/aB4+EWv8A0g/9Hx18uWaEzLkYr6j/AGgv+SQa/wDSD/0fHQM+IJf9Y31plOk++abSEFFFFABRRRQAD3qSNCcE0ka5OauRJ3oAFjwACOalCH0qWOPdyTir0VqGXIGf6UxmY0fHSq7x7TkdK1p4GQ4weaqyxkcYP49qAG25BAI9K1LMbygNYtq+yYRtWzbMFwT0oA1oiAvyjkelWAWAIPAqBZBEcdeO1KrmQ4Jx2oAoajFiXLAgkc1iXy7gVHSuruoxcRKoBLAYBrLt9PYtvmB4PC+p96AObW2cMTg7fYVqW1thVY/hWxJbgDp+ApFhwQNpoA29Hsy1ihHHJorZ0aEf2fHxRQB45cnn8ahqW45aoqQgooooAci7jUvliliXOMCrSxDHTNMZnOpB4pK0zCD/AA1BJaegxSEUxxzWlp1wCdhPNZ7oydRSxMUcMDg0AdKpyKu2/wDqgp/nWTaT7ogfXrV60l3MVGM0xlpkJXkimFlUHjnGc015Qo5zmqxYng0AMvMuue4/CshxudQOp7VrOSR2bPtVa2tWMm8jGDxQBPbcJg9asxMQwI4IpuwDoOacBQB1OlzrdQqM4deuO9XxEIpUdV+QnB9q5jTpzb3AZTgHtXXxsJIAR360AYHiGLZcIwHUYxWUq9B3rp9ah82083HIrniM5GKAGFc/dpwXnOPpTguaeqg4BzzQBJYqWnXgV9N/tCf8kg8QfSD/ANHx1812KYuE7c19J/tC8fB7xB9IP/SiOgD4gf7xpKU/eNJSEFFFFABRRRg+lAFiAZAA71cjXkZqjA44rQiIJBpjLtrHvbJOBWiqjog4HesyJ9uB2rRSRMKB3FADpV3qAO3Tmsy5i2HBPFXi57ZFQSoWUjkmgDCuhhwQa0beRigOKp3SjfjvWnZR5QcUCNyxj8yEPwFA5qeG3O89QOxFR6VIEzE4+RunOOa2BG3GxcdjigY+0jjgKsF5AzzWdqQC3D4xg88Vq20ZMgBHXiszUwBcyDPQigCie468UxRlgMCpWwDgU6JPnHrmgDtNHizp8eBxRVrSEYWEeBx9KKAPAZ/v/So6fKcuaZSEFKg3NikPSrFogY5IoAtQR4xVtFApIlHbrVmOP7u4daYyIIcZxTWUHtzWuLR2TKpgep71UubdomwyFT70hGRPH61QmTaelbEy+vFULmMEZpjHWMmDjsR0rRR9rhgefasOBysgrWhy4AFAjSLbiNvOaBCxOcHPpTtOG2QK2Bn1reissJux0oGZ0VlsRpHHPpUBABIUcVv3CL9lbA525rA9xQBG68EjrUaipmOVI70iL/F+lAh8Yrr9Am863CsecYrkh7Vs6BKYbsKWO1uOaBnSGAS28kR6+lclNCUnKnqDjpXasPLmU9FYZrB8RWpiulkAIVx1oAxwvOKeq/KOOaUKQ3tT0XJH8qBFiwG64Svoz9ob/kj3iD6W/wD6UR1896Yv+koBzzivoP8AaH/5I94g/wC3f/0ojoGfELdTSUH7xopCCiij6UASRrxn1qcRE0tvHkCrqR+v5Uxma9u4OVp8E5jYLIMe9aJjB7VXnhBHTNAFmMhhkcirVsSx2flWPbSNA/ltkqehrTgl2HPUdzQBeJwD69hTTnqTjNPjU4yBnPerEVlJK2XBCnp60AYVzAWfIXvyKvWqsgFb8VhAiE7ctjnNU/KVScD8KAIVPIxXSaDdhmEE3f7ua5twUfAHWrFtIyOpB5ByKAO8FqsciOoyCea5vXoyL84x0rprGX7TZpKD26VleKIGCxS+vGfSgDn1GcDHNORT5i46Z6URqeCaswxZkWgDt9JT/QY/pRVzSoR9hjz6UUAfNkhy5ptK/wB40lIQVpWifKtZyjLAVrWwwAKALMQBPXFaunRDz1fHTnms63+904ro5rK6024a2v7Wa1uIwN8U0ZR1yMjIPI4IP40xkM+/Pzgkk9jiobtiyAMpyPxq7JNGI8jn6ms64us9AFoAyrrGcY5rPn+7XU+FLKDUvGmhWV7H5lrdX8EMqZI3I0ihhkcjIJ5FUPHljBp3i/X7Gxj8u2tb+eGKPcTtRZGCjJ5OAB1oA5aJczAe9dDaRYUcc1jWUZMgJ9a6KBQV78CgB8alTnoa6rTW8+1HrjB9q5hRjrW74ckOWiPrQBduogLd8d1rmGFdfMNxdMcelcrdJ5c7qR3oAgxk+9OHHanKOc9qCOfSgByADFWYchlZTyDUSjgcVNCAOmPpQB2zSebpUE/8eMfSknjjvrAqeXFVtILyeHZQDyknf0qOKRo344x1oAyZbOWJsbTjGfWovL2knBBreLEueMAmopoVbOQM0AQaMu67TPrXvn7RH/JHfEH/AG7/APpRHXhulW5jvQDnJPFe4/tE/wDJHPEP/bv/AOlEdAHxCepooPWikIKkhXc30qOrVoOBQBdgXGD6VcgTc3TpVaIYH1rV09ACxAO8jg+lMBklqzLlVyw7d6pSRtjlcCtoo4IJ5yO9VLqM7SzDHtQMwLlMrnuKmsGaVlReWPFLIpLEAZJq3pUH2e4YEfeHB9KAN7SkRQUbn0J9a11iJQ8DjFYqsBjB6Vv6Q4uF2MPmX9aAGiE+SWxziscnJNdRLFshYDJFcu332A7GgCOVNwyDzTI0IbJqfHIpVXLYoA63wnKZbeS3PVQWH0q/qFubvS5lxl0GRWP4QJXUR2G0g10ltcpFfSRvjy245oA4JQV5I4q5bIGZSPXvWvqGlQpI3lkgFiQPaqMdv5NyvBK54oA77SgRYxjHairGlqPsSdaKAPlhuWNJSnqfrSUhDoxmQVsQfdFZEHMgrVgPAFCBF61UvIq16d8cAW+KutgE5Hkcf9sI68uhfY+5Tg16b8cpp0+KuuCJwo/cf+iI6YHESDA7kd6ryL8pZsKPekkllfh5OfamCJnBOCxz3oGavgFg3xD8MAcgapa/+jVpPiDb7viB4oZ++qXWP+/rVo/D2zA8c+HGbAI1K2P/AJFWl8fov/Cd+IyQOdSuf/RrUAcR5OyRfTNacQ4zSXMOQCMdaki+7igBw6c1q6E4F2g7McVlkVb047bmJunzUAdTJxNyOWNc7q0fl3p44IzXS3OPMBPHFZWvw7hFMvPODQBi45PpjpRjFSIuRRt7UAOUcdOKkhT5t2OtKvQDtU1sN0i5oA6PTiEs1hPG47xz3pNoVx8vbIpIMN2/CrhEcKBpeuflC9fx9KAI40Zl4X5euacISJPmXknHtUbXTA/KETnoBSm9cAZfv0PSgC7YxKZQ38QNet/tFf8AJG/EP/bv/wClEdeSaS/nT56DNet/tFf8kb8Q/S3/APSiOgD4h60UCikIKuWv3fwqnVqz+6AaANGM8CtSylADHuMVlp92r1tJEIwrkqep4pjLn2hifl9KqT+ZKeDn0qyrRzfLCsjZ6nbir1taSKmQgTPUtyaAMmK2KuWIANPaL5gR2rYezKqWU7jVdoArjNAEUOGQVraJIY7xOuDwax9hjlIX8KvWLMkqkkZyOKAOxnH7wr/Cw6Vyl5H5V1KoHeuul5aM+oFc/rcJjv29GGRQBmouKcqdxUka5BNSpyOlAjb0AfZ8FSNzdeOtaMqIj7znJOcVnWeAV7cDBrRklUDAG5h37UDJnxLHuCnA7VWjgDsA45z0NOR5tvyq232GKI5D567gc570AdnpkQ+xx/SirOlqfsUfbNFAHyOeppKM8n60UhElt/rRWrCOKzLYZkrYt0wBkUICSNMjNep/G+It8U9bbHeD/wBER1w+keHtY1WBptK0jUL2FW2NJbWzyKGwDglQecEce9emfGnSdU/4T/W9R/s69/s39x/pXkN5J/dRr9/GPvcdevFMZ5tHbrgnGWJp5QL0HbtVu3jxI+4ZAwfrSiEktxgAdqANPwL8vjbw9kddRtx/5FWqXj848deI/wDsJXP/AKNavY/ghoHhvWdMW6udPDa3plyr+b58g77o32htvUEdP4eawv2htG8P6NLaNp1kI9X1GeS6uJvNkYle/wApYqNzNngfw0AeKyElgB0p4pAMnNOAoAcB6mrdgpkniUD+Kqygk8itzR4BGDcSDgdKANDUHCSgKc8c03K3lq1uwxnpUMyNICR1JpsUbKylScUAZT28kExSRSGBx7U4gde9bcpMitvG8+hrNuYfKlGOEIzz/KgCuB0z2qeIcgg45zSqgIyaci4oA1be4C8knNTREzyMfU5J9frVCM8DGefWtK1AMeAAMCgCby1GAVA6daURKGAKDtToznHrx1+oH9aeFPDAHAx1/H/CgC/oNujzBowVIHevUf2i/wDkjfiH/t3/APSiKvOvDijzgeo6816L+0X/AMkb8Q/9u/8A6URUAfEXYUUelFIQVbshkiqnWtSxXanSgC7bQbz14rWsLaIToGUHJ71St+AABV+3bZKG6kGmM2wETAUAegAoIJ3Z79hUkCeeqkDIPrUzQ4bGOB0oAqk7EPHaqErKqFpCAqjLN6Cr14MALXMeKLryLEQqcSTHB/3e/wDSgC1dXkEcX2nzAYyPlI/i9hVnQRc3DhrhFQu2VXHKr7+9cr4cgnmvYiITLCp6scKp9R716XaQrAnA5x19aBmlJMFMeewAP16/1o12y+128NxAVLoMOvcehqBUBX52JzzVmPIRhzgjmgRzqoyNtYYp4GPp2q9exbvnHUdfeqq8jkcUAWbWVlABPFbNnt2qzDJ9axIcbsGtqy/49yeeMUAXM/L8v5/hRaoTcKDyNwHNCc59R+tT2Sj7cATwGwcdqAO1s4/LgCjt7UVoQWUrQo0YBUgHJ60UAfFnc0tHeikIs2Q+bJrYg6gdKzrRMqK0YMg8dvWmB7b+zR4iNj4lutDnfEGoR74ge0qAnj6ru/75Fdj+0nrpttI0zRoW/eXUpnlA67E4AP1Y5/4DXzxoWoz6Tq9nqNocT2sqzJ9VOcH2rs/iN4kTxj40m1G33fYkjSKAOMEKBk/+PFjQMo20O5R6lc06GI7gGqzZKXiQj+Hipo4+eeoNAG58ItcbQvH9vFMxW0vx9lkz0DE/If8AvrA+jGsX4zax/bnxB1F1bdb2hFpFzkYT735sWP41mXZ2XJGSrqcqQcH6isa6U+exJLknJLHJJoApMMGlUZXipXAJpFQA8UAS2ihpFDCt9eIwqjaCOlYUZ2SKx7VsxSphWzkUAWYV+TgcU4J+B9MVAZ3ZtqnavoKUo3fg0ATyREAnB+tVLhVkjYEdOQfSnmZ48hgxA981BI+4Hbxk8igCMfdpRx2pD1p+MEZGM0AWIh0FalghaSTJ+Upj8azohnBI4FbGmkBkUDr1x2oAUIeh555U9PvD/CrbKGUHB/vfqeKa6gMW/wBrHH0qwoBjByf8igDa8MJh8OAAT1rtv2i/+SNeIf8At3/9KIq4zw8uCvYYzXZftG/8ka8Q/wDbv/6URUAfEQ/pS0UUhD4hlx7VrWwwtZlquXrWhGFAoQIvRAYA6CrsQyR61UiHQGr9ohMqgdKYHSaJGfIO7tyK01gBmYr0PUVFoaqsbHAPNXg0cbbmI9MUDMG+tjI7GPqK5y60qG5vvPusybQFWM8Kv+NdZeo0bGVGyjHkelZMuMk89e9AENqixypgAAHAAGMCtyNvlw3SseNc7ifwq/AzSEKT05NAF5ZB0Xk9MYqZZZExuXIPtUUZCcKDnqTTzKTgjg9OO9AEMzKQWzzjoeapkEdOKszjADjqeOKgbrQBLDjOcY9BWzp+Psxz1yKxU4wBWrpTZLR+vSgDWjTDE/WrNnHm9VuhzmmAfKDyP/1VNpx3XcYPPP8ASgD0XTZsWig5oo02MC0XdgE88iigD4gpV5IpKdH9/FIRpWo6VoQe9ULcHI47Vfg6UxlqLNa1gD5ecZNZUVa9o2yIAdT3oA6PTOLY5zn3qVpkjkB/P3qpZzbbbag+Y96e8efmYksKAIr9UuI3miHzA/lWLcEkANwa6aCEbHXGAw6VzuoxlLhsgj0BoApsOM0i5I54pSc8UuMrz2oAfGMnA/WrUKl325wT+VVYj19RV214fNAGikfl42/rUmM9e4/lTBnGCe2amCkqpH1HvQBAx6gcA81BJHhwRwDVzYCcEc4pJof3SsORnH0PpQBQxzUinLD096U53HOOKeME8UATrgRgdjWlpTYl8s9D3rNA+UfTNT2UhS5ibP8AFzQBvrGSwA4G4VIcbcLlsH+lWZYwGDNwH647dqqkjOAuAec0AdHoEeMZBPOP0zXV/tG/8kZ8Q/8Abv8A+lEVc54fQ7VJ9jj8MV0f7Rv/ACRnxD/27/8ApRFQB8R0UUUhFm0Hf3rUjxx6VnWwwK0YyNo+lMZfh6jFatjgYbvWTbkZBrY0tfMlC5+VeaAOlsJdsW1PvdWP9KsLGkhySSTk1Xtk2rtx+PrV5CqpneM9h3oAbcwbbEHAIzk1zsi5JznHaujebCkE5GOQeaw7lAsjbeh5HtQBUjPJA69qu2pw5Geo61QTiSrcRwwoA0Y/vA9Ae1WCuFzjtUCrlh6Y4q+oDLz19AKAK6xCWJkzgnlT71QdNrbTwa1B8jDsAetUtQXFw2OlADEG3+lXLKXyZ0cjgHmqUWc1YjXLD9aAOtnCiMbTlSMginaJH5l9H0wTTbZjLpFqc/MOKuaFEBfpxgg0Ad4u5QFVsKAAPyoqUx+3XmigD4ZqSL7+ajqS35akI0oSePpV+D+VUIeD+FXojg/WmMtQ5zWpZlnYADmsuI4I962tLj2ruPU0AbNrH5cfznJq2q/JuAzmqsTjb6n3qcTEqdg28dBQAquQ6krwOTzVPUYxcrxgMOQasEPzlRVeQ7e+KAMJ0KOQetIoLAjGatXq5kz3qso9TigB0eBuzwatwg9ulVlUAEHmrMBzwc49qANU4ZUIxnbV23XI28Fc8exqpAcxLn1xmrkQIIydoOOKAGSJ8+VBX1xSRjcWVujD9R0NW5MBd2OvYVWbgj+8O1AGfIuCSR1pUA60+XJUH9Kao4xQBMvI+bHWpE+8uPWohkDH86sRDLKKAOumBW2Td6Z/XNVYkLyDjkHkVduQRDGuOCuKW1iCsrfkfWgDobACK3gQAgyEHPoK2/2jf+SM+If+3f8A9KIqx7UH7RCB0C962P2jf+SM+If+3f8A9KIqAPiOiiikIuwcDFXojkCqcFXIl4470xl6Ejj09q6PSwEt1YEZY9a5m3yozWjbTPGMKeD2oA6dLjYMlqlS7B52/wBaxrXM3zP90frWtEdowOMUAWDOki8DBqlcHLAZqaVFdScY9xVR1KHBoAhdfmyMYqeLGM1G/wBM1JGeCP5UAatv82xh24NXYxgA+v61Q0wgvtJ4Iq8wIXPp3oAlaNWGRwDwaz9RUi6cEcg/4Vp2/wA2FxnJqlqikX8uRjJz+YoApodwPGKsQ1Gq5qaNfagDqdIXdoy8dGOK1tDQNfhup9qztGQ/2OvB+8cVs+H0/wBLVjjBFAHexRgxqTjp3FFWLdT5S4zjFFAHwFU1uvOahqe1/rSEXoiQfWrkDc5IqpGPmq0oBwCcGmMuIcEetbllcgxqMgEdqwIwVx3q3EfwNAG+s6KTu+b2NP8AtcjkKinb/dFZVqhc/MSBWvCgwAB2oARZpRy4f8qUzK6ckbvQ1OM4wcioJUVj86/jQBRmIZ8gcCq6jc2elW3TBIPAPSq4UB+c0ASDntUyDAzUajmrCnkE4waANDTj5iPGevBFaMY3YwvGM81k2DeXdRt2zW64KEjHGTjFACZG3atRSr8gYjk/nTxlTuxznmrLIDbvLj5R3oAxCvzc9KYn+s6VOxyc1En+soAcFy+T0q3ZqWuIlHOWqBRnnFa2hwl9RhIXgHOKAOi1DhoV9qsW6ZCD06VBeZe7wTworQs49xTsfSgDXs1H2iI4HpWj+0b/AMkZ8Q/9u/8A6URVTslzdqKuftG/8kZ8Q/8Abv8A+lEVAHxHSUtFIRft/u1ej+6PpVC2Py1ej6CmMuR4BGOBV2LB9qpRcY71di+Y8d6ANm0G0hQAK1UT5QV/IelZgG3GOOBWnA/7sbTQBYhCEkOCKq3MQJOCCOxq0FHX/JqCbiNjjjOaAKDKOnFPjAprCpkUAdvwoAktnaORWXjaa35oxtUr0YA/SufXgj0rpYzu0yB8ZYjaaAG2aYYZOcVHr0e26RuzoOfpVmEbSOMmpNfiBtoZF/hwP0oAw0TjNSqD+lABOPWplXgZHGKAOu0iPOjpgdq2tAjH2hcHpWdpabNHjHQEVs+H0zcA9cUAd3bKfJWirFquYVop2GfnlU9r/WoKntjzUkmhF96rkJ45HNU4euauQk5xTGWE6irSLkiq8Yz2qzF05oA0rbC7fTFaNuCXHpWfEuFU47Vp24DKDnFAF0RZAC4qGaMAZGDVpGBUAjOO/Sq02cnHT6UAVWiDrgis51IY+ucVoF2BYe9VpVy2e2aAGxruHPBqXHANNRDtzUucAA0APiJOD6dK6YnfZQyHqVrmo1+XIrp7QFtHhJHt9OaAIIVJOeuKvXiEaHIyjBJ6VFEgL8cE96vXcZfSZkzyBnigDmccZpi4GTUgHy0qqD1oAWLpk9K6PwrHvuJHI+6tYKL6cfSuu8KQ4tncj7xoAmdd12x7cCtayT581RVN0px3Oa17RMI7Y74oAu6dzeY9Ks/tG/8AJGfEP/bv/wClEVR6Su67bNSftG/8kZ8Q/wDbv/6URUAfEdBoopCL1uMCr0f3QO9UoOlXIsgc/hTGW4frV2HgDNUYmAwDVyE5HtQBvQurgHHPSr0BGRt6DisOzmAZVc8etbEQO3g845oA0FfdkCo5gfs0hHU4psB24NWpwGsJTjByORQBmFcgYqRRjApFHXFPAOM0ASIAa6PT/m0dSATzxXOxDkEV0+kJu0zFADIshj7Vd1GIPpOV68H6VAkZEuOxrTePOmyDHY0AcnjBA6VYQZRRijgqMgVNEmdoHPPSgDs7VdumxY9BW14cXNxWWF26ao78Vt+Gh+/7UAdxaqPJWin2/wDql4opjPzsqe2HzVBU9qeakk0YfSrcXByeKpw8nNXIskY7UxlqEj1qynJFVE4qzGc4NAGyD+6UdgKtW5ORjpnNUbV/lG7pV6Hg8dDQBpQnJK/rimyjnGeKbEwGCTg1MRk9OvNAGfKBnc3Aqs1XboAQn3POaqrzxQAAflU4A/8A11HEOeaeVIbqNvpQA9BxXU6ZHnQkPbcc5rl16112lqR4fj47k0ARQLyfatA5NrcZX+GqcK81oxj/AEaQeoxzQByKj5acB8306U71HvSgDA9TQBLEOh45rutGi8nTVyCCRmuJt4i0sa+rAV6AF2Wyr6LjFAENsuXJ9K1beIiMA9DzVC3jPGO9a8agJz6UAWdGTddNn1pP2jf+SM+If+3f/wBKIqm0P5rgnsTUP7Rv/JGfEP8A27/+lEVAHxHSUtFIRetz8tXY+VqhbEbQPar8f3RTGieIZOcVdi71UhHU+varUX3uKALEOdwrorXL26sM9ADn1rn4uDXQaQd9vIh7HNAFmFQHya0oVElvJGRww4xWegxg1q2IBJHf/wCtQBiqCOG7VOFJHGOlSXsXl3DZGARSRAbaABAQB1rq9EXdpw+nbvXL44GOtdd4eXNmoHcd6AEKYkGexrVjTdZOPWqbx/OQeue1adqhFq4xkUAcaVALDHQmp7Nd0yAf3gKS7TbcSj0apdNTddQjvuoA7e4UCxj6DJrY8OKMgjvgVkXP/HsgHrW34bGQB+tAHcWwHlCilt8+UuBRTGfnNU1r/WoantO9SSX4DzirsJ5xVOL734Vch4OaYywvNWIunPFV1qxFwMH9aBFy3kK+4rXgYEKR909KxI+BWtpvzxMufucj8aBl5Mg9T+NXIh3I6VWxyvf1q5bfNtHpQBBrC7JEToMZPvVBVIYD1rT1tCfIfsR3qgo2nJzmgBY12575p7KMj3pFBPAqTaQRkUAIo5xXZ2gxoMOeeK5BVIbkV3VtEP7FiBHbNAFGGPA54NacaAwMT9apRZL1pqP9GcdzQBxcoxLIP9omkThhkZFWLlMzyY9TTVjwc9PrQBpaJEJtSgRegOT+FdreHCBdo4PWuZ8Iwl79nIwVXH5101yMvxx7UAOs1+dBnIzWhITziqtgo4YDnFW5+ATjGaANDw+u517c1V/aN/5Iz4h/7d//AEoirQ8Pr8yms/8AaN/5Iz4h/wC3f/0oioA+I6KKKQi1bHpV+JiRzWdan9K0YgcZpjLUP3sZq3By1VIeW96txcYx1oEW4z83StzQSftJQn7y/rWJDWtpR23UZ75oA22i2yEE1fsRg9RzUN1Hhg/qakiYKABQMNXiG1ZB0U1Rhxxmti8j8yyb1AzWOuAKAJwmVz2rsPDag2K965FPucdK7Hw2uLOOgCxcR4mBFXrXBgb1A6VUuTi4wO9aFov+jsfYfzoA5HUEAvJh05zU2ixh9Qi9jmjVVP2+TjrVvw7Hm+78CgDp7oAhVHHQ1teGl6jvmsS6z5vtit7wyRzwOtA0dtbg+UKKfb/6oUUwPzgqa2zuxUNSW5/eVJJpw/ezV2LBFUYOavQgAdaYywnUVPGRg/XvUMeDxU8YA6UAWErU0fH2nGD8wrKjGRxWnpZC3UTH1xQBssmGOOMdjVi24bj0pZ49jEjOc0sIyw+lAFnUYg1qox0XOTWLnsR+ddMyB7Ug+mK52RCHdfQ4oAYgz/8AWqdAcelMjWpRk0AOjQl1HXJHWu/jTZpKAntXDWi7rhBnuBXobxgaWDjmgDIt0w+SK1QgNq/vVO3w2Rjgd60QP9FOfSgDiZwftMmCODTkXOO+aW5wLiX60R/e6daAOp8IQ7YZZT3bA/CtOZf3gPGTUfh+LytLTIxu+b8M4qQne5OaANCxTCD3p96wCnJPPSizI8tcjGOKgvpPnUZoA6Xw6udvv1rJ/aN/5Iz4h/7d/wD0oirZ8OrylY37Rv8AyRnxD/27/wDpRFQB8R0UUUhE9p978a04ay7b7x+takBx9aALUPXNWY+tVocZ96twgkUxlyEdK1LLCyIe4IrNj4xnpWjbgZGeooA7K4jUwo3frVZDhxnpWiBvs42x2qk8YzkE0AX4xugZT06fpWEFOWHTGa6C0XcmD6VjTrsuZF7Z7UAIg+bjoa7Xw6v+hRcdq4zHC+td34fX/QovTFACXIImJPTNadhzAy+1Z1wP3xA9e9aWmL8hXqMUAc1rg234x1xV3w1Hm4kYnoBUfiCMLeI3HcVb8MqAJCc/McUAatySZsdAcCt/w0MEY57GsOfAlx6Yrc8M4Jye54oA7q3/ANUtFJCD5YopjPzgp8PD0ynRn5+Kkk1Lc9PpV2IZGTVGDnGfSrsHXGaYy3GeRirCcnmq0XFW4uTQBYQD+HvVu3/duhHODmq6DgY9KsR84oA6+4AMEb45bFRwKCT2xVlE83TImHbBqGD5GOeaANO3JMRXG04rCvU23L4z0retskA9OKy9WTFyCB1FAFBR6Uqfe5p+3imrgNnt0oAu6aubuEerCvRZEH9nKMDmuC0ZSb+EDpnNd/dHFjEvT2oAy7dSDsIOc1oTD/R+naq9vgyZxzV6Zf3HtQBw90paeYnjmkjQ7lB4NTyqPOk9yetT6RB59/Gp5G7PNAHYwoYLKOLvs24/D/GoEB3njrV2Y8cDp69agjH7wc0AaFmpEQGOc55qne/NdRDpWnbcw528HpWbMN2ooKAOv8OryvFYP7Rv/JGfEP8A27/+lEVdJ4dXG081zf7Rv/JGfEP/AG7/APpRFQwZ8R0UUUhE1t978a0outZtt9+tOEcZoAtQ/eq3C3QdjVSL79W4OvSmMvxD3rRgyBj8qoRDIHpWjB059KAO9sl36anqFFUwAGIrR0pFNgvX7gqmVzIc0AXNLUtuB7VkX6YvpAOtbujr85B6YrJ1hNuoMcYyKAK5UKqnvXc6EcWUZH93pXEgBgAexrudJXbYJn+4DQBDP/rcr61q6VgnFZEjbnz71q6awE2MY4oAzPEseJYjjnmp/DS4jb/eqbxNHmNGxwGpPDq5jm7HtQBcnO659hXQeGwAwrClXMxOOpFdFoAwF6cUDO0h/wBWtFLEP3a/SigR+btKvDj60lKv3h9aQjTtz0q/AvOaz7c9DWjAe1MZaTFTofmHOKroufrVmMEkcUAXIfvD6VciU7h0xVWJRkE1dhwfXNAHZaXh9KTPoKhckSYUdasaAA2mLnPSklUByQKALFp8xGTgD1qpr0aq6OBVy0P3Rj86Zrcf7kEjv1oAxlG5eaIlGRuBx7U9R8vFOQDFAGr4cj3X656Cu11FdsEfc1yvhWL/AE0k5xjvXXatnagFAGfaD5sitCYf6KvsOapW4yM9a0ZVJtQMcUAcPOMzyY9a2vCkO66dyOFFZtyuJnA4O7FdH4Wh8u3d2/iNAF2QnljkZpI8FlJ4p05BHGevemwdcHv0zQBtQAiBR24rMhIbVSSOla0OTbjtjBrKsxu1CQ+hoA7fQBhVrlf2jf8AkjPiH/t3/wDSiKuv0McDFch+0b/yRnxD/wBu/wD6URUMGfEdFFFIRNbffrTizzWdZ/fNakYGKEBYh4/xq3AfzqrEO5q5bgkimMvwitC3J9OKowjmr8H3TxQB6Po4zYR89VqhIuJvpzWpoKj+zoif7v8ASqE8eHOATzQBe0cDzdueqms3X0IvFwOoxWjpJxcx/iKh8SxnfFIB3IoAyokyVA6sRXcWB/dBc8AAYrj7FPMuIh6kV11t8rbfXFAFdxh1PHXmr0BIcAdaqyKfMwcZzV2EguD6daALOrr5+mse4x+lRaEoAZOAWFXli8y1kH8ODVGzBhI2jp1FAGjOh8wbRjjitzQRwc+tZuwSIGHpWxocZCggUAdZF/q1+lFCcIPpRQM/N2lX7w+tJQOtIk07foPWtCH7wzWfakfLmtCHliRwKYy5H94Yq3D9KqQ9atxEnjtQIvRDircY49KqW/PFXolHT+dAzsvDS508fSpCmZGBHHen+FxmzA9RmnTZSV8Y5oAWBPQU7XU/0T2GDUlt1XripPECYsSccECgDmV6cVIq5UcZ+lMQgCrKg7BgdaAOi8IIDPIevbmuj1PBbHpWH4NTO9iMZatq7+Z3HqeKAILYY6960ZAPs+TnPp2qhbEGQBuMVpygm0HFAHFXA/fvx/HXV6WnkWA9SvQ+tc2IzJdsPV66hcCBYx6daAInB2EtwxpYByCecU1uTkn86sRLw30zQBqRMDsX1FZ+ngm9l7Hdjmpo3IALjGBml0yIm+kxzuOaAO40MfuM47Vxf7Rv/JGfEP8A27/+lEVd5pq7YAAOK4P9o3/kjPiH/t3/APSiKgGfEdFFFIRYs/vGtaPAxxWVZDk1qqKEBYQ5B9M1ct+SB2qpFytXbYc0xl+Hhq0LcGqUI/vDitC2XJXigD0nSBtsYxjOEFU7hckkE8etaGn/AC2aDp8uKozEb2B6Z70APs2KOjAdTVrxEoa1DAdCDVSL5kJU5wRitS+iM+msvfbmgDA07H2mMnpkV1sCncvHA/WuQt/lIb05rtbUb4YpF6EdaAKzoRcOW6dRViIck549KbOp80kEbj0NWUiwgYc9+KANGw+a2cHgk1Tiz5zLgdcVcsyUQg9ec1Ei/wCkNgZB7UAaFkPkwRxmt3SI/umsexUDgrtPpXRaeAMHGD6UAbafdFFKv3RRQB+bdKvUUle5/Dv4a2GsfDh2vbFZNd1eK4n06czhWh8raI12bgT5jCTnB4FIR5Ba9qvwVRtwVbawII4INX4enSmMtxHB5q5BVOEH0q9b496BF23461fhwOetUYcZAq9Hz+VAzvfDEf8AoKeuKW6j/e8DHPepvDS4sYj3IpNQAEnQjmgBLQAsOvFWPEYxpufQCmWYG9fzq54hVW01iemBQBySDcBUqDIxzTE4XFToPlGBkmgDqvCCBbYu3Tcavzk7yOQM9qh0JPKtEBAztzVifmWgCvACZjyMHrmttlzbY54Gaw1yshHvxW3B867c98UAc5Zxf6czH+9mtkEkAAd/0qoY9l2+R3q/Fgqx9KYELIAxHXFTISoKnoTzSEcsTwaI1/ecj86QFg8r0xWjo6EbJMfMazolLMu3J479639NjGAgHANAHS6fkxVwP7Rv/JGfEP8A27/+lEVeg2fENefftG/8kZ8Q/wDbv/6URUAfEdFFfQXxo8E+G9N0DxJJ4f0u1t7nRru0DtGZ0aOKZBwxclJSWP8ADjaMZ75QjwiyHWtNOVrNs+lacfYd6YFuNcYq7bfK+DVJOozjAq7bKNwOfzoGaUPTNadgokljBHVgKz4gOBWxokXmXiZ6LzQB3iMUs/rxWe77nJB9hViaT92q54qrFjewPPv6UAWrMZb/AGTW1b4MSqecjvWXZRHzOTitOEcjI4HTFAGHd25t7ll7Z3Cup0gn+yUUnJBJ/Csu8txPKkjZIHFamnDCMvHSgCQxjILHAzUmAoOcnJ9aa4OecdaeGA56nFAF62AEfAx680mSr/K34EVBbHLZOSCcHNOjJ8/OcgHAFAGjAx+VgTuB6muq0zBVTjqK5K3bp2yc8V1ejnKigDdHSigdKKAPzarRh1rVVvLK5XUr0XNnGIrWUTvvgQZwqHOVAyeBjqazj0p0X+sFIRrLI80rSzOzyOSzOxyWJ5JJ7mrsA4zmqEH9K0YPu0xlmIc9au2w5qnF3q9bdRQBehHzjir0I6+tVoeo+lW4ulAHofh5f9AizxxTr9NpycfexzUmgf8AHnF/u03U+v8AwOgCK2ySMDBrT1mMzaUQCPu1Rt/vLWtegf2Y3A+6f5UAcTCpIGat26b5UQcZNU4uorW0gA3seRQB1lioXao6Ad6Rwep7tgUW3+rqWb/VrQBUiUbwTzzmtizB4LcVlR/eH1rdtehoAy9RQLqDlRjI3VJaldwBPLDFS6sP9PT/AK51DF/rU+tAEpUhzkZpyrk5bI5qwfvH6UDrQA60U+cmOcCt7TsFs9Oe9Y9txMcelbOndKaGjorYfuxXnn7Rv/JGfEP/AG7/APpRFXosP3BXnX7Rv/JGfEP/AG7/APpRFSEfEda+reJte1m3WDWNb1O/gVtwjuruSVQfUBiRmsiikIuWNasQ5x6dKzLHpWpD9/8ACmCLUYyeRV63XkcYBqrD1q/D1X60DL0QyfpXTeHY/vuQM9Biuai/h+tdfoA/0NfqaANOZgQBQikMcdajH3qlT/WJ9TQBo2py4btxwa0UBwSBlj+lZlt/D9K1YPuH6/0oAlIARVYDPtUlv8pOMVHL91PpUkP3D9KALGwn5jTvKOenPenw/cWpj0oAggOGI4qaEEv1qKIfN+dTxdvw/nQBZhZtwHvXWaMcouRXKR/60/Wus0boPpTA3KKKKQH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    AP view (panel A) and oblique view (panel B). Note the easily seen calcific density adjacent to both sides of the fracture site (white arrow), indicating the presence of callus. A more subtle sign of callus formation is seen in panel B: diffuse increased bony density overlying the fracture site (black arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_19_28991=[""].join("\n");
var outline_f28_19_28991=null;
